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Myasthenia gravis is an autoimmune disorder of neuromuscular 
transmission caused by antibodies to the acetylcholine receptor 
and related components on the post synaptic membrane of the 
neuromuscular junction. Recent evidence has shown that the 
incidence of late-onset myasthenia gravis, defined as onset at 
more than 50 years of age, has been increasing. We sought to 
prospectively recruit patients newly diagnosed with myasthenia 
gravis and look at their clinical and immunological profile to see 
if there are any differences between early onset and late-onset 
myasthenia gravis. 
Methods:  This was a multicentre study across Nottingham, 
Birmingham and Oxford. We recruited 150 patients with 
myasthenia gravis across the three sites, newly diagnosed 
within the preceding 12 months. We did clinical examinations, 
completed MG composite scores (MGC), MG Quality of life 
scores (MG QOL), and blood tests including serum for 
antibodies, and whole blood for PBMC isolation and T-cell 
studies. These were repeated at annual follow up. The antibody 
studies were performed at Oxford by radioimmunoassay (RIA) 
and cell based assays (CBA) for acetylcholine receptor 
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antibodies (AChR), muscle specific kinase (MuSK) and 
lipoprotein-related protein 4 (LRP4) antibodies. 
Results:  We recruited 150 patients with myasthenia gravis, 76% 
of whom had LOMG, with a female to male ratio of 1:1.6. EOMG 
patients more frequently had ocular myasthenia compared to 
LOMG patients, 94.7% of patients were seropositive for either 
AChR, MuSK or LRP4 antibodies. T-cell studies showed that the 
pro-inflammatory and anti-inflammatory cytokine balance is 
disrupted in all MG patients with decreased Treg percentages 
and increased production of IL10, IL17 and TNF alpha, which is 
more pronounced in patients with AChR antibodies. The clinical 
presentation did not show any difference between the different 
antibody subgroups, but there was a milder, more indolent 
course in seronegative patients, and AChR + MuSK double 
positive patients were more likely to need steroids on 
generalisation. The majority of the patients responded well to 
treatment with improvement in MGC, MG QOL and AChR RIA 
titres with time.  
Conclusions: To our knowledge, this is the largest prospective 
study on the clinical and immunological aspects of late-onset 
myasthenia gravis to date.  Further studies on B cells in MG 
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1 Introduction                   
1.1 What is myasthenia? 
Myasthenia gravis (MG) is an autoimmune disorder of 
neuromuscular transmission caused by antibodies to the 
acetylcholine receptor (AChR) and related components on the 
post synaptic membrane of the neuromuscular junction. It is 
thought to affect approximately 1.5-17.9 per 100,000 of the 
population, as demonstrated in numerous epidemiological 
studies on different continents (Carr et al, 2010)(1). 
 
1.2 History of myasthenia 
Descriptions of a clinical syndrome similar to Myasthenia Gravis 
have been found in the ancient Indian Ayurvedic text Charaka 
Samhita as far back as the 2nd century BCE. Terms such as 
‘Khanja’ meaning ‘limping’ and ‘Urustambha’ meaning ‘thigh 
fatigue’ have been used to describe the clinical presentation. 
The first description of myasthenia gravis in Western literature 
was by Thomas Willis in 1672. An English translation of the 
works of Willis was made by Samuel Pordage in 1683. In his 
book De Anime Brutorum Willis describes in ‘on the palsy’: 
‘persons who in the morning are able to walk firmly, to fling 
about their arms hither and thither, or to take up any heavy 
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thing, before noon at the stock of spirits being spent, which had 
flowed into the muscles, they are scarce able to move the hand 
or foot’. Thomas Willis kept records of patients who presented 
with a chronic condition characterised by muscle fatigue with 
fluctuating progress, typically aggravated by physical effort and 
alleviated by rest. He also suggested the existence of a 
substance in the blood which would help muscle contraction and 
that the clinical presentation was due to fluctuations in the 
concentration of the substance in the blood. He writes ‘it may be 
suspected, that not only de spirits themselves are in fault, but 
the impotency of local motion doth in some measure also 
depend upon the fault of the explosive copula, suffused 
everywhere from the blood, into the moving fibres’ (Willis T 
Pordage, De anima brutorum, 1683). It was however, much later 
in 1903 that an English paediatrician Leonard George Guthrie 
(1858 to 1918) connected the descriptions by Thomas Wills with 
myasthenia gravis (Croitoru, et al, 2016)(2). 
The next description of myasthenia gravis was by Samuel Wilks 
in 1877. His case was described as' bulbar paralysis; fatal; no 
disease found’. He went on to perform an autopsy on the patient 
and examined the medulla oblongata which he remarked as 
being healthy and normal. 
In France, Amand Duchenne (1806 to 1875), Francois Aran 
(1817 to 1861), Jean Charcot (1825 to 1893), Pierre Marie 
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(1853 to 1940) and Joseph Dejerine (1849 to 1917) described 
muscular dystrophies and forms of motor neuron disease at the 
time.  
In Germany, Heinrich Romberg (1795 to 1873), Carl Friedrich 
Westpal (1833 to 1890), and Nikolaus Freidrich (1825 to 1882) 
also made major advances in neuropathology. In 1879 Wilhelm 
Erb described cases of myasthenia gravis which appeared 
under the heading ‘Ueber einen eigentumlichen bulbrern (?) 
Symptomenkomplex’. 
In the 19th century there were several single case reports of 
similar clinical presentations which were in keeping with 
myasthenia gravis. Samuel Goldflam (1852 to 1932) a Polish 
neurologist, gave a complete account of myasthenia gravis 
when he described three cases and reviewed papers of the 
previous neurologists. He gave an analysis of the varying 
presentation, severity and prognosis of the different cases 
(Hughes, 2005)(3). 
In 1935, a Scottish physician called Mary Broadfoot Walker, who 
at the time was working at St Alfege’s hospital in Greenwich, 
described the dramatic improvement of myasthenia gravis 
through the administration of physostigmine and later on through 
Prostigmin (Neostigmine).  She presented her findings at the 
clinical meeting of the Royal Society of medicine (neurology) at 
the National Hospital, Queen Square London on 17 February 
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1938 and this was published in detail. Dr Walker concluded that 
myasthenia gravis was the pathological effect of a substance 
that entered the circulation and caused abnormal fatigability via 
acetylcholine in the neuromuscular junction. She also used 
placebo (saline) to confirm the effect of physostigmine. The 
demonstration of the treatment was recorded in a movie 
produced in 1935 and which is accessible online 
(https://www.youtube.com/watch?v=uRoRsmvkhTI) (Carvalho et 
al, 2017)(4). 
Although Dr Walker was thought to be the first to describe the 
use of Physostigmine, this was in fact first described by Dr Lazar 
Remen, a Polish doctor who described it’s use in Myasthenia 
gravis in a paper published in 1932. He was studying the effects 
of Glycine at the time and the positive results of physostigmine 
on myasthenia were not given much importance (5). 
In the early 1900s Campbell and Bramwell suggested that a 
toxin, possibly of microbial origin was the cause of myasthenia. 
Buzzard, in 1905 then suggested that this was an ‘autotoxic 
agent’ causing symptoms. Wilson and Stoner conducted animal 
experiments in 1944, and suggested that there was a blockage 
of transmission in neuromuscular junction in frogs. This was not 
confirmed by Lammers and Van Spijk, 1954. It was found that 
haemodialysis caused immediate but transient improvement in 
MG patients (Stricker et al, 1960) (6). In 1967, Parkes and 
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McKinna found changes in muscle contraction upon injection of 
globulin fractions from myasthenia serum. In 1973, Bergstrom et 
al studied the effect of thoracic duct drainage which again 
caused improvement in MG symptoms (7). 
The first antibodies demonstrated were by Strauss and 
colleagues in 1960 who found the existence of anti-striated 
muscle antibodies (anti--SM); this is seen in 30% of all MG 
patients and nearly all patients with thymoma. 
It was Prof Ian Simpson in 1964 who hypothesised that 
myasthenia gravis was an autoimmune disorder caused by an 
antibody to an endplate protein (8). Antibodies to the endplate 
protein i.e. acetylcholine receptors was first demonstrated by 
Almon, Andrew and Appel in 1974 (9). They found that serum 
globulins from MG patients could inhibit α bungarotoxin (α-BuTx) 
binding to solubilised rat AChR receptors. 
Mittag, Kornfield, Tormay and Woo compared four different 
techniques of assessing AChR antibodies and found that 
immunoprecipitation of α-BuTx labelled AChR was the most 
effective. This was then described in detail by Lindstrom et al in 
1976 (10). Over the years several different studies have been 
performed. Using subclass specific antisera, Vincent, Lang and 
Newsom-Davies found that most patients have anti-AChR within 
subclasses 1, and occasionally subclass 3 (11, 12). 
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Since then, a lot of work has been done on the diagnosis of 
myasthenia, including studies looking for antibodies to other 
components of the NMJ receptor complex, T cells and their 
pathophysiology, B cells and their receptors; and in the 
treatment of myasthenia including various immunosuppressants, 
monoclonal antibodies, thmectomy and other targeted therapies. 
 
1.3 Pathophysiology of myasthenia 
Myasthenia gravis is an autoimmune disease characterised by 
the presence of autoantibodies against components of the 
muscle membrane at the neuromuscular junction. The most 
common of these is the acetylcholine receptor antibody. 
Antibodies against other components of the postsynaptic 
membrane have also been described including MuSK, LRP4 
and agrin, and to intracellular proteins such as ryanodine 
receptor and titin. The triggers for this autoimmune reaction are 
not yet clear. Many potentially autoreactive CD4+ T cells survive 
clonal deletion during development; their presence in normal 
subjects however does not result in clinically significant 
autoimmune responses. Clinical and epidemiological studies 
suggest that infections may be the triggering factors (Rose et al, 
1998). It has been proposed that there may be molecular 
mimicry between a microbial epitope recognized by CD4+ T 
cells and a self antigen with a similar sequence. 
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Once the tolerance of the self- epitope is lost, T cells which 
recognise that epitope and which can secrete pro-inflammatory 
cytokines migrate into the tissues that contain the antigen. Here 
they can cause an inflammatory response and tissue 
destruction. The antigen presenting cells (APCs) can activate 
these CD4+ T cells and present new epitopes from the same 
antigens or even new antigens. This may become a self-
maintaining process and causecasue chronic tissue destruction 
(13-15). 
The neuromuscular junction (NMJ) is a chemical synapse 
between the motor neurons and the skeletal muscles. When the 
action potentials pass down the motor neuron, the terminals 
release acetylcholine which then activates the acetylcholine 
receptors (AChRs) present on muscle fibres. This triggers 
calcium release from the sarcoplasmic reticulum by polarising 
the muscle cell and this causes muscle contraction. 
NMJs occupy less than 0.01-0.1% of the entire muscle surface. 
Positive factors such as agrin are secreted by the nerve 
terminals and initiate the concentration of the AChRs at the 
NMJ. Agrin promotes  transcription of AChR subunit genes and 
the other proteins required for the NMJ function, AChR transport 
to the junction membrane, AChR clustering, anchoring and 
stability. ACh itself, conversely, is a negative signal and 
suppresses this mechanism is also released. 
18 
 
Acetylcholine receptors are found on the surface of muscle 
membranes but are concentrated at the neuromuscular junction 
where the nerve ending synapses with the muscle. The density 
of AChRs at the endplate is about 15,000-20,000 receptors/μm2. 
The concentration of AChRs is 100 fold lower further away from 
the endplate (16). At a mature endplate, the half-life of AChRs is 
about 8-11 days. The old receptors are not recycled, but are 
internalised and degraded (17). 
Nicotinic acetylcholine receptors (AChRs) are a family of 
acetylcholine gated cation channels. These receptors are seen 
in several parts of the human body; they are present in the 
postsynaptic region in the motor neurons of the skeletal 
muscles, and in autonomic ganglia. In the central nervous 
system they act presynaptically and extrasynaptically. They are 
also present in the skin, bronchial and vascular epithelium, and 
in other non-neuronal tissues where they mediate intercellular 
communication. 
There are many subtypes of AChR depending on the subunits of 
which they are composed. All AChRs have five homologous 
subunits which are organised around a central cation channel. 
There are 17 AChR subunits α 1-10, β 1-4, γ, δ and ε.  
AChR is made up of 5 protein chains- 2αβεδ in adults and 2αβγδ 
in the foetus. They are arranged longitudinally to form a channel 
across the cell membrane. The acetylcholine binds to the α 
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chains on the external side close to but distinct from the 
immunogenic region which is recognised by the AchR Ab. Upon 
binding of the acetylcholine to the 2 α chains, the channel opens 
by a change in shape of the receptor. This allows positively 
charged ions to move intracellularly; end plate potentials are 
generated leading to muscle contraction (18). 
LRP4 (low density lipoprotein receptor - related protein 4) is a 
member of the LDL receptor family. Agrin released by the 
presynaptic terminal binds to LRP4, which in turn activates 
MuSK. This leads to AChR clustering and NMJ formation. MuSK 
activation requires Dok7 which is an adapter like protein. Dok7 
is important for MuSK activity and NMJ formation. 
MuSK activity is also regulated by proteins which interact with 
LRP4- Tid 1, β amyloid precursor protein (APP) and mesoderm 
development candidate 2 (Mesdc2). 
The intracellular pathways downstream of MuSK are not very 
well understood, most of them are possibly modulatory except 
for rapsyn which is important for clustering of AChR. Rapsyn is 
thought to anchor AChR to the cortical cytoskeleton and could 
be a signalling protein and not just an adapter protein.  
ACh-binding protein (AChBP) has been identified which under 
the right circumstances causes suppression of synaptic 
cholinergic transmission. AChBP can diminish or stop 
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acetylcholine response or raise basal AChBP concentration 
such that subsequent responses to acetylcholine are decreased 
(Smit et al, 2001) (19). Other proteins identified in the post 
synaptic membrane and which play a role in synaptic 
transmission are utrophin and other dystrophin-related complex 
proteins. 
In MG patients with AChR Ab, there is reduction of AChR at the 
NMJ junction, and disruption and simplification of the synaptic 
folds visible on electron microscopy of muscle biopsies. The 
primary mechanism seems to be activation of the complement 
pathway with generation of the membrane attack complex. 
There may also be AChR blocking. There is some compensation 
by active synthesis of different AChR subunits. 
The pathogenesis of AChR MG is due to autoantibodies of the 
IgG1 and IgG3 sub classes (12, 20). They induce myasthenia 
through three mechanisms: (i) complement mediated 
postsynaptic membrane damage (21) (ii) cross-linking by 
bivalent IgG1 and IgG3 molecules (antigenic modulation) which 
causes internalisation of AChRs and depletion of its surface 
pools (22) and (iii) competition with ACh on binding sites of 
AChRs preventing activation and opening of the ion channels 
(23). There are also hypotheses which suggest that some 
antibodies may physically block the ion channel pore of the 
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AChR, but this has not been supported by experimental 
evidence (24). 
The muscle type nicotinic AChR with the five subunits has what 
is called the main immunogenic region or MIR. Epitope mapping 
shows that more than half of the different AChR autoantibodies 
bind to a distinct part of the AChR α subunit which is the MIR 
(25, 26). 
Some parts of the β and γ subunits adjacent to the MIR were 
also found to be immunogenic (27). Autoantibodies against the ε 
subunit have been reported which causes slow channel 
myasthenia due to delayed closure of the AChR ion channel 
(28). 
The AChR MIR is mainly located around a loop of amino acids 
66 to 76 on the α-1 subunit (25, 29). The epitope spreading 
hypotheses proposes that the initial epitope target of antibodies 
does not remain fixed but it extends to other epitopes within the 
same protein or even to other closely associated proteins (30). 
The IgG subclasses seen in MG are IgG1 and IgG3 (12, 21) 
which have high affinity for Fc receptors on immune cells and 
they are also potent complement activators in contrast to IgG2 
and IgG4. Complement factor deposition is seen at the NMJ in 
MG (31, 32). Complement consumption increases during 
exacerbation of MG with deficiency of C3 and C5 in EAMG (33, 
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34). Antigenic modulation seen in AChR MG is due to the 
functional bivalency of IgG1 and IgG3 (22, 35). 
 In contrast to AChR MG, MuSK MG is associated with IgG4 
autoantibodies (36). IgG4 antibodies are unable to activate 
complement and they have a low affinity for Fc receptors on 
immune cells (37, 38). The likely mechanism for pathology could 
be related to the epitope to which the antibodies bind. Epitope 
mapping showed that most of the antibodies in MuSK recognise 
epitopes within the first two extracellular IgG-like domains (39, 
40). As this interferes with Wnt receptor and signalling which is 
essential for AChR clustering, the hypotheses is that MuSK 
antibodies induce myasthenia through (i) antigenic modulation 
and internalisation of surface MuSK (ii) inhibition of MuSK 
dimerisation and (iii) interference with MuSK binding partners. 
The findings of a recent study also showed that MuSK 
autoantibodies can prevent the interaction between MuSK and 
Col Q (41). 
In AChR MG the loss of AChR clusters is compensated by 
upregulation of the presynaptic ACh release through retrograde 
signalling (42). In MuSK MG this compensatory upregulation is 
not seen. This may be because the retrograde signalling is 




The thymus is known to be a site of the antigen AChR. Myoid 
cells in the human thymus can yield muscle cells which bear 
AChR. The thymic epithelial cells also contain AChR. The rates 
of anti-AChR synthesis in culture do not suggest that the thymus 
is a major site for anti-ACHR production; the highest rates 
produced by thymus would be around 20 pmoles per 24 hours 
which is less than 1% of the synthesis required to maintain 
serum anti-ACHR levels of 20 nmol per litre, assuming a t1/2 of 
20 days. It seems unlikely that the thymus makes more than a 
small contribution to the whole body production of antibodies. 
This suggests that the clinical benefit from thymectomy does not 
depend only on the removal of the antibody production site. The 
rate of antibody synthesis by thymic cells is also higher with 
longer duration of disease. This suggests that the thymic 
production of AChR is a secondary event. PBMCs can also 
synthesise anti-ACHR antibodies (Vincent et al) (44). 
Both T and B lymphocytes originate in the bone marrow, but 
only B lymphocytes mature there; T lymphocytes mature in the 
Thymus as described below. These are the primary lymphoid 
organs. The secondary lymphoid organs are the lymph nodes, 
the spleen and the mucosal lymphoid tissues. In the lymph 
nodes the B cells are localised in follicles in the outer cortex and 
the T cells are present more diffusely in the paracortical areas or 
T cell zones. In the spleen, the lymphocytes surround an 
arteriole which is called the periarteriolar lymphoid sheath and 
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they are mainly T cells. B cells are present in the interspersed 
lymphoid follicles. In each of the lymphoid organs, the T cells 
and B cells interact along the marginal zones. The peripheral 
lymphocytes are mature lymphocytes comprising of both 
activated cells and naïve cells and continuously circulate 
between the periphery and the lymphoid organs. 
The thymus is a primary lymphoid organ which is 
environmentally complex. T lymphocytes develop from a 
lymphoid progenitor in the bone marrow, some of which migrate 
to the thymus. Here, they receive a signal through the Notch1 
receptor which instructs the precursor to commit to the T cell 
lineage rather than the B cell lineage. Notch signalling is also 
important in the CD4 Vs CD8 decision. The progenitor cells lack 
most of the surface molecules seen in mature T cells. The first 
cell surface marker expressed is CD2; this lacks both CD4 and 
CD8 and is called a ‘double-negative’ thymocyte. After several 
steps of gene rearrangements, the thymocytes express both 
CD4 and CD8 receptors, called ‘double-positive’ thymocytes. As 
they go through the positive selection process (described 
below), they lose one of the receptor molecules, becoming 
‘single-positive’ thymocytes which are either CD4+ or CD8+. 
The thymus is needed for T-cell maturation and differentiation as 
they migrate from the cortical to the medullary compartments. 
This is brought about by an interaction between the thymic 
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epithelial cells and the T cells but also with other cells including 
dendritic cells, fibroblasts and myeloid cells (45, 46). During the 
first differentiation in the cortex, the immature T cells gradually 
become double positive for CD4 and CD8 receptors and they 
acquire a complete T-cell receptor (TCR). Further differentiation 
occurs after interaction of the TCR with the major 
histocompatibility complex (MHC) on the stromal cells. A large 
majority of the thymocytes are eliminated due to this positive 
selection step ie if the TCR-MHC interaction is too weak. In the 
medulla, the thymocytes are eliminated by negative selection ie 
if the TCR-MHC interaction is too strong. This is the basis of 
central tolerance based on the ability of TECs to express tissue 
specific antigens (TSAs) presented to T cells. The expression of 
the tissue-specific antigens is monitored by the autoimmune 
regulator AIRE or the transcription factor FEZ family zinc finger 
(47, 48). The AIRE expression has been shown to be down 
regulated by oestrogen which would explain the female 
predisposition to autoimmunity including myasthenia gravis (49). 
Thymic myeloid cells also display functional AChR. The Thymic 
epithelial cells (TECs) are involved in the selective induction of 
natural regulatory T cells (50). 
In early-onset myasthenia gravis, thymic hyperplasia is 
observed in 50 to 60% of patients and thymoma is detected in 
approximately 15% of AChR+ GMG. In other cases, the thymus 
is atrophic or involuted with adipose tissue and residual areas of 
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thymic parenchyma. In the thymus in myasthenia gravis patient, 
no changes are observed with the frequency of CD4+ and CD8+ 
T cells. However the natural regulatory T cells that are 
differentiated in the thymus are less functional; which is also 
seen, but to a lesser degree, in the periphery (51, 52). The other 
abnormality seen is that the effector T cells from the thymus of 
MG patients are resistant to suppression by T reg cells which is 
likely due to the inflammatory thymic environment. There are 
changes in the expression of pro-inflammatory cytokines by the 
T cells such as IL-17 and increase in interferon gamma, IL 21 
and TNF alpha expression in both the Tregs and effector T cells 
(53). 
B cells are seen at low levels in normal thymic tissue and are 
seen mainly in the medulla and perivascular spaces.  In the 
thymus of an AChR antibody positive myasthenia gravis patient, 
there are increased numbers of B cells, often in germinal 
centres (GCs). There is a difference in the age and gender of 
the patients, with the younger patients displaying higher 
degrees, with three or more GC's, and the older patients 
displaying lesser degrees, with fewer than two GC's per thymic 
section of follicular hyperplasia; 80% of the patients with thymic 
hyperplasia are women (54, 55). 
An increasing number of T follicular helper cells have been 
described in the periphery and in the thymus of MG patients. 
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Truffault et al showed that patients with AChR antibody positivity 
and thymic hyperplasia have higher titres of AChR antibody than 
patients with thymoma or involuted thymus, and there is a clear 
correlation between the degree of thymic hyperplasia and serum 
levels of anti-ACHR antibodies (54). 
In the thymus of MG patients there is increased number of high 
endothelial venules (HEV). Chemokines are expressed by HEVs 
and this is dysregulated in the MG thymus, including CCL 19, 
CCL21, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13 and 
RANTES/CCL5. CXCL13 is the most potent chemoattractant for 
B cells. Inflammation of the thymus is required to reveal the 
chemotactic properties of CXCL13. The inflammation following a 
pathogen infection appears to be important in optimising the 
recruitment of mature lymphocytes. Interferon I that is released 
during infection could favour cell motility (56-58). 
The presence of poliovirus infected macrophages and Epstein-
Barr virus (EBV) infected B cells have been seen in MG 
thymuses. This supports the hypotheses that the innate immune 
system may promote, exacerbate and/or maintain the 
autoimmune condition (59, 60). Toll -like receptors (TLRs) are 
important in innate immunity. In an MG thymus there is 




IFN- I has been implicated in myasthenia gravis- clinical reports 
demonstrating development of MG after interferon-alpha or 
interferon beta therapies (62), antibodies against IFN alpha are 
found in MG patients, mainly those with thymoma (63), and IFN 
beta is overexpressed in MG thymuses (64, 65).  IFN beta 
induces the expression of α-AChR by TECs and also increases 
TEC death. IFN-β triggers the expression of CXCL13 and 
CCL21 by TEC and lymphatic endothelial cells. It induces the 
expression of B cell activating factor (BAFF) which favours B cell 
survival and is overexpressed by TECs in MG thymus. In 
myasthenia patients, IFN beta is overexpressed long after 
disease onset and this is suggestive of the presence of a 
pathogenic agent (66). 
MiRNA are small RNAs that are post transcriptional regulators of 
gene expression. They interact with mRNAs leading to 
degradation or inhibition of translation and cause decreased 
protein expression. The differential expression of some MiRNAs 
in the peripheral blood mononuclear cells are observed in MG 
patients (Cron et al, 2017) (50). 
 
1.4 Clinical presentation of myasthenia 
The signs and symptoms in myasthenia gravis result from 
fluctuating strength of voluntary muscles. The degree of 
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weakness is partly dependent on the exertion of the muscle but 
can vary spontaneously over time for no apparent reason. 
Myasthenia Gravis (MG) may present with a variety of 
symptoms including ptosis, diplopia, drooping of the neck, 
difficulty with chewing, dysarthria, dysphagia, orthopnoea, and 
limb weakness. This can be classified clinically into Ocular 
Myasthenia Gravis (OMG), Bulbar Myasthenia Gravis or 
Generalised Myasthenia Gravis (GMG). Myasthenia Gravis can 
be classified into seropositive or seronegative based on the 
presence or absence of antibodies in the serum. Further 
classification is based on whether the serum is positive for 
AChR Abs, MuSK Abs or LRP4 Abs.  
MG can also be classified based on the severity of presentation. 
The medical scientific advisory board of the myasthenia gravis 
foundation of America formed a task force in 1997 to come up 
with a universally accepted classification grading system and 
method of analysis for patients undergoing therapy for 
myasthenia gravis. This classification is designed to identify 
subgroups of patients with myasthenia gravis who have similar 
clinical features which may indicate different prognoses and 
response to therapy (Appendix 1). 
The MGFA (Myasthenia Gravis Foundation of America) grades 
MG from Class I to Class V; Class I being the least symptomatic 
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with purely ocular symptoms and Class V where patients need 
ventilatory support (323).  
In about 15% of patients with MG, the symptoms can remain 
confined to the ocular muscles. Ocular symptoms are the most 
frequently seen in MG. It is not clear if diplopia or ptosis is the 
more frequent. Any extraocular muscle can be involved leading 
to various presentations of diplopia- horizontal, vertical or 
diagonal. 
Bulbar involvement is that which affects muscles innervated by 
cranial nerves V, VII, IX, X, XI, and XII. Speech difficulty usually 
manifests as a nasal voice or difficulty with articulation. This may 
be isolated or accompanied by dysphagia or difficulty with 
chewing. The symptoms may occur in bouts. If dysarthria is due 
to palatal dysfunction, then nasal regurgitation of fluids may 
occur. Upper pharyngeal muscle weakness gives a sensation of 
food sticking in the throat. There may be preference for cold 
foods in patients with dysphagia (may be due to improvement of 
neuromuscular transmission due to muscle cooling). If there is 
severe weakness of the muscles of mastication, the jaw sags 
open and the patient may need to hold the mouth closed. Most 
patients with chewing problems also have weakness of neck 
flexion/extension. An important correlate with dysphagia is 
weight loss. Weakness of facial muscles may be present which 
may be misdiagnosed as Bell’s palsy. This may manifest as 
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inability to whistle, kiss, difficult eating soup with a spoon or by 
difficulty pronouncing ‘p,f and s’ . 
Weakness in arms, hands or legs as the first presentation is 
seen in 15- 20% of patients. Patients may complain of vague 
symptoms of tiredness or heaviness in their limbs or they may 
complain of difficulty with specific tasks such as hanging out 
laundry, washing their hair, hammering a nail, etc. Pain in the 
back and girdle is seen with weakness of postural muscles.  
In most patients with generalised MG who have not reported any 
respiratory symptoms, there is decrease in vital capacity; even 
in 40% of pure ocular myasthenics, there is decrease in vital 
capacity (Reuther et al)(67). Vital capacity is decreased to a 
greater extent than forced expiratory volume. 
Focal muscle atrophy may be seen in 6-10% of MG patients 
(Oosterhuis et al, Osserman et al, Schimrigk et al, Simpson et 
al) (68, 69). 
There have been suggestions that MG patients have cognitive 
symptoms including abnormalities of visual attention and 
reaction time (70, 71) but this has been refuted by other authors 
(72). Currently there is insufficient data to confirm this. AChR 
Abs do not bind to AChR extracted from human brain making it 
unlikely that central cholinergic receptors are affected in MG. 
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There may be exacerbating factors which may unmask MG 
including infection with fever, psychological stress, hypo or 
hyperthyroidism, drugs such as quinine, chloroquine, 
aminoglycosides, beta blockers and D-penicillamine. The effect 
of pregnancy on MG has been described in thirds: no change in 
a third, improvement in a third and deterioration in a third of 
women with MG. Most patients seem to improve in the second 
half of pregnancy (Plauche et al, 1979) (341). 
Myasthenia may be misdiagnosed as other neuromuscular 
conditions and vice versa. LEMS should be considered in 
seronegative patients with fluctuating weakness. The other 
diagnoses to be considered with more or less fluctuating limb 
weakness are motor neurone disease, polymyositis, endocrine 
myopathies and mitochondrial myopathies. In all these 
conditions, there may be a slight benefit with choline esterase 
inhibitor treatment. With bulbar symptoms, motor neurone 
disease should be thought of and in isolated dysphagia, 
achalasia (disturbance in the parasympathetic innervation to the 
oesophagus) should be considered as the differential diagnosis. 
 
1.4.1 Unusual clinical presentations of MG 
As described above, myasthenia gravis most commonly 
presents with a combination of ocular symptoms of diplopia or 
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ptosis, bulbar symptoms of dysarthria, dysphagia, chewing 
difficulties, neck weakness with head drop, limb weakness and 
respiratory difficulties.  
Limb girdle myasthenia is an uncommon clinical picture; patients 
have predominantly proximal muscle weakness with no ocular, 
bulbar or facial deficit. This could be mistaken for myopathies 
and make diagnosis difficult (Vecchio et al) (73). 
Fearon et al published a case report of a gentleman with a 
history of distal arm myopathy. He had predominant weakness 
of finger extension and mild involvement of finger flexion, wrist 
flexion and wrist and finger extension. He did not have any 
ocular or bulbar symptoms and there was no fatiguability with 
his limb symptoms. He later developed ocular symptoms of 
diplopia and ptosis after which he tested positive for myasthenia 
gravis (74).  
Sih et al retrospectively looked at a cohort of MG patients and 
found that of 146 generalised MG patients, 15 had head drop. 
These patients were older at onset and predominantly men (75).  
Respiratory involvement in myasthenia gravis may be more 
common than previously thought. A Tiawanese study published 
in 2015 (Yeh et al) prospectively looked at 58 patients with 
myasthenia gravis without respiratory symptoms and tested for 
sleep-disordered breathing (SDB) with a watch-PAT (Peripheral 
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Arterial Tone) and concomitant recording of the MG score. This 
showed that the prevalence of SDB in Myasthenia patients with 
mild and moderate weakness was high when using the watch 
PAT. The predictive factors predisposing to the development of 
SDB were patients’ age, male gender and use of azathioprine 
(76).  
Nikolic et al looked at a cohort of MuSK positive and ACHR 
antibody-positive myasthenia patients. They did a clinical 
examination, EMG recording and proton magnetic resonance 
spectroscopy. Myopathic EMG was more frequent in MuSK 
compared to ACHR MG patients. In the ACHR MG patients 
myopathic EMG in facial muscles was more frequent after long-
term corticosteroid treatment. In the MuSK MG patients, facial 
and tongue muscle atrophy was seen in 23% patients. This was 
associated with longer disease duration. Intramyocellular lipid 
deposition in the tongue was present in 85% of MuSK and 20% 
of ACHR MG patients. Myopathic changes in EOMG were more 
common with female MuSK patients and signs of 
Intramyocellular lipid deposition in the tongue were also more 
common in female compared to male patients (77). 
Cartwright et al wrote a case report of a patient who presented 
with worsening dyspnoea with anti-MuSK antibody positivity. 
This patient had atrophy of the diaphragm which is an unusual 
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finding, atrophy of the tongue being more common. There was 
improvement with plasmapheresis and steroids (78). 
Other rare presentations include ophthalmoparesis with 
unilateral finger flexor muscle weakness (Cordeiro Sousa, et al) 
(79). Focal predominant triceps muscle weakness is another 
unusual presentation; in the case report by Abraham et al, this 
was predominantly in African-American males (80). 
There have been case reports of cognitive fatigue in patients 
with myasthenia gravis. Jordan et al published a paper in 2017 
which looked at 33 myasthenia patients with stable generalised 
disease and compared the data with 17 healthy controls. They 
had repeated testing of attention and concentration and paced 
auditory serial addition test. The fatiguability was based on the 
calculation of linear trend (LT). MG patients showed a negative 
LT for testing of attention and concentration indicating cognitive 
fatiguability. This was significantly different from controls with a 
p of <0.05. Paced auditory serial addition test did not show any 
difference (71). 
Olfactory and gustatory dysfunction in myasthenia gravis has 
been reported.  MG patients showed low olfactory and gustatory 
scores studied with sniffin’ sticks test and taste strip test. Tekeli 
et al also showed that olfactory loss correlated with the severity 
of the disease and treatment did not influence the results (81). 
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There is some evidence that acetylcholine receptors on the 
outer hair cells of the ear may also be affected in myasthenia 
gravis causing progressive loss of AChR on the outer hair cells 
decreasing their electromotility. This has been postulated as a 
useful additional tool for diagnosis and monitoring.  Recording 
clinical hearing alterations before the onset of clinically evident 
hearing loss was suggested (Ralli, et al) (82). 
There have been suggestions also of sensory disturbance 
associated with myasthenia gravis. This is thought to be 
because the presynaptic, synaptic and post synaptic 
mechanisms of AChR formation, action and termination are 
found in virtually all cells; widespread sensory dysfunction would 
be explainable. Leon Sarmiento et al tested tactile perceptual 
thresholds which were found to be higher in MG patients 
measured by grating orientation tasks. Tactile thresholds of 
corneal perception measured with asthesiometer were also 
significantly higher in MG patients.  Symptoms similar to 
Restless Legs Syndrome were found in up to 43.8% of MG 
patients. Numbness and tingling were seen in 10% of patients 
and often found at disease onset. Pain scores of moderate or 
high severity were seen in 50% of patients. Coexisting sensory 
neuropathy and neuronopathy have also been reported in a 
number of MG cases. Somatosensory input processed within 
the somatosensory cortex and tested using somatosensory 
evoked potentials have been found to be impaired in myasthenia 
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gravis. There have been abnormalities in latency and amplitude 
of P100 response during visual evoked potentials which 
improved with anti-cholinesterase inhibitors. Orthostatic 
dizziness, abnormal thermoregulatory, sweat testing, impaired 
gastrointestinal function and severe pan-autonomic failure have 
been reported. Patients in myasthenic crisis have also been 
shown to have a wide heart rate and fluctuations of blood 
pressure. Cholinergic transmission is the mechanism used by 
almost all sensory organs. The human skin has the highest 
concentration of free acetylcholine (1000 pmol/ gram). The 
nicotinic receptors play a key role in cell cycle progression, 
apoptosis and differentiation of keratinocytes; muscarinic 
receptors are also involved (83). 
 
1.4.2 Associations of MG with other disorders 
There have been several case reports of amyotrophic lateral 
sclerosis coexisting with myasthenia gravis. In a study by 
Pasqua et al in 2016, they went through a prospective registry of 
all ALS incidences from 2009 to 2014. 671 patients were 
diagnosed with ALS of which five patients were also affected by 
myasthenia. Patients with ALS and myasthenia frequently had 
bulbar onset and a rapidly progressive course. They suggested 
the possibility of a shared immunological dysfunction (84). The 
findings were reflected by a Norwegian study by Gotaas et al 
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who suggested that the prevalence and incidence of myasthenia 
and ALS was far more than expected if the disorders were 
unrelated. This suggested immunological mechanisms in the 
neuromuscular junction which were relevant in ALS 
pathogenesis (85). Similarly, a Chinese study by Tai et al 
suggested that most patients had limb onset ALS, and 
myasthenia symptoms mainly affected the ocular and bulbar 
muscles (86). A study by Amador et al from France also 
suggested the same (87).  
There have been case reports of myasthenia gravis and 
Lambert-Eaton overlap syndrome (MLOS). A review was 
undertaken by Shin Oh, published in 2016, who looked at 55 
possible case reports of MLOS. Of these, 39 cases met the 
diagnostic criteria for myasthenia gravis and LEMS. Analysis of 
clinical data showed that the patients had common MG and 
LEMS symptoms of ocular and bulbar paresis, response to 
anticholinesterase for MG, and limb weakness and decreased or 
absent reflexes for LEMS. The RNS studies showed low 
compound muscle action potentials and incremental response in 
more than 60%. Eight patients had combined AChR antibodies 
or MuSK antibodies and voltage gated calcium channel (VGCC) 
antibodies (88).  
Myasthenia gravis can coexist with other neurological disorders 
including nemaline myopathy (Cao et al) with positive 
39 
 
acetylcholine receptor and Titin antibodies. The pathogenesis 
may be related to AChR antibody and Titin antibody in adult 
onset nemaline myopathy with myasthenia (89).  
There have also been case reports of myasthenia gravis 
associated with Morvan’s syndrome and positive contactin 
associated protein like 2 antibodies. 
Coexistence of MG and neuromyelitis optica (NMO) has been 
described. In most cases MG predated NMO, and most patients 
had a prior history of thymectomy at an early age. This suggests 
that the thymus gland is possibly protective against the 
development of NMO (Gotterer et al) (90). 
Myasthenia gravis can be associated with pathologies in other 
organ systems, heart and skeletal muscles being the most 
commonly reported. This can be asymptomatic ECG changes, 
to giant cell myocarditis with ventricular tachycardia, conduction 
disorders, heart failure and sudden death. Myocardial 
involvement can also appear as Takotsubo Disease. Ryanodine, 
Titin, B1 and B2-Adrenergic Receptors could be the possible 
autoimmune targets in Myasthenia. With heart involvement, 
elevation of Troponin has been reported. Takotsubo Stress 
Cardiomyopathy with Myasthenia seems to be due to emotional 
or physical stress and high levels of circulating catecholamines. 
This could be helped with treatment for myasthenia gravis 
including plasma exchange. 
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In a study by Kubiszewska in 2016 the prevalence of 
autoimmune thyroid diseases was measured in a cross-
sectional study of 343 consecutive patients with myasthenia 
gravis. Autoimmune thyroid diseases were diagnosed in 92 
myasthenia patients (26.8%), including Grave’s disease, 
Hashimoto's thyroiditis and antithyroid antibodies only. Grave’s 
disease patients had ocular symptoms more often than those 
with antithyroid antibodies or Hashimoto's thyroiditis. The 
prevalence was comparable in early and late-onset. 
Immunosuppressive therapy was less frequently needed in 
patients with myasthenia and thyroid problems which indirectly 
indicated a possible milder course of disease. Amongst 
autoimmune diseases, autoimmune thyroid disorders seem to 
be the most associated pathology with myasthenia gravis (91). 
It has previously been reported that the frequency of poly 
immunity in MG is anywhere between 11.6 and 32%. Duarte et 
al looked at all MG patients in a Portuguese tertiary centre. They 
found other autoimmune disorders in 37 patients with MG i.e. 
17%. The frequency of the second autoimmune disorder was 
highest for females with EOMG at 68%. 78% had GMG and 
78% had AChR antibody positivity. 51% had thymectomy with 
thymic hyperplasia being the most common (92).  
Berrih-Aknin also wrote about autoimmune disorders in MG. It 
has previously been shown that familial autoimmunity was 
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common but it was variable. In EOMG, about 40% of patients 
had relatives with autoimmune disorders whereas in LOMG it 
was 20%. Only 4% of individuals had relatives with MG. In 
EOMG females, the known risk allele of the immune regulatory 
gene PTPN22 appears to be more common in patients with a 
second autoimmune disease or autoimmune relatives than in 
those without a second autoimmune disease (93). 
Myasthenia gravis with proteinuria is a very rare disorder. A 
paper published by Tsai et al in 2016 reported 39 cases in 
literature thus far. The most commonly associated disorder 
being minimal change disease. Both these conditions are 
related to dysfunction of T lymphocytes and hence can be 
connected. Treatment for the myasthenia also lowered the 
proteinuria of minimal change disease (94). There is one 
reported case of concomitant myasthenia gravis and Anderson-
Tawil syndrome. This is an autosomal dominant multisystem 
channelopathy characterised by periodic paralysis, ventricular 






1.5 Literature review 
1.5.1 Epidemiology of MG 
Epidemiological studies done since the 1950s have shown an 
increasing incidence rate and prevalence rate of myasthenia 
gravis with time, especially in the older population. Comparison 
across the different studies has been difficult because of 
heterogeneity, different ethnicities and different methods of data 
collection. Before the advent of antibody tests for myasthenia 
gravis, the diagnostic criteria for myasthenia differed in each 
study, being defined by the authors. The age cut off for LOMG 
and EOMG also differed between studies. Since the advent of 
antibody testing in the 1980s, the incidence rates and 
prevalence rates of MG have approximately doubled. The 
methodology and the findings for some of the studies are 
described below; every study has a different method of data 
collection including: AChR Ab assays from national or regional 
immunology labs; discharge diagnosis, antibody tests and 
pyridostigmine used; health-insurance reviews and assessment; 
prospective MG registers; Medicare beneficiaries; cross-
sectional study; complete enumeration approach; clinical 
records and pyridostigmine prescription registers; prescription of 
pyridostigmine alone; and hospital discharge register. The 
majority of the studies are retrospective, with only very few 
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conducted prospectively. The prospective study detailed below 
was based on clinical database and pyridostigmine registers 
rather than follow up of newly diagnosed myasthenia patients 
(Santos et al) (95). Despite the differing methods and 
heterogeneity, when Carr et al did a meta-analysis in 2010, they 
were able to calculate crude estimates which still showed a 
rising incidence rate and prevalence rate. 
In 1900, when Campbell and Bramwell surveyed the literature 
and added one case of their own, they identified 60 cases of 
myasthenia gravis, three of which involved patients who were 
older than 50 years at the onset of the disease. By 1953 
Schwab and Leland reported that 62% of women and 27% of 
men with MG were younger than 30 years at the onset of the 
disease. The corresponding figures reported by Simpson et al in 
1966 were 49% women and 23% men. In both studies the 
disease was uncommon among younger men with the majority 
of male patients being older than 60 years. Men with MG formed 
two groups, one with the peak age at onset between 25 and 35 
years, and the other between 60 and 70 years. These 
observations were reflected in the standard textbooks of 
neurology at the time (Aarli et al, 1999)(96, 97).  
In 1996 Lawrence Phillips et al published a literature review of 
evidence of increasing prevalence of myasthenia gravis. They 
included 33 studies from 1952 to 1995 and found that 
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prevalence and incidence rates increased over time but the 
regression line for prevalence significantly exceeded that for 
incidence. The mortality rates had declined slightly over time. 
They concluded that the prevalence of MG had increased over 
the past 45 years, probably because patients with the disease 
had a longer lifespan owing to improvement in treatment. 
(Phillips et al,1996)(98). 
In 2003 Angela Vincent et al published a paper on 
underdiagnosis of MG in older patients. They identified patients 
only by a positive AChR antibody test using data of all UK 
centres registered for the assay during 1997 to 1999. 3183 
individuals had positive AChR antibody tests giving an annual 
incidence of 1.8 per 100,000. The age-specific incidence in both 
sexes rose steeply between the ages of 45 and 74 reaching 9.9 
per 100,000 in men and then fell with a sharp decline above the 
age of 80. In the prevalence study based on community 
controls, there was only one serum from individuals aged 60 to 
74 years which was positive for AChR antibodies (0.12%); Sera 
from 8 individuals aged ≥75 years were positive (0.7%), only 
one had a previous clinical diagnosis of myasthenia gravis but 
others had histories of stroke or transient ischaemic attacks. 
This suggested that either myasthenia gravis has a temporary 
peak in incidence in the older age groups which then falls off, or 
that the diagnosis is being missed in many older individuals, 
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particularly in those over 80 years of age (Vincent et al, 
2003)(99). 
In 2010 Carr et al(1) published a meta-analysis of all studies 
done to date on the incidence rate (IR), prevalence rate (PR) 
and mortality rate (MR) of myasthenia gravis. Population-based 
epidemiological studies of myasthenia gravis were included and 
cases without a defined denominator population were excluded. 
55 studies were selected for inclusion in the review; these 
included 8033 cases from 1.7×109 person-years studied. The 
time period studied ranged from 1950 to 2007. There was a 
wide geographical distribution of studies with representation of 
all continents except Australia. The incident rates ranged from 
1.7 to 21.3 cases per million person years. AChR MG IR ranged 
from 4.3 to 18 per million. Only two epidemiological studies had 
been performed to date on MuSK MG in Holland and Greece. In 
Holland IR was 0.1 per million person years and in Greece it 
was 0.32 per million person years. 
Linear regression of IR against the final year of study suggested 
a significant correlation equivalent to 3% increase per year (p= 
0.0001). The average incidence rate after 1976 (eIR = 6.5 per 
million person years) was significantly higher (p = 0.0001) than 
before 1976 (eIR = 3.5 per million person years) corresponding 
to an approximate doubling. A bimodal distribution of IR in 
females was observed in 5 of 14 studies. IR in both sexes 
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increased with age peaking between 60 to 80 years in all but 
two studies with apparent male predominance in the older age 
group. The Asian study by Yu et al (100), who looked at the 
point prevelance of MG in the whole territory of Hong Kong, 
stood out, in that the proportion of childhood onset MG (onset 
less than 15 years) appeared to be higher in this population. 
The observed prevalence rates (PR) ranged from 15 to 179 per 
million persons. The prevalence of AChR MG ranged from 70.6 
to 163.5 per million persons. The observed prevalence for MuSK 
MG in southern Holland is 1.9 per million persons representing 
2% of prevalent MG cases in the region; MuSK MG PR in 
Greece is higher at 2.9 per million persons. 
The mortality rate (MR) ranged from 0.06 to 0.89 per million 
person years. The MR for AChR MG in Greece lies within this 
range: 0.43 per million person years. No trend was observed for 
MR with year of study. 
The heterogeneity across the studies in this review was marked. 
Although there was a huge degree of dissimilarity, crude 
estimates were possible. They showed all MG eIR of 5.3 per 
million person years with the range of 1.7 to 21.3, ePR of 77.67 
cases per million person years, AChR MG eIR of 7.3 per million 
person years- range: 4.3 to 18, PR range 70.6 to 163.5 per 
million, MuSK MG IR range of 0.1 to 0.32 per million person 
years, PR range 1.9 to 2.9 cases per million. An increasing trend 
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in IR and PR over time was observed. PR was on average 15 
fold higher than IR across studies. It is notable that no detail was 
available on seronegative MG (Carr et al, 2010). 
An Italian study looking at cases retrospectively (using the 
complete inumeration process by examining all possible sources 
of MG cases) from the Ferrara province in Italy between 1985 
and 2007 showed a mean annual IR of 18 per million without 
any significant temporal trend. The incidence rates in the period 
1985 to 1990 were 14 per million persons both for early and 
LOMG. Thereafter a significant increase in incidence of LOMG 
(P <0.05) and a decrease in early-onset MG were detected (P 
<0.01). These findings were related to non-thymomatous MG. 
The median age at onset of the disease steadily increased over 
time. A changing pattern of MG incidence with an increase in 
frequency of LOMG and a decrease of EOMG was found in the 
last years giving a significant shift to older age at onset of the 
disease. (Casseta, 2010)(101). 
Another epidemiological study published in 2011 in Trento, Italy 
used data from sources including discharge diagnosis, antibody 
tests and anti-choline esterase drugs and was a replicate of the 
previously published study by Casseta et al looking at the same 
region/population group. These were analysed and the 
incidence was calculated from 2005 to 2009. The incidence and 
prevalence were greatly increased in comparison with the 1981 
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to 1990 data. The prevalence rate increased from 82.9 in 1990 
to 129.6 per million population whereas the average annual 
incidence had increased from 7.4 per million person-years in 
1981-1990 to 14.8 in 2005 – 2009. This increase was mainly 
due to increase in patients with late onset MG. (Pallaver et al, 
2011)(102). 
A Taiwanese (retrospective) study published in 2010 identified 
cases from the National health insurance research database 
from January 2000 to December 2007. IR of males to females 
was 0.68. The average annual IR was 2.1 per 100,000 
population per year, MG occurred in all age groups, with higher 
incidence in older individuals and lower incidence in the 10 to 
14-year-olds for both sexes. Among the 5211 cases 12% had a 
neoplasm of the thymus. The prevalence increased steadily 
during the study period from 8.4 per 100,000 in 2000 to 14 per 
100,000 population in 2007 (Lai et al, 2010)(103). 
A Japanese nationwide (retrospective) survey of myasthenia 
gravis was published in 2011. This showed a prevalence of 11.8 
per 100,000. Elderly onset myasthenia gravis, which they 
defined as onset over the age of 65 years, accounted for 7.3% 
in 1987 but this had increased to 16.8% in 2006. Infantile onset 
MG accounted for 10.1% in 1987 and was still as high as 7% in 
2006. The rate of ocular MG was highest (80.6%) in infantile 
onset and lowest (26.4%) in early onset disease but the rate 
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rose again in the late onset group. Anti-acetylcholine receptor 
antibodies were positive in only 50% of infantile onset but nearly 
90% of elderly onset patients. Only 0.7% of cases had a family 
history of MG while 3% had a family history of autoimmune 
disease. The frequency of familial MG was high (2.38%) in the 
infantile onset group but did not reach statistical significance. 
(Murai et al, 2011)(104). 
An epidemiological study of myasthenia gravis was performed 
retrospectively in Australia and published in 2012. They utilised 
prescriptions for pyridostigmine in 2009 from a national 
prescribing database to estimate the incidence and prevalence 
of symptomatic myasthenia gravis and treated disease. They 
found that in 2009 there were 2574 prevalent cases of 
symptomatic treated myasthenia gravis corresponding to an 
annual crude prevalence rate of 117.1 per 1 million residents. 
There were 545 incident cases yielding a crude incidence rate of 
24.9 per 1 million residents. The crude incidence in women and 
men was estimated to be 27.9 and 21.9 per 1 million 
respectively (105).  
Prevalence and incidence rates were higher in women than men 
between the ages of 15 and 64 years and were higher in men 
than women in those older than 65 years. Rates peaked 
between the ages of 74 and 84 years declining thereafter. 
Compared with women, incidence was higher in men for cases 
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younger than 15 years of age. There were 1.9 female cases for 
every male case in those aged younger than 35 years of age. 
The ratio of female to male cases in those aged between 35 and 
64 years was 1.5:1 and there were 1.1 male cases for every 
female case in those over the age of 65 years. They suggested 
that the increasing prevalence and incidence of myasthenia 
observed in recent years likely reflected the improved longevity 
of populations in the developed countries. The declining rates in 
the very old were thought to reflect under-ascertainment. 
Myasthenia gravis in the elderly may be mistaken or masked by 
conditions such as stroke and myopathy, general frailty, 
symptoms of fatigue and weakness in non-neurological 
conditions such as heart failure and anaemia. (Gattelari et al, 
2012)(105). 
An Austrian epidemiological study of myasthenia gravis was 
published in 2012. They retrospectively looked at the yearly 
inpatient prevalence of myasthenia gravis from 1992 to 2009. 
The inpatient prevalence of 2009 was calculated as 8.0 and the 
population prevalence as 15.69 per 100,000 population. They 
observed a 2.2 fold increase in the inpatient prevalence between 
1992 and 2009, which was mainly due to a rise in the number of 
older patients (> 50 years). This could partly be accounted for by 
an ageing of the population as a whole and a rise in the age of 
hospitalised patients. However, after adjusting for demographic 
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factors an unexplained average yearly rise of 3.7-3.9% 
remained (Cetin et al, 2012) (106). 
A Danish (retrospective) study published in 2005 recorded the 
incidence of myasthenia gravis from 1970 through to 1999. The 
annual incidence rate of early-onset myasthenia gravis was 
constant at 3.5 per million, in late-onset myasthenia gravis the 
rate increased from 4.7 to 20.8 per million. The author 
hypothesised that late onset non thymomatous anti-
acetylcholine receptor antibody seropositive MG may be 
provoked by environmental factors (Somnier, 2005)(107). 
However, a further Danish study published in 2013 differed in 
their conclusion. They retrospectively looked at data from 1996 
to 2009 using a combination of diagnosis and prescription data 
from nationwide registers. They found an IR of 9.2 per million 
person-years overall, and 29.9% were classified as early onset 
and 70.1% as late-onset MG. Women predominated in the early 
onset (70.5%) but not in the late-onset group (44.4%). The 
incidence rate of EOMG was 4.2 and LOMG 18.9 per million 
person-years and it did not vary over time in the study period (P 
values for trend 0.54 and 0.15 respectively). They found that 
LOMG comprised a large proportion of all incident cases in 
Denmark, was more common in men than women, and it 
occurred with a stable incidence in the 14 year study period 
(Pedersen et al, 2013)(108). 
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The incidence of AChR antibody positive myasthenia gravis in 
South Africa was published in 2014. They were calculated from 
retrospectively collected positive AChR antibody laboratory data 
between 2011 and 2012 using the 2011 population census data. 
890 individuals were seropositive, giving an annual incident rate 
of 8.5 per million. Age standardised IR for early onset (less than 
50) and late-onset MG were 4.1 and 24 per million respectively 
and 4.3 per million for juveniles. IRs may be higher among 
children with African genetic ancestry (Mombaur et al, 
2014)(109). 
A retrospective prevalence and cost study of myasthenia gravis 
in Medicare beneficiaries sample published in the United States 
of America in 2015 estimated that the US prevalence of MG was 
20 per 100,000 between the years 2011 to 2013. The male and 
female prevalences were 68 and 87 per 100,000 respectively. 
On average male patients were older than females by 2.66 
years (p = 0.01) and were less likely to be receiving Medicare 
disability benefits. Female MG patients were more frequently in 
the highest category for inpatient stays and ER visits (Gordon et 
al, 2015)(110). 
A Portuguese study published in 2016 looked at the northern 
region of Portugal. They used two complementary approaches 
to identifying patients: one was a hospital clinical database 
and/or clinical records of neurologists of the participating 
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hospitals and second was a computerised database of 
pyridostigmine prescriptions by the GPs working in the North 
region. The data was collected prospectively; all patients who 
had disease onset and diagnosis of MG through the end of the 
study period were included. In December 2013 they found that 
the point prevalence was 111.7 patients per million population. 
The highest prevalence was observed in the >65 years age 
group especially in men. During 2013 they estimated an 
incidence rate of 6.3 per million per year.  Among women, the 
incidence rate was highest in the 15 to 49 year age group; in 
men, incidence increased with age up to 22.1 per million in 
those >65 years. The MG related MR was 0.5 per million 
(Santos et al, 2016)(95). 
A Canadian (retrospective) study was published in 2016. They 
performed a population-based epidemiological research study in 
Ontario. In 2013 there were 3611 prevalent cases of myasthenia 
gravis in Ontario. Crude prevalence rate was 32 per 100,000 
population. The age and sex standardised prevalence rates rose 
consistently over time from 16.3 in 1996 to 26.3 in 2013. 
Standardised incidence rates remained stable between 1996 at 
2.7 per 100,000 and 2013 at 2.3 per 100,000. Incidence was 
highest in younger women and older men and geographic 




A retrospective study published in 2016 estimated the incidence 
and prevalence rates of myasthenia gravis using the Korean 
national health insurance claims between 2010 and 2013. In  
2011 there were 1236 incident cases, the standardised 
incidence rate was 2.44 per 100,000 person-years, the 
standardised prevalence rates was 9.67 and 10.66 per 100,000 
persons in 2010 in 2011 respectively. The incidence and 
prevalence rates peaked in the elderly population aged 60 to 69 
years for both sexes (Park et al, 2016)(112). 
Another Korean study (also retrospective) published in 2016 
looked at health insurance review and assessment data from 
2010 to 2014. They quoted a prevalence of MG rate of 10.42 per 
100,000 population in 2010 and this increased every year to 
12.99 per 100,000 in 2014. The average incidence of MG 
between 2011 and 2014 was 0.69 cases per 100,000 person-
years. The prevalence and incidence was higher in the older 
(≥50 years) age group than in the younger (< 50 years) age 
group (Lee et al, 2016)(113). 
A cross sectional study published in 2017 looked at myasthenia 
patients from Norway and Netherlands. They looked at the 
prevalence and clinical aspects of immigrants with myasthenia 
gravis. They found no marked differences in prevalence 
between immigrants and native ethnic groups. MG with MuSK 
antibodies and MG with thymoma were more frequent in Asian 
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immigrants compared with other ethnic groups (8% versus 0 - 
4%; and 21% versus 6 - 10%) respectively. (Boldingh et al, 
2017)(114). 
In 2017, epidemiological data was published from the Catalan 
County of Osona in Spain. The data from a prospective MG 
register were looked at retrospectively for the year 2013. They 
showed a prevalence of myasthenia gravis at 32.89 per 100,000 
inhabitants. The standardised prevalence was 35.47 per 
100,000; the ratio of women to men was 1.3. Overall the group 
of patients older than 65 years accounted for 62.75% of all 
cases. The prevalence of myasthenia gravis increased 
considerably in older age groups, no cases were registered 
among patients under 25 years, prevalence was 21.87 per 
100,000 in the 25 to 64 age group and prevalence in patients 
over 65 years increased to 122.35 per 100,000. The figures 
showed the highest prevalence rate reported to date in Spain 
and the highest prevalence was due to the rate observed among 
patients older than 65 years (Aragones et al, 2017)(115).  
A retrospective nationwide epidemiological study of myasthenia 
gravis in Latvia was published in 2017. They looked at data from 
the Central statistics bureau between January 2010 and 
December 2014. Myasthenia gravis as a diagnosis was 
confirmed in 99 new presenting patients of whom 70% were 
women and 30% were men. 61.1% of the patients were 50 or 
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more years old at the time of onset. The total crude incidence 
was 9.7 per million person years, for women this was 12.5 and 
for men it was 6.1. Crude as well as standardised incidence 
rates were significantly higher for women than for men. The 
incidence of late-onset myasthenia gravis was significantly 
higher than the incidence of early onset myasthenia gravis, 15.2 
and 6.2 respectively. The incidence for women was significantly 
higher than that for men, 10 and 2.5 respectively. There was no 
significant difference in the incidence between the genders in 
late onset MG group, 15.7 and 14.4 for women and men 
respectively (Zieda et al, 2017)(116). 
A retrospective Israeli study published in 2017 looked at the 
differences in clinical presentation of myasthenia gravis in 
different ethnic origins. They found that the frequency of age of 
MG onset was distributed in a bimodal fashion in the female 
patients and increased gradually over time, with a peak around 
70 years of age in male patients. Ocular MG was more frequent 
in males and Ashkenazi (ASH) patients. Male patients had a 
higher proportion of positive serum AChR antibodies than 
female patients, with no ethnic differences in the rates of anti-
AChR or MuSK antibodies. Comorbidity with another 
autoimmune disease was more frequent among female patients 
with late onset MG and non-Ashkenazi (NASH) patients. Male 
MG patients tended to have more malignant comorbidities than 




1.5.2 Genetics in MG 
The first report of HLA association with MG was published in 
1976 (118). Since then, there have been several studies 
showing HLA associations in MG: DQB1*05:02 (119), DRB1*03, 
DRB1*04, DQB1*02 and DQB1*03 (120, 121). In Chinese 
population DRB1*09 was associated with MG while the 
DRB1*08 was protective (97, 122). 
A genome wide association study (GWAS) published in 2012 on 
North Europeans identified a class I SNP rs7750641 as the 
strongest signal in MG. It also identified HLA-B*08 as a major 
risk allele. There was a risk association for HLA-C *07:01. The 
same study also showed a strong LD between HLA-C*07:01 and 
HLA-B*08 (123). 
Age of onset effects of HLA in MG have shown mixed results. 
Multiple studies have reported the extended HLA haplotype 
namely A1-B8-DRW3-DQ 2 as being associated with EOMG in 
European ancestry; however it is unclear whether the signal 
maps in class I or class II genes (124-126). SNP rs1800629 has 
been linked to higher expression level and higher serum levels 
of TNF α in MG (127). In a Norwegian population the 
DRB1*13:01 was found to be protective for EOMG (128), 
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whereas a GWAS performed in the European population found 
a peak of association for EOMG and DQ A1(129). 
The Norwegian study identified DRB1*15:01 as being 
associated with the risk of LOMG whilst DRB1*13:01 was found 
to be protective in LOMG. In an Italian cohort, DQB1*05:02 and 
DRB1*16 were associated with LOMG and Renton et al found 
an association for LOMG at HLA-DQA1(130). 
Four studies found an association of DQ5 with MuSK positive 
MG (131-134) and another Turkish study found an association 
with the DRB1*14 and DRB1*16 in MuSK MG (133) whereas 
DRB1*13 was found in a Serbian study (134) (Misra et al) (135). 
A Chinese study showed an increased risk of EOMG with 
PTPN22R620W polymorphism (Xiong et al) (136). 
A genome wide Association study (GWAS) of MG was published 
in 2015. DNA was obtained from 1032 white caucasians from 
North America who had AChR receptor positive MG and 1998 
race/ethnicity matched controls were also recruited. The 
samples were genotyped. An independent cohort of 423 Italian 
patients and 467 Italian controls were also used. They identified 
association signals at CTLA4, HLA-DQ 1, and TNFRSF11A. The 
findings were duplicated for CTLA4 and HLA-DQA1 in the Italian 
cases and controls. Further distinct but overlapping disease 
associated loci were seen in EOMG and LOMG. In EOMG there 
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were two associated peaks- one in TNFRSF11A and another in 
the MHC on chromosome 6p21 (HLA-DQ1). Association with the 
major histocompatibility complex (MHC) was also observed in 
EOMG cases-HLA-DQ1. The single nucleotide polymorphisms 
were different in EOMG compared to LOMG (129). 
In 2016, Seldin et al published a GWAS on single nucleotide 
polymorphisms (SNPs) in 532 AChR Ab positive LOMG patients 
and 2,128 controls. Their data confirmed the association of 
LOMG with TNSFRF11A, and identified a novel candidate gene, 
ZBTB10. Other SNPs which were thought to be significant were 
rs2476601 encoding the PTPN22 R620W variant in EOMG. 
EOMG associated SNPs in TN1P1 did not show any association 
with LOMG. Many SNPs in the MHC region showed strong 
associations in LOMG but not in EOMG, and the associations 
were in opposite directions.The MHC regions showed three 
distinct peaks for LOMG corresponding to (a) MHC class II 
(DQA1) (b) HLA-A and (c) MHC class III SNPs (137). 
 
1.5.3 Familial MG 
Familial occurrence of myasthenia gravis is estimated at 
approximately 1 to 4%. Familial MG (FMG) tends to occur at a 
younger age and elderly onset FMG has been rarely reported. 
Ramanujam et al estimated that the MG concordance is 
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between 30% and 40% in monozygotic twins compared with 4% 
to 5% in dizygotic twins (138). Similar rates of concordance 
were found in a survey done in Europe and USA. 
Salvado et al from Spain investigated the presence of familial 
cases in 462 MG patients. 16 cases from eight unrelated 
pedigrees were identified. The prevalence of FMG was 3.6% 
and the age of onset was 57.8 yrs, with six ocular patients, four 
MGFA class IIA, four IIB, one IIIA and one IIIB. Two patients had 
thymomas. The MGFA PIS did not differ from sporadic 
autoimmune myasthenia gravis. There was interfamilial 
heterogeneity and also members of the same family affected 
with FMG presented at different ages of onset, severity and 
thymus involvement (139).  
Hirunagi et al reported a case of two siblings with elderly onset 
myasthenia which they defined as being over the age of 65 
years. Both the patients and one unaffected sibling shared the 
same HLA haplotype. Patients developed generalised MG with 
elevated serum anti-AChR antibodies in their 70s. No other 
autoimmune disease was reported in the family and serum 
AChR antibody titres of the other members was normal (140). In 
the case presented by Hirunagi et al, unaffected siblings also 
had HLA-DR15 as did the patients, implying that the disease 
susceptibility is defined not only by HLA-DR but also by other 
genetic factors including gene-gene interactions. 
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Previous FMG studies have shown an earlier age of onset, 
slower progression and lower incidence of peripheral muscle 
involvement compared with sporadic MG. In a previous study in 
the US, 52/134 FMG patients presented with symptoms after the 
age of 18 years (141). In a nationwide epidemiological survey of 
MG in Japan, 2.4% of infantile onset patients had a family 
history of MG wheras only 0.4% of elderly onset patients had a 
family history (104). HLA-DR15 was significantly increased in 
patients with late-onset MG compared with patients with early 
onset MG in a Japanese cohort and HLA15, HLA-DRB1 * 15:01 
was seen in late-onset MG patients in a Norwegian cohort. 
Liu et al published a population-based family study from Taiwan. 
the relative risk (RR) for MG for patient siblings was 17.85, 
parents was 5.334, offspring was 5.82, and spouses without 
genetic similarities was 1.42 (142).  
There was a case report by Chung et al of monozygotic twins 
who had mirror-image myopic anisometropia with ocular 
myasthenia gravis (143). 
 
1.5.4 Viral infection and MG 
Viruses have long been thought to have a role in inducing 
autoimmunity in MG. Cavalcante et al studied EBV virus in 
thymoma associated MG. They looked for EBV markers in MG; 
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EBV DNA and EBV-encoded small nuclear RNA 1 (EBER) 
transcript were detected in 14/26 i.e. 52.8% and 22/26 i.e. 
84.6% of MG thymoma and only 3/14 i.e. 21.4% in non-MG 
thymomas. Latent EBNA2 and late gp350/220 lytic transcripts 
were undetectable in all but one thymoma. EBER 1 and 2 
positive cells were detected in MG but not in non-MG 
thymomas, as well as cells expressing EBV latency proteins 
(EBNA one, LMP1, LMP A) that were mainly of the cell 
phenotype indicating EB association with MG rather than the 
thymoma. TLR 3 transcriptional levels were higher in MG than 
non-MG thymomas and positively correlated with EBER 1 levels 
suggesting a role for EBER in TLR 3 activation. The findings 
showed that EBV is commonly present in thymoma infiltrating B 
cells of myasthenia patients indicating a contribution of EBV to B 
cell-mediated autoreactivity e.g. in MG associated with thymoma 
(144). 
The same group also published data on toll -like receptors 7 and 
9 in MG and showed that TLR7 and TLR9 mRNA levels were 
significantly higher in EBV positive MG compared to the EBV 
negative normal thymus (60). 
In contrast, a Chinese study by Jing et al showed that in a study 
of 30 MG thymic specimens, all were negative for both EBV-
encoded small RNA 1 and EBV latent membrane protein 1. 
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Their results did not support the role of thymic EBV infection in 
MG pathogenesis (145). 
Greco et al looked at seropositivity for West Nile virus (WNV) 
antibodies in MG patients. They looked at 29 patients with 
confirmed MG with AChR antibodies and screened them for 
anti-WNV antibodies. They found positive signals for anti-WNV 
IgG in 17% of MG patients although no clinical manifestations 
related to WNV infection were reported. They postulated that in 
predisposed individuals WNV infection could represent an 
additional risk factor for MG initiation (146). 
Hsu et al looked at a Chinese cohort of patients to assess the 
risk of MG in patients with scabies which is an infectious and 
inflammatory pruritic skin disease. They found that scabies 
patients had a significantly increased risk of MG and proposed 
that prompt diagnosis and treatment of scabies may decrease 
the risk of MG (147). 
Seok et al reviewed MG patients in Korea to look at the effect of 
influenza infection and vaccination on exacerbation of MG. In 
patients who had influenza-like illness, 40% had aggravation of 
MG symptoms, whereas only 1.5% had aggravation of MG 
symptoms following influenza vaccination. The rate of symptom 
aggravation was significantly higher in patients who had 
influenza -like illess than in those with common cold. The results 
suggested that the potential risk of aggravating autoimmune 
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diseases is higher for influenza-like illness than for influenza 
vaccination which suggests that influenza vaccination can be 
offered to patients with MG (148). 
 
1.5.5 Demographics in MG 
For a long time and it was thought that myasthenia gravis 
affected young adults and that it was uncommon after the age of 
50 years. During the 1990s it became clear that myasthenia 
gravis was being diagnosed more often in older patients. In 
1980 Compston and colleagues postulated two categories of 
non-thymoma myasthenia patients, one with presentation at less 
than 40 years of age and one after 40 years of age. Those who 
were younger were more often female, and had HLA-A1, B8, 
and DRW3 positive antigens. In the older age group there was a 
significant association with male gender and the presence of 
HLA-A3, B7 and/or DRW2 (97). In 1991 Somnier and co-
workers reported a bimodal appearance for both sexes with one 
peak in the early onset group and another in the late onset 
group. On the basis of this, they proposed that the separation 
between early onset and late onset should be at the age of 50 
years rather than 40 years. They found that in early-onset male 
patients, the onset was approximately 10 years later than in 
females, while in the late onset group the peak was at the same 
time in years in both sexes. 
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Diagnosis of myasthenia gravis in the elderly is difficult. Ageing 
causes sagging of the eyelids, particularly in men, and the size 
of the total eyelid fissure shortens in older age. Vision 
deteriorates because of other causes such as cataracts and 
macular degeneration making it difficult for patients to pick up on 
diplopia. Cerebrovascular disease is more commonly diagnosed 
when patients present with symptoms of dysarthria or 
dysphagia. Existing conditions such as cardiac or respiratory 
disease and hypertension worsen the condition (96).  
Limburg and colleagues (149) and Mantegazza and colleagues 
(150) found an association between AChR antibody levels and 
age of onset. Late-onset was associated with lower 
concentrations of AChR antibodies and they also had antibodies 
to striated muscle. The younger patients had the same level of 
AChR antibodies irrespective of when they were examined. 
Patients without thymoma and age of 40 years had lower values 
of AChR titres. In MG with thymoma, the concentration of AChR 
Abs was higher. 
Most data indicate that MUSK antibodies are more common 
among younger MG patients. Evoli and co-workers found a 
disease range of onset from 6 to 68 years. The mean age of 
onset was similar, however MUSK positive disease was more 
frequent in younger patients with 56.8% presenting at under 40 
years of age (151). This was not reflected in all studies however; 
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Deymeer and colleagues showed that the age of onset was 
similar between seronegative ACHR and MUSK groups (152). 
Stickler and co-workers showed that MUSK antibody positive 
patients were more frequently female, younger and African-
American and they seem to have a more limited distribution of 
single fibre EMG abnormalities (153). 
Titin antibodies are seen very commonly in late-onset 
myasthenia gravis without thymoma. This is seen in about 50% 
of patients and they are extremely rare in early-onset 
myasthenia gravis. They have never been reported in 
seronegative myasthenia patients. In the early onset group Titin 
abs serve as a marker for thymic neoplasia. 
In Johan Aarli’s paper of 2008, he has suggested that late-onset 
myasthenia is seen only slightly more often in men than women, 
with a ratio of female : male of 3:1 in the early onset and 1:1.1 in 
late onset, whereas Evoli and colleagues stated a ratio of 
female: male of 1:1.9 in the late onset group. 
 
1.5.6 Clinical presentation of antibody subtypes in MG 
A review of the literature suggests that the clinical presentation 
may vary depending on the presence of antibodies and the type 
of antibody. Guptill et al (2010) studied 110 patients with MuSK 
Ab positive generalised myasthenia gravis. This was a 
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retrospective study of all the patients with MuSK MG from two 
clinics in Rome and USA. The mean follow up was 11 years for 
the patients from Rome and 5.3 years for those from USA. Of 
the AChR negative patients, , 39-49% had anti MuSK Ab;85% of 
the MuSK MG patients were female, with onset in the fourth 
decade. 79% of the MuSK positive patients had ocular and/or 
bulbar involvement at onset of the MG. 36% had ocular 
symptoms only at onset but all generalised (NB: some within 2 
weeks and some after 4 years). 85% had MGFA classification of 
III or above, 28% had myasthenic crisis, 93% showed 
improvement with plasma exchange and 61% showed 
improvement with iv Immunoglobulins (iv Ig). Thymectomy was 
done in 36% of the patients and only one had a thymoma. Half 
of the thymectomised patients had a MGFA-PIS of MM or better 
(These patients were also on immunosuppressants) (154). This 
was a large cohort retrospective study but was not unbiased or 
population based. This gives a good clinical description of the 
generalised MuSK MG patients; but, only generalised 
myasthenia patients were included. Where patients were 
classed as having ocular symptoms only at onset, there was no 
clear diagnositic criteria for ocular myasthenia. Whilst 
thymectomy was reported to be beneficial, there was no 
comparison between those thymectomised and those that were 
not. MuSK Abs were tested on RIA, but not on CBA, potentially 
missing some of the MuSK positive GMG patients. 
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Zivkovic et al (2012) (155) described the characteristics of 
LOMG in a retrospective cohort of 174 patients, all seen in the 
neuromuscular clinics in one centre. Patients with thymoma 
were not included. Out of 174 patients, 66% were LOMG 
patients, AChR Ab were positive in 78% (65% in EOMG and 
85% in LOMG), anti MuSK Ab were positive in 38% (similar in 
EOMG and LOMG). 13% of patients had myasthenic crisis and 
this was the same in EOMG and LOMG groups. Ocular 
myasthenia gravis (OMG) was found to be more common in 
LOMG vs EOMG (40% vs 18%). Although a large cohort study, 
there is no description of how the patients were selected, and is 
unlikely to be unbiased. Patients with thymoma were excluded, 
which as we know from other published literature, is more 
common in LOMG. This would suggest that the data is 
potentially skewed, missing out on the older MG patients with 
thymomas. 
Suzuki et al in 2011(156) retrospectively looked at 260 
Japanese patients with myasthenia gravis. They found that 
OMG was more frequent in LOMG than EOMG (67% vs 33%) 
and 68% of the EOMG patients were female with 58% of LOMG 
patients being male. Of the 260 patients, 62 had thymoma and 
they were divided into early onset and late-onset groups with a 
cut-off of 50 years. Thymoma was more frequent in the late 
onset compared to early-onset group. Anti-MuSK positivity was 
seen in 2 to 3% of the AChR negative patients and there was no 
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statistical difference with the presence of HLA-DRB1. Once 
again, a large cohort study from two big centres in Japan, but it 
is unclear if all consecutive patients were included and whether 
the catchment reflected the population in the area. It does 
however show a trend towards OMG in LOMG patients. 
Klein et al (2013) (157) analysed serum/plasma and thymic 
samples from 226 EOMG, 97 LOMG and 150 TAMG patients. 
The samples were obtained from other overlapping studies in 
the UK, thymic tissue from patients referred for thymectomy in 
Germany, and clinical information was obtained retrospectively. 
They found that EOMG patients more commonly had relatives 
with other autoimmune disorders (40%), less so in LOMG 
patients (20%) and even less in patients with Thymoma 
associated Myasthenia Gravis (TAMG) (8%). The patient groups 
were from different cohorts, but the study had large numbers 
and provided good data about associated autoimmune 
conditions. 
Huijbers et al (2014) (41) describe the different phenotypic 
presentations with various antibodies. AChR Abs were positive 
in 85% of MG patients, they had more ocular involvement, and 
generalised in a cranio-caudal distribution. MuSK Abs were 
positive in 8% of patients and they more commonly had 
Generalised MG with bulbar and respiratory involvement. LRP4 
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Abs were positive in 5% of patients and they more commonly 
had Generalised MG, sometimes with bulbar involvement. 
Blum et al (158) looked at 165 Australian patients with 
myasthenia gravis. The patients were recruited via a survey of 
303 patients with myasthenia who were asked to fill in a 
questionnaire. Only 198 responded and 33 of these were 
excluded due to lack of information. They found that patients 
with early onset myasthenia, which they defined as less than 40 
years of age, were frequently female and the elderly patients 
were more frequently male. Occurrence of other immune -
related diseases was seen in about 54% of patients. It is difficult 
to draw any conclusions from this study as it did not represent 
the prevalence or incidence of myasthenia. 
Teo et al published in 2017 (159) looking at conversion rates of 
ocular to generalised myasthenia gravis in Singapore. It was a 
retrospective case series of patients diagnosed with OMG at 
one neuro-opthalmology centre. OMG was defined as purely 
ocular symptoms ‘initially’, but no time limit was stated. Patients 
who generalised within one month of presentation were 
excluded. Follow up was for 2 years. They found that the 
conversion rates of ocular myasthenia to generalised 
myasthenia in Asian patients was low with a rate of 10.6% at 
median follow-up and at two-year follow-up it was 7.7%. This 
was predicted by the presence of acetylcholine receptor 
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antibodies, presence of thymoma and positive RNS studies. 
Given that the patients were all seen at one neuro-opthalmology 
centre, and that OMG was defined as ocular symptoms for 
≥1month, one would assume that the patients who did not 
present to hospital until much later with generalised symptoms, 
or who had early severe GMG were not included in the study. 
This would suggest that the data is skewed towards the milder 
phenotypes.  
A Chinese retrospective study of 41 patients in 2007 by Chan et 
al (160) showed that late onset patients were characterised by 
male predominance, absence of thymic follicular hyperplasia 
and higher striated muscle Ab positivity. There was no 
statistically significant difference in the clinical severity and 
outcome or response to treatment between the early-onset and 
late-onset groups. These patients were all AChR Ab positive, 
had GMG for at least 3 years and did not have radiological or 
histological thymoma. The recruitment was very restrictive which 
means that the results would not be applicable to LOMG as a 
whole. 
In 2017 Evoli et al published a paper with retrospective 
evaluation of 82 MuSK myasthenia patients with GMG who had 
ocular symptoms. Ocular manifestations were seen in 96.4% 
and it was the presenting symptom in 58.5%. They found that in 
myasthenia gravis with antibodies to MuSK, ocular 
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manifestations were as frequent as in other disease subtypes. 
Symmetrical ophthalmoparesis with conjugate gaze limitation 
was common and a proportion of these patients developed 
chronic eye muscle paresis (161). Evoli et al studied 78 patients 
with SNMG all of whom had GMG, using seropositive MG 
controls and healthy controls. Thymic tissue was available from 
29 patients. MuSK Abs were detected in 37/78 (47.4%). 
Myasthenia with anti-MuSK antibodies were reported to be 
characterised by prevalence of female patients, age of onset 
between 6 - 68 years with 56.8% presenting under 40 years of 
age. They had a similar pattern of muscle weakness with 
predominantly cranial and bulbar muscle involvement and 
frequency of respiratory crises. The limb muscles were less 
severely involved. They did not find any association of thymic 
abnormalities in the study (Evoli et al, 2003). Most patients had 
developed permanent facial and pharyngeal weakness with 
some atrophy of facial muscles (151). Both these studies 
provide useful clinical phenotyping of MuSK MG, but do not 
comment on ocular to generalisation rates. Also, the MUSK 
antibody tests were performed using immunoblot (later 
confirmed on RIA in the study by Guptill et al), but no CBAs 
were done. 
There have been reports of double positive myasthenia gravis 
patients with positivity to both ACHR and MuSK antibodies. One 
study published by Zouvelou et al looked at the five year follow-
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up of one such patient; this patient had mainly ocular and bulbar 
symptoms with MGFA classification of IIIB and responded 
quickly and appropriately to prednisolone. The patient was in 
pharmacological remission (PR) at four months (162). 
Antibodies to clustered AChR on cell based assays were first 
described by Leite et al in 2008. The study was done on 
previously collected serum samples from 65 patients with 
generalised myasthenia gravis. These were retested for AChR 
and MuSK antibodies using RIA. Of these, 24 patients were 
seronegative. They also studied thymic tissue from 14 
seronegative myasthenia gravis patients who had been 
thymectomised. Amongst these patients, clustered AChR Abs 
were present in 11/14. For the seronegative myasthenia 
patients, and for those with AChR MG low samples, there was a 
significant correlation between binding to AChR clusters and the 
percentage of thymic tissue with infiltrates. Seronegative 
myasthenia gravis patients who were positive on clustered cell 
based assay had a similar antibody mediated disease to those 
with AChR MG on RIA, and also frequently had thymic changes 
(163).  
Further studies on antibodies to clustered AChR in ocular and 
generalised myasthenia gravis were done by Jacob et al and 
published in 2012. This was a retrospective analysis of 
previously obtained serum samples from 16 patients with 
seronegative ocular myasthenia gravis and a further 28 patients 
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with seronegative myasthenia, 14 of whom had ocular 
myasthenia gravis. Eight of the 16 patients with seronegative 
ocular myasthenia gravis had clustered adult AChR antibodies 
similar to those in patients with GMG. The paper suggested that 
OMG was more common in patients with positive CBA 
compared to positive RIA. The numbers were small and the 
samples retrospective, but appropriate controls were used and 
they demonstrated a trend towards milder disease in patients 
with clustered AChR Abs (164). 
Devic et al studied 37 patients with seronegative myasthenia 
gravis from a French database, and analysed the samples using 
cell based assays. They found 16% to be positive for antibodies 
to clustered AChR. In half of these patients, ocular symptoms 
were predominant; bulbar involvement was seen in half of the 
patients, but never predominant. The maximum severity of MG 
classification ranged from MGFA II to III. No atrophy was found 
in the tongue or axial/limb muscles. Two out of the six patients 
were positive for AChR antibodies and had early-onset 
myasthenia gravis, which in this study was described as below 
40 years of age. One of these had a thymectomy which showed 
hyperplasia. Three patients had late-onset myasthenia gravis 
with thymic involution, and one patient had minimal ocular 
symptoms. The patients responded to variable levels of 
immunosuppression and all of them responded to intravenous 
immunoglobulin (165). The paper does not comment on whether 
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the database was all inclusive or not; if inferred that the data 
was inclusive, then this study provides useful data about 
positivity to AChR on clustered CBA in SNMG. 
Rodriguez Cruz et al in their paper of 2015 suggest that patients 
with clustered AChR antibodies generally have a relatively mild 
disease, and a high proportion have predominantly ocular 
myasthenia. This was based on the paper published by Jacob et 
al, and on unpublished observations. Patients with MuSK 
antibodies on cell-based assays only with negative RIA were 
predominantly young females with a median age of onset of 21 
years. Predilection for bulbar symptoms was noted at follow-up, 
but with MGFA grade < II predominantly, suggesting a milder 
phenotype (166). 
Rodriguez Cruz et al published a further paper which analysed 
sera on 138 patients retrospectively. They all had a diagnosis of 
seronegative myasthenia gravis for both AChR and MuSK 
antibodies on RIA. The diagnosis was based on clinical 
presentation and response to treatment, with or without 
electromyographic evidence. Out of the 138 patients, 51 had an 
uncertain diagnosis, and 45 had other diagnoses. 16 patients 
had positive AChR antibodies on clustered cell based assays. 
Of the 16, 10 were female, and 62.5% were children. The 
presentation was predominantly ocular in 62.5% with no 
generalisation during the follow-up period. Only 25% had bulbar 
symptoms and none had respiratory weakness. Thymectomy 
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was performed in one patient which showed no evidence of 
thymoma or lymphocytic infiltration. When the clinical 
characteristics of the 26 patients with seronegative myasthenia 
gravis with negative CBA results were compared to those with 
clustered AChR antibody positivity, the patients with clustered 
AChR antibody positivity had a younger age of onset and a 
trend towards milder disease, and a higher proportion attained 
clinical remission (167). The study included both paediatric and 
adult patient samples, and does not comment on EOMG/LOMG. 
The sample size is large in number, but tested retrospectively 
from stored sera. 
Huda et al published a paper in 2017 on their study of cell based 
assays for MuSK antibodies in seronegative myasthenia gravis. 
They studied the sera from 69 MuSK RIA positive patients, 169 
patients negative for MuSK RIA and AChR RIA, and 35 healthy 
controls, along with 16 NMDA receptor antibody-positive 
disease controls. They found that MuSK antibody CBA positive 
and RIA negative patients were predominantly female and 
presented at the median age of 25 years. In eight of these 
patients the disease was confined to the ocular muscles. When 
MuSK Ab CBA positive patients were compared with MuSK RIA 
positive patients (defined in the paper as definite MuSK MG), 
female preponderance was noted in both groups but the median 
age at onset was later in the MuSK RIA MG patients at 40 years 
of age compared with 25 years for the CBA positive patients. 
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Generalised myasthenia gravis was seen in all 69 patients with 
definite MuSK MG compared with 8/13 of MuSK CBA positive 
patients and neurophysiology was only positive in half of the 
patients examined in the MuSK CBA patients. Patients with 
MuSK CBA responded better to pyridostigmine with 75% 
showing a good response compared to 20% of those with 
definite MuSK MG, but immunotherapy appeared to be equally 
effective in both the groups. Their findings would suggest a 
milder clinical phenotype in patients who are MuSK RIA 
negative but CBA positive (168). 
There are several published studies on clinical phenotypes with 
different antibodies. All the studies are retrospective, many of 
them include large numbers with clear inclusion criteria and 
matched controls. The studies have shown that with AChR Abs, 
the presentation can be varied, and there is a trend towards 
OMG being more common in LOMG. MuSK Abs are more 
commonly seen in young females and they more commonly 
have bulbar symptoms. Patients who are seronegative on RIA 
but are positive on CBA are likely to have milder disease 
compared to those who are positive on RIA; this has been seen 
for both AChR and MuSK Abs. Whilst there is a large amount of 
literature on antibodies, what is lacking is a prospective study 




1.5.7 Ocular MG 
Ocular myasthenia gravis (OMG) is the most common form of 
MG and varying rates of secondary generalisation have been 
reported. Ocular muscles demonstrate relatively reduced safety 
factor and complement regulation, simplified postsynaptic 
structures, and increased susceptibility to toxins- all of which 
have been postulated as the reasons for predominantly ocular 
involvement in myasthenia gravis. Typically between 50 and 
80% of patients will develop generalised symptoms in the first 
two years and for this reason an arbitrary minimum duration of 
two years of isolated ocular symptoms is considered a 
reasonable limit for diagnosing of OMG. Oosterhuis suggested a 
minimum of three months as a limit for purely ocular symptoms 
before classifying a patient as having OMG (169).  Similarly 
Sommer et al (170) and Monsul et al (171) also suggested 
purely ocular symptoms for at least three months from symptom 
onset to class them as OMG. 
There have been several studies looking at the effect of 
prednisolone on the progression of OMG to GMG. Monsul et al 
looked retrospectively at 56 patients, 27 in the prednisolone 
treated group and 29 in the untreated group. The patient 
selection was from databases of the Yale neuromuscular and 
ophthalmology services. OMG was defined as purely ocular 
symptoms for at least 3 months from symptom onset. The 
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treatment group was defined as patients who had at least 3 
months of oral prednisolone. Patients who had treatment for a 
lesser duration were included in the non treated group. At two 
years their data suggested that significantly fewer patients in the 
treated group progressed to generalised myasthenia compared 
to the untreated group. They suggested that use of steroids may 
decrease progression of ocular to generalised myasthenia 
gravis (171). This was a retropsective study, and the patients in 
the two groups were age and sex matched; however, it does not 
tell us why some patients with OMG were treated whilst others 
were not. Some of the patients in the ‘non-treated’ group had 
some form of immunosuppression albeit for less than 3 months 
duration.  
These findings are reflected in another study by Zach et al who 
looked retrospectively at 44 patients (172) from one 
neuromuscular clinic. Their criteria to define OMG was purely 
ocular symptoms for at least one month. However, another 
study by Nagia et al looked retrospectively at 158 patients from 
a neuro-ophthalmology clinic and they found that the conversion 
rates from ocular into generalised myasthenia gravis may be 
lower than previously reported in both immunosuppressed and 
non-immunosuppressed patients (173). They also defined OMG 
as purely ocular symptoms for ≥1 month. There is potentially 
selection bias here as the patients were recruited from a neuro-
opthalmology clinic, and it is likely that the more severe/ 
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symptomatic patients would have been referred to the 
neurology/neuromuscular clinics. 
A study by Kamarajah et al (including the present author) looked 
at 93 patients from symptom onset. The study reflected the 
natural history of the condition as the patients were steroid naïve 
before generalisation. Of these, 46% of patients developed 
generalised symptoms during the study period which was 11 
years. The median time to generalisation was seven months. 
Time to generalisation was earlier in patients who were positive 
for AChR antibodies, had bilateral ptosis at onset and were 
younger than 50 years at disease onset (174). Whilst the 
patients were seen by a neurologist in a neuro-opthalmology 
clinic, it was not an unselected cohort. 
A study by Imai et al showed that a lower dose of oral 
prednisolone regimen with early combination of other treatment 
options may ensure an early achievement of the treatment 
target in GMG (175). 
 The EPITOME study which was an RCT designed to look at the 
efficacy of prednisolone for the treatment of ocular myasthenia 
was not completed as planned because of failure of recruitment 
of enough patients. They suggested that low-dose prednisolone 
with gradual escalation appeared to be a safe and well tolerated 
treatment for all MG (176). 
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In 2016, Wong et al published a paper on 101 patients with 
OMG recruited from two neuro-ophthalmology centres in 
London. They defined OMG as purely ocular symptoms for ≥3 
months.They proposed three predictors for generalisation of 
OMG: seropositivity (higher Ab titres had greater risk), presence 
of comorbidities (unrelated to age or autoimmunity) and thymic 
hyperplasia (weak association). A risk score (0-3) was 
calculated for each predictive variable and summed to give the 
overall risk score for the patient. The positive predictive value 
using this score was 38% and negative predictive value was 
91% (177). The patient recruitment was retrospective and the 
definition of OMG arbitrary as with all the studies so far. 
There have been no completed RCTs on the use of 
prednisolone in OMG. There have been no prospective clinical 
studies either. There is no consensus on the definition of OMG. 
Traditionally, OMG has been defined as ocular symptoms only 
for at least two years, but published studies have used a cut off 
of between 1 and 3 months. 
 
1.5.8 Investigations in MG 
Other than the standard diagnostic test for MG which is the 
serum antibody test, there are several other supportive 
diagnostic tests which can be performed. 
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The icepack test to diagnose MG was first published in 1979 by 
Saavedra et al. The possible physiological mechanisms of how 
cooling improves neuromuscular transmission are: (i) increased 
postsynaptic receptor sensitivity to ACh (178) (ii) facilitated 
transmitter replacement in the presynaptic terminal (179) (iii) 
efficient utilisation of ACh  (180) (iv) decreased hydrolysis of 
ACh by acetylcholine esterase allowing sustained action of the 
transmitter already released from the axon terminal (181) and 
(v) reduced rate of removal of calcium ions from the nerve 
terminal following stimulation (182) (Yamamoto et al) (183). 
Michael Benatar published a paper in 2006 after conducting a 
systematic review of all diagnostic methods used in MG. He 
found 3 studies describing icepack test for the diagnosis of OMG 
and 5 in GMG, all of which used case control study design The 
pooled estimates of sensitivity were 0.944 for OMG and 0.82 for 
GMG, specificity were 0.974 for OMG and 0.96 for GMG (184). 
Yamamoto et al performed trigeminal nerve RNS, excitation-
contraction coupling assessment, and bite force measurement 
before and after cooling of the masseters in 25 MG patients and 
normal controls. Of the MG patients, 4 had OMG, 21 GMG; 20 
were AChR positive, 1 MuSK positive; 11 were treatment naïve 
and 14 had exacerbation of MG symptoms despite steroids. Ice 
pack test on masseters was done initially and assessed 
subjectively using MG- ADL scores. The bite was increased 
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significantly after cooling in icepack positive MG patients, the 
acceleration and acceleration ratio of jaw movement increased 
significantly after cooling of the masseters in icepack positive 
MG patients compared to negative patients and normal controls. 
The prolonged effect of cooling continued until the end of the 
recording even though decremental response to RNS had 
returned to baseline value (183). Patient selection was not 
explained, but the patients and controls were age and sex 
matched. 
Park et al performed the icepack test on 26 patients with MG 
and 38 controls and assessed response of ptosis. The test was 
repeated two times on separate days. Repeated ice test results 
showed an agreement of 61.5% in MG and 97.4% in non-
myasthenic ptosis. Repeated ice test increased the rate of 
sensitivity by 34.6% compared to a single test (185). The 
patients were recruited from one neuro-ophthalmology centre 
and patient selection was not explained. 
Michael Benatar in his review of 2006 identified a single study 
examining the diagnostic accuracy of Tensilon test. There was 
poor methodology and the sensitivities reported 0.92 and 0.88 
for ocular and generalised MG respectively; Specificities were 
0.97 (184).  
Tsunoda et al have assessed the improvement of voice in one 
patient with MG using voice spectroscopy after injection of IV 
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edrophonium and found that there was a marked improvement 
confirming a diagnosis of MG (186). 
Various other diagnostic tools have been used including single 
breath count, electroglottography, ECG, oculo vestibular evoked 




Neurophysiological tests including repetitive nerve stimulation 
(RNS) and single fibre EMG (SFEMG) have been useful tools in 
diagnosing myasthenia gravis. In 2001 the American 
Association of electrodiagnostic medicine published a literature 
review on the usefulness of RNS and SFEMG in the evaluation 
of patients with MG or LEMS. They found that the results of the 
studies utilising RNS showed that a 10% decrement in 
amplitude from the first to fourth or fifth intravolley waveform 
while stimulating at 2 to 5 Hzs is valid for the diagnosis of MG. 
The degree of increment needed for the diagnosis of LEMS is at 
least 25% but most accurate when greater than 100%. 
Abnormal jitter or impulse blocking are the appropriate criteria 
for the diagnosis of NMJ disorders when using SFEMG. They 
also said that SFEMG was more sensitive than RNS for the 
diagnosis of NMJ transmission disorders; however, they may be 
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less specific and not easily available. Because of this, RNS was 
thought to be the preferred initial test for MG and LEMS (187). 
When Michael Benatar published his review in 2006 he found 
that there were several studies on RNS and SFEMG, however 
they were very heterogeneous and not comparable with each 
other (184). 
Liik et al looked at RNS in all consecutive patients with severe 
GMG at one hospital.They found that of the nine patients with 
acute onset GMG (<4 weeks duration), only one patient had 
abnormal decrement, whereas of the 32 patients with slow onset 
MG (≥4 weeks duration), 26 patients i.e. 84% had decrement. 
Concentric needle EMG jitter was abnormal in all patients. The 
AChR Ab status was comparable whereas the MGFA class was 
higher in the acute onset group. They concluded that RNS is 
frequently normal in cases of acute severe GMG including 
myasthenic crisis. The pathophysiology of this remains unclear. 
Concentric needle electrode jitter analysis was a much more 
useful tool in these cases (188). 
Bou Ali et al conducted RNS on 45 prospectively recuited MG 
patients from one centre; they tested 12 muscles bilaterally and 
found that the global sensitivity of RNS was 82% and specificity 
was 100%. The sensitivity in MG subgroups showed that in 
ocular MG it was 67%, oculobulbar MG it was 86%, and 
generalised MG it was 89%. The most sensitive muscles were 
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found to be the anconeus in the ocular group, orbicularis oculi or 
nasalis in the oculobulbar group, and trapezius in the 
generalised group. The maximum sensitivity was obtained by 
exploring the orbicularis oculi, trapezius and anconeus 
bilaterally. They suggested bilateral exploration of at least three 
muscles; a facial muscle, trapezius and anconeus (189). 
Nikolic et al published their results on the electrophysiological 
findings in patients with LRP4 positive MG in 2016. They 
prospectively recruited patients already diagnosed with MG. 
They conducted RNS and jitter analysis using concentric needle 
electrode in 17 LRP4 positive MG patients and compared it with 
31 MuSK positive patients and 28 AChR positive patients. They 
found that RNS was negative in almost all patients of the LRP4 
group, the seronegative group and in the LRP4 and MuSK 
double positive groups. It was positive most frequently in AChR 
MG group especially those who were not double positive for 
LRP4. The presence of anti-LRP4 antibodies was connected to 
lower decremental values whilst the independent presence of 
anti-AChR or anti MuSK antibodies was connected to higher 
decremental values. The lowest jitter was recorded in patients 
with LRP4 or seronegative MG. Highest percentage was present 
in MuSK and AChR MG patients. The mean consecutive 
difference (MCD) did not change in anti-LRP4 MG whilst it was 
high in AChR and MuSK MG. They concluded that LRP4 MG 
subgroup have rarely any pathological electrophysiological test 
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results (190). The study was not unselected, but good number of 
patients and controls were recruited. 
Abraham et al published a retrospective chart review of 75 MG 
patients. They found that high jitter and decremental values 
were associated with more severe disease, manifested by more 
frequent symptomatic bulbar and limb muscle weakness, more 
frequent ocular and limb muscle weakness on examination, 
higher quantitative MG scores and generalised disease. They 
found that electrophysiological assessment correlated with 
disease severity and the presence of generalised disease (191). 
Similarly, Sanders et al retrospectively reviewed the jitter and 
outcome data from all MG patients over a 32 year period, who 
had at least two jitter measurements in the extensor digitorum or 
frontalis muscle. Of the 789 patients with MG who had 
neurophysiological tests, 279 had at least 2 SFEMG studies. 
They found that absolute and percentage change in mean 
values of consecutive interval differences were equally accurate 
in predicting clinical change and were more accurate than 
change in the proportion of fibre pairs with blocking or normal 
jitter (192). 
Machado et al published a prospective study on 33 MG patients 
on the diagnostic accuracy of concentric needle electrode 
myography (CNEMG) jitter. They found that CNEMG jitter 
yielded high positive rates for ocular MG of 92.3% and GMG of 
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100% and showed high sensitivity and specificity rates (193). 
OMG was defined as patients who remained ocular for at least 2 
years. 
Nikolic et al looked at classical and quantitative EMG in 31 
MuSK and 28 AChR positive patients. It revealed the presence 
of myopathic changes more frequently in MuSK MG compared 
to AChR MG, especially in the facial muscles (194). 
 
1.5.8.2 Imaging  
Plain chest x-ray does not have a role in MG diagnosis due to 
low accuracy. Computed tomography (CT) is the imaging 
modality of choice although differentiation between a small 
thymoma and thymic lymphoid hyperplasia (TLH) may not be 
possible as they both appear as soft tissue masses. Magnetic 
resonance imaging (MRI) is not usually used but it could be 
useful when a CT scan is equivocal. MRI with DWI can 
differentiate lipid-poor normal/hyperplastic thymus from 
thymoma. Positron emission tomography (PET)-CT is not really 
helpful in distinguishing early from advanced thymoma, but can 
help to differentiate between thymic carcinoma from thymoma 




1.5.9 Antibodies in MG 
The first antibodies demonstrated in MG were by Strauss and 
colleagues who found the existence of anti-striated muscle 
antibodies (anti--SM). This is seen in 30% of all MG patients and 
nearly all patients with thymoma. 
Antibodies to the endplate protein i.e. acetylcholine receptors 
was first demonstrated by Alman, Andrew and Appel in 1973. 
They found that serum globulins from MG patients could inhibit α 
bungarotoxin (α-BuTx) binding to solubilised rat AChR 
receptors. 
Mittag, Kornfield, Tormay and Woo compared four different 
techniques of assessing AChR antibodies and found that 
immunoprecipitation of α-BuTx labelled AChR was the most 
effective (196). This was then described in detail by Lindstrom et 
al (197). Over the years several different studies were 
performed. Using subclass specific antisera, Vincent, Lang and 
Newsom-Davies found that most patients have anti-AChR with 
subclasses 1, and occasionally subclass 3. 
A systematic study of AChR antibodies in MG was published by 
Jon Lindstrom in 1976 (10). The assay was based on 
immunoprecipitation by the patient's IgG antibodies of detergent 
solubilised muscle AChR which were mainly obtained from 
amputated limb muscle and which had been labelled with 
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radioactive α bungarotoxin, a toxin that binds irreversibly to 
AChR. The assay is now available commercially for AChR 
autoantibody and MuSK autoantibodies where a carefully 
balanced mixture of detergent solubilised foetal and adult forms 
of the receptor are labelled with radioactive iodine labelled α 
bungarotoxin (Vincent) (11, 197).  
The other form of testing AChR antibodies is by using the ELISA 
method. Nguyen et al first published a paper in 1999 describing 
an enzyme-linked immunosorbent assay (ELISA) for AChR Ab 
detection. They use the AChRTE671 as the antigen. The test was 
shown to be specific and was able to detect AChR antibodies at 
concentrations as low as 3 nmol/l (198). Nonradioactive 
fluorescent immunoprecipitation assay (FIPA) has also been 
done with good results (yang et al) (199). 
The disadvantage of using a radioimmunoassay or RIA is that 
RIA cannot discriminate between antibodies to different channel 
components and cannot discriminate between extracellular and 
intracellular antigens. 
With the advent of MuSK testing in 2001(200), 70% of the 
patients who were negative for AChR Ab were found to be 
positive for MuSK. The remaining GMG patients were classed 
as seronegative MG (SNMG) patients. However there was 
increasing evidence that SNMG was similar to AChR MG in 
clinical picture, response to immunosuppressive treatment and 
91 
 
thymic pathology. The muscle biopsies in these patients also 
indicated loss of AChR and complement deposition similar to 
AChR MG. The possible explanation for this was that the RIA 
did not detect AChR antibodies because of loss of antigenic 
determinants in the solubilised AChR, or because the AChR 
antibodies have low affinity/ability for the soluble AChR.  
Leite et al in 2008 hypothesised that antibodies in SNMG 
patients could be detected by binding to AChRs on the cell 
membrane, particularly if they were clustered at the high-density 
that is found at the NMJ. They expressed recombinant AChR 
subunits with the clustering protein Rapsyn in human embryonic 
kidney cells (HEK) and these were tested for binding of 
antibodies by immunofluorescence. They detected AChR 
antibodies to Rapsyn clustered AChR in 66% of sera which were 
previously negative for binding to AChR in solution. These 
antibodies were mainly IgG1 subclass and they showed the 
ability to activate complement. They also used cell based 
assays to detect MuSK antibodies. These were mainly IgG4 but 
with partially IgG1 subclasses which were capable of activating 
complement bound to MuSK on the cell surface (163). 
Rodriguez Cruz et al looked at clustered cell-based assays in 
138 retrospectively recruited MG patients, mainly paediatric 
patients, and found that clustered AChR antibodies were 
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detected in 38.1% of RIA negative patients with MG with 100% 
specificity (167). 
Huda et al published a paper in 2017 on cell-based assays in 
MuSK positive MG patients. They looked at 69 MuSK positive 
patients (on RIA) with MG, 169 patients negative for MuSK RIA 
and AChR RIA i.e. SNMG, and 35 healthy controls. They also 
used 16 NMDA receptor antibody patients as disease controls. 
Initially, the MuSK CBAs showed low specificity with high 
positive rates in healthy controls and in the disease controls. 
This was thought to be due to anti-IgG (H + L) detection of IgM 
which bound non-specifically to MuSK. They then used an IgG 
Fc gamma specific secondary antibody to eliminate the IgM. 
Repeat CBAs showed that MuSK antibodies were detected in 
99% of definite MuSK MGs and in 8% of seronegative MG, and 
in none of the healthy controls or disease controls. This showed 
increased sensitivity with high specificity (168). 
Cell-based assays provide an excellent diagnostic tool, however 
they are relatively costly and time-consuming compared to RIA. 
Additionally, culture facilities and expertise with performing and 
interpreting the assays is required. CBAs do not provide a titre 
but are subject to measure of positivity based on visual 
interpretation and for this reason titres of antibodies cannot be 
used for monitoring disease activity as can be done with RIA 
(Rodriguez Cruz et al) (166). 
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Jacob et al retrospectively studied 16 patients with seronegative 
OMG to look for binding to clustered AChR. This was correlated 
with their SFEMG results. They found that about 50% of patients 
with previous SN-OMG had complement fixing IgG1 clustered 
AChR antibodies. The IgG binding and complement deposition 
correlated with the mean jitter on SFEMG. When they did their 
CBAs, they found that most of the clustered AChR antibodies in 
OMG were directed against the adult form of AChR and did not 
bind the foetal form which was different to most patients with 
AChR antibody-positive GMG who usually bind foetal forms. 
They suggested that complement fixation is likely to be an 
important pathogenic mechanism in patients with OMG (164). 
The French study by Devic et al looked at sera from 37 patients 
with SNMG using CBAs. 16% of the SNMG patients were found 
to have antibodies to clustered AChR. These included all clinical 
subtypes-EOMG, LOMG and TAMG (165). 
There have been papers suggesting that the relative lack of 
intrinsic complement regulators and the differential expression of 
foetal AChRs on extraocular muscles may be the reason why 
these muscles are more susceptible to autoimmunity in MG.  
It is not entirely clear why some MG patients develop only ocular 
symptoms and why extraocular muscle weakness usually 
precedes generalised muscle weakness. This is often explained 
by the increased susceptibility of extraocular muscles due to 
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their reduced endplate safety factor and lower complement 
inhibitor expression. Recent studies in animal models suggest 
that additional factors may be implicated. In EAMG studies, 
when AChR receptors carrying confirmational epitopes were 
injected into wild-type mice, this caused severe GMG whereas 
injection with recombinant unfolded AChR subunits containing 
linear epitopes induced ptosis without generalisation or mild 
generalised muscle weakness. 
A similar milder picture with ocular symptoms was seen in mice 
that were given deficient T-helper cell mediated antigen with 
recombinant AChR subunits or whole native AChR pentamer. 
Wu et al published their study results in 2017 and hypothesised 
that ocular symptoms observed in earlier stages of MG may be 
triggered by linear and non-conformational AChR epitopes 
which are expressed by the thymic cells or by microorganisms. 
This initial stage of autoimmunity may be managed by T-cell 
independent and B-cell mediated mechanisms which yields low 
affinity AChR antibodies. These antibodies are capable of 
inducing muscle weakness only in extraocular muscles which 
have increased vulnerability due to their inherent biological 
properties. After the initial attack, as AChR bearing immune 
complexes are formed, and when the immune system is able to 
access native AChR in muscle and thymus, a more robust anti-
AChR autoimmunity develops which then produces high affinity 
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AChR antibodies and germinal centre formation in the thymus 
causing severe generalised muscle weakness (201). 
Koneczny et al looked at MuSK myasthenia gravis. They used 
archived samples from therapeutic plasmapheresis in MG 
patients. They found that total IgG, IgG4 or IgG 1 to 3 MuSK 
antibodies were not endocytosed unless they were cross-linked 
by divalent antihuman IgG. The MuSK IgG4 fab fragments and 
IgG4 inhibited the binding of LRP4 to MuSK and reduced agrin 
induced AChR clustering in C2C12 cells. IgG 1 to 3 antibodies 
did not inhibit LRP4/MuSK binding but they did inhibit agrin 
induced clustering. Both IgG4 and IgG1 to 3 dispersed agrin-
independent AChR clusters in Dok7 overexpressing C2C12 
cells. They concluded that interference by IgG4 antibodies of the 
LRP4/ MuSK interaction was one of the pathogenic mechanisms 
of MuSK antibodies but IgG1 to 3 MuSK antibodies also 
contribute to the reduced AChR density and NMJ dysfunction in 
MG patients with MuSK antibodies (202). Similar findings were 
reported by Huijbers and colleagues in 2013 when they looked 
at passive transfer studies in mice (203). 
Koneczny et al looked at IgG4 MuSK antibodies and fab arm 
exchange in 51 MG patients using serum samples and plasma 
from plasmapharesis, all of whom had been 
immunosuppressed. One of the key features of IgG4 antibodies 
is their ability to exchange fab arms with other unrelated IgG4 
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molecules. This can make the IgG4 molecule potentially 
monovalent for that particular antigen. They applied exchange-
inducing conditions to MuSK antibodies and studied these. They 
found that at least 50% of patients had IgG4 but not IgG1 to 3 
MuSK antibodies that could undergo fab arm exchange in vitro. 
They also found that in vivo all MuSK antibodies were divalent 
i.e. more specific for MuSK. This did not prevent the inhibitory 
effect of the serum derived MuSK antibodies on AChR clustering 
in C2C12 myotubes. This suggests that a considerable 
proportion of MuSK IgG4 could already be fab arm exchanged in 
vivo and demonstrates that fab arm exchanged antibodies are 
pathogenic (204). It is not clear how immunosuppression may 
have affected the results. If they were being plasmapheresed it 
is likely that they had marked symptoms.  
Otsuka et al studied the physiological significance of binding 
ColQ to MuSK and the block of this binding by MuSK IgG in 5 
patient samples. They showed that passive transfer of MuSK 
IgG to ColQ knockout mice attenuated AChR clustering 
indicating that lack of ColQ is not the key event causing 
defective clustering of AChR in MuSK MG. They found that 
AChE/ColQ complex blocked MuSK LRP4 interaction and it 
oppressed agrin/LRP4/MuSK signalling. Quantitative analysis 
showed that MuSK IgG suppressed agrin/LRP4/MuSK signalling 
to a greater extent than ColQ (205).  
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Ishikawa et al published a paper on two cases of MG who were 
double positive for AChR and LRP4 antibodies and also had 
invasive thymoma. After treatment they found that AChR 
antibody levels were markedly decreased whereas there was no 
change in the LRP4 antibodies in one case and slight decrease 
in the second case. They suggested that the patients with 
double seropositivity with AChR and LRP4 were likely to present 
with more severe symptoms than those with LRP4 MG alone. 
They concluded that the main affecting course for the symptoms 
in MG in their case was probably AChR antibodies and the 
LRP4 antibodies may have been an exacerbating factor (206). 
Zouvelou et al published a paper with two case reports of 
patients with anti-LRP4 antibodies. The first had isolated neck 
extensor weakness and the second ocular, bulbar and cervical 
weakness; both had mild to severe MG and responded to 
pyridostigmine. One of them also had follicular hyperplasia of 
the thymus (162). 
Zisimopoulou et al published a paper with a comprehensive 
analysis of the epidemiology and clinical characteristics of anti-
LRP4 MG. They screened 800 MG patients from 10 countries 
for LRP4 antibodies. They found that the overall frequency of 
LRP4 MG in SNMG was 18.7% with variations among different 
populations with a range of 7 to 32.7%. They found double 
positive sera in 8/107 anti-AChR positive patients and 10/67 
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anti-MuSK positive patients. They looked at the clinical history 
for these LRP4 positive patients; 81% of patients had mild 
symptoms with MGFA grade 1 or II. Some with thymic changes-
32 with hyperplasia but no thymomas. They felt that the double 
positive patients either with AChR or MuSK had more severe 
symptoms at onset compared with single positive group. Of the 
OMG patients who were seronegative to start off with, 27% had 
LRP4 antibodies. LRP4 antibodies were predominantly IgG1 
and IgG2 subtypes. The prevalence was found to be higher in 
women than men with a ratio of 2.5:1 and an average disease 
age of 33.44 years in females and 41.94 years in males. The 
treatment response was similar to AChR MG (207). 
Hong et al looked at 432 Chinese MG patients and tested them 
for antibodies against AChR, MuSK, Titin and ryanodine 
receptors antibodies. ACHR Abs were found in 82.2%, MuSK 
antibodies in 2.3%, Titin antibodies in 28.4% and Rynodine 
antibodies in 23.8%. Thymoma MG patients had higher 
frequencies of AChR, Titin and Rynodine antibodies. Titin and 
Rynodine antibodies were also present more frequently in 
LOMG patients. They found that patients with Titin and 
Rynodine antibodies tended to have more severe disease and 




Huda et al looked at the characteristics of AChR antibody 
negative MG patients in a South African cohort. The samples 
were tested using RIA and some CBAs for AChR, MuSK and 
LRP4. AChR antibodies were detected in 4/53 and MuSK Abs in 
24%; 60% were triple seronegative. The MuSK MG patients had 
a younger age of onset, were likely to be of African genetic 
ancestry, and had a fourfold higher odds of reaching MGFA 
grade IV/V compared to triple SNMG. They were also ninefold 
more likely to reach at least minimum manifestations after ≥12 
months of therapy (209). 
Chang et al looked at a cohort of 113 patients from Sri Lanka 
recuited both prospectively and retrospectively, and they found 
that the clinical characteristics were similar to other populations 
(210). 
Cordts et al screened 45 AChR negative and 55 AChR positive 
patients who already had a diagnosis of MG for LRP4, agrin and 
Titin antibodies. They found that in 55 AChR antibody positive 
patients, 7% were also positive for LRP4, 5% for agrin, 53% for 
Titin. In 45 AChR antibody negative patients, they had 2% 
positive for MuSK, 2% positive for LRP4, 2% for agrin, and 27% 
for Titin. The phenotype of Titin MG depended on the AChR 
antibodies- if AChR antibody negative, patients presented with 
mostly mild limb weakness but if AChR antibody positive, 
patients had more severe symptoms including crises with bulbar 
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predominance and could be associated with thymoma. 
Additional autoimmune disease was detected in 32% of the MG 
patients, most frequently Hashimoto's thyroiditis in 21% (211). 
Stergiou et al also looked at Titin antibodies using a sensitive 
radioimmunoprecipitation assay (RIPA) in 667 MG patients, 372 
triple seronegative patients, 121 healthy controls, 90 myopathy 
patients and 193 patients with other neurological disorders using 
stored samples.. They found that AChR MG patients had the 
highest frequency of Titin antibodies of 40.9%, in MuSK MG of 
14.6%, and in LRP4 MG of 16.4%. 13.4% of the triple 
seronegative MG patients also had Titin antibodies. None of the 
healthy controls or myopathy controls had Titin antibodies and 
only 3.6% of other neurological patients were positive (212). 
Berger et al looked at 44 patients with paraneoplastic 
neurological syndrome (PNS) to see whether Antititin antibodies 
were significant. They found that in a small proportion of patients 
with PNS they could have Antititin antibodies without a 
predictive relevance for MG or thymoma (213).  
Patients with MG can have antibodies against skeletal muscle 
Rynodine receptor (RyR), which is the sarcoplasmic reticulum 
calcium release channel, and plays a crucial role in excitation 
contraction coupling. Skeie et al studied the role of Rynodine 
receptor antibodies in MG. Their data suggested that the RyR 
sequence defined by residues 799 - 1172 is involved in the 
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regulation of RyR function and dysregulation could be 
functionally affected in vivo in patients with MG (214). 
Romi et al similarly suggested that the occurrence of Rynodine 
receptor (RyR) antibodies increases the risk of severe MG. They 
looked at MG in 152 patients. They found that patients with RyR 
antibodies had the highest rate of bulbar, respiratory and neck 
involvement at MG onset. They also had the highest frequency 
of non-limb MG symptoms. Weakness occurred in 40%. Patients 
with Titin antibodies with or without RyR antibodies had 
respiratory difficulties at onset (215). 
Buckley et al looked at levels of Titin, IFN alpha and IL-12 
antibodies using RIA in 191 MG patients and 82 controls. They 
found that Titin antibodies were uncommon in EOMG; however 
in LOMG, Titin antibodies had similar prevalence and levels to 
those with MG and thymoma. These antibodies were uncommon 
in patients between 40 and 60 years of age without tumour. 
Cytokine antibodies were more common in patients with 
thymoma than in patients without thymoma and increased 
substantially if the thymoma recurred. They concluded that 
measurement of Titin antibodies has limited use in predicting the 
presence of a tumour unless the patient is less than 60 years of 
age but the measurement of IFN alpha and IL-12 antibodies 




Similarly, Szczudlik et al looked at Antititin antibodies in EOMG 
and LOMG. They found that Antititin antibodies have high 
positive predictive value and negative predictive value for 
thymoma in EOMG. In MG without thymoma, antititin antibodies 
could be considered as markers of LOMG but not of a severe 
course (217). 
Illa et al looked at Cortactin, and Cortactin antibody positivity in 
MG patients. By using a protein array to screen reactivity to 
9000 human proteins, they identified Cortactin, an intracellular 
protein which interacts with agrin/MuSK leading to AChR 
aggregation. They identified this as a new antigen in double 
seronegative MG (dSNMG). In the second part of the study they 
looked at Cortactin antibodies, screening 250 patients with MG. 
They found that 23.7% of SNMG and 9.5% of AChR positive 
MGs had Cortactin antibodies. The patients with the SNMG 
cortactin positive MG presented with ocular or mild generalised 
MG without bulbar symptoms. They concluded that Cortactin 
antibodies were biomarkers of MG which when present 
suggested that the disease would be mild (218). 
Tu et al studied 70 MG patient sera and screened them for 
collagen XIII autoantibodies using ELISA. This was then further 
analysed with CBA and western blotting. They found that 5/70 
MG patients had autoantibodies against collagen XIII. All five 
were young women with negative or low levels of AChR 
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antibodies. It was not clear whether collagen XIII autoantibodies 
were pathogenic (219).  
Zhang et al studied autoantibodies to agrin in MG. They found 
that agrin was another autoantigen in patients with MG, and 
agrin autoantibodies may be pathogenic through inhibition of 
agrin/LRP4/MuSK signalling at the NMJ (220). 
Thymus and Antibodies in MG: 
Normally, functional AChR is only expressed by several skeletal 
muscles and thymic myoid cells. In addition, unfolded AChR 
subunits are expressed by medullary thymic epithelial cells, 
partly under the control of the autoimmune regulator (AIRE). 
Autoimmunity against self proteins including AChR is kept in 
check by thymic deletion of autoreactive T cells. Since deletion 
is not 100% efficient, the normal human T cell repertoire 
contains a few potentially AChR reactive effector T cells that are 
kept under control due to T cell anergy, or in the periphery by 
regulatory T cells. This small proportion of potentially AChR 
reactive effector T cells is likely to be involved in the 
pathogenesis of EOMG (64, 221-226). 
In EOMG, normal numbers of T regs with impaired function and 
down regulated Fox P3 are seen in the thymus and peripheral 
blood. In thymomas, there are reduced numbers of intra-
tumourous T regs irrespective of MG status, and the number of 
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naive autoreactive effector CD4+ T cells exported from the 
tumour predicts the MG risk (51, 227-230). 
10 to 20% of MG patients have a thymoma, and about 30% of 
thymoma patients have thymoma associated MG. There is a 
‘gray zone’ in clinical, immunological and pathological terms 
between the ages of 40 and 60 years when patients may suffer 
either from ‘late EOMG’ or ‘early LOMG’. Some LOMG 
thymuses have shown lymphoid follicles like in EOMG even in 
patients over 60 years of age. The lymphoid epithelial tissue of 
the ageing thymus is replaced with fat, but residual parenchyma 
may continue exporting some T cells. In LOMG these T cells 
may rarely show signs of expansion and even infiltration. Thymic 
myoid cells are sparse in LOMG and decline with age, and there 
is also a reduction in the number of AIRE positive cells. There is 
however no difference between LOMG thymuses and age 
controlled matches (128, 222, 231-234). 
There is a lot of similarity between LOMG patients and patients 
with TAMG, with (i) autoantibodies against Titin in 70% of 
patients (ii) neutralising antibodies against IFN alpha and or IL-
12 in 40% (iii) expansion of Vβ T cell subset in more than 50% 
and (iv) expansion of peripheral blood CD8+T cells particularly 
CD45RA+ subset (231, 235-239). 
It is postulated that because the immunological similarities 
between LOMG and TAMG are so close, it appears that 
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aberrations in the aged thymus in LOMG mimics thymoma 
behaviour without frank neoplasia which leads to export, and 
possibly even activation of non-tolerant T cells. There is a 
remote possibility that (i) a small thymoma  could have 
regressed spontaneously before the diagnosis of MG (ii) that a 
small population of highly potent AChR and Titin reactive T cells 
generated in the absence of myoid cells inside a AIRE negative 
atrophic thymus could become activated after exposure to the 
periphery and to trigger LOMG and (iii) that the pathogenic T cell 
population derived from atrophic myoid cell-poor and AIRE-low 
thymus has accumulated in the periphery over a long period 
before the outbreak of LOMG similar to the thymoma patient 
who develops TAMG years after thymoma removal. Once 
initiated, LOMG could become self-perpetuating by stimulatory 
AChR/autoantibody complexes in muscle draining lymph nodes 
(222, 225, 229, 240). 
MuSK MG in a thymoma patient is rarely reported and the 
pathogenic link is questionable. A direct link of the role of a non-
neoplastic thymus in MuSK MG has not been shown, and with a 
few exceptions, thymectomy has not been beneficial in these 
patients. Similarly, the role of thymus in LRP4 MG is not entirely 
clear; given the high proportion of LRP4 positivity in otherwise 
seronegative caucasian MG patients, and the high prevalence of 
thymic hyperplasia in double seronegative MG patients, it is 
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assumed that a proportion of LRP4 MG patients may show 
inflammatory thymic changes (154, 226, 241-245). 
 
1.5.10 B cells in MG 
AChR MG is a CD4 dependent B-cell mediated disease and 
hence the interaction of the follicular helper (Tfh), the follicular 
regulatory (Tfr), and B cells are critical in the development of 
MG. CD4 T cells differentiate into Tfh cells upon expression of 
master transcription factor B cell lymphoma 6 (BCL 6) and 
surface marker CXCR5. This allows migration into the germinal 
centre to help differentiation of B cells into memory B cells and 
antibody secreting plasmablasts and plasma cells. In MG 
thymuses, the frequency of the Tfh cells and B cells is 
increased, and the expression of Tfh associated markers i.e. IL 
21, PD 1 and ICOS is also increased on thymocytes. Tfr cells 
are counterparts to Tfh cells and they suppress Tfh and B-cell 
interactions in the germinal centre. The cells are derived from 
natural T reg precursors and express Fox P3 and BLIMP 1 (246-
251). 
B cells differentiate into plasma cells; immune response 
produces short lived and long-lived plasma cells. Initially blood 
plasma cells are rapidly formed in secondary lymphoid organs 
after antigen encounter where they undergo apoptosis after a 
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few days. A small proportion of plasma cells survive prolonged 
periods to maintain long-term in immunity, called long-lived 
plasma cells and these may play a role in autoimmunity.  
AChR expression by TACs and myoid cells, increased pro-
inflammatory cytokines and defective T reg cells is seen in some 
MG thymuses. B cells present in hyperplastic thymuses express 
markers of activation and display functional signs of activation. 
They are often organised in the hyperplastic thymuses within 
tertiary lymphoid organs. However these characteristics are not 
applicable to the entire MG population, given that in 
approximately 30% of patients with AChR MG the thymuses are 
not hyperplastic. The T cell subset in the thymic tissue which is 
responsible for the detectable AChR antibodies has not been 
precisely defined, but spontaneous production of AChR 
antibodies was demonstrated as most likely due to resident 
plasma cells and possibly plasmablasts. Other studies have 
demonstrated that the AChR autoantibody production by thymic 
lymphocytes can occur spontaneously or with mitogen 
stimulation, suggesting that heterogeneous B cell populations 
make such contributions. AChR autoantibody producing T cells 
can be found in circulation and in the lymph nodes, and have 
also been identified in the bone marrow (53, 252-261). 
Circulating B cell repertoire was characterised through analysis 
of over 500,000 unique sequences and minor deviations from 
normal controls were evident. This indicated that pathogenic B 
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cells make small changes to the global repertoire which may not 
be obvious without very large datasets. The thymus of patients 
with MuSK MG appears different to AChR MG making one infer 
that MuSK antibodies may develop and reside in a compartment 
other than the thymus (245, 262). 
The difference in frequency of B cell populations between AChR 
MG and healthy controls is unremarkable and there is no 
evidence of a general defect in B cell differentiation in patients 
with MG. CD 27- IgD- B cells do not appear to be altered in 
AChR MG. There appears to be an increase in CD5+ B cells in a 
subset of patients with AChR MG that may be associated with 
autoantibody production and regulation, although their roll in 
immunobiology is not unambiguously defined (263-266). 
Next-generation deep sequencing allows for comprehensive 
evaluation of the B cell receptor repertoires in health and 
disease in up to 1011 B cells in humans. Using this approach, 
naive B-cell compartments in patients with AChR and MuSK MG 
showed repertoire features that were not observed when B-cell 
tolerance functioned properly (262, 267). 
B lymphocytes augment immune responses by producing 
antibodies and activating T cells by antigen presentation. 
Studies have highlighted that a specific and functionally 
significant B-cell subset which could downregulate excessive 
immune and inflammatory responses to inhibitory cytokines 
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such as IL-10 and TGF β. The subset is called regulatory B cells 
(Bregs). IL-35 producing Bregs also play a role in 
downregulating immunity. They exert regulatory function mainly 
through suppressing the differentiation of Th1/Th17 cells and 
promoting T cell expansion. Reduced presence of the Bregs is 
associated with progressive neuroimmunological disorders (Han 
et al) (268). 
Karim et al showed that patients with MG had relatively lower 
percentages of CD19+CD5+CD1d+ Bregs cells compared to 
healthy controls. The production of IL-10 and TGF β1 was 
relatively less in patients with MG than healthy controls and was 
linked with more severe MG disease status. The reduction of 
cytokine production was more significant for IL-10 than TGF β1 
(269). 
Lu et al looked at the significance of B10 cells in patients with 
thymoma and MG. A subset of the regulatory B cells (Bregs) 
have been identified- B10 cells, which function by secreting IL-
10. In the study, 156 patients with thymoma were looked at and 
they analysed the percentage of the Bregs/CD19+ B cells and 
CD19+ B cells/PBMC. They also looked at gene and protein 
expressions of CD19 and IL-10. They found that thymoma 
patients without MG mainly had types A and AB thymoma and 
thymoma patients with MG mainly had type B- B1, B2 and B3 
thymoma. ACHR antibody in TAMG group was highest. With the 
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progress of the disease the percentage of the Bregs/CD19+ B 
cells increased and the B10/CD19+ B cells decreased. They 
showed that B10 had the greatest significance for clinical 
directivity of TAMG with a cut-off of 0.55%. In accordance with 
the condition, in thymoma and TAMG group, the content of 
CD19+IL-10+ B10 cells gradually increased. The levels of CD19 
and IL-10 also gradually increased. They found that as the 
severity of MG increases, the function of the Bregs (B10 cells) in 
peripheral blood decreases (270). 
B-cell activating factor (BAFF) is a member of the TNF 
superfamily. It is a potent survival factor for B cells and plays an 
essential role in peripheral B-cell homeostasis. The expression 
of BAFF in secondary lymphoid tissues is essential for 
sustaining the long-term survival of mature B cells in vivo.There 
are three functional receptors for BAFF, B-cell maturation 
antigen (BCMA), transmembrane activator and cyclophilin ligand 
interactor (TACI) and BAFF receptor (BAFF-R). The BAFF-R is 
the main receptor which mediates BAFF signals in naïve B cells. 
Following activation, and during differentiation, BAFF-R 
expression is downregulated while TACI expression is 
upregulated. BCMA expression is upregulated in the terminal 
stages of B cell differentiation. Excess BAFF promotes the 
survival, growth and maturation of autoreactive B cells thereby 
breaking immune self-tolerance (Berrih-Aknin et al) (271). 
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Animals that express high levels of BAFF also suffer from a 
number of autoimmune manifestations including high levels of 
circulating autoantibodies, immune complexes in serum and 
kidneys, and proteinuria due to immune complex-mediated 
glomerulonephritis. Older BAFF transgenic mice also show 
hallmarks of the autoimmune disorder Sjogren’s syndrome. 
Interestingly, a causal relationship between BAFF 
overexpression and human autoimmune disease is also 
suggested by the high levels of serum BAFF found in patents 
with Sjogren’s syndrome and the association between high 
serum BAFF and autoantibody production in several other 
autoimmune diseases. Why age makes autoimmunity more 
common is not clear. 
AIRE plays a role in both the central and peripheral immune 
self-tolerance mechanisms for T cells. AIRE deficiency leads to 
higher numbers of antigen presenting cells. AIRE-deficient mice 
also have higher serum levels of BAFF than wild-type mice, and 
this is associated with increased expression of membrane-
bound BAFF on the surface of dendritic cells. Aging AIRE-/- 
mice have a similar phenotype to BAFF transgenic mice. As 
shown recently, AIRE-/- mice are also susceptible to the 
induction of EAMG, and this appears to be age related. 
The ability of BAFF overexpression to rescue self-reactive B 
cells from deletion is limited to those cells normally deleted 
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relatively late in their maturation. The ability of self-reactive B 
cells to be rescued by BAFF is most likely determined by their 
expression of BAFF-R, which peaks around the point during B 
cell maturation where BAFF-mediated rescue begins to operate. 
It is probable that the expression of BAFF-R is delayed during B 
cell maturation to ensure that B cells with strong self-reactivity 
will not reach the point where they express this pro-survival 
receptor. If this were not the case then the autoimmunity 
associated with increased BAFF expression could well be 
significantly more catastrophic than it is (272). 
Three different studies have shown that serum BAFF levels in 
patients with MG are significantly higher than in non-MG 
controls. There is no association between serum BAFF level and 
the extent or severity of the disease. There is a trend for BAFF 
levels to be higher in patients seropositive for AChR antibodies 
(273-275). 
Lee et al found that the frequency of polyreactive and 
autoreactive B cells receptors (BCRs) was higher in both the 
AChR and MuSK MG patients compared to healthy controls. 
This indicates that both the MG subtypes have defects in central 
and peripheral B-cell tolerance checkpoints (276). 
Yi et al looked at B10 cell frequencies in MG. B10 cells are 
known to inhibit B and T cell inflammatory responses in animal 
models. They found reduced B10 cell frequencies in AChR MG 
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patients which inversely correlated with disease severity. The 
disease severity also affected the function of B10 cells, as B10 
cells in the moderate/severe group of MG patients were less 
effective in suppressing CD4 T-cell proliferation. They 
suggested that B10 cell frequencies may be a useful biomarker 
of disease severity (277). 
Stathopaulos et al looked at the B-cell compartments in MuSK 
MG patients who were treated with rituximab. Autoantibody 
expressing CD27+ B cells were observed within the 
reconstituted repertoire during relapse but not during remission 
or in the controls. They demonstrated that antibody secreting 
CD27hiCD38hi B cells (plasmoblasts) contribute to the production 
of MuSK autoantibodies during relapse (278). 
 
1.5.11 T cells and cytokines in MG 
The immune system is very organised, and proper functioning 
depends on adequate balance between the pro-inflammatory 
and anti-inflammatory signals, and the responses of the cellular 
system- the pro-inflammatory T cells (T helper 17 cells or TH 17 
cells) and the anti-inflammatory cells- the regulatory T cells (T 
regs cells). Defective balance is seen in a lot of autoimmune 
conditions (279-283). There is an increased production of IL-17 
which is a cytokine and is expressed by TH 17 cells. Several 
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studies have shown that in thymic hyperplasia there is increased 
production of pro-inflammatory cytokines like IL-6, IL-1β, 
interferon-γ, and TNFα. There is also increased production of 
the anti-inflammatory cytokine TGF or transforming growth 
factor β-1. The balance between T reg cells and TH 17 cells in 
MG is disrupted. T regs are shown to be defective in their 
regulatory function and can start expressing markers of TH 17 
cells, while the effector T cells or T eff cells (CD4+25-) become 
resistant to suppression (51, 284-287). 
T reg cells (CD4+CD25+FoxP3+) can be divided into natural T 
reg cells, also called thymic T reg cells, and peripheral T reg 
cells, or induced T reg cells. Whilst natural Treg cells 
consistently express FoxP3 and CD25, the peripheral T reg cells 
only express FoxP3 and CD25 after they have been activated, 
and this requires the presence of TGF β (288-290). 
T reg cells regulate the effects/suppress the effector T-cell 
proliferation by cell-cell contact through the expression of 
CTLA4, by depriving IL-2, by expressing anti-inflammatory 
cytokines like TGF β and IL-10 and by expressing granzyme A 
and activating the perforin pathway (291, 292). 
Autoimmune diseases could be caused by a deficiency in the 
number of T reg cells and/or defective suppression by the T reg 
cells. There have been several contradictory studies regarding 
the numbers and function of T reg cells, some of which show 
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that the T reg cell numbers are reduced in MG patients 
compared to healthy controls (227, 293, 294), whereas other 
studies showed no difference in the percentage of CD4+FoxP3+ 
T reg cells in the thymus and peripheral blood (295, 296). Most 
studies report that the T reg cells have reduced suppressive 
activity. A decreased expression of Foxp3 in MG thymus and in 
the peripheral blood could be one of the reasons for the 
impaired suppressive activity (51, 52, 265). 
More recent studies have shown that there is another 
subpopulation of T cells known as T follicular regulatory cells or 
Tfr which are CD4+CXCR5+FoxP3+. These are derived from 
thymic T reg cells and they control the follicular helper cells or 
Tfh cells (297). 
Wen et al looked at a large cohort of 79 MG patients with an 
established diagnosis of MG. Of these, 59 were 
immunosuppression naïve, and 13 went on to have steroids 
during the study. They found that Treg levels were lower in the 
untreated group compared to those who were given steroids. 
They also found significantly lower percentage of 
CD4+CXCR5+FOXP3+ Tfr-like cells and higher percentage of 
CD4+CXCR5+FOXP3- Tfh-like cells in the peripheral blood of 
untreated MG patients compared to treated patients and healthy 
controls. In the 13 treatment naïve patients who went on to have 
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steroids, the Treg levels and Tfr-like cells increased and Tfh-like 
cells decreased (298). 
TH 17 cells are CD4+ T cells which have the phenotype 
RORγT+CCR6+IL-23R+IL-17+. The TH 17 cells are considered 
pathogenic when they differentiate in the presence of IL- 23 and 
overexpress IL-17. IL-17 induces several cytokines such as 
CXCL1, CXCL13, CCL2, CCL 7 and CCL20. It also induces pro-
inflammatory cytokines such as IL-6, TNF α, IL-1 β and G-CSF. 
Overexpression of IL-17 family is seen in hyperplastic thymuses 
in MG (287, 299, 300). 
A study on 11 patients with a prior diagnosis of MG by Cao et al 
showed that AChR reactive CD4+ T cells from MG produce high 
levels of IFN γ and IL-17 which suggests a mixed phenotype of 
TH 1/TH 17 cells. The differentiation of these two subtypes is 
linked to each other. When there is low IL-23, or high IL-12 and 
TNF α, the TH 17 cells can become IFN γ expressing cells. 
These TH 1-like cells derived from TH 17 cells are more 
pathogenic than the original TH 17 cells (301). This was a study 
on a small number of patients with a mixture of treatment naïve 
and immunosuppressed patients. 
There have been other studies which have not reported any 
significant differences in the pro-inflammatory cytokines, and 
similar levels of plasma IL-17 in AChR+ MG patients and healthy 
controls. Another study showed no difference in serum IL-17 
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and IFN-γ between MG patients and healthy controls (Villegas et 
al) (302). 
A study on EAMG by Yang et al which was recently published 
looked at the association of B lymphocyte induced maturation 
protein 1 (blimp1) and T reg cells. The loss of blimp1 has been 
shown to double the number of follicular regulatory T cells (Tfr). 
The study showed that Tfrs indirectly inhibited the activation and 
differentiation of B cells by negatively regulating follicular helper 
T cells which in turn lowers the secretion of antibody. Lack of 
blimp1 makes immune suppression function of Tfr cells impaired 
in vitro. When tested in vivo, Tfrs reduced immune responses in 
germinal centres and improved myasthenia symptoms in EOMG 
(303). 
Zhang et al published a study on 45 patients with an established 
diagnosis of AChR+ MG. They were a mixture of GMG and 
OMG and about half had thymic abnormalities. They studied 
TIPE2, which is a tumour necrosis factor α induced protein 8 like 
2. This is a member of the TNF family and is a negative 
regulator of innate and adaptive immunity. The study 
demonstrated that the expression of TIPE2 mRNA and protein 
was reduced in MG compared to healthy controls, being lower in 
GMG than in OMG. There is a negative correlation with serum 
levels of IL-6, IL-17 and IL-21 in GMG and all MG patients. 
TLR4 activation caused down-regulation of TIPE2 and 
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expression of RORγ T and production of IL-6, IL-17 and IL- 21 
were increased. Their results indicate that TIPE2 participates in 
the development of MG through negative regulation of TLR4 
mediated autoimmune T helper 17 cells (304). The patients had 
not been given immunomodulatory treatment for the three 
months preceding recruitment; however, there is no mention of 
what treatment the patients had had prior to this which makes 
interpreting the results tricky. 
Another Chinese study by Yang et al shows the correlation of 
neutrophil to lymphocyte ratio (NLR) in myasthenia patients. 
They looked at 172 MG patients and 207 healthy controls and 
found that patients with MG had a significantly higher NLR 
compared to healthy control group. This was higher in MG 
patients with severe disease compared to milder disease and 
statistically higher in myasthenic crisis. The study suggested 
that elevated NLR was an independent predictor of severe 
disease activity (305). The study did not categorise patients 
based on whether they were immunosuppressed or not, which 
could potentially change how the data is interpreted and it is not 
clear if the changes are related to MG or to treatment. 
Alahgholi-Hajibehzad et al found in their retrospective study of 
78 MG patients that decrease of FoxP3 was associated with 
lower phosphorylation of STAT 5, and vitamin D3 increased 
suppression and can have modulatory effects (306). 
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A Chinese retrospective study by Zhang et al looked at the 
expression of P2X7 receptor in PBMCs and in myasthenia 
gravis. P2X7 is an activator of innate and adaptive immune 
responses. The study looked at 12 GMG and 20 OMG patients 
and 22 healthy controls. Their results showed increased 
expression of P2X7 mRNA and protein in PBMCs with high 
expression in GMG than in OMG. There was a correlation with 
clinical severity and serum levels of IL-1 β, IL-6, IL-17 and IL-21 
in MG. In cultured MG PBMCs, LPS challenge led to 
upregulation of P2X7 expression with increased production of 
the cytokines and its blockade significantly attenuated the LPS 
induced production of cytokines. This suggests an involvement 
in the pathogenesis of MG by promoting TH 17 immune 
response (307). As with the previous study by the same group, 
immunomodulatory treatment had not been used in the three 
months preceding recruitment; but the study does not outline 
what treatments were used prior to this. 
Luo et al looked at the role of the IncRNA IFNA-AS1 in MG. 
They found that the IFNA-AS1 is abnormally expressed in MG 
patients and is associated with positive AChR antibody levels 
(308). 
Chuang et al looked at immunological correlations between 
LOMG and thymoma associated MG (TAMG) based on the fact 
that both have AChR antibodies, Titin antibodies, antibodies to 
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ryanodine receptor, type I interferons or IL-12. They looked for 
association with CTLA4hi/gain of function+49A/A genotype which is 
seen in TAMG In a total of 152 historically collected patient 
samples. In contrast with TAMG, they found that there was 
CTLA4low+49G+ genotype more frequently in LOMG patients 
with age of onset ≥ 60 years compared to healthy controls. They 
found that thymic export of naïve T cells from non-neoplastic 
thymus in LOMG patients was lower at diagnosis. They 
suggested that there were distinct initiating mechanisms in 
TAMG and LOMG and that the abberant immune regulation was 
in the periphery in LOMG (309). 
Zhang et al looked at CD19+Tim-1+ B cells in 34 patients with 
MG recruited retrospectively. They included both treatment 
naïve and immunosuppressed patients. T-cell immunoglobulin 
mucin domain one (Tim-1) is thought to be essential for optimal 
regulatory B cell function and maintaining immune tolerance. 
Their study showed that mRNA and protein expression of B cell 
Tim-1 in both GMG and OMG were significantly lower than 
those in healthy controls with lower expression in GMG 
compared to OMG. This negatively correlated with clinical 
severity, plasma cell frequency, serum TH 17 related cytokines 
and anti-ACHR antibody levels. This indicated that aberrant 
expression of Tim-1 exists on B cells and this may contribute to 
the TH 17 polarisation and antibody secreting plasma cell 
differentiation in MG patients (310). 
121 
 
Zhang et al looked at circulating CD4+CXCR5+PD-1+ Tfh cells 
in OMG in GMG without thymic abnormalities. They showed that 
circulating Tfh cells are significantly enriched in GMG patients 
but not in all MG patients compared with healthy controls, and 
the proportion of follicular T reg cells was decreased. The 
frequency of plasma cells and B cells was higher and serum 
levels of IL-6 and IL-21 were elevated in MG patients. The 
results suggested that circulating Tfh cells may act in 
autoreactive B cells and contribute to the development of MG in 
patients without thymic abnormalities. 
Alahgholi-Hajibehzad et al retrospectively looked at the effect of 
IL-21 and CD4+CD25++T cells on cytokine production of CD4 + 
responder T cells in 20 patients with AChR+ GMG. They found 
that IL-21 increased the proliferation of the responder T cells 
(Tresp cells) in Tresp/T reg cocultures. Tresp cells in MG 
patients secreted significantly lower levels of IL-2. In these 
patients IL-2 levels did not change with the addition of T regs to 
the cultures whereas it decreased significantly in controls. In 
Tresp/Treg cocultures, IL-4, IL-6 and IL-10 production was 
increased in the presence of T regs in patients. IFN-γ was 
decreased and IL-17 was increased in both patient and control 
groups. This demonstrates that IL-21 enhances the proliferation 
of the Tresp cells in the presence of T regs (311). 
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Jeong et al have found that serum IL-27 levels were significantly 
higher in 32 retrospectively recruited, treatment naïve MG 
patients compared to controls and it was significantly higher in 
EOMG (312). 
Uzawa et al looked at high mobility group box 1 (HMGB1) which 
is an inflammatory mediator, in 70 retrospectively recuited MG 
pts who were positive to either AChR (60) or MuSK (10) Abs. 
They found that serum HMGB1 levels in patients with AChR 
antibody + MG were higher than in the healthy controls. This 
decreased after treatment with immunosuppressants. Anti-
MuSK antibody + patients also showed higher serum HMGB1 
levels than controls but not significantly. GMG patients showed 
higher levels than OMG patients and controls. Patients with 
thymoma showed higher levels than those without thymoma and 
controls (313). 
Xie et al found that IL-17A was higher amongst MG patients 
than in healthy controls. EOMG women without thymoma 
showed greater elevations of IL-17 A. The absence of thymoma 
was thought to be the more significant determinant and levels 
were associated with more severe MG (314). This was a 
retrospective study on 69 treatment naïve MG patients which 
suggests that the patients may have milder MG and does not 
include the wide spectrum of presentations. 
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Yilmaz et al retrospectively looked at plasma levels of cytokines 
related to TH cell subtypes in 46 AChR MG, 23 MuSK MG and 
42 healthy controls. Plasma levels of TH1, TH 2 and TH 17 
related cytokines were overall not significantly different between 
the subtypes and controls. However in vitro stimulated PBMCs 
in MuSK patients but not in AChR showed a significantly 
increased secretion of TH 1, TH 17 and Tfh cells and related 
cytokines which are IFN γ, IL-17a and IL-21. They postulated 
that TH1 and TH17 immune reactions play a role in MuSK MG 
and immunosuppression attenuates the TH1 response in AChR 
MG and in MuSK MG, but it modulates immune responses 
differently in the two groups (315). 
Uzawa et al retrospectively looked at serum levels of 24 
inflammatory cytokines in 43 AChR+ MG and 25 healthy 
controls. They found that in MG serum levels of a proliferation 
inducing- ligand (APRIL), IL-19, IL-20, IL-28A and IL-35 were 
significantly increased as compared to controls. IL-20, IL-28A 
and IL-35 were significantly decreased after treatment (10 
patients). APRIL and IL- 20 was increased in LOMG and IL- 28A 
was increased in patients with thymoma associated MG (316). 
Cufi et al have shown that IFN β could play a central role in 
thymic events and lead to MG by triggering the overexpression 
of αAChR which probably leads to thymic dendritic cell 
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autosensitization, the abnormal recruitment of peripheral cells 
and germinal centre formation (66). 
Dragin et al showed that oestrogens inhibited the expression of 
of AChR and HLA-DR in TECs which suggest that oestrogens 
may alter the tolerization process and favours an environment 
for autoimmune response (49). 
Molin et al published a paper with the profiles of upregulated 
inflammatory proteins in MG patient sera. They looked at sera in 
45 MG patients and investigated 92 proteins associated with 
inflammation. They found that 11 of the analysed proteins were 
significantly elevated compared to healthy controls of which the 
three most significant were: matrix metalloproteinase 10 (MMP-
10), transforming growth factor alpha (TGF α) and extracellular 
newly identified receptor for advanced glycation end products 
binding protein (EN-RAGE) (also known as protein S100-A12). 
Levels of MMP-10, C-X-C motif ligand one (CXCL1) and brain 
derived neurotrophic factor (BDNF) differed between EOMG and 
LOMG (317). 
 
1.5.12 miRNAs in MG 
MicroRNAs (miRNAs) are small non-coding RNA molecules that 
bind to specific mRNA targets and regulate a wide range of 
important biological processes within cells. Circulating miRNAs 
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are released into the extracellular space and can be measured 
in most bio fluids including blood serum and plasma. As 
circulating miRNAs are easily accessible, they can be used as 
markers for different human disorders including autoimmune 
diseases (Punga et al) (318). 
Punga et al published a paper on 34 MG patients who were 
treatment naïve and 37 patients who were immunosuppressed. 
They measured serum levels of miR-150-5p and miR-21-5p; 
these were higher in the MG treatment naive patients compared 
to healthy controls. MiR-150-5p levels were 41% lower and miR-
21-5p levels were 25% lower in MG patients on 
immunosuppression compared to treatment naive patients. In 
autoimmune disease patients mean miR-150-5p and miR-21-5p 
were comparable with healthy controls. The suggestion was that 
the miRNAs have a disease-specific signature and could be 
used as biological markers of MG (319). 
In another study by Punga et al, they looked at miRNAs in 
MuSK+ MG patients. They found elevated levels of let-7a-5p, 
let-7f-5p, miR-151a-3p and miR-423-5p. This profile differed 
from the previously observed AChR positive MG patients (320). 
Zhang et al found that there was significant downregulation of 
miR-181c in PBMCs from MG patients compared with healthy 
controls. There was low expression in GMG patients than in 
OMG patients. MG patients also had increased serum IL-7 and 
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IL-17 levels. Serum IL-7 had a positive correlation with serum IL-
17. MiR-181c levels negatively correlated with serum IL-7 and 
IL-17 in GMG and OMG patients. They suggested that miR-181c 
was a negative regulator of the pro-inflammatory cytokines IL-7 
and IL-17 in MG patients (321). 
Xin et al examined the role of miR-20b in the development of 
TAMG. They found that miR-20b acts as a tumour suppressor in 
the development of thymoma and TAMG. This could be due to 
inhibition of NAFT signalling my depression of NAFT5 and 
CMTA1 expression (322). 
 
1.5.13 Treatment of MG 
Although Dr Walker was thought to be the first to describe the 
use of Physostigmine, this was in fact first described by Dr Lazar 
Remen, a Polish doctor who described it’s use in Myasthenia 
gravis in a paper published in 1932. He was studying the effects 
of Glycine at the time and the positive results of physostigmine 
on myasthenia were not given much importance (5). Myasthenia 
specific treatment was tried by Mary Broadfoot Walker in 1935 
when she tried physostigmine and later prostigmine due to the 
similarity of myasthenia with curare poisoning. Since then 
treatment of myasthenia has improved dramatically with steroids 
being the mainstay of treatment even now. The myasthenia 
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gravis Association of British neurologists’ management 
guidelines was published in 2015 and outlines the stepwise 
management of myasthenia gravis (323). This suggests starting 
treatment with pyridostigmine at a dose of 30mg QDS, and 
gradually increasing to 60mg QDS. The next step is introduction 
of prednisolone gradually, upto a maximum dose of 50mg on 
alternate days (AD) or equivalent once daily (OD) dose for 
OMG, and 100mg AD or equivalent OD dose for GMG. This is 
given for 2-3mths until symptom resolution and then gradually 
withdrawn. If unresponsive to prednisolone, or a relapse occurs 
on dose reduction of prednisolone, then an alternate 
immunosuppressant is introduced, Azathioprine being the most 
commonly used drug. Other immunosuppressants 
recommended are mycophenolate, methotrexate, cyclosporine 
and rituximab.The EFNS/ENS guidelines for the treatment of 
ocular myasthenia published in 2014 is also very similar to the 
ABN guidelines (324).  
There have been two controlled trials looking into the efficacy of 
corticosteroids in GMG; one done by Howard et al looked at 
prednisolone 100 mg on alternate days versus placebo (325). 
Lindbergh et al looked at 20 patients with GMG who were given 
2g IV methylprednisolone versus placebo. A significant 
improvement in the steroid treated group was seen, however, 
the trial was limited because the patients had all had 
thymectomy previously and some of them had received 
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corticosteroids previously (326). Several large-size retrospective 
analyses using oral prednisolone have all demonstrated good 
efficacy, the doses varying from 10 to 100 mg per day. The 
muscle study group trial showed that 75% of patients with mild 
to moderate MG responded well to 20 mg of prednisolone. 
Pradas et al analysed several different variables to see which 
would predict response to corticosteroid therapy. These 
variables included age of onset, sex, disease duration and 
severity. Only age of onset was predictive of treatment response 
and showed that older patients responded better than younger 
patients. MuSK MG patients may have a lower response to 
steroids (327) . 
Within the first 2 to 3 weeks after starting steroids, a small 
portion of patients may have a deterioration or exacerbation of 
their MG symptoms which is called a steroid dip (Gotterer et al) 
(90). The incidence ranges from between 21 to 44% with 
approximately 7 to 11% of patients having a severe 
exacerbation of symptoms. Steroid induced exacerbation is not 
predictive of poor long-term response to steroids. Older patients 
and those with bulbar symptoms and severe disease are more 
likely to develop exacerbation. 
Bae et al studied Fifty-five consecutive patients with MG who 
were administered high doses of prednisolone (40–80 mg) for 
the first time in a tertiary medical centre in Seoul (328). 
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Prednisolone-induced exacerbation was defined as a significant 
reduction in a patient’s Myasthenia Gravis Severity Scale (MSS) 
score within 4 weeks of prednisolone administration. Twenty-
three patients (42%) experienced definite exacerbation after 
prednisolone therapy. Older age, predominantly severe bulbar 
symptoms, and low MSS score were found to be significant 
clinical predictors of exacerbation. A high daily dosage of 
prednisolone was found to be neither a predictor of exacerbation 
nor a predictor of early improvement. 
The hypotheses for the mechanisms of ‘steroid dip’ are: (i) 
action of antibodies released from degrading lymphocytes, (ii) 
increased activity of cholinesterase at the NMJ, and (iii) an 
overall increase in immune reactions (329-331). 
Some studies have found that a stepwise increase in the dose of 
Prednisolone is better than using a large initial dose in 
preventing steroid induced worsening (332-334). Other studies 
however found that using a large initial dose of prednisolone 
produces rapid improvement in MG symptoms (335, 336). 
Certain centres prefer to use an alternate daily regime of 
prednisolone; the rationale being, limitation of dose-related side-
effects, and possibly encouragement of indigenous steroid 
production on the ‘off’ days. There is limited data to suggest that 
daily prednisolone is more effective than alternate day dosing, 
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and patients treated with alternate day therapy often experience 
subjective and objective worsening during their ‘off’ day (337). 
Pulsed IV MEP therapy at regular intervals has been tried in 
some series and has shown short rapid improvement with less 
exacerbation and fewer side effects. Oral dexamethasone 10 to 
20 mg per day has also been shown to be beneficial in a small 
series (337, 338). 
Myasthenic crisis during the tapering of prednisolone is 
uncommon; in one study 18% of patients had one or more 
significant exacerbation when the steroid dose was reduced, but 
no one had myasthenic crisis. Approximately 5 to 20% of 
patients who were on steroid monotherapy were able to 
discontinue the steroids successfully (339, 340). In one study 
three quarters of patients were thymectomized and 50% of 
these patients were able to discontinue steroids. Patients with 
MuSK antibody positive MG may be more refractory to weaning 
off the corticosteroids and they may require two or more forms 
of immunotherapy. 
Approximately 5 to 20% of MG patients do not respond to 
corticosteroids. Side effects of corticosteroid treatment include 
weight gain, cushingoid features, easy bruising, cataracts, 
glaucoma, diabetes mellitus, hypertension, 
hypercholesterolaemia, osteoporosis, and rarely, avascular 
necrosis of the femoral head. 
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The other immunosuppressants which are usually introduced if 
myasthenic symptoms recur on prednisolone withdrawal include 
azathioprine, mycophenolate, methotrexate, cyclosporine and 
tacrolimus. 
Azathioprine is a purine analogue which interferes with DNA 
synthesis. It interrupts the proliferation of B and T lymphocytes. 
Azathioprine has been used as a monotherapy for myasthenia 
since 1964, even before prednisolone was commonly used. 
When used as monotherapy, improvement is seen after 4 to 6 
months. Two RCTs were done looking into azathioprine; the first 
showed no difference between azathioprine alone and 
azathioprine plus prednisolone (341) whilst the other study 
showed that 63% of the patients treated with combination 
treatment were able to discontinue prednisolone eventually 
(342). The maximum therapeutic benefit was seen after two 
years. Gradual azathioprine withdrawal can be considered in 
patients whose MG symptoms have settled. A minimum duration 
of treatment of three years is desirable, although there is not 
enough evidence. The starting dose of azathioprine is usually 50 
mg per day and this is increased every two weeks up to a 
maximum dose of 2 to 3 mg per Kg per day. 
Mycophenolate mofetil (MMF) is a reversible inhibitor of 
Ionosine monophosphate dehydrogenase. MMF blocks the de 
novo pathway of purine synthesis and inhibits proliferation of T 
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and B lymphocytes. It has been used for treatment of 
myasthenia gravis since 1998. Two RCTs show that MMF was 
ineffective and a third RCT showed mild improvement (343-
345); however, widespread clinical experience supports the use 
of MMF for MG treatment. In a study of 85 patients, MMF led to 
improvement in symptoms in 73% and remission in 50%. 
Corticosteroid dose was reduced in 71% and discontinued in 
13%. The starting dose of MMF is 500 mg to 1 g twice a day and 
the maintenance dose is usually 1 g to 1.5 g twice a day. 
Hobson-Webb and team published data on mycophenolate 
mofetil withdrawal. They found that when patients relapsed 
during withdrawal, it was because the mycophenolate was 
tapered quickly. They suggested that tapering MMF appears to 
be safe after years of disease stability and the dose reduction 
needs to be done at a dose of only 500 mg per day every 12 
months (346). 
Cyclosporine inhibits the function of calcineurin and blocks the 
synthesis of interleukin-2 and interferon by helper T cells. There 
are several uncontrolled trials which show improvement in MG 
after 12 to 30 months of treatment. The maintenance dose is 
usually 5 mg per Kg per day. Renal toxicity and potential 
interaction with other medications makes cyclosporine a less 
preferred treatment choice (347-350). 
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Tacrolimus also inhibits calcineurin but it has the advantage of 
being less nephrotoxic than cyclosporine. In a study by Ponseti 
et al with 212 MG patients, they showed remission of symptoms 
in 87.5% of patients and steroid discontinuation in 95.1%. As 
tacrolimus also acts on the ryanodine receptor related 
sarcoplasmic calcium release, it may provide extra therapeutic 
benefit in patients with thymoma.  Dosage of tacrolimus varies 
from 0.05 to 0.1 mg per Kg per day (351). 
Methotrexate is a folate analogue that inhibits purine and 
pyrimidine synthesis and leads to decreased T-cell proliferation. 
This was first used in MG in 1969. In one RCT, 24 MG patients 
on steroids were randomised to azathioprine or methotrexate; 
after two months, the average dose of steroids was reduced by 
more than 50% in both groups without difference. The standard 
dose of methotrexate is 15 to 25 mg weekly (352). 
Rituximab is a genetically engineered chimeric mouse/human 
IgG1: kappa monoclonal immunoglobulin containing murine light 
and heavy chain variable region sequences and human constant 
region sequences. Rituximab acts against the cell membrane 
marker CD20 and leads to B lymphocyte depletion. There are a 
growing number of case series which support its use in severe 
GMG which is refractory to multiple immunosuppressive agents. 
Rituximab is particularly useful for patients with MuSK MG. The 
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standard rituximab dose is 375 mg/m² per week for four weeks 
or 1 g every two weeks for two doses. 
Rituximab is used for the treatment of refractory myasthenia 
gravis. Illa et al reported three patients with AChR positive MG 
and three with MuSK positive MG; all patients improved 
dramatically, antibody titres declined in all the patients, but the 
decline was significantly better in the MuSK positive MG patients 
(353).  
Tandan et al reviewed the efficacy and safety of rituximab in 165 
MG patients from case reports and series. 59% of these patients 
were AChR positive, and 34% were MuSK positive. After 
treatment with rituximab, patients achieved a MGFA PIS score 
(Appendix 1) of MM or better in 44% and a combination of PR 
and CSR in 27%. MM or better was achieved in 72% of MuSK 
MG, and in 30% of AChR MG. Relapses also reduced in MuSK 
MG. The predictors of response to rituximab were MuSK MG, 
less severe disease and younger age at treatment. There was a 
post treatment reduction in antibody titres- 82% in MuSK MG 
and 26% in AChR MG. Depleted CD20+ B cells were observed 
up to 16 weeks after four weekly infusions (354).  
Jing et al have suggested that low-dose rituximab at a dose of 
600 mg may be sufficient in depleting B cells and maintaining 
low counts with improvement of clinical symptoms in six months. 
Afanasiev et al also looked at 28 patients who received 
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rituximab treatment for MG. Based on their PIS score, they 
suggested that rituximab may be efficient in 50% of patients with 
MG resistant to immunosuppressants. They had one patient 
who developed progressive multifocal leukoencephalopathy 
(355). 
Cyclophosphamide is an alkylating agent that interferes with 
DNA replication. It reduces the production of lymphocytes, 
monocytes and macrophages. An RCT by De Feo and 
colleagues with 23 patients with refractory MG compared IV 
cyclophosphamide versus placebo. There was an improvement 
in the extraocular, masticatory and bulbar muscles after 12 
months and there was also a reduction in the average 
prednisolone dosages at six months. In another study with 22 
refractory MG patients, half the patients achieved remission 
after an average treatment duration of 3.6 months (356). 
IV immunoglobulins are used routinely in acute exacerbations 
of myasthenia gravis.  Previous studies have shown an 
improvement in 70 to 80% of MG patients. It can also be used 
as maintenance therapy in refractory MG. Compared to ACHR 
MG, IVIG is less effective in MuSK MG; in some studies only 20 
to 61% of MuSK MG patients improved with IVIG. 
Takizawa et al looked at patients receiving IV immunoglobulins 
and they assessed the patients clinically and included QMG 
scores. They judged that IVIG was ineffective in 18% of MG 
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patients. Significant improvement in QMG was seen after one 
month for AChR MG, there was no significant change seen in 
seronegative patients within three months, for anti-MuSK MG 
the improvement of QMG was significant after two months. They 
suggested that a judgement regarding whether IVIG is 
ineffective for MG patients should be considered at least three 
months after IVIG administration (357). 
Subcutaneous immunoglobulins have also been shown to be 
effective instead of IV immunoglobulins. The mechanism of 
action of IV immunoglobulins includes it’s affect on: (i) 
antibodies, which are reduced (ii) compliment, IVIG inhibits 
complement consumption and intercepts MAC formation (iii) 
genes,  IVIG causes an alteration of the tissue genes associated 
with inflammation, fibrosis tissue remodelling and regeneration 
and (iv) degenerative pro-inflammatory molecules and beta-
amyloid (358). 
IV immunoglobulin was first used in the 1950s as replacement 
therapy in immune deficiencies, but is now widely used for the 
treatment of autoimmune and inflammatory diseases. 
Plasma exchange may also be used as maintenance therapy in 
MG. In a study by Triantafyllou et al, 11 patients with refractory 
MG were treated with Plex on a cyclical basis; all patients 
improved after the first week and stabilised after three months. 
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Plex is effective in MuSK MG and leads to rapid improvement in 
53 to 93% of patients (359). 
Studies comparing IV immunoglobulin with double filtration 
plasmapheresis (DFPP) and immunoadsorption (IA) showed 
that DFPP and IA showed better short-term clinical effectiveness 
than IVIg (Liu et al) (360). A small study by Alipour-Faz et al of 
24 patients comparing IVIG with plasma exchange for patients 
requiring thymectomy showed that in the plasma exchange 
group, post-operative outcomes, which included duration of 
hospitalisation, ICU length of stay after surgery, intubation 
period and duration of surgery, were longer than in the IVIG 
group. They suggested that the Administration of IVIG may be 
more effective in preparation before thymectomy in MG patients 
(361).  
Similarly, another study by Schneider Gold et al comparing 
immunoadsorption versus plasma exchange showed that 
semiselective IA in combination with Plex, and to a lesser extent 
IA alone, was associated with a shorter hospital stay and more 
pronounced reduction of the MG score than Plex. A study by 
Yamada et al looked at 153 MG patients who had plasma 
exchange. 12 of these were positive for anti-MuSK antibodies. 
They suggested that maintenance Plex may be an effective 





An international multicentre randomised study comparing 
thymectomy to no thymectomy in 126 Non-thymomatous 
myasthenia gravis patients receiving prednisolone (MGTX) was 
completed in 2016. The MGTX trial showed that QMG scores 
were significantly lower, with an estimated difference in mean 
scores of 2.85 in the thymectomy group. The alternate day 
prednisolone dose was 44 mg in the thymectomy group 
compared to 60 mg in the prednisolone only group which was 
also statistically significant. MM status was reached in 67% in 
the thymectomy group compared to 37% in the prednisolone 
only group. The study showed that routine thymectomy in 
patients with MG was helpful even without thymoma (363). 
Extended trans-sternal thymectomy for ocular MG was reviewed 
in a study by Liu et al. They reviewed cases of 115 patients with 
MG. Of these, 92.2% had thymic hyperplasia. The results 
indicated that ETT was safe and effective in OMG, particularly in 
patients with a shorter duration of illness (364). 
Kawaguchi et al studied the effects of thymectomy on late-onset 
MG without thymoma. They followed up 34 MG patients over 
two years. Of these, 20 patients underwent thymectomy; these 
patients had more severe disability at entry than the non-
thymectomized patients but compared to the non-
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thymectomized patients they showed a greater percentage of 
clinical remission (365). 
As described in section 1.5.9, there is a ‘gray zone’ in clinical, 
immunological and pathological terms between the ages of 40 
and 60 years when patients may suffer either from ‘late EOMG’ 
or ‘early LOMG’. Some LOMG thymuses have shown lymphoid 
follicles like in EOMG even in patients over 60 years of age. The 
lymphoid epithelial tissue of the ageing thymus is replaced with 
fat, but residual parenchyma may continue exporting some T 
cells. This could explain why thymectomy appears to be 
effective in LOMG patients. 
Other treatments: 
The REGAIN study which looked at the safety and efficacy of 
Eculizumab in ACHR antibody-positive refractory GMG 
published their results in 2017. The phase 2 study suggested 
that Eculizumab produced clinically meaningful improvements in 
these patients. In the phase 3 study, the primary analysis 
showed no significant difference between Eculizumab and 
placebo. Eculizumab is a humanised monoclonal antibody that 
specifically binds with high affinity to the human terminal 
compliment protein C5, inhibits enzymatic cleavage to the 
protein C5a and C5b which in turn prevents the C5b- induced 
chemotaxis of pro-inflammatory cells and formation of the C5b 
induced membrane attack complex (366). 
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Bortezomib is a proteasome inhibitor and is known to be 
effective in the elimination of malignant plasma cells in multiple 
myeloma and it causes a depletion of short lived and long-lived 
B cells. Schneider Gold et al published a case report on a 
patient with severe refractory MuSK antibody positive MG who 
was treated with Bortezomib. The patient achieved a significant 
and rapid improvement of the severe myasthenia symptoms 
(367).  
Tocilizumab is a blocker of interleukin-6 signalling and has 
been trialled in myasthenia gravis. Jonsson et al published a 
case report of two patients with ACHR antibody myasthenia 
gravis who responded insufficiently to rituximab. The patients 
responded well to Tocilizumab (368). 
There have been case reports where a patient with coexisting 
MuSK antibody positive myasthenia gravis and polycythaemia 
Vera was treated with Ticlopidine and Ruxolitinib which led to 
an improvement of myasthenic symptoms. Ruxolitinib is a 
selective inhibitor of JAK1 and JAK3. 
Acetyl cholinesterase inhibitor is used for temporary 
symptomatic treatment of muscle weakness. There are no large 
randomised or quasi randomised trials for the drug in GMG. 
There was one crossover randomised trial using intranasal 
neostigmine which included 10 patients, three with OMG and 
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seven with GMG. Symptoms improved in nine out of the 10 
participants after a two-week neostigmine treatment. 
Ephedrine was trialled in four patients with AChR MG (Lipka et 
al). Ephedrine as an add-on treatment for MG showed a small 
but consistent reduction of symptoms and weakness in patients 
with moderate disease severity but did show a prolonged 
corrected QT interval (369). 
Leflunomide treatment was trialled in corticosteroid dependent 
MG. Leflunomide is an immunosuppressant that blocks 
pyrimidine nucleotidase biosynthesis. 15 patients who had all 
undergone thymectomy were recruited. After six months, there 
was a significant improvement in QMG by three points or more 
and an improvement in ADL score in 10 participants. In 12 
patients the dose of prednisolone was reduced from an average 
of 24.3mg to 12.3 mg per day. This was a small but promising 
pilot study which showed that leflunomide may be a safe steroid 
sparing immunosuppressant. A longer duration of follow-up and 
a further placebo-controlled study would be helpful (370). 
Several other therapeutic options are being trialled and have 
been suggested. Linarin is a flavone glycoside in plants and is 
shown to have a potent AChE inhibitory activity. It may be a 
promising therapeutic agent in conditions such as myasthenia 
gravis, glaucoma, gastric motility and Alzheimer's disease (371). 
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Autologous haematopoietic stem cell transplantation has 
also been shown to be effective in isolated case reports. 
Fingolimod and Siponimod have been trialled in MG, and 
although there were subtle changes in T-cell responses, they 
had no significant effect on antibody titres or disease severity 
(372). There have been case reports of severe refractory MG 
being treated with high-dose vitamin D treatment (373). 
Rapamycin has been shown to reduce Th17 cells and increase 
the proportion of the Tregs in MG patients in Experimental 
autoimmune myasthenia gravis (EAMG) (374). In rat models, 
preconditioned human mesenchymal stem cells have been 
shown to improve MG symptoms (375). The selective 
Immunoprotease inhibitor ONX-0914 has been shown to 
ameliorate EAMG (376). Immature exosomes derived from 
micro-RNA-146a can work as antigen-specific therapy in MG 
and it is shown to be of benefit in EAMG (377). Hinge-deleted 
IgG4 blocking therapy has been shown to be successful in 
AChR receptor MG in rhesus monkeys (378). Delivery of miRNA 
155 inhibitor by anti-CD20 single chain antibody into B cells 
reduced AChR receptor antibodies and ameliorated EAMG 
(Wang et al) (379). 
Novel biological agents which are relevant and can be tested in 
MG include those that work on: (i) T cell intracellular signalling 
molecules such as anti-CD52, anti-IL-2 receptors, anti-
costimulating molecules and JAK1 and JAK3 (ii) B cells and the 
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trophic factors directed against key B cell molecules (iii) 
complement C3 or C5 (iv) cytokines and cytokine receptors such 
as IL-6 or P 40 subunit of IL-12/IL23 and (v) T and B cell 
transmigration molecules (Dalakas) (380). 
Secondary MG:  
With the advent of immunotherapies, there have been significant 
advances in cancer treatments. One such treatment is the use 
of anti-programmed cell death 1 (anti PD-1) antibodies which is 
used for metastatic melanoma and other cancer entities. They 
act via blockade of PD-1 receptors and inhibit the T-cell effector 
mechanism that limits immune responses against tumours. 
Pembrolizumab and Nivolumab are the anti-PD 1 antibodies 
commonly used. Zimmer et al looked at the immune related 
adverse events associated with PD-1 antibodies; these were 
seen in 138 of 496 patients. In 77 of the 138 patients this 
affected the nervous system. The neurological side effects of 
anti-PD-1 therapy include polyneuropathy, seizures, cranial 
nerve palsies, GBS, meningo-radiculitis and myasthenia gravis 
(381). 
The other immune checkpoint inhibitor commonly used is 
Iplimumab which is a humanised monoclonal antibody directed 
against the immune checkpoint cytotoxic T-lymphocyte antigen-
4 (CTLA-4).  In Makarious et al’s paper of 2017 they reported 
that among the 23 reported cases of immune checkpoint 
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inhibitor associated MG, 2.7% were de novo presentations, 
18.2% were exacerbations of pre-existing MG, and 9.1% 
exacerbations of subclinical MG. The average onset of 
symptoms was within six weeks of treatment initiation. There 
was no association with elevated ACHR antibody titres. There 
was a 30.4% MG specific related mortality (382). 
There are case reports of myasthenia gravis developing with 
chronic graft-versus-host reaction in a patient with acute myeloid 
leukaemia who underwent allogenic haematopoietic stem cell 
transplant. There are other similar case reports in literature 
(Tsutsumi et al) (383). 
Treatments for myasthenia gravis can also be associated with 
complications; steroids are commonly associated with a lot of 
side effects as described above. There has been a case report 
of pyridostigmine causing leucocytoclastic vasculitis as a 
hypersensitivity reaction. Petramala et al reported a case of a 
woman who had an adrenal mass and hypertension. She also 
had subclinical hypercortisolism. An adrenalectomy was done; 
five months later she presented with symptoms and signs of 
myasthenia gravis. It appears that the patient with the 





1.5.14 Outcomes in MG 
Kupersmith retrospectively looked at the long-term follow-up 
database of 147 patients with EOMG who generalise to GMG, 
and suggested that prednisolone delayed the onset of GMG and 
had sustained benefit in reducing the incidence of GMG and 
controlling diplopia. Without steroids, GMG developed in 50% of 
all MG patients, usually within one year (385).  
Heckman and team published a unique sub-phenotype of 
myasthenia gravis which they called ophthalmoplegic 
myasthenia gravis which most commonly affects acetylcholine 
receptor antibody positive patients with juvenile onset 
myasthenia gravis and African genetic ancestry. A few cases 
were found with MuSK antibodies and also in triple seronegative 
myasthenia (386). 
Although myasthenia patients respond well to treatment 
including immunotherapy, a small proportion of patients become 
refractory. Refractory patients are defined as those who cannot 
lower their immunotherapy without clinical relapse and are 
clinically controlled on their immunotherapy regimen, or have 
severe side effects from immunosuppressive therapy. Suh et al 
looked at a retrospective cohort of 122 myasthenia patients who 
were referred to the tertiary neuromuscular clinic. The patients 
were classified as refractory or non-refractory based on 
predefined criteria and the clinical features were compared. 
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14.8% of these patients were classed as refractory.The 
refractory patients were more likely to be younger at onset, 
female, Thymomatous, and anti-MuSK antibody positive (387). 
Myasthenia gravis may become life-threatening if patients have 
respiratory insufficiency or dysphagia, called life-threatening 
events (LTE's). Ramos-Fransi et al did a retrospective analysis 
of 648 patients who presented with MG. Of these, 62 patients, ie 
9.56% had an LTE. 32 classified as class V according to the 
MGFA classification and 30 as class IVB. The median duration 
of disease before the LTE was 24 months. The most common 
related factor was infection. All patients received IV 
immunoglobulins, some requiring a second infusion and a 
further few patients receiving plasma exchange. Median time to 
weaning from ventilation was 12 days and was significantly 
shorter in late-onset myasthenia group. LTE improved in less 
than two weeks in 55.8%, in 20% of patients this took more than 
one month. Four patients died (388). 
Hong et al looked at the prognosis of ocular myasthenia gravis 
in Korea as they conducted a retrospective analysis of 376 
patients with a diagnosis of myasthenia gravis. Patients were 
classed as ocular myasthenia gravis at the time of symptom 
presentation. They looked at secondary generalisation which 
developed in 23.3%, mostly within the first six months, while the 
disease remained ocular throughout the follow-up duration 
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(which was a median of 11.8 months) in the remaining patients. 
AChR antibody positivity and abnormal repetitive nerve 
stimulation and thymoma were frequently observed in patients in 
the generalised group. The study also showed that oral 
prednisolone treatment significantly reduced the risk of 
secondary generalisation whereas abnormal AChR antibodies 
and thymoma were predictive of development of secondary 
generalisation. It is to be noted however that the follow-up 
duration for the study was quite short and the definition of ocular 
myasthenia gravis was at symptom onset rather than three 
months or two years (389). 
Akaishi et al did a two-step cluster analysis of 923 consecutive 
MG patients. They looked at the period from the start of 
treatment until achievement of MM status. They found that 
patients who had ocular MG showed the best early-stage 
response to treatment and stability; this was followed by 
thymoma associated MG and AChR antibody positive MG 
without thymic abnormalities. They found that AChR antibody -
negative MG showed the worst early-stage response to 
treatment (390). 
The outcome of myasthenia gravis treatment can be measured 
using the MGFA post intervention status (PIS). This classifies 
patients as being in complete stable remission (CSR), 
pharmacological remission (PR), having minimum 
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manifestations (MM), having improved (I), remaining unchanged 
(U), becoming worse (W), have an exacerbation (E) or having 
died from MG (D) (391) (Appendix1).  
Andersen et al gathered information from 268 myasthenia 
patients; of these, 64% had attained optimal outcome at two 
years of follow-up, 73% at five years and 75% after 10 years. 
This was more likely to be achieved in patients with late-onset in 
those who had thymectomy and those who had ocular-only 
disease. They concluded that prognosis was favourable for the 
majority of MG patients regardless of age, maximum disease 
severity or antibody status (392). 
A Danish study by Hansen et al looked at all AChR antibody 
seropositive myasthenia patients between 1985 and 2005 and 
were followed up until 2009. Mortality rates (MR) and estimated 
mortality rate ratios (MRRs) were calculated. Of the 702 
myasthenia patients, 302 died during follow-up. The overall 
mortality was higher for patients with myasthenia gravis 
compared to the control group with a mortality rate ratio of 1.41. 
In late-onset women and men, the MRRs were 1.64 and 1.02 
respectively. The total MRR was highest during the first five 
years after diagnosis (393).  
A Thai study from 2017 showed that pneumonia, being on a 
mechanical ventilator, and septicaemia were independent 
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factors associated with poor treatment outcomes in the elderly 
hospitalised myasthenia patients (394). 
Citirak et al have shown that in patients with generalised 
myasthenia gravis, there is significant muscle weakness, and 
this is more pronounced in men than women. Shoulder 
abductors, hip flexors and neck muscles are the most affected 
muscle groups. The duration of disease or treatment intensity 
alone did not predict loss of muscle strength in GMG (395). 
Myasthenic crisis can develop in 15 to 20% of myasthenia gravis 
patients and usually this happens in the first year of illness. This 
may be the first presentation in about 20% of patients. Women 
are twice as likely as men to be affected by crisis and the 
average age is around 59 years (Godoy et al). Myasthenic crisis 
is characterised by severe weakness of the bulbar muscles 
and/or respiratory muscles which causes inability to maintain 
adequate ventilation or permeability of upper airways causing 
respiratory failure and which requires artificial airway or 
ventilatory support. The usual predicting factors are respiratory 
infection in 40%, emotional stresses and micro aspirations in 
10%, changes in medication regimen in 8%, and surgery or 
trauma (396).  
There are many drugs that can exacerbate myasthenia gravis. 
This includes antipsychotics such as the phenothiazines, 
sulpiride, atypical antipsychotics such as clozapine; 
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neuromuscular blocking drugs such as succinylcholine and 
vecuronium;  anticholinergic drugs; cardiovascular medications 
including lidocaine, procainamide, propranolol, quinidine, 
verapamil and statins; neurologic and psychoactive medications 
including chlorpromazine, lithium, phenytoin, carbamazepine, 
trihexyphenidyl and trimethadone; antibiotics including all 
aminoglycosides, ciprofloxacin, macrolides, erythromycin, 
clarithromycin, polymyxins and tetracycline; haematological and 
immunosuppressive medications such as chloroquine, 
penicillamine, occasionally prednisolone and interferons and 
other medications which include  iodinated contrast agents, 
Magnesium, acetazolamide, methocarbamol, interferon-alpha, 
etc. 
A retrospective Taiwanese study of 2016 identified 29 patients 
with myasthenia gravis with 49 admissions to hospital. Of these, 
16 patients were admitted with myasthenia gravis and 13 with 
myasthenic crisis. There were several readmissions reported 
amongst the 15 patients with myasthenic crisis; 14 were 
admitted to the intensive care unit, 8 were intubated and put on 
mechanical ventilators; the median ICU stay was seven days 
and one patient died during hospitalisation and another during a 
further hospitalisation within two years. Most of the patients 
responded well to treatment, plasma exchange being the most 
common one used. Infection was the most common trigger of 
myasthenic crisis and was a significant cause of death. They 
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showed that despite significant morbidity and mortality in 
patients with myasthenic crisis, a favourable long-term outcome 
is possible with intensive treatment (397).  
Records of Chinese GMG patients from 1997 to 2012 were 
reviewed and the findings published in 2015 by Lee et al. The 
median follow-up duration was 114 months and the patients had 
received a variety of immunosuppressive therapy including 
corticosteroids, azathioprine, mycophenolate, cyclosporin and 
thymectomy. Of these, 35 patients i.e. 28.5% had myasthenic 
crisis, 2 patients died. 78% patients had good outcome defined 
by MGFA PIS of ‘complete stable remission’, ‘pharmacological 
remission’ or ‘minimal manifestation’. 19.5% had intermediate 
outcome defined by MGFA PIS of ‘improved’, 2.4% had an 
MGFA PIS of ‘unchanged’, ‘worse’, ‘exacerbation’ or ‘died’. 
Azathioprine therapy was the only independent predictor of good 
outcome (398). 
 
1.5.15 Pregnancy and MG 
Myasthenia gravis is not associated with infertility but it can 
expose pregnant women to an increased risk of maternal and 
foetal complications. Approximately 30% of pregnant women 
have been reported to have experienced an improvement in 
their symptoms, and a third experienced worsening, especially 
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in the first trimester and during the postpartum period. An 
increased rate of exacerbation during pregnancy in the first 2 to 
3 years after diagnosis has also been reported. There is no 
indication for a caesarean delivery as smooth muscle is not 
affected, however, during the third stage of labour, there is 
contraction of the voluntary striated muscles, and hence 
assistance during vaginal delivery may be required. 
Management of pre-eclampsia is particularly challenging 
because of the use of magnesium sulphate which can 
exacerbate myasthenia. When eclampsia is present, alternative 
medications such as phenytoin, phenobarbital, amobarbital or 
benzodiazepines should be used to control seizures. Neonatal 
myasthenia gravis affects 12 to 20% of newborn babies of 
affected mothers. This usually presents with a weak cry and 
swallowing and suckling difficulties and usually is apparent 
during the first hours of life. This usually improves within two 
months. Atypical forms of arthrogryposis multiplex congenita are 
reported to occur in 29% of patients with neonatal myasthenia 
gravis. 
A Portuguese study of 25 pregnant patients with myasthenia 
gravis was reported by Costa Braga et al. Mean maternal age 
was 32.4 years, miscarriage rate was 6.7%, deterioration in 
myasthenia symptoms during pregnancy happened in 43.3%, 
and 46.4% occurred postpartum. There were no maternal or 
neonatal deaths. Mean gestation at time of delivery was 38.2 
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weeks. There were no cases of foetal growth restriction, pre-
eclampsia, preterm delivery, or foetal demise. The caesarean 
section rate was 64.3%. Two newborn babies developed 
transient neonatal myasthenia. A high rate of clinical worsening 
of myasthenia in the mother was observed in this retrospective 
study (399). 
Boldingh et al did a cross-sectional population-based based 
cohort study to look at the risk of clinical onset of myasthenia 
gravis during pregnancy. They found that 11.5% of Dutch and 
18% of the Norwegian patients had their first myasthenia 
symptoms during pregnancy or postpartum period. Postpartum 
period was thought to be significantly associated with the onset 
of symptoms of myasthenia and the risk was highest after the 
first childbirth (400). 
A Brazilian study by Ducci et al found that 50% of pregnant 
women with MG deteriorated, mainly during the second 
trimester, 30% improved, and 20% remained unchanged. The 
course of myasthenia in the second pregnancy was different 
from that in the previous pregnancy in 65.3% of cases. Obstetric 
complications were reported in 20, the most common being 
preterm premature rupture of membranes, and the more severe 
was abortion in 11.4% and foetal death in 2.9%. Most patients 
had a caesarean section (in 66.7%) and transient neonatal 
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The epidemiological studies done to date have shown an 
increasing incidence rate and prevalence rate of myasthenia 
gravis, especially in the older population. Two peaks in 
incidence have been described: in the younger females between 
25 and 35 years of age, and the older males between 60 and 70 
years of age. The majority of the studies are retrospective, and 
in the few done prospectively, the studies include patients with 
an established diagnosis of MG, on a variety of treatments and a 
few new patients diagnosed within the study period. Before the 
advent of antibody tests, the diagnostic criteria for myasthenia 
gravis differed in each study, being defined by the authors. The 
age cut-off for LOMG and EOMG also differs between the 
studies. The method of data collection differs and there is a lot 
of heterogeneity. 
The reason for the increasing incidence has been attributed 
partly to better diagnosis and partly to reduced mortality. 
However, this still does not fully explain the increasing incidence 
of MG. Several hypotheses have been postulated including 
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vaccine exposure, cohort effect, and viral infections. None of 
these have been proven conclusively. 
Studies on ocular myasthenia gravis are also very varied, mainly 
because of the criteria used to define OMG. Some studies 
define OMG as ocular symptoms only for at least two years, and 
some as ocular symptoms only for 3 months. A lot of studies 
define OMG as ocular at diagnosis, or ocular at recruitment 
which is completely arbitrary. These patients have different 
median follow-ups with no prospective data and there are no 
long-term longitudinal studies. The generalisation rates of ocular 
myasthenia gravis also defer because of the different criteria 
used. 
Previous studies have shown clinical and immunological 
differences between late-onset and early-onset MG patients. In 
some studies, LOMG patients are reported to have low AChR 
antibody titres, and are more likely to have anti-striated muscle 
antibodies. In younger patients, AChR antibody levels are 
thought to remain stable and not change with time. AChR 
antibody levels are higher in patients with thymoma and lower in 
patients without thymoma, and who are less than 40 years of 
age. MuSK antibodies are more common in the younger female 
patients in some studies, whereas other studies show that 
MuSK seropositivity is the same as in seronegative myasthenia 
gravis and in EOMG and LOMG. Patients with MuSK antibody 
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positivity are thought to have a more severe clinical course with 
ocular, bulbar and respiratory symptoms, with the majority being 
classified as MGFA class III or more, and a quarter of them 
having myasthenic crises. The treatment response is also 
thought to be different between AChR antibody positive patients 
and MuSK antibody positive patients. LRP4 antibodies are 
thought to be associated with milder disease, more common in 
younger women, with double positive patients having a more 
severe course of MG.  
The big drawback in interpreting the above is that all the studies 
on antibodies in MG are retrospective, with patients on a variety 
of different treatment modalities and disease durations. 
Thymic hyperplasia is thought to be very uncommon in LOMG 
patients. In patients with MG with thymic hyperplasia, studies 
show raised IL-6, interferon-gamma and TNF alpha. Studies on 
Treg levels in MG are contradictory, where some studies report 
low Treg levels and others report normal levels compared to 
healthy controls. There are several studies which show that the 
Tregs are defective in their function. Almost all the studies are 
retrospective, with a handful of prospective studies; even in 
these studies, patients have an established diagnosis of MG for 




Treatment response and outcomes in MG are reported variably, 
again all in retrospective studies. The outcome in ocular LOMG 
patients is better than the other subgroups, although most 
patients do well.  
From the above, we gather that, firstly, there do seem to be 
differences between LOMG and EOMG, and we are trying to 
define this more accurately. Secondly, there is a lack of a large 
prospective cohort study with patients being recruited at 
diagnosis when they are treatment naïve, and lack of long term 
follow up to plot the natural course of the disease and treatment 
response. We are trying to do this by performing a unique, large, 
incident cohort study from diagnosis, with full follow-up, which 
has never been done before. From this careful work, it is then 
possible to make assumptions about LOMG compared to 
EOMG. We aim to do this by studying the clinical aspects, 
including MGC and MGQoL scores, antibody aspects, and 
immunological aspects including Treg cells. 
By doing this, the following questions were addressed: 
 Is the incidence of LOMG greater than EOMG? 
 Could there be a cohort effect leading to increasing 
incidence of LOMG? Could this be attributed to 
environmental exposure, Immunisation or viral infections? 
 Is there a difference in the sex distribution between 
LOMG and EOMG? 
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 Is there a difference in clinical presentation between 
LOMG and EOMG? 
 Is OMG more common in LOMG or EOMG? 
 Is the rate of generalisation of ocular symptoms different 
in LOMG and EOMG? 
 Is there a difference in thymic abnormalities between 
LOMG and EOMG patients? 
 Is antibody positivity different between LOMG and 
EOMG? 
 Is there any difference in clinical presentation between 
the different antibody subgroups? 
 Is there a difference in T reg levels and cytokine levels in 
the peripheral blood lymphocytes of MG patients 
compared to healthy controls and in LOMG patients 
compared to EOMG patients? 
 Is the treatment response different in LOMG and EOMG? 





2.1.1 Patient recruitment 
The Study was conducted at three sites: Nottingham (Queens’ 
Medical Centre), Birmingham (Queen Elizabeth Hospital 
Birmingham) and Oxford (John Radcliffe Hospital). Dr Paul 
Maddison, Consultant Neurologist and the chief investigator 
supervised recruitment in Nottingham, Dr Saiju Jacob, 
Consultant Neurologist and co-Investigator supervised 
recruitment in Birmingham and Dr David Hilton-Jones, 
Consultant Neurologist and Co-Investigator supervised 
recruitment in Oxford. Ethics approval was obtained from the 
NRES committee West Midlands – South Birmingham, REC 
number 12/WM/0414, first of February 2013. 
Approximately 40 patients per year (20 at Nottingham, 10 at 
Oxford, 10 at Birmingham) obtain a new diagnosis of LOMG, 
which would be sufficient numbers to detect significant 
differences in regulatory T-cell function, viral antibody levels, 
and also in V-beta T-cell receptor repertoires (additional to Dr 
Tackenberg’s stored peripheral blood lymphocytes (PBL) 
samples). Power calculations were based on previous studies 
by Tackenberg B et al (237) which indicate that a minimum of 75 
MG patients would be required to have a 90% chance of 
detecting (significant at the 5% level) a significant increase in 
even the most exceptionally expanded (+) T cell Vbeta receptors 
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(>8SD above the mean) compared to controls. Even smaller 
sample sizes would still pick up moderate or major (+) T cell 
Vbeta receptor expansions in LOMG patients compared to 
controls. Roughly 21% of healthy controls show a CD8 TCR 
Vbeta expansion of >3SD. Treg cells form between 1- 20% of 
the CD4+ cells (depending on gating used), and as there are 
twice as many CD4+ cells as there are CD8+ cells, the numbers 
required would be much less than 75. We therefore aimed to 
recruit 35 patients with LOMG and 35 patients with EOMG each 
year for the first two years of the study. In many respects, the 
size of the study in terms of patients was calculated 
pragmatically, the aim to include every single patient with new 
onset MG over the 2 to 3 years (certainly in the Nottingham 
region, where additional researchers, i.e. Dr Maddison, could 
help with the recruiting). Patients would be invited to join the 
study, and planned to be subsequently followed for up to 5 years 
(initially up to 3 years as part of the fellowship, and continued 
follow-up by the lead clinicians for a further 2 years).  
Information about the study was sent to all the Neurologists in 
the three centres and in the peripheral hospitals connected to 
the three hospitals (In Nottingham this was extended to 
contacting Ophthalmologists and going through laboratory data 
for AChR/MuSK Ab test requests). They were requested to 
inform us of any newly diagnosed patients with Myasthenia who 
fit into the inclusion criteria below and to give the patients the 
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information sheets. The patients were then contacted by the 
clinical research fellow (me) or the investigating neurologist. 
Patients were seen at one of the three hospitals- Queen’s 
Medical Centre, Nottingham, Queen Elizabeth Hospital 
Birmingham or John Radcliffe Hospital, Oxford. The study 
details were explained once again and a written consent 
obtained. 
Whilst the aim of the study was to prospectively recruit as many 
newly diagnosed patients with myasthenia as possible across 
the three sites, the recruitment rates varied. It was most 
successful at Nottingham where all newly diagnosed patients 
were recruited making it possible to study demographics further. 
The Birmingham cohort of patients, whilst missing some 
patients, was unselected with no age, sex or race bias. 
 
2.1.2 Inclusion criteria 
Patients had to be above the age of 18 years and should have 
been able to understand the patient information sheet and 
provide informed consent. 
Patients should have had a new diagnosis of Myasthenia Gravis 
(within 12 months of recruitment). On paper this would appear to 
skew the recruitment towards the more mildly affected patient as 
they did not require treatment immediately. However, we aimed 
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to recruit all newly diagnosed patients including those presenting 
within days of symptom onset. The recruitment would run over a 
period of 2 to 3 years, which would balance the recruitment of 
the milder and the more severely affected patient. 
The diagnosis of Myasthenia Gravis was based on clinical 
presentation, positive antibodies in serum to either AChR, MuSK 
or LRP4 and/or electropysiological evidence of Myasthenia on 
Single fibre Electromyography or repetitive nerve stimulation, or 
have shown good response to pyridostigmine and/or steroids. 
Patients should not have been on immunosuppressive 
treatment. They could be on Pyridostigmine. (Caveat to this was 
the newly diagnosed patient admitted either in crisis or as an 
emergency for iv Immunoglobulins, Plasma exchange or 
steroids- these patients would be included, but coded 
separately. This was to ensure that the whole spectrum of the 
disease was covered.) 
 
2.1.3 Withdrawal criteria 
If the patient lost the capacity to understand the nature of the 
study during the study period, they would be withdrawn from the 
study as advised by their attending Neurologist. 
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2.1.4 Proforma for clinical data collection 
Patients were assessed at recruitment and then at year 1 and 
year 2, with an option to be followed up for a further 3 years by 
the recruiting neurologist after the completion of the study. 
Detailed history was taken and a proforma filled in. The 
questions included in the proforma were: 
 Age, sex and race 
 Date of diagnosis and time since symptom onset to recruitment 
 What was their first symptom 
 Do they/did they have ocular symptoms? Is the ptosis unilateral 
or bilateral, partial or complete, variable and fatigable 
 Do they/did they have bulbar symptoms of difficulty with 
chewing, dysarthria, dysphagia; was it variable and fatigable 
 Do they/did they have drooping of the neck 
 Do they/did they have difficulty with breathing; is this exertional 
and/or do they have orthopnoea 
 Do they/did they have limb weakness; is this proximal or distal, 
in the upper limbs or lower limbs 
 Dates of onset of all the symptoms 
 Any other symptoms such as dry mouth or other autonomic 
symptoms; weight loss 
 Past medical history with duration; in particular, past medical 
history of autoimmune conditions 
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 Medication history; in particular whether they are or have been 
on statins with dose and duration 
 Is there a family history of autoimmune conditions 
 Smoking and alcohol history 
 Details of examination findings 
 Quality of Life (QoL) score and MG composite score are 
measured 
 In pure ocular myasthenia patients, Ocular MG score and VFQ 
25 scores. 
 Treatment history during follow up 
 Steroid and other immunosuppressant doses and duration at 
follow up 
 MG PIS scores at follow up 
 Details of hospital admissions and outcomes 
 Time to generalisation of ocular onset myasthenia 
 
 
2.1.5 Myasthenia Gravis (MG) composite score 
The MGC is made up of 10 items including tests for ocular 
involvement (3 items), bulbar involvement (3 items), respiratory 
involvement (1 item), neck involvement (1 item) and limb 
involvement (2 items). Each of these is scored differently with 




The MG composite score as an assessment tool in MG was first 
proposed by Ted Burns and colleagues in 2010 (402). The MGC 
was constructed using the best performing items from the 
quantitative myasthenia gravis scale (QMG), MG manual muscle 
testing (MG-MMT), and MG activities of daily living (MG-ADL). 
The skills were selected for each of 10 functional domains i.e. 
talking, breathing and upper limb strength. Item performance 
from these three scales was based on each item's performance 
during two randomised controlled trials of patients with 
seropositive generalised MG. 
Validity testing of the MGC was conducted in 2008 to 2009 at 11 
neuromuscular centres, nine in the United States and two in 
Europe during the routine care of adults with MG. 175 MG 
patients were enrolled at 11 sites and 151 patients were seen at 
follow-up. During the validation study which included test-retest 
analysis, it was determined that a three point improvement in 
MGC scores reliably indicated clinical improvement. A three 
point improvement in MGC also appeared to be meaningful to 
the patient. Rasch analysis of the MGC confirmed that all 10 
items belonged and could be summed to provide a total score 





2.1.6 Myasthenia Gravis quality of life score (MG QoL) 
The MG QoL score is a health related quality of life score and 
provides information of the patients’ perception of impairment 
and disability from their illness. The MG QoL consists of 15 
items related to everyday life and is scored from ‘not at all’ - 0 
points to ‘very much’- 4 points (Appendix 1). 
The 15 item myasthenia gravis quality of life scale (MG-QOL 15) 
is a health related quality of life (HRQOL) evaluative instrument 
for patients with MG. This was designed to be easy to 
administer and interpret. Ted Burns and colleagues presented 
the study results in 2010 (403). This was a multicentre study 
which demonstrated the construct validity of the MG-QOL15 in 
practice setting. Score distributions were examined for test items 
in different MG patient groups that represented the clinical 
spectrum of the disease. Patients in remission more frequently 
scored test items as ‘normal’ than did patients in other groups. 
Patients with lower/better MG composite scores also more 
frequently scored items as normal than did patients with higher 
or worse scores. There was also appropriate correlation 
between the MG-QOL and the other MG specific scales studied. 
The study findings reflected what troubled MG patients. The 
MG-QOL 15 was found to have construct validity in the clinical 
practice setting and represented an efficient and valuable tool 
for assessing HRQOL for patients with MG. 
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In 2016, Burns and colleagues reviewed the use of the MG-QOL 
15. They performed a rasch analysis on more than 1300 15 item 
MG-QOL completed surveys (404). These results were 
discussed with specialists and biostatisticians. The decision was 
made to revise three items and prospectively evaluate the 
revised scheme using either 3, 4 or 5 responses. Rasch analysis 
was repeated. The MG-QOL 15r performed slightly better than 
the MG-QOL 15. The three response option MG-QOL 15r 
demonstrated better clinicometric properties than the 4 or 5 
option scales. Relative distributions of item and person location 
estimates showed good coverage of disease severity. They 
concluded that the MG-QOL 15r was now the preferred HRQOL 
instrument for MG because of improved clinicometrics and ease-
of-use. This revision did not negate previous studies or 
interpretations of results using the MG-QOL 15. 
As our study was set up in 2014, before the revised score was 
introduced, we continued to use the old MG QoL 15 scores in all 
patients at recruitment and follow-up. 
 
2.1.7 Blood samples 
2.1.7.1 Whole blood samples in Lithium heparin 
20 mls of whole blood was collected in lithium heparin bottles. 
The samples were taken to the laboratory (either at the Queen’s 
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medical Centre, Nottingham or at Birmingham University) within 
4 hours of collection. Peripheral Blood Monocytic Cells (PBMCs) 
also called Peripheral Blood Lymphocytes (PBLs) were isolated 
as per the procedure detailed later in chapter 5. These were 
frozen for further studies of regulatory T cells, Th17 cells and 
cytokines using flow cytometry.  
2.1.7.2 Serum samples 
8-16 mls of whole blood was collected in yellow/golden topped 
serum tubes. These were taken to the laboratory for spinning on 
the same day. The samples were centrifuged at 40C, 3000 rpm 
for 10 mins, at maximum acceleration and brake settings. The 
supernatant which is the sera was pipetted into 0.5 ml eppindorf 
tubes and stored at -800C. In the final year of the PhD, the 
samples were studied at the laboratory at the Department of 
Neurosciences, West wing, John Radcliffe Hospital, Oxford, to 
look for antibodies to AChR and MuSK using 
Radioimmunoprecipitation assays (RIA/RIPA), and AChR, 
MuSK and LRP4 antibodies using cell based assays. 
Additionally, stored serum samples were sent to Sweden to Dr 
Punga’s lab for miRNA testing. 
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2.1.7.3 PAXgene samples 
An aliquot of whole blood was collected in PAXgene tubes 
(Qiagen, Valencia, CA, USA). These were stored in the -80 
freezer for further studies. 
2.1.7.4 EDTA samples 
EDTA samples were obtained and have been stored at -80 for 
future studies on HLA typing (P Gregersen et al, 2012; Renton 
et al, 2015). 
2.1.8 Flow cytometry 
Flow cytometry is the technology that is used to analyse 
physical and chemical characteristics of particles which are in a 
fluid state as it passes through at least one laser. The cell 
components are fluorescently labelled and then they are excited 
by the laser which in turn makes the cells/particles emit light at 
various wavelengths. The fluorescence is measured to 
determine various properties of the single particles, usually cells. 
Up to thousands of particles per second can be analysed as 
they pass through the liquid stream. Examples of the properties 
which can be measured include the cells’ relative granularity, 




Flow cytometry is a standard laboratory tool which is used in the 
evaluation of haematopoietic cells including identifying 
subpopulations of cells referred to as immunophenotyping. 
The cell populations can be characterised using a combination 
of antigens which are both on the surface and intracellularly. 
The practical applications include immunophenotyping, 
measuring intracellular cytokine production, cellular proliferation, 
assessing cell viability and analysis of cell type, stem cells and 
fluorescent proteins. 
It is important to have correct controls to set up the flow 
cytometer and to compensate for any overlap in the emission of 
fluorescence as increasingly multiple antigen markers are used 
during flow cytometry. These controls are usually unstained 
cells, single colour controls and fluorescence minus one (FMO) 
where all antibodies in the panel are added to the cells removing 
a single antibody in turn. 
T regs were officially identified as a distinct population of CD4+ 
T cells which express the α chain of the IL-2 receptor, CD25. 
However CD25 is also expressed by a significant proportion of 
CD45R+ CD45R- effector/memory CD4+ T cells. It was thought 
that 1 to 3% of circulating human CD4+ T cells were T regs, 
however this proportion varied between 1.4 and 20% in various 
studies depending on where the CD25 gate was placed. 
Fazekas de St Groth et al discovered that costaining for CD25 
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and CD127 (α chain of the IL-7 receptor) separated a distinct 
CD25+127 low population; these expressed very high levels of 
FoxP3 mRNA. Staining for these markers is what is commonly 
used for T reg cells although there is no universally accepted 
method (405). 
As well as T reg cells, cytokine levels including IFNα, IFNγ, 
TNFα, IL17, IL4 and IL10 were studied. This was based on 
previously published literature on cytokine abnormalities seen in 
MG. IFNα however, was added on as part of the panel with IFNγ 
and TNFα, and the author acknowledges that this is unlikely to 
provide much information in this context. 
 
2.1.9 Treatment 
Patients recruited into our study were treated in the same 
manner as all other patients, starting with pyridostigmine and 
adding immunosuppressants as and when required. The 
treatment schedule strictly followed the UK myasthenia study 
group national guidelines published in Practical Neurology in 
2015 (although this was a year after we started, because the 
principal supervisor was a co-author for these guidelines, we 
followed the schedule even before publication) (323). If patients 
diagnosed with myasthenia referred to us to be included in our 
study had already been started on pyridostigmine in the 
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meantime, we asked them about their quality of life and 
composite scores pre-pyridostigmine treatment. 
 
2.1.10 Follow up 
Patients were followed up on an annual basis (non-research 
related/clinical follow up in between times was as per individual 
patients’ clinical indication) for two years with an option to be 
followed up for 5 years by the recruiting neurologist. At every 
follow up, the MG composite score and Quality of Life scores 
were repeated along with routine history taking and examination. 
Serum samples were taken to be tested for antibodies. These 
were compared with samples on recruitment to look at the 
effects of time and treatment on antibody levels. In 24 patients, 
whole blood was also taken at first year follow up for PBMC 
isolation and flow cytometric studies. 
 
2.2 Preliminary Work 
In a study supported by the Sir Halley Stewart Trust, Liete et al 
(including the principal supervisor) retrospectively analysed the 
case records of 636 MG patients, with onset of disease at ≥50 
years, who had been studied at one of four UK Myasthenia 
Clinics (Oxford, Belfast, Nottingham and Glasgow), assessing 
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the clinical distribution of muscle weakness, results of 
serological tests and delays in the diagnosis (Leite et al, 2012).  
They found an increasing male bias after onset-age 50; as many 
as 27% of patients had purely ocular symptoms during follow-
up, with a rate of seronegative generalised MG of 13.6%. AChR 
antibodies were identified in more than 50% of the female ocular 
LOMG patients but only in 25% of the male ocular LOMG 
patients. Fifteen percent of patients were misdiagnosed at 
onset, most typically as stroke. In this population, thymoma 
occurrence was low at 3.5%. Sera on 38 of the seronegative 
patients was available for cell-based assay analysis, and found 
to be positive for binding to clustered AChRs (n=15) or MuSK 
(n=10). 
 
2.2.1 Principal aims 
There is accumulating evidence that late onset myasthenia 
gravis (LOMG, disease onset after the age of 50 years) is 
becoming more common for reasons that are not fully 
understood (1). From the initial clinical and immunological UK 
retrospective studies, it was found that myasthenia may present 
differently in this age group, with distinct initial diagnostic 
features, clinical outcomes and responses to treatment 
compared to patients with early onset disease. We aimed to 
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study a prospective cohort of patients with LOMG to establish 
the defining clinical and immunological features which may give 
us an insight into the pathogenesis in this age group, and some 
explanation for the rise in incidence.       
 
2.2.2 Study outcome measures 
This is an observational study of the clinical and immunological 
features of LOMG compared with EOMG. 
2.2.2.1 Primary endpoint 
To define a cohort of MG patients to assess: 
1. Demographic characteristics (including sex ratios) in unbiased, 
unselected, consecutive groups of prospectively recruited 
patients 
2. Associated conditions and family history of autoimmunity 
3. Presenting clinical features: is LOMG worse/milder than EOMG 
at onset, diagnosis, worst stage? 
4. Responses to medication, relapse rates, and outcomes in 
LOMG and EOMG: which drug combinations are beneficial? 
2.2.2.2 Secondary endpoint 
1. To Clarify the immunological features of LOMG to: 
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a. Determine the antibody profile to a number of neuromuscular 
targets (AChR MuSK, LRP4): are these antibodies predictive of 
disease outcome in LOMG, (and possibly thymoma 
development) compared to EOMG? 
b. Assess the frequencies of functional regulatory T-cells: do they 







3 Clinical profile and Phenotypes    
3.1 Introduction 
Epidemiological studies done since the 1950s have shown an 
increasing incidence rate and prevalence rate of myasthenia 
gravis with time, especially in the older population. Initial studies 
show that early-onset myasthenia gravis was more common in 
women and late-onset myasthenia gravis was more common in 
men (96). Meta-analysis of all studies done by both Phillips et al 
(98) and Aarli et al (96) show an increasing prevalence and 
incidence rate of myasthenia gravis, particularly in the older 
population which was variably described as > 40 years of age, 
>45 years, >50 years and >60 years. Myasthenia Gravis was 
also thought to be underdiagnosed in the older patients given 
the other coexisting comorbidities (99). Since then several 
studies have been done across different countries and different 
continents showing an increasing incidence rate of myasthenia 
gravis. The majority of the studies were in patients with AChR 
antibody positivity with a couple of studies on MuSK MG. 
Familial MG was thought to occur in approximately 1 to 4% 
(138). Viruses are thought to have a role in inducing 
autoimmunity in MG and studies on EBV DNA and nuclear RNA 
in thymic tissue was shown to be increased in MG patients (60, 
144) but these studies were not replicated by another Chinese 
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study (145). Similarly, West Nile virus was also thought to be an 
additional risk factor for MG initiation (146).  
For a long time it was thought that myasthenia gravis affected 
young adults and that it was uncommon after the age of 50 
years. During the 1990s it became clear that myasthenia gravis 
was being diagnosed more often in older patients. In 1980 
Compston and colleagues (97) postulated two categories of 
non-thymoma myasthenia patients, one with presentation at less 
than 40 years of age and one after 40 years of age. Those who 
were younger were more often female, and had HLA-A1, B8, 
and DRW3 positive antigens. In the older age group there was a 
significant association with male gender and the presence of 
HLA-A3, B7 and/or DRW2. In 1991 Somnier and co-workers 
reported a bimodal appearance for both sexes with one peak in 
the early onset group and another in the late onset group (406). 
On the basis of this, they proposed that the separation between 
early onset and late onset should be at the age of 50 years 
rather than 40 years. They found that in early-onset male 
patients, the onset was approximately 10 years later than in 
females, while in the late onset group the peak was at the same 
time in years in both sexes. 
Ocular MG has been difficult to define with various cut-off points 
for diagnosis of ocular MG being used. Sommer et al (170) and 
Monsul et al (171) suggested  purely ocular symptoms for at 
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least three months from symptom onset to class them as ocular 
MG. There have been several studies looking at the effect of 
prednisolone on the progression of ocular to generalised MG. 
Several studies (171, 172, 175, 385, 389) have suggested that 
the conversion from ocular to generalised MG was lower in 
patients who were treated with steroids, however Nagia et al 
(173) suggested that conversion rates from OMG to GMG was 
similar in both immunosuppressed and non-immunosuppressed 
patients. 
Patients with LOMG were thought to be more likely to be male 
and did not have thymic hyperplasia (160).  
Clinical presentation of MG is thought to be different between 
different antibody subtypes. Patients with MuSK antibody 
positivity were commonly female, young, and had ocular, bulbar 
and respiratory symptoms. They responded better to plasma 
exchange compared to iv immunoglobulins (151, 154, 407). 
Zivkovic et al (who looked at the clinical presentation of LOMG 
in a retrospective cohort of 174 patients) (155) and Suzuki et al 
(156) suggested that OMG was more common in LOMG 
compared to EOMG; both groups had the same rate of 
myasthenic crisis in EOMG  and LOMG. 
Although the treatment regime for myasthenia gravis is different 
across different countries, in the UK, the treatment regime is 
usually pyridostigmine first, followed by steroids, usually 
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prednisolone, followed by other immunosuppressants if 
necessary. The ABN guidelines for management of myasthenia 
gravis were published in 2015; however, since our principal 
investigator was one of the authors of these guidelines, we 
followed the same treatment plan for all of our patients recruited 
into the study (323). Along with corticosteroids, the other 
immunosuppressants which have been shown to be useful in 
myasthenia include azathioprine, methotrexate, mycophenolate, 
iv immunoglobulins, plasma exchange, and rituximab in 
refractory cases. Several other monoclonal antibodies are also 
being studied. 
There have been several studies on the benefits of thymectomy 
in patients with thymic enlargement; however, the MGTX trial 
compared thymectomy versus no thymectomy in non-
thymomatous myasthenia gravis patients who were receiving 
prednisolone. This showed a significant improvement in QMG 
scores and also dose reduction of prednisolone in the patients 
who were thymectomised (363). This was also reflected in other 
studies (364, 365). 
The refractory patients are thought to be more likely to be 
younger at onset, female, thymomatous and anti-MuSK antibody 
positive (387). The most common reason for patients developing 
myasthenic crisis was thought to be an infection. They showed 
good response to IVIG and plasma exchange; the median time 
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to weaning of ventilation was thought to be shorter in LOMG 
(388). 
Studies looking at the start of treatment until achievement of MM 
status found that OMG patients showed the best early-stage 
response, followed by TAMG and AChR MG without thymic 
abnormalities. AChR antibody negative MG patients showed the 
worst early-stage response to treatment (390). Previous studies 
(408) have also shown that the majority of MG patients had a 
favourable prognosis regardless of age, maximum disease 
severity and antibody status although LOMG patients were more 
likely to achieve optimal outcome. 
Mortality rates in MG have been shown to be higher compared 
to control groups and this is highest during the first five years 
after diagnosis (393).  
The majority of the studies are retrospective and in the few done 
prospectively, the studies included patients with an established 
diagnosis of MG, on a variety of treatments and a few patients 
newly diagnosed within the study period. Before the advent of 
antibody tests, the diagnostic criteria for myasthenia gravis 
differed in each study, being defined by the authors. The age 
cut-off for LOMG and EOMG also differs between the studies. 
The method of data collection differs and there is a lot of 
heterogeneity. Studies in ocular MG are also very varied mainly 
because of the criteria used to define OMG. 
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The drawback in interpreting the above data from the previous 
studies is that the majority of the epidemiological studies, clinical 
studies, and all of the antibody studies were done 
retrospectively, with patients on a variety of different treatment 
modalities and disease durations. 
We tried to perform a unique large incident cohort study from 
diagnosis with full follow-up which has never been done before. 
By doing this, we sought to answer the following questions:  
• Is the incidence of LOMG greater than that of EOMG? 
• Could there be a cohort effect leading to increasing 
incidence of LOMG? Could this be attributed to 
environmental exposure, Immunisation or viral infections? 
• Is there a difference in the sex distribution between 
LOMG and EOMG? 
• Is there a difference in clinical presentation between 
LOMG and EOMG? 
• Is OMG more common in LOMG or EOMG? 
• Is the rate of generalisation of ocular symptoms different 
in LOMG and EOMG? 
• Is there a difference in thymic abnormalities between 
LOMG and EOMG patients? 
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• Is there any difference in clinical presentation between 
the different antibody subgroups? 
• Is the treatment response different in LOMG and EOMG? 




This study was a multicentre prospective study conducted 
across three sites: in Nottingham at the Queen's medical Centre, 
Birmingham at the Queen Elizabeth Hospital Birmingham, and in 
Oxford at the John Radcliffe Hospital. The patients were 
prospectively recruited as soon as possible after a diagnosis of 
myasthenia gravis, but within 12 months of diagnosis. Patients 
were referred to the specialist Neuroimmunology/ 
Neuromuscular clinic at one of the three sites. Referrals from 
other neurologists and GPs were the primary source of 
recruitment, but patients were also recruited after inpatient 
admissions, after email advertisements to ophthalmology 
colleagues, neurophysiology colleagues and general 
neurologists across the region. The study was also advertised 
on the Myaware website. We went through laboratory requests 
for ACHR and anti-MuSK antibody testing in the 
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Nottinghmashire and Derbyshire regions (excluding the northern 
districts) which ensured 100% recruitment rates. 
Whilst the study could not predict the incidence and prevalence 
of MG in all the areas except for the Trent region (as mentioned 
above) (NB: see Table 3), we think that it was powered enough 
to answer the primary and secondary endpoint questions. 
A total of 150 patients with a new diagnosis of myasthenia 
gravis where recruited to the study. All patients were seen and 
assessed by the author at recruitment. During annual follow-ups, 
the patients were reviewed mostly by the author, but also by the 
chief investigator, or by the local investigating officers who 
clinically assessed the patients and performed blood tests and 
questionnaires including the MG composite scores and MG QoL 
scores. Other than for 15 patients, the remaining 135 patients 
were treatment naïve at the point of recruitment. The 15 patients 
(one EOMG and 14 LOMG) who were immunosuppressed had 
been either admitted to hospital, or needed urgent 
immunomodulatory treatment because of crisis or 
bulbar/respiratory symptoms. Most received iv immunoglobulins 
and oral prednisolone (8 patients), others prednisolone only (5 
patients) and two received iv immunoglobulins, prednisolone 
and Azathioprine. Nearly all the patients were recruited during 




Previous literature has shown that EOMG and LOMG may differ 
in severity. Our patient recruitment was unselected, so patients 
of all ages with a diagnosis of MG within the preceding 12 
months were recruited. This ensured that the realtively mildly 
symptomatic patients (in either group) were also recruited. We 
do not think that the differing severity of illness in EOMG and 
LOMG has influenced case ascertainment. 
Patients were followed up on an annual basis for research 
purposes at which time they had a clinical assessment, 
medications were reviewed, MG composite scores and QoL 
scores were repeated, and they had blood tests for serum. 24 
patients, half of whom had been immunosuppressed since 
recruitment and the other half who had not, also had whole 
blood taken at first year follow up for PBMC testing. Home visits 
were done for a few of the patients to ensure good follow-up 
rates. Of the 150 patients, 4 patients were lost to follow-up and 6 
patients had died upto the end of July 2017. 
Patients with thymic abnormalities on imaging were offered 
thymectomy. Patients under the age of 50 years who did not 
have imaging abnormalities were also offered thymectomy 
(although not in all patients) if they had symptoms for less than 
three years. We found that, over the course of the study, we 
were approaching more people with milder symptoms because 
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of the availability of VATS thymectomy. Not all the patients 
opted to have surgery. 
The data included in the current study are from 1st August 2014 
up to 31st July 2017. At the end of this time, the mean follow-up 
time was 354 days, the median time being 330 days. Of the 150 
patients, 120 patients had had their first year follow-up at the 
time the analysis was done and 65 patients had had a second 
year follow-up. 
Some of the clinical data, including for ocular myasthenia gravis 
(OMG), and the antibody profiles was updated in May 2018 with 
further follow up data to include those patients who remained 
ocular at 2 years. 
All the data was analysed by the author using GraphPad Prism 
version 7.01. 
 
3.3 Results  
3.3.1 Demographics 
During the period from August 2014 to July 2017, the patients 
recruited from Birmingham and Oxford were selective, but every 
single patient with myasthenia from a study population covering 
the counties of Nottinghamshire and Derbyshire, UK, excluding 
the northern districts, were included. 
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Of the 150 patients with MG in our cohort, 26% belonged to the 
EOMG group and 74% to the LOMG group. In EOMG, 23 of the 
39 patients were female i.e. 59%, and the remaining 16 of 39 i.e. 
41% were male. In the LOMG group 68/111 i.e. 61.3% were 
male and 43/111 i.e. 38.7% were female (Figure 1). The total 
number of female patients in the whole cohort was 66/150 i.e 
44%; of these, 23 i.e. 34.85% were early onset, and 43 i.e 
65.15% were late onset. There were a total of 84 male patients 
(56%), of these 68 i.e. 80.95% were late onset and 16 i.e. 
19.05% were early onset (Figure 2).  
The mean age of female patients was 57.6 years; in EOMG this 
was 36.17 years and in LOMG this was 66.8 years. The mean 
age of male patients was 61.24 years; in EOMG this was 40.42 
years and in LOMG this was 66.74 years.  
Racial distribution showed no significant difference when 
compared to the national statistics for the area, except for 
under-representation of Asians in the south-east area including 













































Figure1 Male:Female ratio in EOMG and LOMG
Figure 2 EOMG Vs LOMG in Males and Females
 





Birmingham 3 3 41 
Nottingham 2 4 89 
Oxford 1 0 7 
Total 6 7 137 
Percentage 4% 4.67% 91.33% 
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Table 2 Racial distribution compared to national statistics (EM- East 
Midlands, WM- West Midlands, SE- South East)  
Afrocarribean   p value 
Study Vs national statistics 4% Vs 3.3% 0.6313 
Study Vs EM statistics 2.11% Vs 1.8% 0.7823 
Study Vs WM statistics 6.38% Vs 3.33% 0.0373 
Study Vs SE statistics 12.5% Vs 1.6% <0.0001 
Asian 
  
Study Vs national statistics 4.67% Vs 7.5% 0.1882 
Study Vs EM statistics 4.21% Vs 6.5% 0.2553 
Study Vs WM statistics 6.38% Vs 10.8% 0.0811 
Study Vs SE statistics 0% Vs 5.2% 0.0041 
Caucasian 
  
Study Vs national statistics 91.33% Vs 86% 0.0599 
Study Vs EM statistics 93.68% Vs 89.3% 0.0827 
Study Vs WM statistics 87.23% Vs 89.3% 0.4121 
Study Vs SE statistics 87.5% Vs 90.7% 0.1772 
All p value were calculated using the Mann Whitney test 
Data collection for the study was continued after the study 
period included in this thesis (August 2014 to July 2017). In 
March 2019, we had data on 213 patients in total. The clinical 
and immunological profiles of the patients in Nottingham (with 
100% recruitment rates) and Birmingham/Oxford were 
compared (Table 3). There were no staistically significant 
differences between the two groups. This shows that there was 
no bias in the study population between the unselected 
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Nottingham patients (complete case recruitment) and the more 
selected Birmingham/Oxford group. 
Table 3 Comparison of clinical and demographic data between the 
Nottingham region and Birmingham/Oxford regions 






Number 158/213 (74.2%) 55/213 (25.8%)  




64 (18-89) 64 (28-89) P=0.92 
Age ≥50 years 
(LOMG) 
123/158 (77.8%) 40/55 (73%) P=0.46 
Proportion 
female 
75/158 (47.5%) 22/55 (40%) P=0.35 
Ocular 
symptoms only 
at 3 months 





7 (4-12) 7 (4-13.3) P=0.86 
Median MG 
QoL score at 
diagnosis 
19 (6-35) 25 (11.5-34) P=0.13 




175/94 (80%) 48/55 (87%) P=0.27 
1
64 Nottingham patients still needed AChR antibodies assaying (RIA) 
 
3.3.2 Ocular myasthenia gravis defined 
Ocular myasthenia gravis (OMG) is the most common form of 
MG and varying rates of secondary generalisation have been 
reported. Typically between 50 and 80% of patients will develop 
generalised symptoms in the first two years and for this reason 
an arbitrary minimum duration of two years of isolated ocular 
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symptoms is considered a reasonable limit for diagnosing OMG. 
Oosterhuis suggested a minimum of three months as a limit for 
purely ocular symptoms before classifying a patient as having 
OMG (169).  Similarly Sommer et al and Monsul et al also 
suggested purely ocular symptoms for at least three months 
from symptom onset to class them as OMG (170, 171). 
During the course of the study, we first categorised Ocular 
myasthenia Gravis (OMG) in those patients who had ocular 
symptoms at first symptom onset. We then categorised OMG as 
those patients who had purely ocular symptoms at diagnosis. 
However, during final analysis we focused mainly on those 
patients who had purely ocular symptoms at three months since 
symptom onset. This was based on the previous literature as 
above but also on our own findings of ‘time of symptom onset’. 
We found that the median time for onset of bulbar, generalised 
and respiratory symptoms was less than three months. The 
recruitment was unselected, so we do not think that there was a 
selection bias towards the more unwell/ rapid generalisers. 
In total we had 79/150 patients (52.67%) who had OMG at three 
months of whom 27 were EOMG (69.23% of all EOMG) and 52 
were LOMG (46.84% of all LOMG) (p = 0.0163). Amongst the 
younger MG group, 14 were female and 13 male; in the LOMG 
group 19 were female and 33 male (Figure 3).  
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Mean time to generalisation was 457.2 days, and the median 
time was 331.5 days. The shortest time to generalisation was 91 
days and the longest time was 1825 days. At the time of 
analysis, 11 of the early onset OMG patients i.e. 40.74% had 
generalised and 21 of the 52 LOMG patients i.e. 42% had 
generalised (p=0.1353) (Figures 6 and 8). The total 
generalisation rate was 40.51%. (NB: This statistic is different to 
that depicted on Figure 14 because on the graph, all MG patient 
data is included, ie those with OMG only at 3 months, which is 
the data shown here, and GMG, showing when patients first 
developed generalised symptoms. There is an argument then to 
classify some of the GMG patients who generalised quite early 
on in their illness as ‘early generalisers’, those that generalised 
just after 3 months as ‘intermediate generalisers’ and those that 
generalised after 2 years as ‘late generalisers’. For the purposes 
of this thesis, this distinction has not been made). 
The majority of the patients generalised in under one year with a 
rate of 20.25% in total, 14.81% in EOMG and 23.08% in LOMG 
(p=0.2764) (Figure 8). 12 patients generalised between one and 
two years from symptom onset which was 15.19%; the 
distribution was 18.5% in EOMG and 13.46% in LOMG. As the 
data after two years was limited in this analysis, the numbers 
were small; generalisation rate between 2 to 3 years when the 




















Figure 3 OMG (3 mths) with 
EOMG and LOMG distribution




















Figure  4 Unilateral and 
























Figure  5 Ptosis and diplopia in EOMG and LOMG
 
In our cohort we found that 25 EOMG patients had unilateral 
ptosis and 9 had bilateral ptosis; 49 LOMG patients had 
unilateral ptosis and 48 had bilateral ptosis (Figure 4 and 5). 
There was no significant difference between time to 
generalisation between patients with unilateral ptosis and 
bilateral ptosis, both in the EOMG group and the LOMG group. 
Time to generalisation with ptosis only in EOMG versus LOMG 
showed  a significant difference, with generalisation occurring 
much quicker in the LOMG group with a median of 35 days, 
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whereas with EOMG this was 608 days ( p value =0.0385). It is 
not clear why this difference was noticed, but numbers with 
ptosis only in the EOMG group was small (3) and could be one 
of the reasons for this (Figure 7). There was no difference in 
time to generalisation when the ptosis only group was compared 
to patients who had both ptosis and diplopia. 
Ocular QMG scores were recorded in 34 patients with ocular 
myasthenia at recruitment, VFQ 25 scores were recorded in 28 
and VFQ 10 supplement was recorded in 27 patients. In EOMG, 
the median of the ocular QMG score was 4, the VFQ 25 was 
68.5 and VFQ 10 supplement was 24. In LOMG, ocular QMG 
was 4, VFQ 25 was 45, and VFQ 10 supplement was 24. There 
was no statistically significant difference between Ocular QMG 
scores between early onset and late-onset groups (Figure 10). 
There was no difference in VFQ 25 scores between LOMG and 
EOMG, with a p value of 0.0727, the scores being higher in the 
LOMG group (Figure 11). There was no difference between 
VFQ 10 supplement between EOMG and LOMG groups.  
The survival curve of ‘time to generalisation’ in OMG  in patients 
when given steroids pre-generalisation did not show any 
statistical difference compared to when patients were not given 
steroids pre-generalisation (Figure 9). There was no statistical 
difference between time to generalisation of MG between the 
early-onset and late-onset groups with steroids either. 
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Figure 6 Time to generalisation in 
days of OMG (with medians) in 
EOMG and LOMG p-0.1353
Figure 8 Survival curve for time to 
generalisation (in days) EOMG Vs 
LOMG p-0.2764
Figure 7 Time to generalisation 
(with median) with ptosis in EOMG 
and LOMG p=0.0385
Figure 9 Survival curve for time to 
generalisation of OMG in patients 
given steroids pre-generalisation 
and those not given steroids
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed 






Figure 12 Steroid doses in EOMG at 
first and second year follow up (with 
standard error) p=0.0117
Figure 10 Ocular QMG scores (with 
medians) in EOMG and LOMG
Figure 11 VFQ 25 scores (with 
medians) in EOMG and LOMG 
p=0.0727
Figure 13 Comparison of steroid 
doses at first year follow up in 
OMG and GMG
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed 
 
When we compared the steroid doses required in patients with 
EOMG at first year follow up and second year follow-up, there 
was a significant difference in the average doses required. The 
median dose was 10 mg at first year follow up and 7 mg at 
second year follow-up, p = 0.0117 (Figure 12). When the steroid 
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dose in OMG patients was compared with generalised MG at 
first year follow-up, there was no statistically significant 
difference, similarly at second year follow-up (Figure 13).  
 
3.3.3 Symptom onset in myasthenia gravis 
The most common first symptom on presentation was ocular, 
including either ptosis alone, diplopia alone or a combination of 
the two. Of the total of 150 patients, 116 (77.33%) had ocular 
symptoms at onset; this was either purely ocular or in 
combination with bulbar and generalised symptoms. 23 patients 
(15.32%) had bulbar symptoms, 21 patients (14%) had 
generalised symptoms and 2 patients (1.33%) had respiratory 
symptoms at onset. Comparison between the early-onset group 
and late-onset group showed a difference in ocular and 
generalised presentation, being more commonly ocular in 
younger patients and more commonly generalised in the older 
patients but this was not statistically significant (Table 4). 
Although the data is presented in a table form, the comparisons 
made were between individual parameters, e.g, OMG in EOMG 
compared to LOMG. However, when Bonferroni correction was 




Table 4 First symptom onset, either on their own or as a combination 
with other symptoms 




















Ocular 116 77.33% 34 87.18% 82 73.87% 0.0887 
Bulbar 23 15.33% 4 10.25% 19 17.12% 0.3073 
Generalise
d 
21 14% 2 5.13% 19 17.12% 0.0643 
Respiratory 2 1.33% 0 0% 2 1.80% 0.4005 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed; two 
individual parameters were compared 
 
The times of onset of each of the symptoms was recorded for 
every patient recruited and updated during follow-up. This was 
analysed and plotted on a graph as below. Median time of onset 
of ptosis and diplopia was 0 days, dysphagia was 37 days, 
dysarthria 39 days, difficulty with chewing 55 days, limb 
weakness 21 days, neck weakness 70.5 days, and respiratory 





Figure 14 Time of onset of MG symptoms in days with medians. A: all 
patients, B: EOMG, C: LOMG
Medians were used as these were easier to compare. All p values were calculated 
using the Mann-Whitney test as the comparison was between medians of two 
independent groups and not normally distributed. 
 
On comparison of the EOMG and LOMG groups, the order in 
which patients generalised was different for the EOMG and 
LOMG groups. In EOMG, the order of median times of symptom 
onset was: ptosis, diplopia, limb weakness, chewing difficulties, 
dysarthria, neck  weakness, shortness of breath and dysphagia 
(Figure 14 B); whereas in the LOMG patients this was: ptosis, 
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diplopia, limb weakness, dysphagia, dysarthria, chewing 
difficulties, neck weakness and shortness of breath (Figure 
14C).  
The median length of time for generalisation was not different 
(p=0.0581) in the younger and older patients when all the 
medians for the various symptoms were compared. When the 
last to generalise symptoms were compared, again, there was 
no difference; in the younger patients the longest median time 
for generalisation was 561.5 days (dysphagia) whereas for the 
older patients this was 62.5 days (SOB) (p=0.0862). 
Dysphagia appears to affect the younger patients at a 
significantly later stage. On comparison of the time of onset of 
dysphagia in EOMG and LOMG, there was a significant 
difference in median times, 636 days in early-onset and 31 days 
in late-onset, p = 0.0037 (Figure 15A). Onset of dysarthria was 
also once again significant, with median onset time in days of 35 
in late onset and 304.5 in early onset, p = 0.0331 (Figure 15 B).  
There was no statistically significant difference between difficulty 
chewing, with median time of onset in young patients of 184 
days and late onset of 46.5 days, p = 0.1033. Median time of 
onset of neck weakness in younger patients was 636 days and 
in older patients it was 59 days, p = 0.0063 (Figure 15C). There 
was no difference in the median time of onset of limb weakness; 
in younger patients it was 110 days and in older patients it was 
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30 days, p = 0.14364. There was a significant difference in the 
onset of respiratory symptoms with a median of 502 days in 
younger patients and 62.5 days in older patients with p = 0.0009 
(Figure 15D). When Bonferroni correction was applied (adjusted 
alpha level or t* of 0.00625), time of onset of dysphagia and 
respiratory symptoms were still significantly different between 
EOMG and LOMG. 
A B
C D
Figure 15 Comparison of time of onset of (A) dysphagia p=0.0037, (B) 
dysarthria p=0.0331, (C) neck weakness p=0.0063 and (D) SOB in EOMG and 
LOMG p=0.0009
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
201 
 
3.3.4 Clinical phenotypes in early onset myasthenia versus late 
onset myasthenia gravis 
Bulbar symptoms were seen in 13/39 i.e. 33.33% of EOMG 
patients and 68/111 i.e. 61.26% of patients in LOMG. The 
difference was statistically significant, p=0.0027. Limb weakness 
and shortness of breath were present in varying proportions in 
the EOMG and LOMG subgroup as detailed in Table 5 below. 
The frequency of limb weakness in EOMG was 38.46% and 
49.54% in LOMG, p = 0.2344; there was no significant 
difference seen between the males and females in either group.  
Table 5 Presence of limb weakness and shortness of breath (SOB) in 
EOMG and LOMG 
Limb weakness in EOMG: 15/39= 38.46% 
Limb weakness in EOMG Male: 5/16 = 31.25% 
Limb weakness in EOMG Female: 10/23= 43.47% 
Limb weakness in LOMG: 55/111= 49.54% 
Limb weakness in LOMG Male:32/68= 47.05% 
Limb weakness in LOMG Female: 23/43= 53.48% 
SOB EOMG: 7/39 
SOB LOMG: 32/111 
SOB EOMG Female: 5/23 
SOB EOMG Male: 2/16 
SOB LOMG Female: 13/43 
SOB LOMG Male: 19/68 
Shortness of breath was seen in 17.9% of EOMG patients and 
20.83% of LOMG patients, once again not statistically significant 
with p = 0.1842 (Table 6). There was no difference between the 
males and females in either group. Patients with limb weakness 
presented with varying combinations of distal and proximal 
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upper or limb weakness, most commonly both upper and lower 
limb proximal weakness. 
Table 6 p values of number of patients with limb weakness and 
shortness of breath (SOB) between the various subgroups 

























0.2344 0.4465 0.4981 0.2579 0.4328 
SOB 0.1842 0.4654 0.7962 0.2021 0.464 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
We looked at the occupations for all of our patients and there 
was no particular occupation that was more common than the 
other. 
All patients had repeat MG composite scores during follow-up; 
the MG composite scores were also repeated when and if there 
was clinical worsening, or if they were admitted to hospital with 
worsening symptoms or crises. The first MG composite score at 
symptom onset and at their worst (whether at presentation, 
recruitment, follow up or clinical worsening) were recorded, 
along with the time from first symptom onset. The median time 
to worst MG composite score was 91 days with the minimum 
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being at symptom onset and the maximum at 4354 days (Figure 
16). On subgroup analysis, the median time to worst composite 
score in EOMG was 109 days and in LOMG was slightly earlier 
at 90 days. This was not statistically significant with a p value of 
0.1339 (Figure 17). 
Figure 16 Time in days from first MG 
symptom onset and worst MG 
composite score
Figure 17 Time in days (with medians) 
from first symptom onset to worst MG 
composite scores, EOMG Vs LOMG 
p=0.1339
Figure 19 Correlation between 
diagnostic delay and first MG 
composite score
Figure 18 Time from Symptom onset 
to diagnosis in months (with 
medians), EOMG Vs LOMG p<0.0001
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
Figure 19: Simple linear regression used 
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Time taken from initial MG symptom onset to MG diagnosis and 
recruitment was also recorded. The median time from MG 
symptom onset to MG diagnosis in months was 3 months, from 
diagnosis to recruitment was 2.48 months, and time from 
symptom onset to recruitment was 7.895 months. There was a 
significant difference in time to diagnosis from symptom onset 
between EOMG (median of 13.5 mths) and LOMG (median of 2 
mths), older patients being diagnosed quicker than EOMG, 
p<0.0001 (Figure 18). This is different to previously published 
data (99). 
There was no significant difference in MG composite scores 
between patients diagnosed early or late (Figure 19). The other 
more commonly reported symptoms in our cohort were: dribbling 
of saliva, snarl on smiling, difficulty moving the tongue, 
numb/swollen tongue, difficulty pursing lips, facial weakness, 
difficulty opening the mouth, urinary Sx, constipation, dry mouth, 
increased lacrimation, body ache, generalised fatigue, dizziness, 
decreased appetite, weight loss and falls/unsteadiness. 
The more common of these were: dry mouth: 13/150= 8.67%, 
urinary Sx: 4/150= 2.67%, generalised fatigue: 9/150= 6%, and 




3.3.5 Clinical phenotypes with AChR, MuSK, LRP4 Ab positivity 
and seronegative patients 
All 150 of our patients had blood tests looking for anti-AChR, 
anti-MuSK and LRP4 antibodies. Of these, 142 patients were 
positive for one or more antibodies. We had 8 seronegative 
patients (NB: one of these 8 had positive AChR Abs on RIA 
when recruited, but repeat tests including CBAs were negative). 
AChR single positivity was seen in 107 patients, MuSK single 
positivity in 6 patients, LRP4 single positivity in 2, AChR and 
MuSK double positivity in 15, AChR and LRP4 double positivity 
in 9, MuSK and LRP4 double positivity in 1 and seronegativity in 
8. Two patients were positive for all antibodies but the 
conclusion for these patients was that the MuSK and LRP4 
antibodies were possibly non-specifically binding and they were 
likely to be single positive for AChR. The distribution of the 
subtypes is in Table 6. 
A significant difference was seen in AChR single positivity 
between females in the early-onset and late-onset groups. In 
early-onset this was 11/23 and late-onset it was 32/43, p= 
0.0319. Similarly, younger female patients were more likely to 
be double positive for AChR & MuSK antibodies compared to 
the older female patients, but this was not statistically significant 
with p = 0.0824. There was no significant difference between 
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antibody positivity in any of the other subgroups (Tables 7 and 
8).  
Table 7 Antibody positivity in the different subgroups  
      Numbers Percentage   
AChR single + 
EOMG 
Female (23) 11 47.80 
Male (16) 12 75 
LOMG 
Female (43) 32 74.42 
Male (68) 52 76.46 
MuSK single + 
EOMG 
Female (23) 2 8.69 
Male (16) 0 0 
LOMG 
Female (43) 1 2.32 
Male (68) 3 4.41 
AChR & MuSK 
double + 
EOMG 
Female (23) 5 21.74 
Male (16) 1 6.25 
LOMG 
Female (43) 3 6.98 
Male (68) 6 8.82 
AChR & LRP4 
double + 
EOMG 
Female (23) 2 8.69 
Male (16) 1 6.25 
LOMG 
Female (43) 3 6.98 
Male (68) 3 4.41 
Seronegative 
EOMG 
Female (23) 1 4.34 
Male (16) 1 6.25 
LOMG 
Female (43) 3 6.98 





Table 8 Comparison of antibody positivity between subgroups, p 
values 


























- - - 0.5615 0.565 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
Thymic abnormalities were seen in a total of 23 patients who 
had either thymic mass (possibly thymoma) or thymic 
enlargement (possibly hyperplasia). The only significant 
difference in antibody positivity in these patients was in those 
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who had LRP4 antibodies. They were more likely to have thymic 
enlargement/hyperplasia compared to AChR single positivity 
with a p value of 0.0057 (Table 9). However, it is to be borne in 
mind that we only had 2 LRP4 single positives in our cohort. 
Ocular myasthenia gravis was seen in all antibody subtypes 
without a significant difference; the notable difference being 
between patients who were AChR single positive compared to 
AChR & LRP4 double positive (p = 0.0938), OMG being more 
common in double positives (Table 10). 
Table 9 Comparison of thymic abnormalities between AChR single 
positive and the other antibody subgroups, p values.  


























107 6 2 15 9 1 8 
AChR +       0.539
9 










    
All p values were calculated using the Mann-Whitney test as the comparison was 




Table 10 Comparison of OMG occurrence in different antibody 
subtypes, p values. 

















107 6 2 15 9 1 8 
AChR +   0.3903 0.9688 0.7342 0.0938   0.2155 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
There was no difference in first presenting symptoms amongst 
the different antibody subtypes. Over the course of the disease, 
100% of the patients who were MuSK Ab single positive, LRP4 
Ab single positive, AChR & MuSK double positive and AChR & 
LRP4 double positive had ocular symptoms of ptosis and/or 
diplopia. In AChR single positive patients this was 92.5%, in 
seronegative patients ocular symptoms were seen at a slightly 
lower rate of 87.5%.  
There was no difference in the presence of limb weakness. 
Seronegative patients were more likely (but non-significant) to 
have limb symptoms at 62.5% compared to 47.7% with AChR 
single positivity (p=0.4212) and 33.3% with AChR and LRP4 
double positivity (p=0.2433). 
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Bulbar symptoms were seen with equal frequency in AChR 
single+ (58.9%), MuSK single+ (50%) and AChR and MuSK 
double + (60%) patients. However, seronegative patients were 
much less likely to have bulbar symptoms compared to AChR+ 
(p=0.0112) and compared to AChR & MuSK double+ (p=0.0323) 
but there was no difference compared to MuSK+ or LRP4+ 
patients (Table 11). 
There was no difference in respiratory symptoms in any of the 
antibody subgroups including in MuSK MG (Table 12). 
There was no difference in steroid requirements pre- 
generalisation in any of the antibody subgroups but there was a 
significant difference in steroid requirement post-generalisation 
in the antibody subgroups. This was most pronounced in AChR 
and MuSK double positivity with 80% of patients requiring 
steroids compared to 25.2% with AChR single positivity 
(p<0.0001). AChR & MuSK double positive patients were more 
likely to require steroids post- generalisation compared also to 
the MuSK single positives (p = 0.0011), AChR & LRP4 double 
positives (p = 0.0065) and seronegative group (p = 0.0024). 
There was no difference between AChR & MuSK double 




Table 11 Comparison of bulbar symtoms in the antibody subtypes with 























  107 6 2 15 9 1 8 
AChR + 63   0.6683 0.0962 0.9356 0.3997 0.2365 0.0112 
MuSK + 3             0.1386 
LRP4 + 0             0.6171 
AChR & MuSK 
+ 
9             0.0323 
AChR & LRP4 
+ 
4             0.1621 
MuSK & LRP4 
+ 
0             0.7231 
Seronegative 1               
All p values were calculated using the Mann-Whitney test as the comparison was 





Table 12 Comparison of respiratory symptoms in antibody subtypes 
















  107 6 2 15 9 1 8 
AChR + 30   0.5477 0.4962 0.2281 0.7346 0.5355 0.8557 
MuSK + 1               
LRP4 + 1               
AChR & MuSK 
+ 
2               
AChR & LRP4 
+ 
3               
MuSK & LRP4 
+ 
0               
Seronegative 2               
All p values were calculated using the Mann-Whitney test as the comparison was 




Table 13 Comparison of steroid requirement pre and post- 
generalisation in different antibody subtypes, p values.  













107 6 2 15 9 1 8 
AChR +   0.4100 0.6337 0.2719 0.2795 0.7360 0.8451 
MuSK +               
LRP4 +               
AChR & MuSK 
+ 
              
AChR & LRP4 
+ 
              
MuSK & LRP4 
+ 
              
Steroids post 
generalisation 
Seronegative               
AChR +   0.1606 0.4153 <0.0001 0.8424 0.5640 0.4213 
MuSK +               
LRP4 +               
AChR & MuSK 
+ 
  0.0011     0.0065 0.0833 0.0024 
AChR & LRP4 
+ 
              
MuSK & LRP4 
+ 
              
Seronegative               
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
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In comparison, the requirement for alternate 
immunosuppressants in the AChR single positives compared to 
AChR & MuSK double positives was not significant, p = 0.1592. 
Table 14 Comparison of number of hospital admissions in different 
antibody subtypes, p value.  














107 6 2 15 9 1 8 
AChR +   0.4151 0.3286 0.5767 0.5180 0.4888 0.0535 
MuSK +               
LRP4 +               
AChR & 
MuSK + 
  0.3180     0.3806 0.4386   
AChR & 
LRP4 + 
              
MuSK & 
LRP4 + 
              
Seronegativ
e 
              
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
We compared the number of patients requiring hospital 
admissions based on antibody subtypes. There was no 
significant difference in any of the subgroups (Table 14).  None 
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of our 8 seronegative patients required admission to hospital 
with myasthenic crises or worsening symptoms when compared 
to patients with AChR single positives, p value was 0.0535. 
There was no difference in bulbar symptoms between AChR+ 
and MuSK+ patients, and although LOMG patients more 
commonly had bulbar symptoms compared to EOMG patients, 
AChR positivity (including OMG and GMG) was similar in EOMG 
and LOMG. This does not differentiate between LOMG patients 
with GMG who were the ones more likely to be admitted to 
hospital, and who were more likely to be AChR+ compared to 
EOMG. 
The seronegative patients included had the following clinical 
presentation: (NB: Of the 8 seronegatives described above, 1 
had positive AChR RIAs when recruited, but repeat tests 
including CBAs were negative. This patient’s details were 
included in the sero-positive group when neurophysiology 
comparisons were made) (Table 15). 
1.NHS LRP4 +, fatiguable ptosis, no response to pyridostigmine 
2.NHS MuSK CBA +, Thymic hyperplasia, no MG symptoms 
3.Treatment response to pyridostigmine 
4.MG post pembrolizumab treatment 
5.Treatment response to steroids 
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6.NHS AChR RIA +, on no treatment, typical ptosis & diplopia, 
IBM 
7.NHS AChR RIA +, typical ocular MG which then generalised 
 
Table 15 Clinical information for seronegatives on study samples (7 
patients) 
Early onset 2 
Late onset 5 
Ocular Sx at onset 6 
Ocular MG at 3 mths 4 
Generalised MG 2 
Asymptomatic 1 
Bulbar Sx 1 
Limb weakness 5 
Respiratory Sx 2 
Neurophysiology done 5 (all normal) 
 
3.3.6 Effect of co-morbidities in myasthenia gravis 
Along with the clinical presentation of myasthenia, a detailed 
history of other past medical history, comorbidities, smoking 
history, use of statins, alcohol, occupation, preceding infections 
prior to the onset of myasthenia, family history of autoimmune 
conditions, and medication history were obtained in detail. 
Details of smoking, alcohol and preceding infections are 
included under the section on MG composite and Qol scores.  
Our cohort of patients had several different associated 
autoimmune conditions, Asthma being the most common, seen 
in nearly half the patients, followed by hypothyroidism in nearly a 
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quarter. The full list is in Table 16.  43.58% of EOMG patients 
had associated autoimmune conditions compared to 34.23% of 
LOMG patients, p = 0.2989. 43.93% of all the females in the 
study had associated autoimmune conditions compared to 
30.95% of all males, p = 0.1027. 47.82% of female EOMG 
patients had associated autoimmune conditions compared to 
37.5% of male EOMG patients, p = 0.5280.  
Table 16 Frequency of other autoimmune conditions in the MG cohort 
AI condition Total Percentage 
Asthma 27 49.09% 
Hypothyroidism 13 23.63% 
Hyperthyroidism 4 7.27% 
Eczema 2 3.63% 
Pernicious anaemia 2 3.63% 
Primary biliary 
Cirrhosis 2 3.63% 
Type I DM 2 3.63% 
Vasculitis-various 2 3.63% 
Lupus 1 1.81% 
Multiple Sclerosis 1 1.81% 
Polymyalgia 
Rheumatica 1 1.81% 
Psoriasis 1 1.81% 
Scleritis/Episcleritis 1 1.81% 
Urticaria 1 1.81% 
Vitiligo 1 1.81% 
 
There was a family history of autoimmune conditions in 40% of 
all our patients, 51.28% in EOMG and 36.03% in LOMG 
(p=0.0956). Hypothyroidism was the most common (15/60) 
followed by myasthenia gravis in 10/60 (2 of these patients 
belong to EOMG and 8 LOMG). All the affected relatives with 
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MG bar one were first-degree relatives (Table 17). There was no 
correlation between thymic abnormalities and autoimmune 
conditions, either in patients or in their families. 
Table 17 Frequency of autoimmune conditions in family members 
Conditions Numbers 
Hypothyrodism 15 
Myasthenia Gravis 10 
Rheumatoid arthritis 9 
Multiple Sclerosis 7 
Asthma 6 
Type I DM 6 
Lupus 5 
Coeliac disease 2 
Hyperthyroidism 2 
Inflammatory Bowel disease 2 
Pernicious anaemia 2 
Polycythaemia 2 
Ptosis 2 
Aplastic anaemia 1 
Macular degeneration 1 
MND 1 
Myelofibrosis 1 
Polymyalgia Rheumatica 1 
Pulmonary fibrosis 1 
 
Other than for autoimmune conditions, there was no recurring 
theme with other comorbidities, other than the most commonly 
seen comorbidities in an elderly population including 
hypertension and diabetes. There were a few patients who also 
had cancers; 5 patients in our cohort had breast cancer- 4 were 
positive for AChR antibodies, and one was double positive for 
AChR & MuSK; 1 patient with AChR antibody had thyroid 
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cancer; 1 patient with gastric cancer was AChR & MuSK+; 2 
patients with colorectal cancers were positive for AChR 
antibodies; 1 patient with lung cancer developed MG after 
Pembroluzimab infusion and was seronegative, and 1 AChR 
antibody-positive patient with prostate cancer. We also had two 
patients with inclusion body myositis of whom 1 was 
seronegative for MG antibodies and the other positive for both 
MuSK and LRP4. 
We compared AChR titres in patients who were on statins with 
those who were not on statins; this did not show any statistically 
significant difference p = 0.630. As salbutamol is used for the 
treatment of Congenital Myasthenia, we were interested to see 
whether usage of salbutamol inhalers for asthma made any 
difference to ACHR titres. There was no significant difference 
when compared to patients who did not use salbutamol, p = 
0.8137; there was no significant difference in their MG 
composite scores either. (NB: Most patients used salbutamol on 
an ‘as needed basis’ and not regularly). 
 
3.3.7 Neurophysiological findings  
Neurophysiological studies in our cohort consisted of repetitive 
nerve stimulation (RNS) and/or single fibre electromyography 
(SFEMG). Some patients also had routine nerve conduction 
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studies (NCS) and/or electromyography (EMG). When this data 
was analysed at the end of July 2017, a total of 55 patients had 
neurophysiology studies done; 18 EOMG patients and 37 LOMG 
patients. The subdivision was 10 female EOMG and 8 male 
EOMG, 14 female LOMG and 23 male LOMG. The total number 
of SFEMGs performed was 49 and of these 14 were normal. Of 
the 35 abnormal SFEMGs, 33 showed increased jitter and 21 
showed conduction blocks. RNS was done in 38 patients, of 
these, 22 were normal and 16 abnormal, all of which showed a 
decrimental response. 4 patients also had routine EMGs, 3 of 
which were normal and 1 showed myopathic changes. 2 
patients had NCS, one of which was normal and one showed 
neuropathic changes. The breakdown of the neurophysiology 









Table 18 Results of neurophysiological studies. N: Normal, D: 
Decremental response, J: Increased Jitter, B: Conduction Block, nd : 
not done 




















1 D J B 16.46 2.5 2 0.5 
2 N J B 1217.73 3 0 0 
3 nd N   0.72 1 1.5 2.5 
4 nd N   -0.16 1.5 0 0 
5 nd J B 1.70 0 1.5 0 
6 D J   1855.07 3 0 0 
7 N N   0.07 2 0 0.5 
8 D J   -3.65 3 1 0 
9 N J B 161.20 2.5 0 0 
10 nd J B 25.98 1 0.5 0 
Mal
e 
11 D J B 6.07 2.5 0 0 
12 nd J   6.03 2 0 0 
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13 nd N   0.69 0.5 0 0 
14 nd N   2.20 0 0 0 
15 N J   4.67 2 0 0 
16 N N   4.82 0 0 2 
17 nd J   20.08 2.5 0 0 






19 D J B 1640.42 3 0 0 
20 N J   300.85 3 0 0 
21 N N   0.77 0.5 0 0 
22 nd N B 0.97 0 0 0 
23 D J B 374.94 3 0 1 
24 D J   9.41 0 0.5 0 
25 D nd   941.02 3 0 0 
26 N nd B 0.94 0 0 0 
27 D J   1.79 3 0 0 
28 N N   386.55 3 0 0 
29 D nd   34.45 2 1.5 0 
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30 N nd   1239.29 3 0 0 
31 N J B 281.37 2.5 0 0 
32 N N   58.87 2 0 0 
Mal
e 
33 N nd   177.32 2 0 0 
34 nd J B 304.12 2.5 0 2 
35 N N   191.20 2.5 0 0 
36 N N   -0.04 0 0 0 
37 nd J B 122.61 2.5 0 0 
38 N N   2.67 0 0 0 
39 N J B 185.67 3 0 0 
40 nd J   68.17 2 0 0 
41 D J B 46.74 2.5 0 0.5 
42 D J B 15.38 3 0 0 
43 D nd   12.38 3 2 0 
44 D nd   312.84 2.5 0 0 
45 nd N   14.32 2 0 0 
46 N J B 451.32 3 2 0 
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47 N N   706.82 2.5 2 2.5 
48 nd J B 0.85 0 1 0 
49 D J B 69.11 2.5 0 0 
50 nd J B 1237.67 2.5 0.75 0 
51 N J   986.15 2.5 0 0 
52 D J B 97.98 3 0 0 
53 N J   300.32 3 0 0 
54 nd J   34.03 1.5 0.5 1.5 
55 nd J   291.82 2.5 0 0 
 
Five of our eight seronegative patients had neurophysiology 
studies done. (NB: one of these 8 had positive AChR RIAs when 
recruited, but repeat tests including CBAs were negative and 
was included in the sero-positive group when neurophysiology 
comparisons were made). 
 
3.3.8 The Thymus gland in myasthenia  
Of our 150 patients, 137 patients had their thymus imaged, and 
almost all of them were CT scans. Of these, EOMG patients 
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were 36/39 and LOMG 101/111. Abnormalities were found in a 
total of 32/137; EOMG 18/36 (50%) and in LOMG 14/101 
(13.86%). Thymic abnormalities in EOMG versus LOMG: 
p<0.0001. NB: Not all patients were imaged, and not all patients 
who had thymic abnormalities on imaging had a histological 
diagnosis. 
Thymic enlargement or hyperplasia (possible hyperplasia on CT 
or confirmed on histology) were seen in 61.11% of EOMG 
patients with thymic abnormalities (11/18). The proportion of 
thymic enlargement/hyperplasia in EOMG when compared with 
all EOMG patients who had their thymus imaged was 30.55% 
(11/36), thymoma(possible thymoma on CT or confirmed on 
histology) was 16.67% (3/36). None of the LOMG patients had 
thymic enlargement/hyperplasia, EOMG Vs LOMG for thymic 
enlargement/hyperplasia was significant, p<0.0001. 
Thymoma/thymic mass in all LOMG patients imaged was 
10.89% (11/101), compared with EOMG this was not statistically 
significant (p = 0.664). There were 4 EOMG and 3 LOMG 
patients who had residual thymic tissue, also reported as an 
abnormality in the statistics above. This classification of thymic 
abnormalities has been used by Klimiec et al in their paper on 




The number of EOMG patients who had a histologically 
confirmed diagnosis of thymic hyperplasia was 8 and thymoma 
was 2. The total number of scan abnormalities in EOMG 
(excluding a confirmed diagnosis of thymoma) was 16 i.e. 
43.24%. If we were to assume that, by definition, all EOMG 
patients have thymic abnormalities, this is perhaps indicative of 
the numbers in whom the thymus is enlarged enough to be 
picked up on imaging. 
AChR RIAs were compared in patients with thymoma/thymic 
mass in the LOMG and EOMG groups; there was no statistically 
significant difference (p = 0.2799) and this still remained 
statistically insignificant when the seronegatives were taken out 
of the calculation, p = 0.6593 (Table 19 and Figure 20). 
Figure 20 AChR RIA titres (with medians) 





Table 19 Thymic abnormalities with antibody titres and scores 






























2.5 2 0.5 
2.75 0 0 0 
1217.73 3 0 0 
23.55 2 0 0 
2.24 0.75 0 1.5 
4.82 0 0 2 
242.9 2.5 0 1 







2.0 0 2 0 
2.64 1 0 0 





3 1.5 0 
91.75 Median: 
91.75 
3 0 0 
CT 89.59 2.5 0 0 
Residual 
thymic 
Surgery           
CT 0.72 Mean: 6.80 1 1.5 2.5 
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0 0 1 




Surgery -    -  - - 





3 0 0 
260.85 1.5 0 0 
408.02 Median: 
408.02 
3 0 0 
68.17 2 0 0 
2725.15   3 0 0 







453.64 3 0 0 
250.66 2.5 0 0 
1239.29 3 0 0 
417.90 2.5 0 0 







3 0 0 








3.3.9 MG composite scores 
The MG composite score is a clinical questionnaire based on 
clinical examination and history taking. The minimum score is 
zero (asymptomatic) and the maximum 50 (severe MG, on 
mechanical ventilation). We filled in MG composite scores on all 
patients at recruitment and at annual follow-up (f/u). When we 
compared the MG composite scores in all patients at point of 
recruitment with first year follow-up, there was a significant 
change in the medians (6 at recruitment and 0 at 1st year f/u) 
with p<0.0001 (Figure 21A and B). This was reflected in both the 
EOMG group where medians were 6 at recruitment and 0.5 at 
first year follow-up, p<0.0001; and in the late onset group with a 
median of 7 at recruitment and 0 at first year follow-up, 
p<0.0001.  
We further analysed the MG composite scores in patients who 
were immunosuppression naive at recruitment and 
immunosuppressed at first year follow-up. There was a 
significant difference in medians of 7 at recruitment and 0 at first 
year follow-up, p< 0.0001.  
When the MG composite scores were compared between 
EOMG and LOMG groups this was significantly different, 
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p=0.0287; the median for EOMG was 6 and for LOMG was 7 
(Figure 23).  
We compared MG composite scores in patients who had a 
history of preceding infections prior to the onset of MG with 
those who did not give any history of preceding infections. There 
was no significant difference in their MG composite scores. This 
was the same in both EOMG and LOMG groups. 
A B
Figure 21 MG composite scores at recruitment and first year follow up 
in all patients A: with  medians, B: paired p<0.0001
Figure 22 MG composite scores (with 
medians) at recruitment and at first 
year follow up, subdivided into those 
who were given steroids in the first 
year to those who were not
Figure 23 Comparison of diagnositic
MG composite scores between EOMG 
and LOMG (with medians) p=0.0287
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
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MG composite scores were compared between patients with a 
smoking history and non-smokers; there was no significant 
difference, p = 0.9698, and was similar in the EOMG and LOMG 
groups. The MG composite scores in the male smokers 
compared to the female smokerswas also not statistically 
significantly different, p = 0.0803 (Figure 24). 
Patients with a history of alcohol intake were divided into 
groups- ‘consuming no alcohol’, ‘drinking alcohol rarely’, 
‘moderate amounts of alcohol’ and ‘history of alcohol excess’. 
They were compared using the one way ANOVA test. There 
was no significant difference amongst the groups. 
MG composite scores were compared between patients who 
used salbutamol inhalers for asthma with those that did not; 
there was no statistical significance between the groups. 
MG composite scores at point of recruitment were compared 
between those patients who were immunosuppressed at 
recruitment with those patients who were immunosuppression 
naive at recruitment. The median was 17 for the 
immunosuppressed patients and 6 in the non-
immunosuppressed patients with p< 0.0001 (Figure 25).  
The MG comp scores of patients who were immunosuppression 
naive at recruitment but were immunosuppressed at first year 
follow-up were compared; the median for first year follow-up was 
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0 and at recruitment was 1 and there was no statistical 
significance, p = 0.7099 (Figure 22). Similarly at the second year 
follow-up there was no statistically significant difference between 
patients who were immunosuppression naive at recruitment but 
had been immunosuppressed at second year follow-up. 
Figure 24 Comparison of 
diagnostic MG composite scores 
between female and male smokers 
(with medians) p=0.0803
Figure 25 Comparison of diagnostic 
MG composite scores (with medians) 
in patients immunosuppressed at 
recruitment with those who were 
immunosuppression naïve p<0.0001
Figure 26 Comparison of MG 
composite scores (with medians) in 
single Ab positive patients with double 
seropositive patients p=0.4694
Figure 27 Correlation between MG 
Composite scores and MG QoL at 
recruitment p<0.0001 and R2 of 
0.3309  
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 




MG composite scores were compared in patients who were 
seropositive for a single antibody compared to all double 
seropositives in any combination; there was no statistically 
significant difference between their medians, p = 0.4694 (Figure 
26). 
We compared the MG composite and QoL scores at 
recruitment; there was a significant correlation, with p<0.0001 
and R2 of 0.3309 (Figure 27). 
 
3.3.10 Quality of life scores 
MG quality of life score (MG-QoL 15) measures how the patients 
perceive their illness and how they feel that myasthenia impacts 
on their lifestyle. We measured MG-QoL scores at recruitment 
and at annual follow-up. The minimum score obtainable is 0, 
meaning the patient was happy, and the maximum is 60, 
meaning the patient had a very poor quality of life. We 
compared the MG-QOL scores at recruitment and at annual 
follow-up; there was a significant difference in the scores, 
median at recruitment was 22 and at first year follow-up was 5, 
p<0.0001 (Figure 28A and B, Figure 33). This difference was 
more significant in the LOMG group with a median of 22 at 
recruitment and 5 at first year follow up, p<.00001 (Figure 31). 
For the EOMG patients the difference was just below 
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significance with medians of 18 at recruitment and 4.5 at first 
year follow-up, p = 0.0594 (Figure 30).  
There was a significant difference in the MG-QOL in patients 
who were treatment naïve at recruitment and were given 
immunosuppression at first year follow up (median 27.5 at point 
0 and 10 at year one follow-up, p <0.0001) (Figure 32).  
 
Figure 28 Comparison of QoL scores at recruitment and first year follow up in 
all patients; A: with medians, B: paired p<0.0001
A B
Figure 29 Comparison of MG QoL
(with medians) between EOMG and 
LOMG at recruitment p=0.4629
Figure 30 Comparison of QoL scores 
(with medians) at recruitment and 
first year follow up in EOMG patients 
p=0.0594  
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
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We looked at correlation between changes in composite score 
and QoL from point of recruitment to 1st year follow-up; the 
trend was improvement in both parameters with a few outliers 
(Figure 34). 
There was no difference between MG-QOL scores between 
EOMG and LOMG patients at recruitment (p = 0.4629) (Figure 
29); there was no significant difference in MG-QOL in patients 
who had preceding infections prior to MG onset compared to 
those who did not, and this was the same in both the EOMG and 
LOMG groups. 
There was no difference in the MG QoL between smokers and 
non-smokers, p = 0.3311; this was the same in the EOMG and 
LOMG subgroups. There was no difference in MG-QOL scores 
between the male and female smokers either. There was no 
difference between the MG-QOL scores between patients who 
drank no alcohol, compared to the other categories which were 
‘rarely drinks alcohol’ ‘moderate alcohol’ and ‘excess alcohol’. 
There was no statistically significant difference between MG-
QOL in patients who were on statins compared to those who 
were not on statins. 
There was no difference in MG-QOL scores between patients 
who were positive for a single antibody compared to those who 




Figure 31 Comparison of QoL scores 
(with medians) at recruitment and first 
year follow up in LOMG patients 
p<0.0001
Figure 32 Comparison of QoL scores 
(with medians) at recruitment and 
follow up in patients who were 
immunosuppression naive at 
recruitment and were treated with 
steroids in the first year p<0.0001
Figure 33 Comparison of MG QoL
scores (with medians) at recruitment 
(treatment naive) with first year follow 
up - on immunosuppression and 
without immunosuppression
Figure34 Correlation between 
percentage change MG composite 
scores and QoL scores over the first 
year
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 





3.3.11 Myasthenia related admissions to hospital 
We analysed the data up to the end of July 2017 looking at 
patients who were admitted to hospital during the period of the 
research study over three years. 6/39 EOMG patients (15.38%) 
and 40/111 LOMG patients (36.03%), p = 0.025, were admitted 
to hospital (Table 20). The total number of admissions also 
differed between the younger and older patients, older patients 
frequently requiring more than one admission (EOMG Vs LOMG 
admissions, p = 0.0036).  
Table 20 MG related admissions (Percentages are of total admissions, 7 
for EOMG and 15 for LOMG) 


















2 28.57% 15 30% 
Admission for 
another reason, 
diagnosed with MG 
during admission 






2 28.57% 14 28% 
Admission for 
exacerbation of MG 
Sx 
3 42.86% 13 26% 
Admission for non 
MG reasons 
0 0% 5 10% 
Admission with side 
effects of MG Rx 
0 0% 2 4% 
Total admissions 
  





1 14.29% 1 2% 
Steroids only 
  
2 28.57% 13 26% 
ivIg only 
  
0 0% 4 8% 
Plex only 
  
0 0% 1 2% 




4 57.14% 23 46% 





Steroids and other 
immunosuppressant 
  
0 0% 2 4% 
Other Rx (eg. 
Antibiotics) 
  
0 0% 5 10% 
PEG/NG fed 
  




1 14.29% 2 4% 
Good outcome 
  




3 50% 2 5.12% 
Death 
  
0 0% 1 2.56% 
 
There were several different reasons for admission; some 
patients were admitted with myasthenic symptoms but without a 
known diagnosis at that point, but most admissions were 
because of exacerbation of myasthenia symptoms or elective 
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admissions for initiation of steroids. There were a couple of 
admissions because of side-effects of myasthenia treatment. 
More than half the patients required a combination of IV 
immunoglobulins and steroids (and also an additional 
immunosuppressant in some patients) in both the EOMG and 
LOMG groups. About a quarter of the patients required steroids 
only, 3 patients in total required ITU admission- 1 EOMG and 2 
LOMG patients. The majority of patients in the LOMG group had 
a good outcome; half the patients had a good outcome in the 
EOMG group and the other half were categorised as moderate 
outcome. There was one death in the LOMG group during 
admission. 
The overall mortality over the three-year period was 4/150 
(2.6%), all of them in the LOMG group. One female patient died 
from aspiration pneumonia; of the three male patients, one had 
cardiac failure and dilated cardiomyopathy with AF and was 
thought to have passed away from non-myasthenia related 
problems. One patient had acute coronary syndrome and 
respiratory arrest which was thought to have been contributed to 
by myasthenia, the fourth patient had a malignant thymoma, 
although the exact cause of death was not clear. Overall, the 





3.3.12 Treatment and effect of early immunosuppression on 
disease progression 
Of our 150 recruits, 15 patients were immunosuppressed at the 
time of inclusion into the study. This was because of bulbar or 
respiratory symptoms and/or myasthenic crisis. 14 of the 15 
belonged to the LOMG group, 4 females and 10 males; and 1 
was a younger female. Of the 15, 14 had generalised MG at 
diagnosis and one had OMG. The majority of patients were 
older- this could be due to several factors including other co-
existing comorbities which meant that they sought or were 
referred to hospital earlier than younger patients, or as 
described earlier in the chapter, LOMG patients had a higher 
MG composite score at recruitment compared to EOMG, 
perhaps indicating a more symptomatic onset in these patients. 
All 15 patients were given steroids, 10 patients had IVIG, and 
none of the patients had plasma exchange or IVIG on its own. 8 
patients had a combination of IVIG and prednisolone, 2 patients 
had a combination of IVIG, prednisolone and were started on 
azathioprine, and 5 patients had prednisolone only. The dosage 
of IVIG used was 0.4g/Kg/day for five days. In all patients 
prednisolone was started at either 5 mg or 10 mg a day (or 
equivalent alternate day dosing) and increased gradually to 
between 25 mg a day and 60 mg a day. One of the patients was 
admitted to ITU, needed mechanical ventilation, had a 
respiratory arrest and an acute coronary event and died. 
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Amongst the remaining 135 patients, all patients were treatment 
naïve at recruitment which ensured a realistic comparison of 
treatment response. We divided the daily dose of steroids 
required into categories:  <5 mg, 5 to 9.9 mg, 10 to 14.9 mg, 15 
to 19.9 mg, 20 to 29.9 mg, 30 to 39.9 mg, 40 to 49.9 mg and 
≥50 mg. The distribution of numbers and the comparison of 
doses are listed in Table 21. NB: during analysis of the data, 
less than half the patients (65) had had a second year follow-up. 
The daily dosage of steroids required in all patients was 
compared at first year follow-up and second year follow-up; 
there was a significant difference in dosage (p = 0.0053) (Figure 
35A and B). There is no set way to measure steroid 
requirements. We documented what dose of steroids the patient 
needed at the time of assessment (yearly follow ups) for 
symptom control and compared these doses. 
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24/12 




















There was a significant difference in the steroid doses in EOMG 
(OMG and GMG) at first and second year follow-up, the median 
being 16 mg at 1st year follow-up and 6.25 mg at second year 
follow-up, p = 0.0333 (Figure 35C). There was a difference also 
in steroid doses in LOMG (OMG and GMG)  at first and second 
year follow-up, median of 10 mg at first year follow-up and 7 mg 
at second year follow-up, P = 0.0195 (Figure 35 D).  
There was no significant difference in the steroid doses between 
EOMG and LOMG at first year follow-up, p = 0.2515 (Figure 
36A) or at second year follow-up, p = 0.5290 (Figure 36B). 
Steroid doses in OMG at first and second year follow-up were 
significantly different, p = 0.0117, with a median of 10 mg at first 
year follow-up and 7 mg at second year follow-up (Figure 36A). 
The average steroid dose in GMG at first and second-year 
follow-up did not show any difference, the medians being 10 mg 
in both cases, p = 0.2502 (Figure 36B). 
There was no difference in steroid dose between OMG and 
GMG at first year follow-up p = 0.6862; there was no statistically 
significant difference in steroid dosages in OMG and GMG at 
second year follow-up, 7 mg in OMG and 10 mg in GMG, p = 



















































































Figure 35 Comparison of steroid doses at 1st and 2nd year follow up (with 
medians). A: number of patients in each category, B: in all patients p=0.0053, 




All p values were calculated using the Mann-Whitney test as the comparison was 








Figure 36 Steroid doses (with medians) in EOMG and LOMG at (A) first year 
p=0.2515 and (B) second year follow up p=0.5290
Figure 37 Comparison of steroid doses (with medians) at 1st and 2nd year 
follow up in (A) OMG p=0.0117 and (B) GMG p=0.2502
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
We compared the data for conversion rates for OMG to GMG. 
The survival curve did not show a significant difference. When 
the medians were assessed using the Mann Whitney-U test, 
there was no difference in P value either. There was no 
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difference in time to generalisation between LOMG and EOMG 
(p = 0.1353) (Figure 40). 
Figure 39 Comparison of AChR RIA 
titres (with medians) pre-treatment at 
recruitment, with titres at 1st year 
follow up on immunosuppression 
p<0.0001
Figure 38 Comparison of steroid 
doses (with medians) between OMG 
and GMG at 2nd year follow up 
p=0.1674
Figure 40 Survival curve for time to generalisation 
of OMG with and without steroids pre-
generalisation p=0.1353
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 





MGFA PIS scores were calculated for all patients at annual 
follow-up. When the MGFA PIS scores were compared at first 
year follow-up between EOMG and LOMG, there was a 
difference, LOMG patients did better than EOMG, similarly at 
second year follow-up (Figure 42). When all patient categories 
were compared, there was no significant difference in their PIS 
scores at first and second year follow-up (Figure 41). 
Figure 41 MGFA-PIS in all patients at 
1st and second year follow up. 0: 
CSR, 1: PR, 2: MM-0, 3: MM-1, 4: MM-
2, 5: MM-3, 6: I, 7: U, 8: W, 9: E, 10: D
Figure 42 Comparison of MGFA-PIS in 
EOMG and LOMG at 1st year follow up
Figure 43 MGFA-PIS (paired) patients at 1st and second year follow up in (A) 
OMG and (B) GMG. 0: CSR, 1: PR, 2: MM-0, 3: MM-1, 4: MM-2, 5: MM-3, 6: I, 7: U, 
8: W, 9: E, 10: D
A B
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
249 
 
When MGFA PIS scores in OMG patients was compared at first 
and second year follow-up, there was an improvement (Figure 
43A). When MGFA PIS in GMG were compared at first and 
second year follow-up, there was no statistically significant 
difference (Figure 43B). 
Clinical improvement as measured by the MG composite score 
had also improved from point of recruitment to first year follow-
up; and although there was no statistically significant 
improvement between first and second year follow-up, the trend 
was towards improvement. Similarly with the QOL scores, there 
was an improvement between scores at recruitment and first 
year follow-up and although patients continued to improve, there 
was no statistically significant difference between first and 
second year follow-up scores. 
AChR RIA titres also fell significantly from point of recruitment to 
follow-up, with a significant improvement in the first year, and a 
further slight reduction in the second year (Figure 39). 
 
3.4 Discussion of clinical findings 
In the introductory chapter, we listed a set of questions which we 
sought to answer with our prospective study. We were able to 
answer almost all these questions based on the results above. 
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Is the incidence of LOMG greater than that of EOMG? 
Epidemiological studies in the last 65 years have shown that late 
onset myasthenia gravis is becoming increasingly more 
common. In our cohort of 150 MG patients, more than three 
quarters of the patients (76%) were over the age of 50 years, in 
keeping with published data. The mean age of female patients 
was 57.6 years and in males was 61.24 years, again depicting 
the more frequent incidence in late-onset group. We found a 
difference in the medians of peak age of 4 years in male and 
female EOMG patients (lower in females) which is less than that 
reported by Somnier et al but the peak age in LOMG males and 
females is no different, which is consistent with that previously 
reported (406). Whilst our study recruited all the newly 
diagnosed patients in the Trent region, this was not the case 
with Birmingham and Oxford and so we could not comment on 
increasing incidence rates of LOMG overall, but we have shown 
that that LOMG is more common than EOMG. 
Could there be a cohort effect leading to increasing incidence of 
LOMG? Could this be attributed to environmental exposure, 
Immunisation or viral infections? 
From our detailed questionnaire (listed in chapter 2), we were 
unable to ascertain any environmental, infectious, occupational 
or medication triggers in our patients in either EOMG or LOMG. 
This analysis was based purely on the questionnaire and no 
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laboratory or immunological tests were done to look into this. 
We did not check for EBV infection for example which has 
previously been shown to have some association with MG (144). 
Is there a difference in the sex distribution between LOMG and 
EOMG? 
In Jon Aarli's paper of 2008 he found that the female to male 
ratio was 1:1.1 for LOMG, and 3:1 in EOMG (96). Evoli and 
colleagues stated a female to male ratio of 1:1.9 in LOMG (151). 
Our data has shown a female to male ratio of 1:1.6 in LOMG 
and 1.4:1 in EOMG. Our study has shown that late-onset 
myasthenia gravis in male patients has increased even further 
whilst the number of female EOMG patients has dropped.  
There have been a few studies on racial distribution in MG. 
Population-based studies in several different countries and 
across continents show a similar incidence and prevalence rate 
and similar distribution of EOMG and LOMG patients. A study by 
Oh and colleagues in Alabama, USA showed that AChR Ab 
positivity was more common in white americans (WA) compared 
to African-americans (AA), SNMG AA patients were more likely 
to be MuSK Ab positive, three quarters of OMG AA patients 
were seronegative, and disease onset was earlier and more 
common in females amongst AA patients compared to WA 
patients in whom it was later in onset and more common in 
males (410). Whilst this was large study with 235 patients and 
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good follow up, it was a retrospective study looking at patienst 
treated in a single neuromuscular clinic, and may not reflect the 
true incidence or prevalence. Another study in Norway and 
Netherlands looked at the prevalence between the native and 
emigrant population and did not find any difference. They noted 
that the incidence of MuSK MG and MG with thymoma was 
higher in the emmigrant population compared to the native 
population (114). In our cohort, there was no significant 
difference in racial distribution across the three regions where 
patients were recruited i.e. West Midlands, East Midlands and 
the South East England. Whilst recruitment in Birmingham and 
Oxford was selective, we recruited all patients with a diagnosis 
of myasthenia across Nottinghamshire and Derbyshire excluding 
the northern districts, and hence these results are truly 
representative of the racial distribution of myasthenia in the 
area. 
Is OMG more common in LOMG or EOMG? And, Is the rate of 
generalisation of ocular symptoms different in LOMG and 
EOMG? 
Ocular myasthenia gravis (OMG) has been more difficult to 
define because of varying time limits applied across several 
different studies. Defining OMG based on ocular symptoms at 
diagnosis or recruitment is completely arbitrary and does not 
provide any useful clinical information about disease 
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progression (172, 173). Oosterhuis suggested a minimum of 
three months as a limit for purely ocular symptoms before 
classifying a patient as having OMG (169).  Similarly Sommer et 
al and Monsul et al also suggested purely ocular symptoms for 
at least three months from symptom onset to class them as 
OMG (170, 171). 
We defined our cohort of OMG patients as all patients who had 
purely ocular symptoms up to and including three months from 
symptom onset. This was based on previous literature but also 
on our own findings of ‘time of symptom onset’. We found that 
the median time for bulbar, generalised and respiratory 
symptom onset was less than three months. There is an 
argument to classify some of the GMG patients who generalised 
quite early on in their illness as ‘early generalisers’, those that 
generalised just after 3 months as ‘intermediate generalisers’ 
and those that generalised after 2 years as ‘late generalisers’. 
For the purposes of this thesis, this distinction has not been 
made 
Whilst previous studies have shown that OMG was more 
common in LOMG compared to EOMG (155, 156) neither of the 
papers mentions how they defined OMG. This means that 
interpreting this data is almost impossible and difficult to 
compare. Our study has shown that younger patients have 
ocular myasthenia gravis more frequently compared to LOMG, 
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whereas the older patients more frequently have generalised 
myasthenia gravis. Generalisation of OMG has not been 
reported in an entirely treatment naïve cohort of patients before. 
We found that the generalisation time from OMG is similar in 
both EOMG and LOMG patients. It appears that the majority of 
the patients generalise in under a year, more frequently in 
LOMG than EOMG. We had reviewed 120 patients for their first 
year follow-up and 65 patients for their second year follow-up at 
the time of data analysis, and although this data was not 
complete at the time of writing, the numbers are still significant 
enough to reflect realistic generalisation rates. As there are no 
large-scale studies looking at treatment naive patients over a 
course of time, we did not have any published data to compare 
this against. The one study by Kamarajah et al which studied 93 
MG patients from symptom onset over a period of 11 years (and 
for which the author and chief investigator of this research study 
are co-authors), looked at the natural history of ocular patients 
who were not treated with immunosuppression. They found that 
46% of the patients during the study period developed GMG. 
They also showed that the median time to generalisation was 
earlier in patients who were AChR antibody-positive, had 
bilateral ptosis at onset, and were younger in age (174). 
In our own cohort, there was no difference in presentation with 
unilateral or bilateral ptosis in the EOMG and LOMG patients, 
and there was no significant difference between time to 
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generalisation between unilateral ptosis and bilateral ptosis in 
either group. In patients who had ptosis only, there was a 
difference between the EOMG and LOMG groups with 
generalisation occurring more quickly in the older patients 
(perhaps due to smaller numbers in the EOMG group who had 
ptosis only); but when generalisation rates were compared 
between the ptosis only group and patients who had both ptosis 
and diplopia, there was no statistically significant difference. It is 
not entirely clear whether presenting with ptosis only in an older 
patient is an independent risk factor for generalisation. 
There have been several studies looking at the effect of 
prednisolone on the progression of OMG to GMG. Several of the 
studies suggest that early treatment with steroids decreases the 
progression of OMG to GMG. The EPITOME study which was 
the only RCT designed to look prospectively at steroid response 
in patients with OMG was not completed as planned although 
they did suggest that low dose prednisolone appeared to be 
safe and well tolerated for treatment for all types of MG (176). In 
our cohort, when we looked at the survival curve for time to 
generalisation in OMG patients who were given steroids pre-
generalisation against those who were not given steroids pre-
generalisation, there was no difference. There was no difference 
between the EOMG and LOMG groups either. There was no 
difference in time to generalisation of OMG between LOMG and 
EOMG; however, LOMG patients as a whole developed 
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generalised symptoms earlier than EOMG, which was just under 
statistical significance, p=0.0581 (described below). From our 
data, it appears that treating an OMG patient with steroids does 
not change generalisation rates. This is important in clinical 
practice; however, this was not a drug trial. In order to confirm or 
refute this, an RCT would be required. Given that the well 
designed, international EPITOME trial failed to recruit patients, 
this may be difficult to do, but should nonetheless be tried. 
There was no significant difference between VFQ 25 scores 
VFQ 10 supplement scores in EOMG and LOMG groups. 
Essentially, our data shows that OMG is more common in 
EOMG than LOMG, which is different to previously published 
data. This difference is perhaps in part due to different 
definitions of OMG used, and partly because our study was a 
prospective longitudinal study whilst the published papers were 
retrospective. However, there is no difference in the type of 
ocular presentation or generalisation rates of OMG in EOMG 
and LOMG. This is novel data that has not been published 
before. 
Is there a difference in clinical presentation between LOMG and 
EOMG? 
Because of the prospective nature of our study, recruiting 
patients when they were treatment naïve, and within the first 
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year of diagnosis, we were able to plot the onset of all MG 
symptoms from point zero and compare the median times of 
symptom onset for all the different symptoms. This has not been 
done before and is novel data. The median time of symptom 
onset for all symptoms when compared shows that the longest 
median time of symptom onset is less than three months at 87 
days. This was one of the reasons why we defined ocular MG as 
ocular symptoms only for more than 3 months.  
Although the general order of symptom onset seems to be 
similar in all patients, with ocular symptoms occurring first, 
followed by other generalised symptoms, there was a difference 
in the order of symptom onset between EOMG and LOMG 
groups. Neither presentation with ocular symptoms (more 
common in EOMG) nor generalisation rates (quicker in LOMG) 
were significantly different. EOMG patients presented with 
dysphagia, dysarthria, neck weakness and respiratory 
symptoms at a much later stage than LOMG patients which was 
statistically significant. The median time of onset of chewing 
difficulties and limb weakness was not significantly different 
between the two groups.  
During the course of the disease, bulbar symptoms were seen 
much more commonly in LOMG patients compared to EOMG 
patients. There was no difference in limb weakness in the 
EOMG and LOMG groups, nor with respiratory problems. There 
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was no difference in symptom presentation in males and 
females in any of the groups.  
We looked at the timing of the worst MG composite scores from 
symptom onset in all patients and found that the majority of the 
patients had the worst MG composite score during the first year, 
in nearly 3/4 of them, and most of them within the first 100 days, 
in 53.33%. This would suggest that patients are at their worst 
with MG-related symptoms during the first year and 
subsequently improve, with or without treatment. On subgroup 
analysis, there was no difference in time to worst MGC between 
EOMG and LOMG. 
We compared MG composite scores in patients who were 
diagnosed early compared to those in whom there had been a 
diagnostic delay and there was no difference. There was a 
significant difference in time to diagnosis from symptom onset 
between EOMG (median of 13.5 mths) and LOMG (median of 2 
mths), older patients being diagnosed quicker than EOMG. This 
is different to previously published data (99). The study by 
Vincent et al was a very large prospective study using positive 
AChR Ab test results from all UK centres. This was not a clinical 
study and was not longitudinal. Our study on the other hand is 
prospective with high quality recruitment including referrals from 
other Neurologists, GPs, Ophthalmologists, Neurophysiologists 
and Laboratory data. The patients were recruited from regions 
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where there was a neurology service which ensured better pick 
up rates and reduced selection bias. Also, LOMG patients more 
commonly present with GMG, are more likely to have other 
comorbid conditions, and more commonly require admission to 
hospital, which may be why we see this difference. 
Older patients were also more likely to require admission to 
hospital. This could be multiple times compared to younger 
patients. There are contradictory reports in literature, where 
some studies suggest that MG crises are more common in 
younger females, whilst other show no difference (390) (392, 
394). It is to be noted that, in our cohort, amongst the LOMG 
patients needing admission, nearly three quarters were not for 
MG crises (Table 19), whereas nearly half the admissions in 
EOMG patients were with MG crises. So, whilst the total number 
of admissions is greater in LOMG patients, within the total MG 
admissions, MG crises were more common in younger patients. 
One could argue that neurologists have a lower threshold for 
admitting older patients to hospital as they are more likely to 
have other co-morbidities making them more susceptible to 
deterioration/ steroid dips, whereas younger patients are 
admiited when they are clinically much worse and/or in crisis. 
MG composite scores, which we used as our tool for clinical 
assessment for patients at recruitment and follow-up, showed a 
significant change in median scores at first year follow-up 
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compared to at recruitment in both EOMG and LOMG. Similarly, 
this difference was seen in patients who were treatment naïve at 
recruitment and were immunosuppressed at first year follow-up. 
There was also a significant difference in the MG composite 
scores between EOMG and LOMG groups, being higher in 
LOMG compared to EOMG. This suggests that patients do 
better with time, and that older patients have a more severe 
illness at onset. 
The MG composite scores for the 15 patients who were 
immunosuppressed at recruitment compared to the patients who 
were immunosuppression naïve at recruitment showed a 
significant difference. This was likely to be reflective of the fact 
that patients who required immunosuppression at recruitment 
were at the severe end of the disease spectrum, requiring 
admission to hospital in crises or bulbar/respiratory symptoms. 
MG composite scores in patients who were immunosuppression 
naïve at recruitment but were immunosuppressed at first year 
follow-up did not show any statistical significance and there was 
no difference at second year follow-up either.  
The MG composite scores and QOLs seem to have a linear 
correlation. There was no difference between MG QOL between 
EOMG and LOMG patients at recruitment. The MG QOL in our 
cohort also improved when recruitment scores were compared 
with first year follow-up and this difference was more significant 
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in the LOMG group compared to the EOMG group. The QoL 
scores in the older patients may have been influenced by other 
co-existing medical problems. There was also a significant 
difference in MG QOL in patients who were treatment naïve at 
recruitment and those who were immunosuppressed in the first 
year. LOMG patients had worse MG composite scores and QOL 
scores at recruitment but seemed to respond well to treatment 
clinically and in quality of life, doing much better than EOMG 
patients. 
There was no difference in MG composite or MG QoL scores in 
patients who had preceding infections prior to the onset of MG 
symptoms to those who did not; there was no difference in both 
the scores between smokers and non-smokers. Alcohol intake 
and salbutamol inhalers did not make any difference to their 
scores either. Although unlikely, the reasoning behind asking 
about inhalers was to see if Salbutamol, which is used in some 
forms of congenital MG, made any difference to the symptoms. 
This is of course not a direct comparison, as the doses used and 
methods of delivery are different in the two conditions. There 
was no difference in MGC or MG QOL in patients who were 
single positive for one antibody compared to double positives. 
There were other associated symptoms seen in our patients, 
including dry mouth in 8.6% urinary symptoms in 2.67%, fatigue 
in 6%, and weight loss in 7.33%. This is similar to reported 
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literature, although none of the studies were longitudinal cohort 
studies (71, 83, 411). Whether urinary symptoms are related to 
MG or to the use of pyridostigmine is unclear. 
Other autoimmune diseases associated with myasthenia have 
been reported to be very common, the most common being 
autoimmune thyroid disorders (91). It has also been reported 
that the frequency of second autoimmune disorders is higher in 
females and EOMG group who are more likely to be AChR 
antibody-positive and have GMG (93). In our cohort we found 
that asthma was the most common other autoimmune disorder 
followed by hypothyroidism. Comparison between EOMG and 
LOMG patients did not show any difference at 43.58% and 
34.23% respectively; 43.93% of all the females in the study and 
30.95% of all the males in the study had associated autoimmune 
conditions. There was no difference between the younger 
female and younger male patients either. This may be partly 
because asthma was not included as an AI condition in the other 
papers, and this may have narrowed the difference in our own 
cohort. 
Previous literature has reported that familial autoimmunity in 
patients with MG is common and has been seen in 40% of 
EOMG patient relatives and 20% of LOMG relatives (93). 4% of 
the relatives had MG. In our cohort we found that family history 
of autoimmunity was 40% overall, more common in EOMG at 
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51.28% and 36.02% in LOMG in keeping with literature; 
however, this was not statistically significant. Hypothyroidism in 
the family seems to be the most common autoimmune disease 
followed by myasthenia gravis in 10/60 patients (16.67%) and a 
rate of 6.67% overall of familial MG.  Studies on the effects of 
HLA on the age of onset of MG have shown mixed results. 
Different HLA haplotypes have been linked to EOMG and 
LOMG, but it is not clear why familial MG and indeed of other 
autoimmune conditions is more common in EOMG (129-142). 
One explanation could be that although HLA haplotypes may be 
shared between siblings, disease susceptibility could be defined 
not only by HLA-DR but also by other genetic factors including 
gene-gene interactions. Why this would be different in younger 
patients compared to older patients is unclear. 
Other than for autoimmune conditions, there was no correlation 
with other comorbidities in our MG cohort. We had two patients 
with inclusion body myositis in our cohort, one of whom was 
seronegative and one who was double positive for MuSK and 
LRP4. 
There have been several case reports in literature associating 
statin use with myasthenia gravis (412). We compared AChR 
titres, MG composite scores and MG QOL in all patients who 
were on statins with those who were not on statins and there 
was no significant difference. The rationale for looking into this 
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was to see if patients on statins had a more severe illness/ had 
worse MGC scores. 
Previous studies and literature have shown that single fibre 
EMG (SFEMG) has more sensitivity and specificity compared to 
RNS; however, because of the easy availability of RNS this was 
the diagnostic test recommended by AAEM (413). In a study by 
Punga and colleagues (188) they showed that RNS was normal 
in patients with severe GMG and they recommended using 
concentric needle electrode myography instead. In our cohort, 
SFEMG was abnormal in 66.67% compared to 43.24% of RNS 
abnormalities; this was not statistically significant, although in 
keeping with literature. Only four patients had routine EMG of 
which one showed myopathic changes. Of the 8 seronegative 
patients, 5 had neurophysiology of which two were abnormal 
showing blocks on SFEMG, the other three were normal.  
Our data shows that LOMG patients are more likely to have 
bulbar and respiratory symptoms than EOMG patients, and they 
also develop these symptoms significantly earlier than EOMG 
patients. Age seems to be the factor here rather than sex, as 
there was no difference between male and female patients. 
LOMG patients have worse MG composite scores and QOL 
scores at recruitment but seem to respond well to treatment 
clinically and in quality of life, doing much better than EOMG 
patients. The rates of autoimmunity were the same in EOMG 
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and LOMG, but family history of autoimmunity was more 
common in EOMG than LOMG. 
Is there any difference in clinical presentation between the 
different antibody subgroups? 
Of our 150 patients, the majority were single positive for AChR 
antibodies, with a small proportion positive for MuSK antibodies 
and LRP4 antibodies. We had a large number of patients who 
were double positive for AChR and MuSK, AChR and LRP4, or 
MuSK and LRP4, and 8/150 who were seronegative. Two 
patients were triple positive but were thought to be single 
positive for AChR with non-specific binding for the other two. 
The reason for this differentiation between double postives and 
triple positives was that in the double positives, the binding was 
to the expressed receptors- either EGFP tagged AChR or MuSK 
or untagged LRP4 receptors, whereas in triple positives, the 
binding was to the cell surface/ other proteins as well as the 
expressed receptors. 
There was a significant difference in AChR single positivity in 
the females in EOMG and LOMG in our cohort, being much 
more frequent in LOMG patients. This is different to previously 
published data by Burke and colleagues who suggested that 
LOMG patients had lower AChR titres and were more likely to 
have striated muscle antibodies (414). Although more younger 
female patients in our cohort were double positive to AChR and 
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MuSK compared to older female patients, this was not 
statistically significant. Previous studies by Zisimopoulou et al 
looked at double positivity with LRP4 Abs. They found that it 
was more common in young females, and they had a more 
severe illness than those with single positivity to LRP4. Our 
study has found this with MuSK and AChR; whilst this cannot be 
directly compared, we can infer that as both these antibodies 
are pathogenic at different targets, together they can cause a 
more severe disease (207). MuSK antibody positivity was also 
not statistically significant in our EOMG or LOMG groups or 
between males and females, which is different to published 
literature which suggest that MuSK positivity is more commonly 
seen in young females (151, 154). This is discussed in more 
detail in the antibodies chapter. Ocular myasthenia gravis was 
also seen at the same rate in all antibody subtypes, and 
although OMG was more common in AChR and LRP4 double 
positivity, this was not significant. This is again different to 
previously published data which suggests that AChR and LRP4 
double seropositivity is more likely to be associated with bulbar 
symptoms and a more severe course (206). It is not entirely 
clear why this difference was seen, but the number of LRP4 Ab 
positive patients in our cohort was relatively less than that in the 
study. 
There was no difference in first presenting symptom in our 
cohort amongst any of the different antibody subtypes. Over the 
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course of the disease, all patients (100%) who had antibodies to 
MuSK, LRP4, MuSK and AChR double positive, and AChR and 
LRP4 double positive had ocular symptoms, whereas AChR 
single positive patients had ocular symptoms in 92.5% and 
seronegative patients had ocular symptoms in 87.5%; neither of 
which were statistically significant. This would suggest that 
AChR Abs and seronegative patients can have ocular sparing 
MG, whereas this is not the case with the other Abs. 
Previous literature has suggested that patients with MuSK 
antibodies are more likely to be female, younger, without 
thymoma and more likely to have bulbar and respiratory 
involvement (154, 161). They were also found to remain 
immunosuppression dependent and needing rituximab. In our 
cohort we did not find any difference in bulbar symptoms 
amongst patients who had antibodies to MuSK, AChR, and 
MuSK and AChR double positive. However, seronegative 
patients were much less likely to have bulbar symptoms 
compared to AChR single positives, and compared to AChR and 
MuSK double positives. This difference was not seen between 
seronegatives and MuSK and LRP4 single positive patients. 
One could assume that seronegative patients have an as yet 
unidentified Ab that is less pathogenic than AChR. However, 
since they are clinically more similar to patients with MuSK and 
LRP4 Abs, this does not make sense. Any interpretation of this 
should be made with caution as the number of single positive 
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LRP4 patients was small, and there were only 8 seronegative 
patients. The subgroups did not show any difference in the 
frequency of limb weakness. There was no difference in 
respiratory symptoms in any of the antibody subgroups including 
in MuSK MG. Whilst there was a trend towards MuSK MG 
patients being more commonly female and having more bulbar 
and respiratory symptoms, this was not statistically significant. 
Whether this is a reflection of the fact that this was a prospective 
study with follow up data for two years in the majority of patients, 
and whether these patients would deteriorate later on in their 
course of illness is unclear. This is discussed further in the 
antibodies chapter. 
We did not find any difference in thymic abnormalities in the 
different antibody subgroups except for patients with LRP4 
antibodies who were more likely to have thymic hyperplasia 
compared to AChR single positivity. However, it is to be borne in 
mind that we only had 2 LRP4 single positive patients in our 
cohort. Also to be borne in mind, the data was based on scan 
findings of thymic enlargement with subsequent tissue diagnosis 
in most of these patients. This presumes that a normal scan 
excludes thymic abnormality which may not be the case, 
particularly in EOMG. 
Steroid requirements pre-generalisation was no different in any 
of the antibody subgroups; but, post generalisation i.e. in GMG 
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patients with AChR and MuSK double positivity, the steroid 
requirement was much higher (80%) compared to AChR single 
positives (25.2%), MuSK single positives, AChR and LRP4 
double positives, and the seronegatives. When compared to the 
MuSK and LRP4 double positive group, it was still higher but not 
statistically significant. In comparison, the requirement for 
alternate immunosuppressants in AChR single positive 
compared to AChR and MuSK double positive was not 
significant. It has been reported in literature that MuSK MG 
follows a more severe course, and patients were more likely to 
require alternate immunosuppression- more commonly plasma 
exchange or rituximab. We did not see this difference in our 
cohort, except for higher rates of steroid requirement in AChR 
and MuSK double positives. This would suggest that in our 
cohort, although the clinical presentation between the AChR and 
MuSK subgroups was not significantly different, the double 
positives were harder to treat implying perhaps a more brittle 
myasthenia? 
Our data of the clinical phenotypes in the different antibody 
subgroups suggests that there is no difference in bulbar, limb, 
respiratory and ocular symptoms in any of the subgroups, 
except for seronegative patients who are less likely to have 
bulbar symptoms. AChR Ab positivity is seen more commonly in 
older females compared to younger females; all the other 
antibody subgroups are comparable between younger and older 
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patients and females and males. AChR and MuSK double 
positive patients require steroids more frequently in GMG 
compared to other antibody subgroups. Seronegative patients in 
our cohort did not require admission to hospital suggesting that 
they may have a less severe illness and a more indolent course 
compared to the antibody positive subgroups. 
Is there a difference in thymic abnormalities between LOMG and 
EOMG patients? 
Previous reports in literature have shown that thymic 
hyperplasia is seen in 50-60% of EOMG patients and is not 
seen in LOMG patients (51, 52, 415).  
Of our 150 patients, 137 had imaging to look for thymic 
abnormalities. The total number of abnormalities, including 
thymoma/thymic mass, thymic hyperplasia/enlagment and 
thymic remnants, are more commonly seen in EOMG patients, 
in 50% compared to LOMG, 13.86%. Thymic 
enlagment/hyperplasia (depending on CT findings or confirmed 
on histology) was much more commonly seen in EOMG patients 
in 30.55% compared to 0% in LOMG. Thymomas/thymic mass 
(depending on CT findings or confirmed on histology) were seen 
in 16.67% of EOMG patients, compared to 10.89% in LOMG 
patients which was not significantly different. We did not find any 
difference in AChR titres amongst patients with thymoma in the 
LOMG and EOMG group. Overall, in our cohort, younger 
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patients appear to have more frequent thymic 
hyperplasia/enlargement and thymoma/thymic mass compared 
to LOMG. The data was based on scan findings of thymic 
enlargement with subsequent tissue diagnosis in most of these 
patients. This presumes that a normal scan excludes thymic 
abnormality which may not be the case, particularly in EOMG. 
This means that our data is not directly comparable to published 
studies, and this would require categorising patients into 
histologically normal and abnormal groups; however, our data 
suggests that thymic hyperplasia is much more common in 
EOMG than LOMG. 
 
Is the treatment response different in LOMG and EOMG? And, 
Is the clinical outcome different in LOMG and EOMG patients? 
Previous studies have reported that 14.8% of MG patients are 
refractory to treatment and they are more likely to be young 
female patients with anti-MuSK antibodies and with thymomas. 
Life-threatening events have been shown to occur in 9.56% of 
MG patients (387, 388). In our cohort, we found that 15.38% of 
EOMG patients and 36.03% of LOMG patients required 
admissions to hospital for MG related reasons. The older 
patients were also more likely to be admitted more frequently 
compared to younger patients. The majority of admitted patients 
were older- this could be due to several factors including other 
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co-existing comorbities which meant that they sought or were 
referred to hospital earlier than younger patients, or as 
described earlier in the chapter, LOMG patients had a higher 
MG composite score at recruitment compared to EOMG, 
perhaps indicating a more symptomatic onset in these patients. 
Previous studies have shown that prognosis is favourable in all 
MG patients, but LOMG patients are more likely to achieve an 
optimal outcome (392). In keeping with this, the majority of the 
patients in our cohort responded well to treatment with 92.5% of 
LOMG patients attaining a good outcome compared to 50% in 
EOMG patients. 2.56% of patients, all LOMG, died during an 
admission to hospital. It would seem then, contradictory to say 
that LOMG patients had a better outcome. This is explained by 
the fact that the majority of patients admitted to hospital had a 
proportionately good outcome compared to the EOMG patients. 
The overall mortality rate over the three-year period in our 
cohort was 4/150 i.e. 2.6%, all of them in the LOMG group. Of 
these, three were thought to have been caused by or 
contributed to by myasthenia gravis. This is similar to previously 
published literature (393).  
Most of the literature which compares steroid doses in MG 
patients has been in those who have had thymectomy versus 
those who have not had thymectomy. There was no comparable 
data in literature for steroid doses in OMG and GMG patients as 
a natural cohort.  
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When we compared the daily dose steroid requirement in all 
patients at first year follow-up with second year follow-up 
(patients being treatment naïve at recruitment), there was a 
significant difference in doses, with patients at second year 
requiring less average daily dose steroids compared to the first 
year, both in EOMG (16mg Vs 6.25mg) and in LOMG (10mg Vs 
7mg). There was no significant difference in the steroid doses 
between EOMG and LOMG at first year follow-up or at second 
year follow-up, but the dose requirements at first year follow up 
in LOMG is slightly less than EOMG. This would be in contrast 
to the clinical presentation of worse disease in LOMG with more 
GMG. This could be explained by the fact that LOMG patients 
required earlier initiation of steroids during the first year and 
doses were tapered down by their first year follow up. It could 
also suggest that LOMG patients responded more rapidly to 
treatment. 
The steroid doses in OMG at first year were higher than at 
second year; however, in GMG there was no difference between 
first and second year steroid dosages. On direct comparison 
between OMG and GMG, there was no difference in steroid 
doses at first year follow up, or at second year follow up. It 
appears that OMG patients respond more quickly to steroids 
than GMG, leading to clinically significant improvement and 
reduced steroid doses with time.  
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When we compared the MGFA-PIS scores at first year follow-
up, LOMG patients did better than EOMG patients and this trend 
was seen even at second year follow-up. When the whole cohort 
of patients was compared at first and second year follow-up, 
there was no difference in their PIS scores. The MGFA PIS in 
OMG patients was better at second year follow-up compared to 
first-year, but not inin GMG patients. The AChR RIA titres also 
fell significantly from point of recruitment to follow up with a 
significant improvement in the first year and a further slight 
reduction in the second year.  
In conclusion, our data shows that LOMG is more common than 
EOMG, and EOMG is more common in females and LOMG 
more common in males, although the difference between 
younger males and females is becoming less significant. OMG 
is more common in EOMG than LOMG; however, there is no 
difference in the type of ocular presentation or generalisation 
rates in EOMG and LOMG. LOMG patients are more likely to 
have bulbar and respiratory symptoms than EOMG patients, and 
they also develop these symptoms significantly earlier than 
EOMG patients. Age seems to be the factor here rather than 
sex, as there is no difference between male and female patients. 
LOMG patients have worse MG composite scores and QOL 
scores at recruitment but seem to respond well to treatment 
clinically and in quality of life, doing much better than EOMG 
patients. The rates of autoimmunity were the same in EOMG 
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and LOMG, but family history of autoimmunity was more 
common in EOMG than LOMG. Clinical phenotypes in the 
different antibody subgroups suggests that there was no 
difference in bulbar, limb, respiratory and ocular symptoms in 
any of the subgroups, except for seronegative patients who 
were less likely to have bulbar symptoms. AChR Ab positivity 
was seen more commonly in older females compared to 
younger females; all the other antibody subgroups were 
comparable between younger and older patients and females 
and males. AChR and MuSK double positive patients required 
steroids more frequently in GMG compared to other antibody 
subgroups. Seronegative patients in our cohort did not require 
admission to hospital suggesting that they may have a less 
severe illness and a more indolent course compared to the 
antibody positive subgroups. OMG patients respond more 
quickly to steroids than GMG, leading to clinically significant 
improvement and reduced steroid doses with time. One could 
argue that this would suggest that OMG is a milder disease than 
GMG. It has been postulated that ocular muscles are more 
susceptible to being affected by Abs in MG, which is why OMG 
is more common than GMG; hence one explanation would be 
that ocular muscles respond more quickly and effectively to 
steroids compared to muscles elsewhere. Taken together, this 
would suggest that patients present with their worst MG 
symptoms during the first year, more often in the first three 
276 
 
months, there is an improvement in all scores including MG 
composite scores, QOL scores and PIS scores in parallel with 
improvement in AChR RIA titres. The overall improvement 
appears to be much more marked in the LOMG patients 
although they are more likely to have GMG compared to the 
EOMG patients.  
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4 Antibodies in myasthenia      
4.1 Introduction 
The first antibody tests for myasthenia gravis were 
demonstrated in 1973 by Almon, Andrew and Appel (9) and the 
detailed immunoprecipitation assay using α bungarotoxin 
labelled AChR was described by Lindstrom et al (10). Later 
studies using subclass specific antisera showed that anti-AChR 
subclasses 1, 2 and 4, and occasionally subclass 3 were seen. 
AChR antibodies were found to be positive in between 85-90% 
of GMG patients and 75% of OMG patients (44). AChR Ab titres 
were reported to be higher in patients with thymic hyperplasia 
(54). 
The assay now available commercially for AChR autoantibodies 
and MuSK autoantibodies is a carefully balanced mixture of 
detergent solubilised foetal and adult forms of the receptor 
labelled with radioactive iodine labelled α bungarotoxin (12, 44). 
Testing of AChR antibodies using ELISA was first described in 
1999 (198). 
Anti MuSK antibodies were first detected and found to be 
pathogenic in 2001. Radioimmunoassay for testing of anti-MuSK 
antibodies were described in the same paper by Hoch et al 
(200). 70% of the patients who were negative for AChR 
antibodies were positive for MuSK. Despite this, a fair number of 
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patients continued to remain seronegative. These patients 
behaved similarly to ACHR MG clinically, in their response to 
immunosuppressive treatment, and in thymic pathology. In 2008 
Leite et al hypothesised that antibodies in SNMG could be 
detected by binding to ACHRs on the cell membrane, 
particularly if they were clustered at the high-density that is 
found at the NMJ. They described the clustered cell based 
assays for AChR and MuSK antibodies. These antibodies were 
mainly IgG1 subclass for ACHR and showed the ability to 
activate complement in cell based assays; in MuSK antibodies 
IgG4 was the main pathogenic subclass and partially IgG1 
subclass (163). Clustered ACHR antibodies were detected in 
38.1% of RIA negative patients with MG with 100% specificity 
(167). Clustered AChR antibodies were seen in 16% of 
seronegative MG patients in a study by Devic et al, including 
both EOMG and LOMG (165). 
In 2017 Huda et al described clustered cell based assays to 
detect MuSK antibodies using an additional IgG Fc gamma 
specific secondary antibody to eliminate the IgGM making the 
assay much more specific. By doing this, they detected MuSK 
antibodies in 99% of definite MuSK MGs (positive on RIA) and in 




Higuchi et al described the pathogenic properties of LRP4 
antibodies in 2011 along with Pevzner et al in 2012 and Zhang 
et al in 2012 (243, 244, 416). 
Zisimopoulou et al published a comprehensive analysis of the 
epidemiology and clinical characteristics of anti-LRP4 MG. They 
found an overall frequency of LRP4 MG in SNMG of 18.7% with 
a range of 7 to 32.7%. They found double positivity with ACHR 
and LRP4 in 8/107 (7.45%) and LRP4 and anti-MuSK in 10/67 
(14.92%). They felt that double seropositive patients had more 
severe symptoms at onset compared to single positive patients. 
Patients who have pure LRP4 positivity had milder symptoms 
with MGFA grade I or II; some had thymic hyperplasia but no 
thymomas (207). 
Cordts et al described double seropositivity with ACHR and 
LRP4 of 7%, ACHR and agrin of 5%, and ACHR and Titin in 
53%. In the seronegative group they found 2% positivity for 
MuSK, 2% for LRP4 and 2% for agrin (211). 
Several other autoantibodies have also been described in MG 
including Titin antibodies in 28.4% and Rynodine antibodies in 
23.8%. Thymoma MG patients had higher frequencies of AChR, 
Titin and Rynodine antibodies. Titin and Rynodine antibodies 
were also present more frequently in LOMG patients. They 
found that patients with Titin and Rynodine antibodies tended to 
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have more severe disease and worse outcomes and they may 
need more active suppressive treatment (208, 417). 
Stergiou et al found that ACHR MG patients had the highest 
frequency of Titin antibodies compared to MuSK MG and LRP4 
MG (212). Titin antibodies were uncommon in EOMG unless 
associated with thymoma in LOMG patients. Titin antibodies had 
similar prevalence and levels as those with MG and thymoma 
(216, 217).  
Cortactin antibodies have also been found to be pathological in 
MG; they were found in 23.7% of SNMG and 9.5% of ACHR 
positive MG. These antibodies were thought to be biomarkers of 
MG and which when present suggested that the disease would 
be mild (218).  
Agrin antibodies are also thought to be pathogenic through 
inhibition of agrin/LRP4/MuSK signalling at the NMJ (220). 
Collagen XIII autoantibodies have been found in MG but it is not 
clear whether these antibodies are pathogenic or not (219). 
Antibodies in myasthenia gravis and the assays for them have 
been well established with good sensitivity and specificity; 
however, there have been no large-scale prospective cohort 
studies on treatment naive patients with long-term follow-up. Our 
study was a unique chance to check antibodies from a 
diagnostic cohort longitudinally. This would then give us a 
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chance to assess the utility of RIA and cell-based assays in 
parallel. It would also give us an opportunity to test patient sera 
for antibodies to other targets even when they are positive for 
ACHR antibodies. It would also be a good opportunity to see if 
there are any differences in antibody positivity, titre levels and 
response to treatment in EOMG and LOMG patient groups. 
In testing for AChR, MuSK and LRP4 antibodies, we sought to 
answer the following questions: 
 Is antibody positivity different in EOMG and LOMG? 
 Is there a difference in the antibody subgroups 
between EOMG and LOMG?  
 Is there a difference in antibody titres in EOMG and 
LOMG? 




All the experiments to look for MG antibodies were done at the 
laboratories at the Nuffield Department of Clinical 
Neurosciences, Oxford. All RIA analysis for AChR and MuSK 
Abs were done by the author. For high positive titres, serial 
dilutions were done until the Counts Per Minute or CPM value 
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dropped by half and then the titres were calculated. VGCC Ab 
RIAs were done by Dr Bethan Lang and Ms Selina Tomsen. 
All 150 MG patients in the study had serum samples taken at 
recruitment and 120 patients had serum samples at first year 
follow-up. ACHR RIA was tested on all patient samples at 
recruitment and first year follow-up. MuSK RIA was tested on all 
150 of the recruitment patient samples. VGCC antibodies on 
RIA were tested in 139 patients at recruitment.  
General principles for RIA: 
Radioimmunoassay (RIA) or radioimmunoprecipitation assay 
(RIPA) involves precipitating radioactively labelled antigen and 
antibody complex. In the first step patient sera is incubated with 
I125 labelled antigen. Any specific antibody in the sera binds to 
the antigen. In the second incubation step the antigen-antibody 
complexes are precipitated using a precipitation agent. The 
precipitate is washed with buffer. After centrifugation and 
decanting of the supernatant, radioactivity in the precipitate is 
counted using a gamma counter. The intensity of the 
radioactivity is proportional to the concentration of specific 
antibody in the patient serum. The antibody concentration is 






Serum samples which were stored either at -20°C or -80°C were 
left to thaw at room temperature for a few minutes. The first 
assays were done using test serum (patient samples) with a 
concentration of 5 µL which was diluted to 250 μl using PTX. We 
obtained our AChR assay kit from RSR laboratories. 50 µL of 
I125 α bungarotoxin ACHR was added to each of the test 
samples. This was briefly mixed and left in the fridge overnight. 
The next day, human IgG serum of 50 µL diluted up to 250 µL 
using PTX was added to each test serum. This was left to 
precipitate for 30 minutes and then centrifuged. The supernatant 
was discarded and the pellets were washed a couple of times. 
After the second wash, the eppindorfs were placed in the 
gamma counter to count radiation in counts per minute (CPM).  
For samples with very high CPM counts, i.e. equal to or more 
than the control serum, the samples were tested with serial 
dilutions starting with 2.5 μl and progressively more dilute 
samples up to a concentration of 0.1 µL were tested. When the 
CPM counts dropped by 50%, this was taken to be the correct 
titre for the sample. The titres were then converted into 10-10 
moles per litre using the formula below. Values of ≥5 X 10-10 




nmol/L AChR = (CPM test sample - CPM negative control) X A  
C X K X BX 2.22 
A – Decay factor between receptor labelling day and day of 
assay  
B - Counter efficiency (which was 80% on the machine in the 
Oxford lab) 
C- Volume of serum used in the assay 
K - Specific activity of 125I at the time it was used. 
A, C and K were on the sheet included with every bottle of 125I 
AChR. 
These titres were multiplied by 10, to give the values in 10-10 
mols/L 
For MuSK RIA assays, the procedure was the same as for 
ACHR including for the dilutions. The kit used was RSR I125 
MuSK, and the formula to calculate the titres was the same as 
for ACHR. Values of ≥0.5 X 10-10 moles per litre were 
considered abnormal. 
CBA Method 
For CBAs, the human embryonic kidney (HEK) 293 cell line was 
grown in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% FCS and 100 units per ML each of 
penicillin G and streptomycin at 37°C in an atmosphere of 5% 
CO2 to 50% confluence on 13 mm glass cover slips which were 
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placed in six well cell culture plates. For the clustered AChR 
assay, the cells were transiently cotransfected using 
polyethylenimine with the plasmids encoding for subunits of 
human adult AChR and Rapsyn with EGFP. A total of 3 µg of 
DNA was used in a proportion of α:β:δ:ε:Rapsyn of 2:1:1:1:1, 
respectively. For MuSK CBA, 3 µg of MuSK-EGFP DNA was 
transfected. For LRP4 CBA, LRP4 CASPR and LRP4 AP were 
transfected in a proportion of 5:1 and a total of 6 µg of DNA was 
used for transfection. For each of the assays, the medium was 
changed 16 hours post transfection. 
After 24-hours, the cover slips were transferred into a 24 well 
cell culture plate. To these cells, human sera (patient samples 
and controls) diluted to 1:20 using DMEM, HEPES and bovine 
serum albumin (BSA) was added. This was incubated for one 
hour at room temperature. After washing, this was fixed with 3% 
formaldehyde. After further washing, the secondary Fc antibody 
(blocking) (we used Invitrogen goat anti-human IgG Fc cross-
adsorbed secondary antibody) was added in a dilution of 1 in 
750. This was incubated for 45 minutes at room temperature in 
the dark. After further washing, the tertiary antibody (blocking) 
(we used Alexa fluor 568 donkey anti-goat IgG) in 1 in 750 
dilution was added. This was incubated for a further 45 minutes 
at room temperature in the dark. After final washing the cover 
slips were mounted on the mounting media using 1% DAPI. The 
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slides were allowed to dry for at least an hour before reading 
using an Axion Zeiss inverted fluorescent microscope. 
The assays were read based on the degree of cell-surface 
fluorescence and co- localisation as per Dr Leite's paper of 2008 
(163).  
(0) = no labelling  
(0.5) = very weak labelling of very few transfected cells with no 
obvious co-localisation 
(1) = weak labelling of some of the transfected cells, with co-
localisation 
(2) = moderate labelling of some (approximately 20 to 50%) of 
transfected cells, with precise co-localisation 
(3) = moderate/strong labelling of approximately 50 to 80% of 
the transfected cells, with perfect co-localisation 






4.3.1 Anti Acetyl choline receptor antibodies (AChR Abs) 
We performed radioimmunoassays (RIA) for AChR, MuSK and 
VGCC antibodies. We also performed cell based assays (CBA) 
for AChR, MuSK and LRP4 antibodies. All 150 patient samples 
were tested for AChR and MuSK on RIA. Cell based assays 
were performed on all 150 recruitment samples for AChR and 
MuSK and 147 samples were tested for LRP4. 139 patient 
samples were also tested for VGCC on RIA. The AChR RIA 
titres are reported as X 10-10 moles per litre. 
During follow-up, serum samples were collected at annual 
follow-up; 120 patient samples were collected at first year follow-
up, all of which were tested for AChR on RIA and CBA. 36 
patient samples were collected at second follow-up which were 
once again tested for AChR on RIA and CBA. We had three 
patient samples for year three follow-up which were tested for 
AChR on RIA and CBA.  
In OMG, positivity for AChR was seen in 75% in EOMG and 
80% in LOMG, P = 0.6985. When tested on CBA, the number of 
LOMG patients positive was still 80% whereas the EOMG 
patients increased in number to 87.5%. The difference was not 
statistically significant. Seropositivity on RIA in younger GMG 
patients was low at 56.5% compared to LOMG patients where it 
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was 91.4%, p< 0.0001; with cell based assays, positivity in the 
younger GMG patients increased to 82.6% and in the older 
patients to 93.8% (p=0.0372). Overall, AChR positivity in EOMG 
(85.05%) and LOMG (86.9%) are comparable (p=0.7725). All p 
values were calculated using the Mann-Whitney test as the 
comparison was between medians of two independent groups 
and not normally distributed. 
The breakdown of all positive cell based assays is as below, 
with 8 seronegatives (5.32%) (Figure 44). NB: one of these 8 














Figure 44 Breakdown of all positive CBAs
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Figure 46 Photographs of the Clustered AChR CBA; top row shows the 
healthy control, middle row the strong positive control and the bottom 
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Figure 47 Photographs of the Clustered MuSK CBA; top row shows the 
healthy control, middle row the strong positive control and the bottom 
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sample- red light
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Figure 48 Photographs of the LRP4 CBA; top row shows the healthy 
control, middle row the strong positive control and the bottom row 
shows the patient sample 
 
The breakdown of the positive AChR CBA results is as per 
figure 45. Of all the positive AChRs on cell based assays, we 
had 107 who were positive for AChR alone i.e. 81.06%, 15 
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double positive with MuSK i.e. 11.36%, 8 double positive with 
LRP4 i.e. 6.06%, and 2 patients i.e. 1.52% were positive for all 
three antibodies. The triple positives were thought to represent 
AChR single positives with non-specific binding to the other 
antibodies. The reason for this differentiation between double 
postives and triple positives was that in the double positives, the 
binding was to the expressed receptors- either EGFP tagged 
AChR or MuSK or untagged LRP4 receptors, whereas in triple 
positives, the binding was to the cell surface/ other proteins as 
well as the expressed receptors. 
There was a significant drop in AChR RIA titres when the 
recruitment samples were compared to the first year follow-up 
P< 0.0001 (Figure 49A). This was also seen when CBAs were 
analysed (Figure 49B). There was a significant difference when 
AChR RIAs were compared between patients who were 
treatment naïve at recruitment and the immunosuppressed at 
first year follow-up. Although there was a drop in titres in 
patients who remained immunosuppression naïve at first year 
follow-up, this was no longer statistically significant. There was 
linear correlation between AChR RIA at recruitment with their 
MG composite scores with p=0.0011 and R2 of 0.0671 (Figure 
50A). Similarly, there was linear correlation between MG QOL 
and AChR RIA titres at recruitment, p=0.0070 and R2 of 0.04623 
(Figure 50B) ACHR RIA titres were compared at recruitment 
between the EOMG and LOMG groups and there was a 
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significant difference with a median of 20.08 x10-10mol/l in 
EOMG and 176.8 x10-10mol/l in LOMG, P=0.0005; when the 
seronegatives were taken out of the equation so as to not skew 
the data, the difference was still statistically significant at p = 
0.0498 with a median for EOMG of 91.75 x10-10mol/l and for 
LOMG 196.8 x10-10mol/l (Figure 51).  
Figure 49 Comparison of AChR (with medians) at point 0, 1st and 2nd 
year follow up p<0.0001; A: on RIA, B: on CBA
A B
Figure 50 Correlation between AChR RIAs at recruitment with (A) 
MG composite scores p=0.0011, R2 of 0.0671 and (B) MG QoL scores 
at diagnosis 0.0070, R2 of 0.04623
A B
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
Figure 50 A and B: Simple linear regression used 
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ACHR RIAs in EOMG and LOMG patients with thymic 
abnormalities were compared; there was no significant 
difference in patients with thymoma or thymic hyperplasia. There 
was no difference between patients who were reported to have 
residual thymus, with medians being lower in the EOMG 
patients compared to LOMG, p value of 0.0571 (Figure 52). NB: 
The data was based on scan findings of thymic enlargement 
with subsequent tissue diagnosis in most of these patients. This 
presumes that a normal scan excludes thymic abnormality which 
may not be the case, particularly in EOMG. 
Our cell-based assays were not performed using serial dilutions 
so AChR RIA titres were not directly comparable with the cell 
based assays, however we did plot both of these on GraphPad 
Prism and there was a linear correlation between the readings, 
p<0.0001 and R2 of 0.1656 (Figure 53) There was no significant 
difference in AChR RIA titres between patients on statins and 
those who were not on statins; similarly there was no significant 
difference between the AChR RIAs in patients who used 





Figure 53 Correlation between AChR RIAs and 
AChR CBAs at recruitment p<0.0001, R2 of  
0.1656 
Figure 51 Comparison of AChR
RIAs (with medians) without 
seronegatives at recruitment 
between EOMG and LOMG 
p=0.0498
Figure 52 Comparison of 
AChR RIAs (with medians) in 
patients reported to have 
thymic remnants in EOMG and 
LOMG p=0.0571
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
Figure 53: Simple linear regression used 
 
4.3.2 Anti Muscle specific kinase antibodies (MuSK Abs) 
Of the 150 patient samples tested at recruitment, MuSK RIA 
was positive in one patient. Clustered cell based assay for 
MuSK Ab was positive in a total of 24 patients. Of these, 6 
patients (4%) were single positive for MuSK Ab, 15 patients 
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(10%) double positive for AChR and MuSK antibodies, 1 patient 
(0.67%) was positive MuSK and LRP4 antibodies. 2 patients 
were positive for all three antibodies but as mentioned in the 
previous section, the conclusion was that the antibodies were 
non-specifically binding to MuSK and LRP4. 
All positive CBAs were repeated to confirm results. In the case 
of MuSK antibodies, because of the high rate of positivity and 
double positivity, most samples were assayed 3 times and the 
results read by three different observers including the author. 
Low positive results with a score of 0.5 and 0.75 were excluded 
from the analysis, and only scores of 1 or more were included. 
The scoring was based on previous literature (163) and 
laboratory practices where a score of 1 is reported as positive 
and anything below as possible/ maybe.  
Table 22 Breakdown of MuSK seropositivity in EOMG and LOMG (O: 
Ocular, G: Generalised, F: Female, M: Male, T: Total)  
   O +ve O + % G +ve G + % 
EOMG 
F 4 28.6 4 44.4 
M 1 7.7 0 0 
T 5 18.5 4 33.3 
LOMG 
F 2 10.5 3 12.5 
M 6 18.2 4 11.4 
T 8 15.4 7 11.9 
Total number of patients in each subgroup ie denominators were: OMG in EOMG- 27, 
with 14 female and 13 male; OMG in LOMG- 52, with 19 female and 33 male; GMG in 




Amongst the total MuSK positives, single positivity was seen in 
25%, double positivity with ACHR was 62.5%, double positivity 
with LRP4 was 4.1%, and triple positivity was 8.33% (Figure 54). 
33.3% of the younger patients with GMG were positive for MuSK 
antibodies on CBA compared to 18.5% in the OMG patients.  
Table 23 MuSK seropositivity in subgroups with p values.  
 
Ocular Generalised P value 
EOMG 18.5% 33.3% 0.3174 
LOMG 15.4% 11.9% 0.5924 
P value 0.7262 0.0638 
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
MuSK positivity in the GMG patients in EOMG was 33.3% and  
LOMG 11.9%, this was not significantly different, p=0.0638. 
Similarly, younger female patients were more likely to be MuSK 
positive (30.43%) compared to younger male patients (6.25%), 
but the difference was not statistically significant, p=0.0694 
(Tables 22 and 23). When female EOMG and LOMG patients 
were compared, although the trend was towards the younger 
females being more likely to be positive (30.43% Vs 11.62%), 
this was just under statistical significance (p=0.0610). The 
clinical presentations with MuSK Ab positivity has been 
described in the previous chapter. 
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Figure 54 Breakdown of all MuSK positives on CBA
Figure 55 Breakdown of all LRP4 positives on CBA
 
4.3.3 Anti LRP 4 antibodies 
Cell-based assays for LRP4 antibodies were done in 147/150 
patient samples at recruitment. Of these, 14 patients were 
positive for LRP4 antibodies. 3 were positive purely for LRP4, 8 
were double positive for ACHR and LRP4 and 1 patient was 
double positive for MuSK and LRP4. Two patients were positive 
for all three antibodies (see NB in above section). Amongst the 
LRP4 positives, 21.43% were single positive, 57.14% were 
299 
 
double positive for ACHR, 7.14% double positive for MuSK and 
14.29% triple positive (Figure 55). 
Table 24 Breakdown of LRP4 seropositivity in EOMG and LOMG (O: 
Ocular, G: Generalised, F: Female, M: Male, T: Total)  
    O +ve O + % G +ve G + % 
EOMG 
F 4 28.6 0 0 
M 1 7.7 1 33.3 
T 5 18.5 1 8.3 
LOMG 
F 2 10.5 2 8.3 
M 2 6.1 2 5.7 
T 4 7.7 4 6.8 
Total number of patients in each subgroup ie denominators were: OMG in EOMG- 27, 
with 14 female and 13 male; OMG in LOMG- 52, with 19 female and 33 male; GMG in 
EOMG- 12, with 9 female and 3 male; GMG in LOMG- 59, with 24 female and 35 
male 
 
The division of positives amongst the subgroups is listed in 
tables 24 and 25. 18.5% of the ocular EOMG patients were 
positive for LRP4 antibodies as opposed to 8.3% of generalised 
EOMG patients. In LOMG, the OMGs positive for LRP4 
antibodies were 7.7%, and in GMG were 6.8%. 
Table 25 LRP4 seropositivity in subgroups with p values.  
  Ocular Generalised P value 
EOMG 18.5% 8.3% 0.4209 
LOMG 7.7% 6.8% 0.8556 
P value 0.1545 0.8543   
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
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4.3.4 Seronegative myasthenia 
Of our cohort of 150 patients, 8 were seronegative (5.33%). One 
of the 8 patients however was positive on AChR RIA when first 
diagnosed, RIA when repeated during the study, and CBA were 
negative. 
The distribution of negatives in the subgroups is shown in table 
26. There was no statistically significant difference amongst the 
subgroups. 
Table 26 Subgroups in triple seronegative patients 
      Numbers Percentage 
Seronegative 
EOMG 
Female (23) 1 4.34 
Male (16) 1 6.25 
LOMG 
Female (43) 3 6.98 
Male (68) 3 4.41 
 
In seronegative patients, ocular symptoms were seen slightly 
less at 87.5% compared to antibody positives. Seronegative 
patients were more likely to have limb weakness at 62.5% 
compared to 47.7% with AChR single positivity and 33.3% with 
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4.3.5 Does immunosuppression change the Ab profile? 
When we compared AChR RIA titres in all patients at 
recruitment with first year follow up samples, there was a 
significant drop in titres p<0.0001. We then analysed the 
samples without seronegatives so that the data was not skewed, 
and there was still a significant drop in titres at first year follow 
up, p=0.0002 (Figure 56). 
We performed subgroup analysis comparing AChR RIA titres in 
patients who were treatment naïve at recruitment and were 
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treated with immunosuppression (mainly steroids) in the first 
year, with their titres at first year follow up. There was a 
significant drop in titres, p<0.0001 (Figure 58). Titres in the 
patients who remained immunosuppression naïve at first year 
follow up also showed a drop, but not statistically significant, 
p=0.0891 (Figure 57).  
Figure 56 Comparison of ACHR RIAs 
(with medians) in all patients at 
recruitment and first year follow up 
p=0.0002
Figure 57 Comparison of ACHR RIAs 
(with medians) in immunosuppression 
naïve patients at recruitment and still 
immunosuppression naive at first 
year p=0.0891
Figure 58 Comparison of ACHR RIAs 
(with medians) in treatment naïve 
patients at recruitment and after 
receiving steroids at first year follow 
up p<0.0001
Figure 59 Survival curve for time to 
generalisation in OMG comparing 
patients who received steroids pre-
generalisation to those who did not
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 




From this data, it appears that immunosuppression does lead to 
a fall in AChR RIA titres. As mentioned in the chapter on clinical 
phenotypes, steroids do not seem to alter the generalisation 
rates in OMG significantly in our cohort (Figure 59).  
 
4.4 Discussion 
We performed radio immunoassays (RIA) for AChR, MuSK and 
VGCC antibodies on patient samples at recruitment. AChR and 
MuSK was tested on all 150 patient samples, and for VGCC in 
139 patient samples. We also did cell based assays for AChR, 
MuSK and LRP4 antibodies, AChR and MuSK were done on all 
150 recruitment samples and 147 samples were tested for 
LRP4. First year follow-up samples in 120 patients were tested 
for AChR on RIA and CBA. 36 patient samples at second year 
follow-up were tested for AChR on RIA and CBA and 3 third 
year follow-up samples were also tested for AChR on RIA and 
CBA.  
It has been reported in previous literature that AChR positivity is 
seen in 85-90% of GMG patients and between 50-75% of OMG 
patients (44, 419). There is wide variability in MuSK antibody 
positivity, with initial reports of 7%, but other papers reporting 
anywhere between 3.8 and 47.4% (151, 200, 420). Most studies 
have shown that AChR titres are lower in LOMG patients with no 
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thymic abnormalities (96, 97, 149, 150, 421), patients with 
thymoma had higher titres (no age correlation) and EOMG 
patients with thymic hyperplasia had higher titres (10). A study 
by Iwasa et al differed slightly when they found raised AChR 
titres amongst MG patients in Japan for a brief period of time; 
this was more pronounced in LOMG patients (422). 
Is antibody positivity different in EOMG and LOMG? And, Is 
there a difference in the antibody subgroups between EOMG 
and LOMG?  
In our study, we found that in OMG, AChR positivity was seen in 
75% in EOMG and 80% in LOMG on RIA and 87.5% and 80% 
respectively on CBA. The difference in positivity on RIA and 
CBA was not statistically significant. The positivity on RIA in 
younger GMG patients was low at 56.5% compared to the 
LOMG patients at 91.4%; however with CBAs the positivity in 
EOMG GMG patients increased to 82.6% and in LOMG patients 
to 93.8%, which was still statistically significantly different 
(p=0.0372).  
Zivkovic et al have published similar results in their retrospective 
study where they found AChR positivity to be more common in 
LOMG than in EOMG (p=0.0026). They did not differentiate 
between OMG and GMG, but mention that OMG is much more 
common in LOMG than in EOMG. Jacob et al suggest that 
patients with AChR antibodies positive only on clustered cell 
based assays more commonly have OMG. This is different to 
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what our study suggests; however, the study by Jacob et al was 
a small retrospective study, and whilst showing a trend, the 
results were not conclusive (155, 164). 
It appears that the EOMG patients in our cohort, particulary 
those with GMG, may have low affinity antibodies to AChR 
which were not detected in the solution phase (used in RIA), but 
were detectable on CBAs. As has been shown previously, low 
affinity Abs are still pathogenic in vivo against the AChR clusters 
at the NMJ (163). It appears that EOMG patients have highly 
pathogenic, but low affinity AChR Abs compared to LOMG. 
Of our 150 patient samples, when tested for all three antibodies 
on RIA and CBA, we had 8 seronegative patients (5.32%) (one 
of these patients was initially positive for AChR on RIA). The 
majority of patients were positive for AChR (71.33%). The rates 
of AChR single positivity in our cohort was lower than previously 
published, however, we had a further 15.33% who were double 
positive, bringing the total AChR positivity to 86.66% which is 
more in keeping with published literature. In routine clinical 
practice, serum is tested for AChR antibodies first and if this is 
negative, they are tested for MuSK antibodies on RIA followed 
by clustered CBA. It is possible that there are a small number of 
patients in the community who have been diagnosed with AChR 
MG, but who may well have a second antigenic target which has 
not been tested for.  
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The rates of LRP4 (2%) and MuSK MG (4%) was in keeping 
with published literature.  
We had quite a few patients who were double positive. AChR 
and MuSK double positivity was seen in 10%, which is slightly 
less than previously published data of 12.5% (423). AChR and 
LRP4 double positivity was seen in 5.33%, again, less than 
previously published rates of 7.45% (207). MuSK and LRP4 
double positivity was seen in 0.67%, this is much less than 
previously published rates of between 14.92% and 19.8% (207, 
423). The previously published data is mainly from a 
multinational retrospective study of 904 stored serum samples. 
Two patients were positive for all three antibodies, although the 
conclusion was that the MuSK and LRP4 antibodies were 
probably non-specifically binding. This was thought to be the 
case as the binding with these stains was not just to the 
expressed MuSK/LRP4 receptors, but to other cell wall proteins 
as well.  Triple seropositivity has also been described before at 
a similar rate (423). 
There was no difference between MuSK positivity in EOMG and 
LOMG in ocular patients. MuSK seropositivity in GMG in EOMG 
patients compared to LOMG was not significantly different 
although there was a trend towards higher positive rates in 
EOMG. There was no significant difference in MuSK 
seropositivity amongst the EOMG group when OMG and GMG 
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were compared, neither was there any difference in the LOMG 
subgroup. There was a trend towards higher numbers of female 
EOMG patients being positive to MuSK Abs (30.43%) compared 
to male EOMG patients (6.25%), but this was not significantly 
different. Similarly, when female EOMG and LOMG patients 
were compared, although the trend was towards the younger 
females being more likely to be positive (30.43% Vs 11.62%), 
this was not significantly different (p=0.0610). This is different to 
previously published data which report that MuSK Abs are more 
common in younger females (151, 154, 407). The study by 
Guptill et al was a large cohort retrospective study; however, all 
the antibody tests were done on RIA, and not on CBAs. It is 
possible that lower affinity MuSK Abs, which may well be what is 
seen in LOMG patients, were missed (NB: the majority of our 
MuSK positives were on CBA alone), skewing the data towards 
the younger females. In the study by Evoli et al, who noticed a 
striking female preponderance, MuSK Abs were tested using 
immunoblot. The study by Huda et al showed that although 
female preponderance was seen with MuSK CBA+ RIA- 
patients, the age of onset was less, and they were more likely to 
have OMG, suggesting a milder phenotype in these patients. 
Our MuSK cohort was predominantly RIA- CBA+. This could be 
one of the reasons why our results differ from published 
literature. For future studies, this subgroup will need to be 
looked into more carefully by recruiting higher numbers of 
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patients who are MuSK RIA+, and comparing them with those 
who are MuSK CBA+ RIA-. 
LRP4 seropositivity in our cohort was similar to published data. 
There was no difference between OMG and GMG in EOMG and 
LOMG, and no difference between EOMG and LOMG (both for 
OMG and GMG) either. This is different to previously published 
data which report that LRP4 single positivity is associated with 
milder disease and double positivity with more severe disease 
(207). Our LRP4 cohort was predominantly double positive with 
less than a quarter of them being single positive. This is perhaps 
why, clinically, as a group, the phenotype was not dissimilar to 
the other subgroups. 
In our cohort of 150 patients, 8 patients were seronegative, as 
explained previously, one of these patients was positive on an 
initial AChR RIA when diagnosed and all the repeat testing on 
RIA and CBA were negative. Among the seronegative patients, 
ocular symptoms were seen slightly less frequently at 87.5% 
compared to antibody positive patients; however, this was not 
statistically significant.  
Does antibody positivity and titres change with time and 
treatment? 
There have been no large prospective studies looking at AChR 
titres with longitudinal data and long term follow up of patients. 
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Our study provides novel data on AChR titres. We compared the 
titres of AChR RIA in patients at recruitment and at annual 
follow-up. We found a significant drop in titres over the first year. 
The drop in titres was seen mainly in patients who were 
treatment naïve at recruitment and who were 
immunosuppressed at first year follow-up, and although there 
was a drop in titres in patients who remained 
immunosuppression naïve throughout the first year, it was not 
statistically significant. There was a comparable drop in scoring 
on AChR CBA as well when recruitment samples were 
compared with first year and second year follow-up samples. 
Both AChR RIA titres and MG composite scores fell during the 
first year, with linear correlation; similarly with MG QOL. It 
appears that with a clinical response to treatment, there is a 
corresponding fall in AChR titres. This would make sense 
theoretically. It appears that in an individual patient, falling titres 
may indicate clinical improvement, and vice versa. However, 
functional studies were not done. 
Is there a difference in antibody titres in EOMG and LOMG? 
There was a significant difference between AChR RIA titres in 
EOMG and LOMG, with the titres being much higher in LOMG. 
Compston et al found in their retrospective study of stored 
serum samples, that patients with thymoma had the highest 
titres of AChR Abs, followed by the EOMG patients, and then 
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the LOMG patients. They used 40 years as the age cut off. This 
was similar to data published by Lindsburg et al and 
Mantegazza et al. Somnier et al found lower concentrations of 
AChR in LOMG, but non significantly. In contrast, Lindstrom et 
al did not find any correlation with age. Neither Linstrom nor 
Somnier divided the groups into thymomatous and non-
thymomatous. Our analysis also did not differentiate between 
thymomatous and non-thymomatous patients. As explained in 
previous chapters, the relationship between thymic 
abnormalities and LOMG is not entirely clear. It is postulated 
that abberations in the aged thymus in LOMG mimics thymoma 
behaviour without frank neoplasia, or, a small thymoma could 
have regressed spontaneously before the diagnosis of MG. It is 
therefore possible that our LOMG cohort reflects this 
immunological similarity with TAMG with high AChR titres.(97, 
149, 150, 421). 
We did not find a difference in AChR RIAs in EOMG and LOMG 
patients with thymic abnormalities. This could be because we 
did not thymectomise all EOMG patients; it is possible that a 
proportion of patients with no radiological abnormalities had 
histological abnormalities which were not picked up, and so a 
proportion of the data may be missing. (10, 97). 
There was no significant difference in AChR RIA titres in 
patients who were on statins compared to those who were not 
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on statins. Similarly, there was no difference between patients 
who used salbutamol inhalers and those who did not. There is 
no previous literature on this. 
In conclusion, our study has shown a lower rate of AChR single 
positivity, but when double positives were added, the positivity 
rates were similar to published data. EOMG patients were less 
likely to be positive on RIA, possibly due to lower affinity 
antibodies. AChR titres were higher in LOMG compared to 
EOMG. The titres dropped after treatment on annual review. 
There was no difference in AChR titres in patients with (mainly 
radiological) thymic abnormalities. There was no difference in 
MuSK or LRP4 positivity in the different subgroups, and we had 




5 Regulatory T cells      
5.1  Introduction 
Myasthenia gravis is the best characterised antibody mediated 
autoimmune disease where patients have autoantibodies 
against nicotinic acetylcholine receptor at the neuromuscular 
junction. Although the condition is antibody mediated, anti-
AChR-T cells have a crucial role in the pathogenesis because 
they permit and modulate the synthesis of the high affinity 
antibodies. Activation of potentially self reactive CD4+ T cells 
may be the primary event in the pathogenesis of myasthenia; 
this may occur because of cross-reactivity of self reactive CD4 T 
cells with microbial antigens or because of the action of 
microbial super antigens (Oldstone, Brocke et al) (424, 425). 
The immune system is very organised, and proper functioning 
depends on adequate balance between the pro-inflammatory 
and anti-inflammatory signals, and the responses of the cellular 
system- the pro-inflammatory T cells (T helper 17 cells or TH 17 
cells) and the anti-inflammatory cells the regulatory T cells (T 
regs cells). Defective balance is seen in a lot of autoimmune 
conditions (279-283). The balance between T reg cells and TH 
17 cells in MG is disrupted. T regs are shown to be defective in 
their regulatory function and can start expressing markers of TH 
17 cells while the effector T cells or T eff cells (CD4+25-) 
become resistant to suppression (51, 284-287). 
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One large cohort study of 79 MG patients with an established 
diagnosis of MG, 59 of whom were immunosuppression naïve, 
and 13 of whom went on have steroids during the study, found 
that Treg levels were lower in the untreated group compared to 
those who were given steroids. In the 13 treatment naïve 
patients who went on to have steroids, the Treg levels and Tfr-
like cells increased and Tfh-like cells decreased (298). 
Autoimmune diseases could be caused by a deficiency in the 
number of T reg cells and/or defective suppression of the T reg 
cells. There have been several contradictory studies regarding 
the numbers and function of T reg cells, some of which show 
that the T reg cell numbers are reduced in MG patients 
compared to healthy controls (227, 293, 294), whereas other 
studies showed no difference in the percentage of CD4+FoxP3+ 
T reg cells in the thymus and peripheral blood (295, 296). Most 
studies report that the T reg cells have reduced suppressive 
activity. A decreased expression of Foxp3 in MG thymus and in 
the peripheral blood could be one of the reasons for the 
impaired suppressive activity (51, 52, 265). 
There is an increased production of IL-17 which is a cytokine 
and is expressed by TH 17 cells. Several studies have shown 
that in thymic hyperplasia there is increased production of pro-
inflammatory cytokines like IL-6, IL-1 β, interferon-γ, and TNF α 
(250, 310). There is also increased production of the anti-
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inflammatory cytokine TGF or transforming growth factor β-1. 
Serum IL-27 is a heterodimeric cytokine and is produced by 
APCs. It promotes Th1 differentiation and suppresses 
inflammation by inhibiting Th17 and Th2 cells. Serum IL-27 
levels have shown to be significantly higher in MG patients 
compared to controls and it was significantly higher in EOMG 
suggesting that it could possibly contribute to MG pathogenesis 
or immunoregulation (312). Other studies have shown that IL-
17A was higher amongst MG patients with EOMG, women 
without thymoma showing the greatest elevations of IL-17A 
(314).  
In vitro stimulated PBMCs in MuSK Ab positive MG patients but 
not in AChR Ab positive MG patients have been reported to 
show a significantly increased secretion of IFN gamma, IL-17A 
and IL-21. It was postulated that TH1 and TH 17 immune 
reactions play a role in MuSK MG and immunosuppression 
attenuates the TH1 response in AChR MG and in MuSK MG, 
but it modulates immune responses differently in the two groups. 
So far, except for a few, all studies on Tregs and cytokines in 
MG have been done on a small number of patient samples. 
What is particularly lacking is data on treatment naïve patient 
samples. There are no large scale prospective studies to date. 
Our study was a unique chance to look at the Immunological 
profile from a diagnostic cohort longitudinally. This would then 
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give us a chance to assess Treg levels, and some of the 
cytokines that are thought to be deranged in MG, compare 
EOMG with LOMG, and look for changes with time and 
treatment. 
With our prospective study with long term follow up, we sought 
to answer the following questions: 
• Is there a difference in T reg levels in the peripheral blood 
lymphocytes of MG patients compared to healthy 
controls? 
• Is there a difference in T reg levels in the peripheral blood 
lymphocytes and in LOMG patients compared to EOMG 
patients? 
• Is there a difference in the cytokines IFNα, IFNγ, TNFα, 
IL-10, IL-17 and IL-4 in the peripheral blood lymphocytes 
of MG patients compared to healthy controls? 
• Is there a difference in the cytokines IFNα, IFNγ, TNFα, 
IL-10, IL-17 and IL-4 in the peripheral blood lymphocytes 
and in LOMG patients compared to EOMG patients? 
• Is there a difference in Treg levels and cytokines in 
patients with thymic abnormalities? 
• Is there a difference in Treg levels and cytokine levels in 




5.2  Methods 
Whole blood was collected from 135 MG patients and 8 LEMS 
patients at recruitment and 24 MG patients at first year follow 
up, 9 of whom had been immunosuppressed in the first year, 11 
who were immunosuppression naïve at first year follow up and 
the remainder had been immunosuppressed at recruitment. 
Peripheral blood monocytes/lymphocytes (PBMCs) were 
isolated using the method described below by the author within 
4 hours of sample collection. The majority of the PBMC isolation 
was done in the laboratory at the Neurology research unit at the 
Queen’s Medical Centre, Nottingham. Some of the samples 
collected at Birmingham and Oxford were processed at the 
University of Birmingham laboratories. 
The method of PBMC isolation is the same as that used by the 
MS research team at Nottingham (Prof Constantinescu and Dr 
Gran) and is described here briefly. The detailed protocol and 
controls used for flow cytometry are described in Appendix 3. 
Peripheral blood mononuclear cells (PBMCs) were isolated from 
whole blood which was drawn from patients in heparinised 
tubes. This was layered on histopaque and centrifuged for 20 
minutes. The PBMCs were recovered from the interface, 
washed and viability checked using trypan blue. Cell counts 
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were noted and the PBMCs were preserved initially in the -800C 
refrigerator and then transferred to liquid nitrogen. 
Table 28 Consumables and reagents used in PBMC staining 
ITEM (Panel 1-Treg) LOCATION ORDERING 
CD4 FITC 
 
Fridge (4C) BD biosciences 
(555346) 
CD 25  PE Fridge BD biosciences 
(555432) 
CD127 PE-Cy7  BD biosciences 
(560822) 
FoxP3 Alexa Flour 647 
 
Fridge BD biosciences 
(560045) 
Human FoxP3 Buffer Set 
BD biosciences 
 BD biosciences 560098 
Live/Dead fixable blue 






FITC Mouse IgG1, κ 
Isotype Control Clone 
MOPC-21 
 BD biosciences 555748 
PE Mouse IgG1, κ Isotype 
Control Clone MOPC-21 
 BD biosciences 555749 
PE-Cy 7 Mouse IgG1, κ 
Isotype Control Clone 
MOPC-21 
 BD biosciences 557872 
Alexa Flour 647 Mouse 
IgG1, κ Isotype Control 
Clone MOPC-21 
 BD biosciences 557714 





 Biolegend 506510 
INFα PE 
 
 BD biosciences 560097 
TNFα PerCP-Cy5.5 
 
 Biolegend 502926 
CD3 APC-Fire 750 
 
 Biolegend 344840 
CD4 FITC Fridge (4C) BD biosciences 555346 
CD8 PE-Cy7 
 
 Biolegend 301012 
Fixation/Permeabilization 
solution Kit 
 BD GolgiStop 554715 
Live/Dead fixable blue 






APC Mouse IgG1 κ 
Isotype Control 
 Biolegend 400142 
PE Mouse IgG1 κ Isotype 
Control Clone MOPC-21 
 BD biosciences 555749 
PerCP-Cy5.5 Mouse IgG1 
κ Isotype Control Clone 
MOPC-21 
 Biolegend 400150 
APC- APC/Fire 750 Mouse 
IgG1 κ Isotype Control 
Clone MOPC-21 
 
 Biolegend 400196 
FITC Mouse IgG1, κ 
Isotype Control Clone 




PE-Cy7 Mouse IgG1 κ 
Isotype Control Clone 
MOPC-21 
 
 Biolegend 400126 
ITEM (Panel 3-Th2) LOCATION ORDERING 
IL17 PE  Biolegend 512306 
IL4 PerCP-Cy5.5  BD biosciences 561234 
IL10 APC  Biolegend 506807 
CD3 APC/Fire 750 
 
 Biolegend 344840 
CD4 FITC Fridge (4C) BD biosciences 555346 
CD8 PE-Cy7  Biolegend 301012 
Fixation/Permeabilization 
solution Kit 
 BD GolgiStop 554715 
Live/Dead fixable blue 






PE Mouse IgG1 κ Isotype 
Control Clone MOPC-21 
 Biolegend 400140 
PerCP-Cy5.5 Mouse IgG1 
κ Isotype Control Clone 
MOPC-21 
 BD biosciences 550795 
APC Rat IgG2a κ Isotype 
Control Clone R35-95 
 Biolegend 400512 
APC/Fire 750 Mouse IgG1 
κ Isotype Control Clone 
MOPC-21 
 Biolegend 400196 
FITC Mouse IgG1, κ 
Isotype Control Clone 
MOPC-21 
 BD biosciences 555748 
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PE-Cy7 Mouse IgG1 κ 
Isotype Control Clone 
MOPC-21 
 Biolegend 400126 
ITEM LOCATION ORDERING 
EDTA 100 mM (20 
ul/tube)*7 tubes 
Room temp  
Formaldehyde 4% (1 
ml/tube)*7 tubes & 0.5% 
(0.4 ml/tube)*11 tubes 
(40% stock w/ isoton dil.) 
Room temp B8F77119 (Philips-
Harris) 
Isoton diluent Room temp 8448011(Beckman-
Coulter) 
Aluminium foil (kitchen 
quality) 
Room temp Terinex 
PBA (0.5%): BSA (0.5%) in 
PBS: (3 ml/tube)*4 tubes 
(0.25 ml 30% BSA, add 
PBS up to 15 ml) 
Fridge A7284 (Sigma) 
PBS (diluents to BSA) Room temp LH-SIG2017E (MSS) 
 
All of our samples were cryopreserved. The PBMCs were 
thawed in batches for the staining. 
Once the PBMCs were thawed, they were washed and the cells 
counted again. They were placed into 96 well plates and stained 
with live/dead stain. We used three separate panels for staining. 
The stains used for each of the panels are listed in the table 
above. The first panel was for Treg cells. Panel two was for IFN 
gamma, IFN alpha and TNF alpha. Panel three was for IL-17, IL-
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4 and IL-10. After extracellular staining, the well plates were 
covered in foil and incubated for 30 minutes.  
After washing, Panel 1 was fixed and permeabilised with the 
FoxP3 buffer set. Panels two and three were also washed and 
fixed and permeabilised using the fixation and permeabilisation 
kit. Following this, intracellular stains were added and the plates 
were incubated for a further 30 minutes. These were washed 
and resuspended, in preparation for flow cytometry.  
We used single colour controls for each colour used with 
compensation beads. Flow cytometry these days uses many 
different fluorochromes to analyse different proteins/ cells. The 
success of polychromatic flow cytometry depends on a number 
of hardware factors that need optimising and calibrating to 
obtain the best results. One of the ways to calibrate this is by 
using beads. The identification of cells on flow cytometry 
depends on the levels of background signals, which can arise 
from various sources. The cleanest method for assessing the 
background is by using compensation beads which are singly 
stained with the fluorochromes used in the experiment. This 
process reduces spreading error and increases the dynamic 
range of cell population determination (426). 
In our experiment, 25 µL of compensation beads were added for 
each single colour control used; these were vortexed, covered in 
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foil and incubated for 15 minutes. They were then diluted with 
250 µL of PBS. 
During flow cytometry, the contents of each well were 
transferred into a FACS tube and run on the flow cytometry 
machine. The results were interpreted using the Kaluza 
software. For panel one, the cells were first gated and separated 
into live cells, then CD4+ cells. The next gating was 
CD4+/CD127low cells, and the final gating was 
CD4+/CD127low/CD25+/FoxP3+ cells. For panel two, the gating 
was CD3+ then CD3+CD4+CD8-. These were separated into 
interferon gamma+, TNF Alpha+, and interferon-alpha+. Further 
separate gating was used for CD3+CD4-CD8+ and again 
separated into the individual cytokines. For panel three the 
gating used was CD3+CD4+CD8- and then separated into IL-10 
IL-4 and IL-17 and then separate gating used for CD3+CD4-
CD8+ and separated into the individual cytokines. 
All the results obtained on Kaluza were converted into an Excel 
spreadsheet and analysed using GraphPad Prism software. 
The software provides results in both absolute numbers and 
percentages; Treg percentage represents the percentage of all 
CD4+ cells which express CD25 and FoxP3, and have low 
expression of CD127. As absolute numbers change with each 
sample tested, and depend on whether they are fresh or 
cryopreserved, percentages are a better way of comparing data. 
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Our cohort was very large with many samples which were tested 
in batches on different days, and we felt that expressing the 
results as percentages would make them more comparable. 
 
5.3 Results 
5.3.1 Treg cell population 
T reg proportions were measured according to the method 
described above. Although in literature the percentage of T regs 
have been described to be anywhere between 1 to 10%, in our 
cohort, all had lower readings of less than 1% with a few outliers 
with higher percentages. The few outliers amongst the Treg 
patient samples who had much higher percentages than the 
median were looked at; there were 8 samples, 5 of whom  had 
OMG- of these 3 generalised later on; 3 patients had GMG- 1 
with associated malignant thymoma and another with associated 
MGUS. 
After discussion with the immunologists, we concluded that as 
the same staining method and protocol was used for all patient 
samples and healthy controls, the results could still be 
compared, but comparison with published literature needed to 
be done cautiously. 
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The median for T regs in patient samples was 0.06% and in 
healthy controls it was 0.51%, P <0.0001 (Figure 60) (Table 28). 
T regs in EOMG and LOMG at recruitment did not show any 
statistically significant difference; median for EOMG was 0.035% 
and LOMG was 0.065%, P = 0.1635 (Figure 61).  
Figure 60 Comparison of T reg
percentages (with medians) in patient 
samples and healthy controls 
p<0.0001
Figure 61 Comparison of T reg
percentages (with medians) at 
recruitment in EOMG and LOMG 
p=0.1635
Figure 62 Comparison of T reg
percentages (with medians) in paired 
patient samples at recruitment and 
first year follow up p-0.9591
Figure 63 Comparison of T reg
percentages (with medians) in paired 
patient samples who were 
immunosuppression naïve at 
recruitment and immunosuppressed 
at first year follow up p=0.0625  
All p values were calculated using the Mann-Whitney test as the comparison was 




T regs compared between immunosuppression naïve patients 
and immunosuppressed patients at recruitment (non-paired 
samples) did not show any significant difference, median of 
0.06% in the immunosuppression naïve patients and 0.015% in 
the immunosuppressed patients with P = 0.8004. For 24 
patients, we obtained whole blood at first year follow up and 
isolated PBMCs. Of the 24 patients, 9 patients were treatment 
naïve at recruitment and were immunosuppressed at first year 
follow up, 11 patients were still treatment naïve at first year 
follow up, and the remainder had been immunosuppressed at 
recruitment and continued to be immunosuppressed at first year 
follow up. 
When all the paired samples were compared at recruitment and 
first year follow up, the medians were 0% for both, p = 0.9591 
(Figure 62). 
Comparison of T regs in immunosuppression naïve patients at 
recruitment with their paired samples at first year follow up after 
being immunosuppressed did not show  a difference, p = 0.0625 
(Figure 63); the median for immunosuppression naive patients 
was 0.68% and immunosuppressed patients at first year follow 
up was 0.54%.  
There was no significant difference in T reg levels in patients 
who were immunosuppression naïve at recruitment with their 
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paired samples at first year follow up in those patients who 
remained immunosuppression naïve, P = 0.6250. 
The T regs in LOMG patients at recruitment compared to paired 
first year samples did not show any statistical difference, P 
=0.3223.  
T regs at recruitment were compared in those patients with 
thymic abnormality (including histological abnormalities, and 
those with radiological abnormalities only) and those with normal 
thymuses; median for thymic abnormality was 0.03% compared 
to normal thymus 0.06%;this did not reach statistical significance 
p = 0.4035. There was no difference in T regs in patients with 
normal thymus and thymic hyperplasia p = 0.965 (Figure 64) 
and no difference in normal thymus versus thymoma either, P = 
0.6792 (Figure 65). T reg percentages at recruitment were 
plotted against ACHR RIA titres at recruitment using simple 
linear regression, and there was no linear correlation. 
When the recruitment samples of AChR Ab patient T regs were 
compared with T regs from healthy controls, there was a 
significant difference in numbers with the Treg count of 0.07% in 
AChR positive patients compared to 0.51% in the healthy 
controls P = 0.0005 (Figure 67). We did not analyse AChR RIA 
postives and CBA positives separately. There was a significant 
difference also when the T regs from healthy controls were 
compared with the T regs from all double seropositive patients, 
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median of the double positive being 0.06% and for healthy 
controls 0.51%, P = 0.0021. The Tregs were compared between 
AChR positive patients with the MuSK positive patients and 
there was no statistical statistically significant difference, P = 
0.2591.  
Figure 64 Comparison of T reg percentages (with medians) in patients 
with normal thymus and with thymic hyperplasia p=0.965
Figure 65 Comparison of T reg percentages (with medians) in patients with 
normal thymus and with thymoma p=0.6792
 
All p values were calculated using the Mann-Whitney test as the comparison was 




Figure 66 Correlation between T reg
percentages and AChR RIAs in patient 
samples at recruitment p=0.7838 on 
simple linear regression
Figure 67 Comparison of T regs (with 
medians) at recruitment in AChR+ 
patients and healthy controls 
p=0.0005
Figure 68 Comparison of Tregs (with 
medians) in MuSK+ patients and 
healthy controls p=0.0018
Figure 69 Comparison of Tregs (with 
medians) in LRP4+ patients and 
healthy controls p=0.8417
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
Figure 66: Simple linear regression used 
 
The T regs at recruitment in MuSK positive patients were 
compared with healthy controls. There was a statistically 
significant difference with median of 0.03% in the MuSK positive 




The Tregs in LRP4 positive patients was compared with healthy 
controls. There was no statistical significance with median of 
0.475% in the LRP4 group and 0.5% in healthy controls, 
p=0.8417 (Figure 69). 
 
5.3.2 Cytokines and Treg cells 
In addition to the Treg panel as described above, we did a 
further 2 panels, the second panel looking at interferon alfa, IFN 
gamma, and TNF alpha production by CD4 and CD8 cells; and 
panel three looking at IL-17, IL-10 and IL-4 production by CD4 
and CD8 cells. This was based on previously published 
literature on cytokine abnormalities seen in MG. IFNα however, 
was added on as part of the panel with IFNγ and TNFα; we 
acknowledge that this is unlikely to provide much information in 
this context and has not been included in the analysis. The 
staining methods and flow cytometry was as described above.  
CD4 interferon-gamma in patient samples at recruitment 
compared to healthy controls did not show a significant 
difference, median for patient samples was 22.82% and for 
healthy controls was 15.62%, P= 0.1692 (Figure 70A) (Table 
28). 
CD4 interferon-gamma in patients who were treatment naïve at 
recruitment with those who were immunosuppressed at 
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recruitment showed no difference with median for 
immunosuppression naïve patients of 24.17% and 
immunosuppressed patients of 19.59%, P = 0.0749 (Figure 
70B). 
Figure 70 Comparison of CD4 IFN-γ (with medians) in (A) patient samples and 
healthy controls p=0.1692 (B) patients who were immunosuppressed and those 
who were not, at recruitment p=0.0749 (C) ACHR+ patients and healthy 




All p values were calculated using the Mann-Whitney test as the comparison was 




Patients who were treatment naïve at recruitment and were 
given steroids in the first year did not show any significant 
difference in their interferon-gamma levels either, P = 0.9453. 
Patients who remained immunosuppression naïve through their 
first year also did not show any difference in CD4 interferon-
gamma, P = 0.4609. 
EOMG patients did not show any difference in their CD4 
interferon-gamma levels at recruitment and first year follow-up, 
p> 0.9999. Similarly LOMG patients did not show a difference 
either with p>0.9999. 
The percentage of CD4 interferon-gamma positive cells was 
compared between AChR positive patients and healthy controls; 
there was no statistically significant difference with median for 
AChR positive patients of 26.29% and healthy controls of 
15.62%, P = 0.1453 (Figure 70C). There was no difference in 
the double seropositives compared to healthy controls either 
and there was no difference between AChR positive patients 
and MuSK positive patients; median for AChR positive patients 
was 26.29% and for MuSK positive patients 13.13%, P = 
0.1826. 
CD4 interferon-gamma in MuSK patients compared to healthy 
controls did not show any statistically significant difference; 
median for MuSK patients was 13.13% and in healthy controls 
was 15.62%, P = 0.6216 (Figure 70D). 
332 
 
CD8 interferon-gamma in patient samples at recruitment 
compared to healthy controls did not show a  difference with 
median for patient samples of 41.13% and healthy controls of 
26.08%, P = 0.0795 (Figure 71A). 
There was a statistically significant difference between the 
percentage of CD8 interferon-gamma positive cells in EOMG 
and LOMG patients at recruitment, median of 30.49% in EOMG 
patients and 47.98% in LOMG patients, P = 0.0002 (Figure 
71B).  
There was no statistically significant difference between EOMG 
patient samples compared to EOMG healthy controls, P = 
0.6917; nor was there a difference between LOMG patients & 
LOMG healthy controls, P = 0.0818. 
There was no difference in CD8 interferon-gamma levels 
between patients who were immunosuppression naïve and 
those were immunosuppressed at recruitment, P = 0.6889. 
When paired samples were compared for CD8 interferon-
gamma, there was no difference between recruitment samples 
and first year samples, P = 0.7987. In patients who were 
immunosuppression naïve at recruitment and those who 
received steroids over the first year, there was no difference in 
CD8 interferon-gamma, p= 0.578. There was no difference when 
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patients remained immunosuppression naïve for the first year 
either, P = 0.4609. 
A
Figure 71 Comparison of CD8 IFN-γ (with medians) in (A) patient samples and 
healthy controls p=0.0795 (B) EOMG and LOMG  at recruitment  p=0.0002 (C) 





All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
There was no difference in EOMG patient samples at 
recruitment and at first year follow up with p>0.9999 and the 
LOMG patient samples were also not significant. 
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CD8 interferon-gamma was compared between AChR positive 
patients and healthy controls; there was no difference with 
median of 41.13% in AChR patients compared to 26.08% in 
healthy controls, p = 0.0978 (Figure 71C). There was no 
difference when this was compared between double 
seropositives and healthy controls, P = 0.2322; and there was 
no difference between AChR positive and MuSK positive 
patients, P = 0.6536. 
CD8 interferon-gamma in MuSK positive patients compared to 
healthy controls was not statistically significant; median for 
MuSK patients was 41.03% and healthy controls was 26.08%, P 
= 0.7539 (Figure 71D). 
The percentages of CD4 TNF alpha positive cells in recruitment 
patient samples compared to healthy controls were significantly 
different, median for patient samples was 63.52% and for 
healthy controls was 53.7%, P = 0.0237 (Figure 72A). 
CD4 TNF alpha in EOMG patients was positive in 60.66% 
compared to LOMG patients 64.11%, this was not significantly 
different, P = 0.067 (Figure 72B). EOMG patient samples 
compared to healthy controls at recruitment did not show a 
statistically significant difference, P = 0.1499 nor did LOMG 
patients compared to healthy controls, p = 0.4065. This may be 
because the number of healthy controls was less. 
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CD4 TNF alpha levels between immunosuppressed and 
immunosuppression naïve patients at recruitment was not 
significantly different, P = 0.4130. CD4 TNF alpha levels in 
paired samples at recruitment and first year follow-up was not 
significantly different, p = 0.2726 (Figure 72C). 
Figure 72 Comparison of CD4 TNFα (with medians) in (A) patient samples and 
healthy controls p=0.0237 (B) EOMG and LOMG  p=0.0670 (C) paired patient 
samples at recruitment and first year follow up p=0.2726 and (D) AChR+ 




All p values were calculated using the Mann-Whitney test as the comparison was 




In patients who were immunosuppression naïve at recruitment 
and given steroids over the first year, the CD4 TNF alpha levels 
were not significantly different, P = 0.3223. There was no 
significant difference between patients who remained treatment 
naïve over the first year either, P = 0.595. 
CD4 TNF alpha in EOMG patients at recruitment and first year 
follow-up did not show any significant difference, P =0.2500. 
LOMG patients did not show a difference either, P = 0.6226. 
CD4 TNF alpha in AChR positive patients compared to healthy 
controls were significantly different; median for AChR positive 
patients was 62.93% and for healthy controls was 53.7%, P = 
0.0279 (Figure 72D); the difference was still significant in double 
seropositives, P = 0.0285. There was no statistically significant 
difference between the AChR positive and MuSK positive 
patients, P = 0.6156. 
CD4 TNF alpha in MuSK positive patients compared to healthy 
controls was not statistically significant; median of 53.7% in 
MuSK patients and 68.23% in healthy controls (p=0.2566) 
(Figure 73A). This was different to the AChR antibody positive 
patients in whom there was a statistically significant difference. 
This could be because we only had 5 MuSK+ samples which 
were tested for TNFalpha. 
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The percentages of CD8 TNF alpha positive cells in patient 
samples at recruitment showed a difference compared to 
controls; median for patient samples was 44.4% and healthy 
controls was 28.86%, P = 0.0489 (Figure 74A). CD8 TNF alpha 
in EOMG and LOMG groups at recruitment was also 
significantly different, median for EOMG being 29.77% and 
LOMG 52.95%, P <0.0001 (Figure 74B). CD8 TNF alpha in 
EOMG patients at recruitment compared to EOMG healthy 
controls was not statistically significant, p> 0.9999; there was no 
difference in the LOMG patients at recruitment compared to the 
healthy control LOMG patients, p= 0.2336. This may be because 
the number of healthy controls was lower, and so, on subgroup 
analysis, the difference was not significant. 
CD8 TNF alpha in patients who were treatment naïve at 
recruitment compared to those who were immunosuppressed at 
recruitment was not statistically significantly different, P = 
0.4293. 
Comparison of paired samples at recruitment and first year 
follow-up did not show any statistically significant difference in 
CD8 TNF alpha, P = 0.0858 (Figure 74C). There was no 
difference in patients who were treatment naïve at recruitment 
and immunosuppressed at first year, P = 0.8125; and there was 
no difference in patients who remained treatment naïve over the 
first year, P = 0.191. 
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Figure 73 Comparison between (with medians) MuSK+ patients and healthy 
controls of (A) CD4 TNFa p=0.2466 and (B) CD8 TNFa p=0.1299
 
All p values were calculated using the Mann-Whitney test as the comparison was 




Figure 74 Comparison of CD8 TNFα (with medians) in (A) patient samples and 
healthy controls p=0.0489 (B) EOMG and LOMG p<0.0001 (C) paired patient 
samples at recruitment and first year follow up p=0.0858 and (D) AChR+ 
patients and healthy controls p=0.0636
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
The percentage of CD8 TNF alpha positive cells did not change 
statistically in the EOMG group from recruitment to first year 
follow-up, P = 0.5000 and they did not change in the LOMG 
group either, p= 0.2633. 
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CD8 TNF alpha compared between AChR positive patients and 
healthy controls did not show a difference, median being 
43.86% in AChR positive patients and 28.86% in healthy 
controls, P = 0.0636 (Figure 74D). There was no difference 
when double seropositives were compared with healthy controls 
p = 0.1425, and there was no difference when AChR and MuSK 
positives were compared with each other. 
CD8 TNF alpha in MuSK positive patients was also not 
significantly different from healthy controls; median for MuSK 
positive patients was 61.32% and healthy controls was 28.86%, 
P = 0.1299 (Figure 73B). 
Percentage of CD4 cells producing IL-10 were significantly 
greater in the patient samples compared to healthy controls at 
recruitment; the median for patient samples was 6.51% and 
healthy samples was 2.185%, P = 0.0082 (Figure 75A). 
There was no difference in CD4 IL-10 between EOMG and 
LOMG at recruitment, p= 0.5642 (Figure 75B). When EOMG 
patient samples at recruitment were compared to EOMG healthy 
controls, there was a significant difference in CD4 IL-10, P = 0 
(Figure 75C). There was no difference in LOMG patient samples 




There was no difference in CD4 IL-10 between patients who 
were treatment naïve and those who were immunosuppressed 
at recruitment, P = 0.8728.  
 
Figure 75 Comparison of CD4 IL10 (with medians) in (A) patient samples and 
healthy controls at recruitment  p=0.0082 (B) EOMG and LOMG p=0.5642 (C) 
EOMG patient samples and EOMG healthy controls at recruitment  p=0.0400 





All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
When paired samples at recruitment and first year follow-up 
were compared, there was no difference in CD4 IL-10, p= 
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0.7843. There was no difference in treatment naïve recruitment 
samples compared to their paired first-year follow-up samples 
when they were immunosuppressed either, p= 0.4961. There 
was no difference in CD4 IL-10 counts between 
immunosuppression naïve patients at recruitment who remained 
treatment naïve at first year follow-up, P = 0.5195. Similarly 
there was no difference in EOMG patients between recruitment 
and first year follow-up, p=0.2500, nor was there any change in 
LOMG patients from recruitment to first year follow-up, P = 
0.70124. 
CD4 IL-10 was compared between AChR positive patients and 
healthy controls; this showed a significant difference with 
median of 6.57% in AChR positive patients and 2.185% in 
healthy controls, P = 0.0098 (Figure 76A). It was still statistically 
significant when double seropositives were compared with 
healthy controls, P = 0.0196. There was no difference between 
MuSK and AChR positive patients. 
CD4 IL-10 in MuSK positive patients was not statistically 
significantly different to healthy controls; median for MuSK 
patients was 5.64% and healthy controls was 2.185%, P = 
0.4998 (Figure 76B). 
CD8 IL-10 did not show significant difference between patient 
samples at recruitment compared to healthy controls; median for 
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patient samples was 2.785% and for healthy controls was 
1.035%, P = 0.5097 (Figure 77A). 
There was no significant difference between the EOMG and 
LOMG subgroup either at recruitment, P = 0.6988. This was no 
significant difference between EOMG patient samples at 
recruitment compared to EOMG healthy controls, P = 0.55930, 
and there was no difference in the LOMG patient samples at 
recruitment compared to LOMG healthy controls, P = 0.9677. 
Figure 76 Comparison of CD4 IL10 (with medians) at recruitment in (A) AChR+ 





All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
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This was no statistically significant difference between the 
patients who were immunosuppression naïve compared to those 
who were immunosuppressed at recruitment, P = 0.8952. 
When paired samples were compared at recruitment and first 
year follow-up, there was no significant difference in CD8 IL-10 
counts, P = 0.8986. There was no significant difference between 
patients who were treatment naïve at recruitment and who were 
given steroids and first year follow-up, p=0.2500, and there was 
no difference in paired samples in patients who were treatment 
naïve at recruitment and stayed treatment naïve at first year 
follow-up, P = 0.4688. 
Paired samples in LOMG at recruitment and first year follow-up 
did not show any significant difference in CD8 IL10, P = 0.8986. 
There was no difference in CD8 IL-10 between AChR positive 
patients and healthy controls, median for AChR positive patients 
was 3.85% and healthy controls was 1.035%, P = 0.5063 
(Figure 77B). There was no difference between double 
seropositives and healthy controls. There was no difference in 
CD8 IL 10 between AChR positive patients and MuSK positive 
patients, median for AChR positive patients being 2.85% and 
MuSK positive patients 1.05%; P = 0.0871 (Figure 77C). CD8 IL-
10 in MuSK positive patients was not statistically significantly 
different from healthy controls; median for MuSK positive 
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patients is 1.05% and healthy controls was 1.035%, P = 0.5115 
(Figure 77D). 
Figure 77 Comparison of CD8 IL10 (with medians) in (A) patient samples and 
healthy controls at recruitment p=0.5097 (B) AChR+ patients and healthy 
controls p=0.5063 (C) AChR+ and MuSK+ patients p=0.0871 and (D) MuSK+ 




All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
CD4 IL-17 in patient samples at recruitment compared to 
healthy controls showed a significant difference, median for 
patient samples was 1.525% and for healthy controls it was 
0.705%, P = 0.0009 (Figure 78A). 
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There was no significant difference in CD4 IL-17 between the 
EOMG and LOMG patients at recruitment, P = 0.3159 (Figure 
78B). There was a difference between EOMG patient samples 
at recruitment compared to EOMG healthy controls, P = 0.0159 
(Figure 78C) but there was no statistically significant difference 
in the LOMG patient samples compared with LOMG healthy 
controls at recruitment, P = 0.2488 (Figure 78D). 
Figure 78 Comparison of CD4 IL17 (with medians) in (A) patient samples and 
healthy controls at recruitment p=0.0009 (B) EOMG and LOMG  p=0.3159 (C) 
EOMG patient samples and EOMG healthy controls at recruitment  p=0.0159 





All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
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There was no difference in CD4 IL-17 in patients who were 
immunosuppression naïve and those who were 
immunosuppressed at recruitment, P = 0.2249. 
CD4 IL-17 in paired samples at recruitment and at first year 
follow-up did not show a significant difference, P = 0.8695. 
Paired samples in patients who were treatment naïve at 
recruitment compared to after they were given steroids at the 
first year follow-up did not show any significant difference in 
CD4 IL-17, P > 0.9999 and there was no difference in 
immunosuppression naïve patients remained 
immunosuppression naïve at first year follow-up, P = 0.9453. 
The EOMG patients also did not show a difference in CD4 IL-17 
with their paired samples at recruitment and first year follow-up, 
P > 0.9999; similarly LOMG patients did not show a difference in 
CD4 IL-17 in their paired samples at recruitment and first year 
follow-up either, P = 0.9530. 
There was a difference in the CD4 IL-17 levels between AChR 
positive patients and healthy controls with a median of 1.6% in 
AChR positive and 0.705% in healthy controls, P = 0.0014 
(Figure 79A). The difference between double seropositives and 
healthy controls was also significant with P = 0.0008, and there 
was no statistically significant difference between AChR positive 
and MuSK positive patients, median being 1.6% in AChR and 
0.97% in MuSK patients, P = 0.1728. 
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CD4 IL-17 in MuSK positive patients compared to healthy 
controls was not statistically significant with a median of 0.97% 
in MuSK positive patients and 0.705% in healthy controls, P = 
0.5593 (Figure 79B). This was different to the AChR positive 
patients in whom there was a statistically significant difference in 
values. 
Figure 79 Comparison of CD4 IL17 (with medians) at recruitment in (A) AChR+ 
patients and healthy controls p=0.0014 and (B) MuSK+ patients and healthy 
controls p=0.5593
A B
Figure 80 Comparison of CD8 IL17 (with medians) in (A)  patient samples and 




All p values were calculated using the Mann-Whitney test as the comparison was 




CD8 IL-17 in patient samples and at recruitment compared to 
healthy controls did not show a significant difference, median for 
samples was 0.965% and median for healthy controls was 
0.33%, P = 0.439 (Figure 80A). There was no difference in 
EOMG and LOMG patient samples at recruitment either, P = 
0.2283. 
EOMG patient samples at recruitment compared to the EOMG 
healthy controls did not show any significant difference in CD8 
IL-17, P = 0.4723 similarly there was no significant difference in 
LOMG patients at recruitment compared to LOMG healthy 
controls, P = 0.3500.  
There was no significant difference between CD8 IL-17 in 
patients who were treatment naïve at recruitment compared to 
those immunosuppressed at recruitment, P = 0.2018. 
Paired samples at recruitment and at first year follow-up did not 
show any significant difference in CD8 IL-17 either, P = 0.9799. 
This was not significant in patients who were treatment naïve at 
recruitment compared to after they had been 
immunosuppressed at first year either, P = 0.975. Treatment 
naive patients at recruitment and first year follow-up also did not 
show difference in CD8 IL-17, P = 0.8125. CD8 IL-17 in LOMG 
patients at recruitment and first year follow-up did not show a 
difference, P = 0.9799. 
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CD8 IL-17 in AChR positive patients and healthy controls 
showed a median of 0.74% in AChR patients and 0.33% in 
healthy controls, P = 0.6385 (Figure 80B). There was no 
significant difference between double positive patients 
compared to healthy controls and there was no difference 
between AChR and MuSK positive patients either. 
There was no difference in the CD8 IL-17 counts between MuSK 
positive patients and healthy controls. Median for MuSK positive 
patients was 0.94% and healthy controls was 0.33%, P = 
0.9467. 
CD4 IL-4 in patient samples at recruitment compared to healthy 
controls did not show a significant difference, median for patient 
samples was 5.42%, and for healthy controls was 5.21%, P = 
0.7063 (Figure 81A).  
There was no significant difference between EOMG and LOMG 
subgroup, P = 0.5649. There was no difference in EOMG 
patients at recruitment compared to EOMG healthy controls, P = 
0.5619 and similarly there was no difference in LOMG patient 
samples at recruitment compared to LOMG healthy controls 
either, P = 0.7131. Patients who were treatment naïve and those 
immunosuppressed at recruitment did not show a difference in 
their CD4 IL-4 either, P = 0.3293. 
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When CD4 IL-4 was compared between patients at recruitment 
to their paired samples at first year follow-up was not 
significantly different, P = 0.060 (Figure 81B). There was no 
difference in CD4 IL-4 in patients who were treatment naïve at 
recruitment and who were given steroids at first year follow-up, 
P = 0.1641. There was no difference in patients treatment naïve 
at recruitment and stayed immunosuppression naïve at first year 
follow-up either, P = 0.1230. 
Figure 81 Comparison of CD4 IL4 (with medians) in (A) patient samples and 
healthy controls at recruitment p=0.7063 (B) paired patient samples at 
recruitment and first year follow up p=0.0600 (C) AChR+ patients and healthy 




All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
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Paired samples in EOMG patients at recruitment and first year 
follow-up did not show a difference in CD4 IL-4, P = 0.3750. 
LOMG patients did not show a difference in CD4 IL-4 at 
recruitment and first year follow-up either p= 0.1231. 
CD4 IL-4 in AChR positive patients compared to healthy controls 
did not show any difference with a median of 5.92% in AChR 
positive patients and 5.21% in healthy controls, P = 0.4288 
(Figure 81C). There was no difference in double seropositives 
compared to healthy controls and there was no difference 
between MuSK and AChR positive antibodies patients either. 
CD4 IL-4 in MuSK positive patients was not significantly different 
to healthy controls; median for MuSK positive patients was 
14.61% and healthy controls was 5.21%, P = 0.432 (Figure 
81D). 
The CD8 IL-4 did not show a significant difference between 
patient samples at recruitment compared to healthy controls, P = 
0.4905 (Figure 82A). There was no difference in EOMG and 
LOMG patient samples at recruitment with CD8 IL-4 of 1.95% in 
LOMG patients and 0.69% in EOMG patients, P = 0.0682 
(Figure 82B). 
There was no difference in CD8 IL-4 in EOMG patients at 
recruitment compared to EOMG healthy controls, P = 0.4346 
and there was no difference in LOMG patients either at 
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recruitment compared to LOMG healthy controls, P = 0.2588. 
There was no difference in CD8 IL-4 in patients who were 
suppression naïve at recruitment compared to those who were 
immunosuppressed at recruitment, P = 0.9729.  
CD8 IL-4 at recruitment compared to their paired samples at first 
year follow-up did not show significant difference, P = 0.1388. 
There was no difference in CD8 IL-4 in patients who were 
treatment naïve at recruitment and were immunosuppressed at 
first year follow-up, median for treatment naïve patients at 
recruitment was 0.95% and for immunosuppressed patients at 
first follow-up was 2.01%,  p= 0.0547 (Figure 82C).  
There was no difference in CD8 IL-4 in patients who were 
treatment naïve at recruitment and remain treatment naïve at 
first year follow-up, P = 0.4688. There was no difference in the 
LOMG samples at recruitment compared to their paired samples 
at first year follow-up, P = 0.1388. 
CD8 IL-4 in AChR positive patients compared to healthy controls 
did not show statistically significant difference, median for AChR 
positive patients was 1.65% and healthy controls was 1.605%, P 
= 0.5449 (Figure 82D). There was no statistically significant 
difference between double seropositives and healthy controls 
and between AChR and MuSK positive patients. 
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There was no statistically significant difference between CD8 IL-
4 in MuSK positive patients and healthy controls; median for 
MuSK positive patients was 0.36% and healthy controls was 
1.605%, P = 0.204. 
Figure 82 Comparison of CD8 IL4 (with medians) in (A) patient samples and 
healthy controls at recruitment p=0.4905 (B) EOMG and LOMG p=0.0682 (C) 
paired patient samples at recruitment when immunosuppression naïve with 
first year follow up after treatment with steroids p-0.0547 and (D) AChR+ 




All p values were calculated using the Mann-Whitney test as the comparison was 





T cells and Thymic abnormalities 
We looked at the Treg proportions and CD4 and CD8 production 
of interferon-alpha, interferon-gamma, TNF alpha, IL-10, IL-17, 
and IL-4. We then compared these in patients who had normal 
thymuses with those who had thymic abnormalities (this 
includes patients with thymoma, thymic remnant and thymic 
hyperplasia). NB: Not all patients were imaged, and not all 
patients who had thymic abnormalities on imaging had a 
histological diagnosis. The number of EOMG patients who had a 
histologically confirmed diagnosis of thymic hyperplasia was 8 
and thymoma was 2. The total number of scan abnormalities in 
EOMG (excluding a confirmed diagnosis of thymoma) was 16 
i.e. 43.24%. If we were to assume that, by definition, all EOMG 
patients have thymic abnormalities, this is perhaps indicative of 
the numbers in whom the thymus is enlarged enough to be 
picked up on imaging. 
CD4 interferon-gamma in normal thymus as compared to thymic 
abnormalities was not significant, P = 0.4540; it was not 
significant in normal thymus as compared to thymoma either, P 
= 0.4802 and similarly with thymic hyperplasia compared to 
normal thymus, P = 0.3970. CD8 interferon-gamma in normal 
thymus compared to thymic abnormalities did not show any 
significant difference, P = 0.1701; there was no significant 
difference between normal thymus and thymoma, P = 0.4474, 
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but it was significant in normal thymus compared to thymic 
hyperplasia with a median of 21.01% in thymic hyperplasia and 
42.22% in normal thymus, P = 0.0235 (Figure 83). 
CD4 TNF alpha in thymic abnormalities compared with normal 
thymus was not significant, P = 0.8382; normal thymus 
compared to thymoma was not significant, P = 0.6248, and 
normal thymus compared to thymic hyperplasia was not 
significant either, P = 0.3132. 
CD8 TNF-alpha in thymic abnormalities compared to normal 
thymus does not show any difference with a median of 31.67% 
in thymic abnormalities compared to 46.25% in normal thymus, 
P = 0.0778 (Figure 85A). Normal thymus compared to thymoma 
was not significant, P = 0.2586. There was a significant 
difference in CD8 TNF alpha in thymic hyperplasia compared to 
normal thymus; median for thymic hyperplasia was 29.57% and 
for normal thymus was 46.25%, P = 0.012 (Figure 85B). 
CD4 IL-10 in thymic abnormalities compared to normal thymus 
was not significant, P = 0.8219; it was not significant in thymoma 
compared to normal thymus either, P = 0.2336; and it was not 





Figure 83 Comparison of CD8 IFNγ
(with medians) in patients with 
normal thymus and thymic
hyperplasia p=0.0235
Figure 85 Comparison of CD8 TNFα (with medians) in (A) patients with normal 
thymus and all thymic abnormalities p=0.0778 and (B) in patients with normal 
thymus and thymic hyperplasia p=0.012
A B
Figure 84 Comparison of CD4 IL17 
(with medians) in patients with normal 
thymus and thymoma p=0.0086
 
All p values were calculated using the Mann-Whitney test as the comparison was 
between medians of two independent groups and not normally distributed. 
 
CD8 IL-10 in thymic abnormalities compared to normal thymus 
was not significant, P = 0.7352; was not significant in thymoma 
compared to normal thymus, P = 0.4769 and it was not 




CD4 IL-17 in thymic abnormalities compared to normal thymus 
was not significant, P = 0.1801; however it was significantly 
different in thymoma compared to normal thymus, median for 
thymoma was 0.52% and for normal thymus was 1.61%, P = 
0.0086 (Figure 84). It was not significant in normal thymus 
compared to thymic hyperplasia, P = 0.9157. 
CD8 IL-17 in thymic abnormalities compared to normal thymus 
was not significant, P = 0.8329, in thymoma to normal thymus it 
was not significant, P = 0.6315, and not significant in normal 
thymus and thymic hyperplasia, p=0.6917. 
CD4 IL-4 in thymic abnormalities compared to normal thymus 
was not significant, P = 0.7218; it was not significant in normal 
thymus compared to thymoma, P = 0.9606 and was not 
significant in thymic hyperplasia compared to normal thymus, P 
= 0.7259. 
CD8 IL-4 was not significantly different in thymic abnormalities 
compared to normal thymus, P = 0.3074, not significant in 
thymoma compared to normal thymus, P = 0.440, and in thymic 






Table 29 Summary of flow cytometry results 
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0.51 15.62 53.7 26.08 28.86 2.185 0.705 5.21 1.035 0.33 1.605 
0/12  
 
0.07 22.82 63.52 41.13 44.4 6.51 1.525 5.42 2.785 0.965 1.71 
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0.1692 0.0237 0.0795 0.0489 0.0082 0.0009 0.7063 0.5097 0.4394 0.4905 
EOMG Vs 
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0.6792 0.4802 0.6248 0.4474 0.2586 0.2336 0.0086 0.9606 0.4769 0.6315 0.4340 

































0.0005 0.1453 0.0279 0.0978 0.0636 0.0098 0.0014 0.4288 0.5063 0.6385 0.5449 
MuSK+ Vs 
controls  




0.0021 0.2490 0.0285 0.2322 0.1425 0.0196 0.0008 0.5186 0.8222 0.3375 0.4358 
AChR+ Vs 
MuSK+  
0.2591 0.1826 0.6156 0.6536 0.3897 0.7034 0.1728 0.6942 0.0871 0.6569 0.3579 
 
 
5.3.3 Does immunosuppression change Treg function? 
When we compared the samples of patients at recruitment and 
at their first year follow-up in patients who were 
immunosuppression naïve at recruitment and 
immunosuppressed during the first year (9 patients), there was 




Recruitment samples in patients who were treatment naïve and 
the 15 who were immunosuppressed during recruitment did not 
show any difference in T regs, CD4 TNF alpha, CD8 interferon-
gamma, CD8 TNF alpha, CD4 IL-10, CD4 IL-17, CD4 IL-4, CD8 
IL-10, CD8 IL-17 and CD8. The only difference was seen in CD8 
interferon-alpha.  
Comparison of T regs in immunosuppression naïve patients at 
recruitment with their paired samples at first year follow up after 
being immunosuppressed in the first year did not show a 
difference, p = 0.0625; the median for immunosuppression naive 
patients was 0.68% and immunosuppressed patients at first 
year follow up was 0.54%.  
CD4 interferon-gamma in patients who were treatment naïve at 
recruitment with those who were immunosuppressed at 
recruitment did not show a difference with median for 
immunosuppression naïve patients of 24.17% and 
immunosuppressed patients of 19.59%, P = 0.0749. 
There was no difference in CD8 IL-4 in patients who were 
treatment naïve at recruitment and were immunosuppressed at 
first year follow-up, median for treatment naïve at recruitment 
was 0.95% and for immunosuppression at first year follow-up 
was 2.01%,  p= 0.0547. It could be assumed that patients 
remaining treatment naïve at first year follow up have a milder 
disease, and their immune markers would be different to those 
363 
 
receiving immunosuppression. Although the difference in T regs 
between treatment naïve and immunosuppressed patients was 
not significant, there was a tendency towards improvement of T 
reg levels after immunosuppression. CD8 IL-4 also showed a 
tendency towards improvement with increasing percentages 
after immunosuppression. CD8 interferon-alpha in patients who 
were immunosuppressed at recruitment was much lower than 
treatment naïve patients showing that immunosuppression 
reduces levels of CD8 interferon-alpha. Similarly CD4 interferon-
gamma also appears to be suppressed with lower levels in 
patients who received steroids at recruitment. CD4 interferon-




The Treg proportions we found in our study were much lower 
than those reported in literature where they have been shown to 
be anywhere between 1 and 10% (405), whereas in our cohort 
we found that the readings were much lower than 1%. There 
were a few outliers amongst these patient samples with higher 
percentages. However, we found that the median for both the 
patient samples and our healthy controls was much less than 
published in literature and concluded that this was due to our 
gating mechanism. We did not think that this would affect results 
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as the same staining methods and gating were used for the 
patient samples and healthy controls. Stringent controls were 
used during the experiment to ensure that the staining methods 
were appropriate. The proportions in the controls were as 
normally expected and therefore lower levels but the proportions 
remain plausible.However, we accept that our data needs to be 
interpreted with caution because of the low percentages, and 
because of this, may not be directly comparable to published 
literature. 
Is there a difference in T reg levels in the peripheral blood 
lymphocytes of MG patients compared to healthy controls, and 
in LOMG patients compared to EOMG patients? 
The percentage of T regs in our patients was significantly lower 
than healthy controls. There was no statistically significant 
difference between EOMG and LOMG at recruitment. The 
EOMG patient samples compared with EOMG healthy controls 
shows a significant difference; LOMG patients compared to 
LOMG healthy controls also showed a difference but to a slightly 
lesser degree. Due to our large sample size, 135 of which were 
treatment naïve samples, we think that these results are 
indicative of the immunopathogenesis in MG, but accept that the 
percentages are too small to make accurate predictions. 
Published data so far have been contradictory, some showing 
reduced Treg numbers, and others no difference in Treg 
numbers in MG. The data on Treg in aging (and thus 
corresponding to EOMG vs LOMG) are also contradictory, with 
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some studies showing an increase and others a decrease (51, 
52, 265). What most papers agree on is that there is a functional 
defect in the Tregs, irrespective of numbers/percentages. We 
did not perform functional studies on our patient samples, and 
so this information is not available. Initial immunosuppression at 
recruitment does not seem to change the Treg percentages as 
seen when we compared the 15 immunosuppressed patients at 
recruitment with the 135 immunosuppression naive patients. 
There was no difference in the Treg levels at recruitment and at 
first year follow up in the 24 patients whose samples were tested 
at recruitment and a year later; and, although there was a further 
drop in Treg levels in patients who went to have 
immunosuppression, this was not statistically significant.  The 
paired LOMG samples did not show any difference either. We 
were unable to compare the EOMG patient samples as there 
was no mean difference between the two values.This is different 
to the one study by Wen et al which looked at 59 treatment 
naïve patients, 13 of whom then had immunosuppression, 
where they found that Treg levels in treated patients was 
significantly higher than untreated patients and the levels 
improved after treatment (298). It can also be assumed that if 
the patients were on low dose steroids, the differences in Treg 
may be minor. Braitch et al have shown a modestly increased 
percentage in Tregs in MS after iv methylprednisolone, but after 
6 weeks they were back to baseline levels (427). 
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Is there a difference in Treg levels in patients with thymic 
abnormalities? 
T regs showed a trend towards being lower in patients with 
thymic abnormalities (radiologically abnormal with many 
histologically confirmed) as a whole compared to patients with a 
normal thymus, but it was not significantly different. There was 
no difference in T regs in patients with normal thymus and 
thymic hyperplasia/enlargement nor was there a difference in 
normal thymus compared to thymoma/thymic mass. Previous 
studies have shown contradictory results on Treg numbers in 
MG with thymic abnormalities, with no consensus. Once again, 
with low Treg percentages, interpretation of our data is difficult. 
We analysed our data on radiologically abnormal thymuses 
(most of whom also had a histological diagnosis). This does not 
take into account those patients who may have a histological 
abnormality with normal radiological appearances, particularly in 
EOMG. Perhaps if this is looked into in more detail in future 
studies, we may get data that is comparable to published 
literature. 
Is there a difference in Treg levels levels in the different antibody 
subgroups? 
There was a significant difference in the Tregs in AChR 
antibody-positive patients compared to healthy controls and in 
MuSK positive patients compared to healthy controls, but there 
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was no difference between Tregs in LRP4 positive patients 
compared to HCs. NB: We had fewer LRP4+ patients compared 
to the other subgroups. There was a significant difference also 
when T regs were compared between double seropositive 
patients and healthy controls. There was no difference however 
when AChR antibody-positive patients’ T regs were compared to 
MuSK positive patients’ T regs. Although there is some literature 
on cytokines in the antibody subgroups, there is no large scale 
data on Treg levels in the different antibody subgroups. 
Is there a difference in the cytokines IFNγ, TNFα, IL-10, IL-17 
and IL-4 in the peripheral blood lymphocytes of MG patients 
compared to healthy controls and in LOMG patients compared 
to EOMG patients? 
Although IFNa was tested on the flow cytometry panel, we 
realise that this is unlikely to add to the current study and so has 
not been included in this discussion. When cytokine levels 
(using the percentage of expressing change as a surrogate for 
the levels) were compared between recruitment patient samples 
and HC, the proinflammatory cytokines TNFa and IL-17 were 
higher, and IFNg and IL-4 did not show any difference. The anti-
inflammatory cytokine IL-10 was higher in patient samples 
compared to HC. For cytokines IL-17 and IL-10, this difference 
was seen only in EOMG and not in LOMG patients. Previous 
studies have shown an increase in several pro-inflammatory 
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cytokines in MG including IFNγ, TNFα and IL-17 (250, 310). Our 
study has shown an increase in IL-17 and TNFa, and although 
there is a trend towards higher IFNg in the MG patients, this was 
not significant. In keeping with literature, this increase was seen 
mainly in EOMG patients (314). 
IFNg levels were lower in treatment naïve patients compared to 
those who were immunosuppressed at recruitment. There are 
no studies comparing cytokine levels in treatment naïve and 
immunosuppressed patients. It could be postulated that 
treatment naïve patients have milder disease and so their 
inflammatory markers are less than those with more severe 
disease needing immunosuppression. 
When EOMG was compared to LOMG, the only significant 
difference was in IFNg levels which were higher in LOMG 
patients, IL-4 levels were slightly higher in LOMG compared to 
EOMG. There are no large studies comparing cytokines in 
EOMG and LOMG and this is novel data. As mentioned before 
in the chapter on clinical presentation and antibodies, the LOMG 
patients in our cohort seem to have more severe disease, and 





Is there a difference in cytokine levels in the different antibody 
subgroups? 
In AChR MG patients, the pro-inflammatory cytokine IFNg was 
slightly higher, TNFa was higher, IL-17 was higher and the anti-
inflammatory cytokine IL-10 was higher than HC. In contrast, 
MuSK MG patients had no increase in the pro-inflammatory 
cytokines or anti-inflammatory cytokines. This is different to 
previously published data which reports that MuSK MG patients 
have higher IFNg and IL-17 levels, and not AChR MG patients, 
in direct contrast to our study results (315). The majority of the 
patients in the published study were on immunosuppression, 
some on two or more drugs. We did not perform subgroup 
analysis on patients who were immunosuppressed in each 
antibody category. 
Double sero-positive patients had cytokine levels similar to 
AChR MG with lower IFNa levels, higher TNFa, IL-17 and IL-10 
levels, but no increase in IFNg compared to HC. 
When we compared AChR and MuSK MG patients, IL-10 was 
no different in AChR MG compared to MuSK MG,. 
Our T reg and cytokine analysis in the antibody subgroups 
shows a mixed anti-inflammatory and pro-inflammatory picture. 
The percentage of CD8 cells producing cytokines (which we 
used as surrogate markers instead of measuring cytokines), was 
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not significantly altered other than slightly increased pro-
inflammatory cytokines IFNγ and TNFα in AChR Ab + patients. 
In AChR MG, the main cytokine producing T cell appears to be 
the CD4+ cells, which shows increased production of the pro-
inflammatory cytokines TNFα and IL-17. This, along with 
reduced T regs indicates a ‘pro-inflammatory’ environment. At 
the same time, there is increased production of the anti-
inflammatory cytokine IL-10 indicating an ‘anti-inflammatory’ 
environment. This kind of defective balance is seen in a lot of 
autoimmune conditions. 
In contrast to AChR MG, in MuSK MG, Tregs are reduced 
indicating a ‘pro-inflammatory’ environment only. 
Is there a difference in cytokines in patients with thymic 
abnormalities? 
There was no difference in cytokines between patients with 
normal thymuses and thymic abnormalities as a whole; CD4 IL-
17 is significantly lower in patients with thymoma/thymic mass 
compared to patients with normal thymuses, CD8 interferon-γ 
and CD8 TNF α are significantly lower in patients with thymic 
hyperplasia/enlargement compared to normal thymuses. This is 
different again to previous literature which has shown increased 
pro-inflammatory cytokines in thymic hyperplasia (250, 310). We 
accept that our study results are not conducive to a direct 
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comparison, as not all patients had a histological diagnosis, and 
comparison was made between radiologically abnormal (with 
histological conformation in many), and radiologically normal 
thymuses. 
In conclusion, in our patient cohort, IL-10 which is an anti-
inflammatory cytokine is increased in patient samples. This 
suggests an anti-inflammatory environment. At the same time, 
Treg cell population is reduced in patient samples both in EOMG 
and LOMG, and the pro-inflammatory cytokine TNFα is 
increased in patient samples, as is IL-17. This mixed picture 
would suggest that there is a defective balance in immune 




6 Conclusion       
6.1 Summary of findings and General discussion 
To our Knowledge, this is the largest prospective study on the 
clinical and immunological aspects of late-onset myasthenia 
gravis to date. It is also the only study which has 100% 
recruitment rates from Nottinghamshire and Derbyshire over the 
three-year recruitment period. Between August 2014 and July 
2017, we recruited 150 patients newly diagnosed with 




Epidemiological studies in the last 65 years have shown that late 
onset myasthenia gravis is becoming increasingly more 
common. In our cohort of 150 MG patients, more than three 
quarters of the patients (76%) were over the age of 50 years in 
keeping with published data with a mean age of 57.6 years in 
females and 61.24 years in males. We found a difference in the 
medians of peak age of 4 years in male and female EOMG 
patients (lower in females) which is less than that reported by 
Somnier et al but the peak age in LOMG males and females is 
no different, which is consistent with that previously reported 
(406). Whilst our study recruited all the newly diagnosed 
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patients in the Trent region, this was not the case with 
Birmingham and Oxford. However, we have shown that there 
was no bias in patient recruitment amongst the different regions 
(Table 3), there was no difference in the racial distribution 
compared to the national statistics for the regions, and that the 
incidence of LOMG in the Nottingham area is increasing. From 
this, we can infer that our study shows that the incidence of 
LOMG is increasing in all the regions.  
Previous studies have suggested that the incidence of LOMG 
may be rising because of an ageing population as a whole, 
declining mortality rates, and possibility of better ascertainment 
of cases that were previously misdiagnosed. All these factors 
did not fully explain the percentage of rise in incidence of 
LOMG; environmental factors were postulated, but not proven 
(98, 99, 106). 
From our detailed questionnaire (listed in chapter 2), we were 
unable to ascertain any environmental, infectious, occupational 
or medication triggers in our patients in either EOMG or LOMG. 
This analysis was based purely on the questionnaire and no 
laboratory or immunological tests were done to look into this. 
We did not check for EBV infection for example which has 
previously been shown to have some association with MG (144). 
In Jon Aarli's paper of 2008 he found that the female to male 
ratio was 1:1.1 for LOMG, and 3:1 in EOMG (96). Evoli and 
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colleagues stated a female to male ratio of 1:1.9 in LOMG (151). 
Our data has shown a female to male ratio of 1:1.6 in LOMG 
and 1.4:1 in EOMG. Our study has shown the same trend, and 
that late-onset myasthenia gravis in male patients has increased 
even further whilst the number of female EOMG patients has 
dropped. Why there is a male bias in LOMG is not clear; in most 
conditions where oestrogen has a role to play, incidence 
between males and females equalises as they get older. It is 
possible that different HLA haplotypes play a dominant role in 
disease susceptibility in males and females in LOMG. 
There have been few studies on racial distribution in MG. 
Population-based studies in several different countries and 
across continents show a similar incidence and prevalence rate 
and similar distribution of EOMG and LOMG patients. A study by 
Oh and colleagues in Alabama, USA showed that AChR Ab 
positivity was more common in white americans (WA) compared 
to African-americans (AA), SNMG AA patients were more likely 
to be MuSK Ab positive, three quarters of OMG AA patients 
were seronegative, and disease onset was earlier and more 
common in females amongst AA patients compared to WA 
patients in whom it was later in onset and more common in 
males (410). Whilst this was a large study with 235 patients and 
good follow up, it was a retrospective study looking at patients 
treated in a single neuromuscular clinic, and may not reflect the 
true incidence or prevalence. Another study in Norway and 
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Netherlands looked at the prevalence between the native and 
emigrant population and did not find any difference. They noted 
that the incidence of MuSK MG and MG with thymoma was 
higher in the immigrant population compared to the native 
population (114). In our cohort, there was no significant 
difference in racial distribution across the three regions where 
patients were recruited i.e. West Midlands, East Midlands and 
the South East England. Whilst recruitment in Birmingham and 
Oxford was selective, we recruited all patients with a diagnosis 
of myasthenia across Nottinghamshire and Derbyshire excluding 
the northern districts, and hence these results are truly 
representative of the racial distribution of myasthenia in the 
area. 
 
6.1.2 Ocular Myasthenia Gravis 
Ocular myasthenia gravis (OMG) has been more difficult to 
define because of varying time limits applied across several 
different studies. Defining OMG based on ocular symptoms at 
diagnosis or recruitment is completely arbitrary and does not 
provide any useful clinical information about disease 
progression (172, 173). Oosterhuis suggested a minimum of 
three months as a limit for purely ocular symptoms before 
classifying a patient as having OMG (169).  Similarly Sommer et 
al and Monsul et al also suggested purely ocular symptoms for 
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at least three months from symptom onset to class them as 
OMG (170, 171). 
We defined our cohort of OMG patients as all patients who had 
purely ocular symptoms up to and including three months from 
symptom onset. This was based on previous literature but also 
on our own findings of ‘time of symptom onset’. We found that 
the median time for bulbar, generalised and respiratory 
symptom onset was less than three months. There is an 
argument to classify some of the GMG patients who generalised 
quite early on in their illness as ‘early generalisers’, those that 
generalised just after 3 months as ‘intermediate generalisers’ 
and those that generalised after 2 years as ‘late generalisers’. 
For the purposes of this thesis, this distinction has not been 
made 
Whilst previous studies have shown that OMG is more common 
in LOMG compared to EOMG (155, 156) neither of the papers 
mentioned how they defined OMG. This means that interpreting 
this data and comparing our study with theirs is not possible. 
Our study has shown that younger patients have ocular 
myasthenia gravis more frequently compared to LOMG, 
whereas the older patients more frequently have generalised 
myasthenia gravis.  
Generalisation of OMG has not been reported in an entirely 
treatment naïve cohort of patients before. We found that whilst 
377 
 
the generalisation time from OMG is similar in both EOMG and 
LOMG patients, with the majority of the patients generalising in 
under a year, generalisation occurred more frequently in LOMG 
than EOMG. We had reviewed 120 patients for their first year 
follow-up and 65 patients for their second year follow-up at the 
time of data analysis, and although this data was not complete 
at the time of writing, the numbers are still significant enough to 
reflect realistic generalisation rates. As there are no large-scale 
studies looking at treatment naive patients over a course of time, 
we did not have any published data to compare this against.  
In our own cohort, there was no difference in presentation with 
unilateral or bilateral ptosis in the EOMG and LOMG patients, 
and there was no significant difference between time to 
generalisation between unilateral ptosis and bilateral ptosis in 
either group. In patients who had ptosis only, there was a 
difference between the EOMG and LOMG groups with 
generalisation occurring more quickly in the older patients 
(perhaps due to small numbers in the EOMG group); but when 
generalisation rates were compared between the ptosis only 
group and patients who had both ptosis and diplopia, there was 
no statistically significant difference. It is not entirely clear 
whether presenting with purely ptosis in an older patient is an 
independent risk factor for generalisation. 
Ocular myasthenia gravis was also seen at the same rate in all 
antibody subtypes, and, although OMG was more common with 
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AChR and LRP4 double positivity, this was not significant. This 
is different to previously published data which suggests that 
AChR and LRP4 double seropositivity is more likely to be 
associated with bulbar symptoms and a more severe course 
(206). It is not entirely clear why this difference was seen, but 
the number of LRP4 Ab positive patients in our cohort was 
relatively less. There was no difference in first presenting 
symptom in our cohort amongst any of the different antibody 
subtypes. Over the course of the disease, all patients (100%) 
who had antibodies to MuSK, LRP4, MuSK and AChR double 
positive, and AChR and LRP4 double positive had ocular 
symptoms, whereas AChR single positive patients had ocular 
symptoms in 92.5% and seronegative patients had ocular 
symptoms in 87.5%; neither of which were statistically 
significant. This would suggest that AChR Abs and seronegative 
patients can have ocular sparing MG, whereas this is not the 
case with the other Abs. Again, it is not clear why this difference 
is seen between the antibody subgroups; one would assume 
that as ocular muscles are more susceptible to circulating MG 
antibodies, they should be equally vulnerable to all subtypes. Is 
it possible that the IgG1 subclass of AChR Abs has a slightly 
less pathogenic effect on ocular muscles compared to IgG4 




6.1.3 Clinical Presentation 
Because of the prospective nature of our study, recruiting 
patients when they were treatment naïve, and within the first 
year of diagnosis, we were able to plot the onset of all MG 
symptoms from point zero and compare the median times of 
symptom onset for all the different symptoms. This has not been 
done before and is novel data. The median time of symptom 
onset for all symptoms when compared shows that the longest 
median time of symptom onset is less than three months at 87 
days. This was one of the reasons why we defined ocular MG as 
ocular symptoms only for more than 3 months.  
Although the general order of symptom onset seems to be 
similar in all patients, with ocular symptoms occurring first, 
followed by other generalised symptoms, there was a difference 
in the order of generalised symptom onset between EOMG and 
LOMG groups. There was no significant difference in 
presentation of ocular symptoms (although more common in 
younger patients), nor in development of generalised symptoms 
(although quicker in older patients). EOMG patients presented 
with dysphagia, dysarthria, neck weakness and respiratory 
symptoms at a much later stage than LOMG patients. The 
median time of onset of chewing difficulties and limb weakness 
was not significantly different between the two groups.  
During the course of the disease, bulbar symptoms were seen 
much more commonly in LOMG patients compared to EOMG 
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patients. There was no difference in limb weakness or 
respiratory symptoms in the EOMG and LOMG groups. There 
was no difference in symptom presentation in males and 
females in any of the groups.  
Previous literature has suggested that patients with MuSK 
antibodies are more likely to be female, younger, without 
thymoma and more likely to have bulbar and respiratory 
involvement (154, 161). They were also found to remain 
immunosuppression dependent and needing rituximab. In our 
cohort we did not find any difference in bulbar symptoms 
amongst patients who had antibodies to MuSK, AChR, and 
MuSK and AChR double positives. However, seronegative 
patients were much less likely to have bulbar symptoms 
compared to AChR single positives, and compared to AChR and 
MuSK double positives. This difference was not seen between 
seronegatives and MuSK and LRP4 single positive patients. 
One could assume that seronegative patients have an as yet 
unidentified Ab that is less pathogenic than AChR. However, 
since they are clinically more similar to patients with MuSK and 
LRP4 Abs, this does not make sense. Any interpretation of this 
should be made with caution as the number of single positive 
LRP4 patients was small, and there were only 8 seronegative 
patients.The subgroups did not show any difference in the 
frequency of limb weakness. There was no difference in 
respiratory symptoms in any of the antibody subgroups including 
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in MuSK MG. Whilst there was a trend towards MuSK MG 
patients being more commonly female and having more bulbar 
and respiratory symptoms, this was not statistically significant. 
Whether this is a reflection of the fact that this was a prospective 
study with follow up data for two years in the majority of patients, 
and whether these patients would deteriorate later on in their 
course of illness is unclear.  
We looked at the timing of the worst MG composite scores from 
symptom onset in all patients and found that the majority of the 
patients had the worst MG composite score during the first year, 
in nearly three quarters of them, and most of them (53.33%) 
within the first 100 days. This would suggest that patients are at 
their worst with MG-related symptoms during the first year and 
subsequently improve, with or without treatment. On subgroup 
analysis, there was no difference in time to worst MGC between 
EOMG and LOMG. 
We compared MG composite scores in patients who were 
diagnosed early compared to those in whom there had been a 
diagnostic delay and there was no difference. There was a 
significant difference in time to diagnosis from symptom onset 
between EOMG (median of 13.5 mths) and LOMG (median of 2 
mths), older patients being diagnosed quicker than EOMG. This 
is different to previously published data (99). The study by 
Vincent et al was a very large prospective study using positive 
AChR Ab test results from all UK centres. This was not a clinical 
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study and was not longitudinal. Our study on the other hand is 
prospective with high quality recruitment including referrals from 
other Neurologists, GPs, Ophthalmologists, Neurophysiologists 
and Laboratory data. The patients were recruited from regions 
where there was a neurology service which ensured better pick 
up rates and reduced selection bias. Also, LOMG patients more 
commonly present with GMG, are more likely to have comorbid 
conditions, and more commonly require admission to hospital, 
which may be why we see this difference. 
Older patients were also more likely to require admission to 
hospital. This could be multiple times compared to younger 
patients. There are contradictory reports in literature, where 
some studies suggest that MG crises are more common in 
younger females, whilst others show no difference (390) (392, 
394). It is to be noted that, in our cohort, amongst the LOMG 
patients needing admission, nearly three quarters were not for 
MG crises (Table 19), whereas nearly half the admissions in 
EOMG patients were with MG crises. So, whilst the total number 
of admissions is greater in LOMG patients, within the total MG 
admissions, MG crises were more common in younger patients. 
One could argue that neurologists have a lower threshold for 
admitting older patients to hospital as they are more likely to 
have other co-morbidities making them more susceptible to 
deterioration/ steroid dips, whereas younger patients are 
admitted when they are clinically much worse and/or in crisis. 
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Previous studies have reported that 14.8% of MG patients are 
refractory to treatment and they are more likely to be young 
female patients with anti-MuSK antibodies and with thymomas. 
Life-threatening events have been shown to occur in 9.56% of 
MG patients (387, 388). In our cohort, we found that 15.38% of 
EOMG patients and 36.03% of LOMG patients required 
admissions to hospital for MG related reasons. The older 
patients were also more likely to be admitted more frequently 
compared to younger patients. The majority of admitted patients 
were older- this could be due to several factors including other 
co-existing comorbidities which meant that they sought or were 
referred to hospital earlier than younger patients, or, as we saw 
earlier, LOMG patients had a higher MG composite score at 
recruitment compared to EOMG, perhaps indicating a more 
symptomatic onset in these patients. Previous studies have 
shown that prognosis is favourable in all MG patients, but LOMG 
patients are more likely to achieve an optimal outcome (392). In 
keeping with this, the majority of the patients in our cohort 
responded well to treatment with 92.5% of LOMG patients 
attaining a good outcome compared to 50% in EOMG patients. 
2.56% of patients, all LOMG, died during an admission to 
hospital. This is slightly contradictory to saying that LOMG 
patients had a better outcome. This is explained by the fact that 
the majority of LOMG patients admitted to hospital had a 
proportionately good outcome, compared to the EOMG patients. 
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The overall mortality rate over the three-year period in our 
cohort was 4/150 i.e. 2.6%, all of them in the LOMG group. Of 
these, three were thought to have been caused by or 
contributed to by myasthenia gravis. This is similar to previously 
published literature (393).  
When we compared the MGFA-PIS scores at first year follow-
up, LOMG patients did better than EOMG patients and this trend 
was seen even at second year follow-up. When the whole cohort 
of patients was compared at first and second year follow-up, 
there was no difference in their PIS scores. The MGFA PIS in 
OMG and GMG patients at second year follow-up compared to 
first-year was not significantly different. The AChR RIA titres fell 
significantly from point of recruitment to follow up with a 
significant improvement in the first year and a further slight 
reduction in the second year. MG composite scores showed a 
significant change in median scores at first year follow-up 
compared to at recruitment in both EOMG and LOMG. Similarly, 
this difference was seen in patients who were treatment naïve at 
recruitment and were immunosuppressed at first year follow-up. 
There was also a significant difference in the MG composite 
scores between EOMG and LOMG groups, being higher in 
LOMG compared to EOMG. This suggests that patients do 
better with time, and that older patients have a more severe 
illness at onset. 
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The MG composite scores and QOLs seem to have a linear 
correlation. There was no difference between MG QOL between 
EOMG and LOMG patients at recruitment. The MG QOL in our 
cohort improved when recruitment scores were compared with 
first year follow-up and this difference was more significant in 
the LOMG group compared to the EOMG group. The QoL 
scores in the older patients may have been influenced by other 
co-existing medical problems. There was also a significant 
difference in MG QOL in patients who were treatment naïve at 
recruitment and those who were immunosuppressed in the first 
year. LOMG patients had worse MG composite scores and QOL 
scores at recruitment but seemed to respond well to treatment 
clinically and in quality of life, doing much better than EOMG 
patients. 
There was no difference in MG composite or MG QoL scores in 
patients who had preceding infections prior to the onset of MG 
symptoms to those who did not; there was no difference in both 
the scores between smokers and non-smokers. Alcohol intake 
and salbutamol inhalers did not make any difference to their 
scores either. Although unlikely, the reasoning behind asking 
about inhalers was to see if Salbutamol, which is used in some 
forms of congenital MG, made any difference to the symptoms. 
This is of course not a direct comparison, as the doses used and 
methods of delivery are different in the two conditions. There 
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was no difference in MGC or MG QOL in patients who were 
single positive to one antibody compared to double positives. 
There have been several case reports in literature associating 
statin use with myasthenia gravis (412). We compared AChR 
titres, MG composite scores and MG QOL in all patients who 
were on statins with those who were not on statins and there 
was no significant difference. The rationale for looking into this 
was to see if patients on statins had a more severe illness/ had 
worse MGC scores. 
There were other associated symptoms seen in our patients, 
including dry mouth in 8.6% urinary symptoms in 2.67%, fatigue 
in 6%, and weight loss in 7.33%. This is similar to reported 
literature, although none of the studies were longitudinal cohort 
studies (71, 83, 411). Whether urinary symptoms are related to 
MG or to the use of pyridostigmine is unclear. 
Other autoimmune diseases associated with myasthenia have 
been reported to be very common, the most common being 
autoimmune thyroid disorders (91). It has also been reported 
that the frequency of second autoimmune disorders is higher in 
females and EOMG group who are more likely to be AChR 
antibody-positive and have GMG (93). In our cohort we found 
that asthma was the most common other autoimmune disorder 
followed by hypothyroidism. Comparison between EOMG and 
LOMG patients did not show any difference at 43.58% and 
387 
 
34.23% respectively; 43.93% of all the females in the study and 
30.95% of all the males in the study had associated autoimmune 
conditions. There was no difference between the younger 
female and younger male patients either. This may be partly 
because asthma was not included as an AI condition in the other 
papers, and this may have narrowed the difference in our own 
cohort. 
Previous literature has reported that familial autoimmunity in 
patients with MG is common and has been seen in 40% of 
EOMG patient relatives and 20% of LOMG relatives (93). 4% of 
the relatives had MG. In our cohort we found that family history 
of autoimmunity was 40% overall, more common in EOMG at 
51.28% and 36.02% in LOMG in keeping with literature; 
however, this was not statistically significant. Hypothyroidism in 
the family seems to be the most common autoimmune disease 
followed by myasthenia gravis in 10/60 patients (16.67%) and a 
rate of 6.67% overall of familial MG.  Studies on the effects of 
HLA on the age of onset of MG have shown mixed results. 
Different HLA haplotypes have been linked to EOMG and 
LOMG, but it is not clear why familial MG and indeed other 
autoimmune conditions are more common in EOMG (129-142). 
One explanation could be that although HLA haplotypes may be 
shared between siblings, disease susceptibility could be defined 
not only by HLA-DR but also by other genetic factors including 
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gene-gene interactions. Why this would be different in younger 
patients compared to older patients is unclear. 
Other than for autoimmune conditions, there was no correlation 
with other comorbidities in our MG cohort. We had two patients 
with inclusion body myositis in our cohort, one of whom was 
seronegative and one who was double positive for MuSK and 
LRP4. 
 
6.1.4 Effects of Immunosuppression 
There have been several studies looking at the effect of 
prednisolone on the progression of OMG to GMG. Several of the 
studies suggest that early treatment with steroids decreases the 
progression of OMG to GMG. The EPITOME study which was 
the only RCT designed to look prospectively at steroid response 
in patients with OMG was not completed as planned (176). In 
our cohort, when we looked at the survival curve for time to 
generalisation in OMG patients who were given steroids pre-
generalisation against those who were not given steroids pre-
generalisation, there was no difference. There was no difference 
between the EOMG and LOMG groups either. There was no 
difference in time to generalisation of OMG between LOMG and 
EOMG; although LOMG patients as a whole developed 
generalised symptoms much earlier than EOMG, this was not 
significantly different. From our data, it appears that treating an 
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OMG patient with steroids does not change generalisation rates. 
This is important in clinical practice; however, this was not a 
drug trial. In order to confirm or refute this, an RCT would be 
required. Given that the well designed, international EPITOME 
trial failed to recruit patients, this may be difficult to do, but 
should nonetheless be tried. 
Most of the literature which compares steroid doses in MG 
patients has been in those who have had thymectomy versus 
those who have not had thymectomy. There was no comparable 
data in literature for steroid doses in OMG and GMG patients as 
a natural cohort.  
When we compared the daily dose steroid requirement in all 
patients at first year follow-up with second year follow-up 
(patients being treatment naïve at recruitment), there was a 
significant difference in doses, with patients at second year 
requiring less average daily dose steroids compared to the first 
year, both in EOMG (16mg Vs 6.25mg) and in LOMG (10mg Vs 
7mg). There was no significant difference in the steroid doses 
between EOMG and LOMG at first year follow-up or at second 
year follow-up, but the dose requirements at first year follow up 
in LOMG was slightly less than EOMG. This would be in 
contrast to the clinical presentation of worse disease in LOMG 
with more GMG. This could be explained by the fact that LOMG 
patients required earlier initiation of steroids during the first year 
and doses were tapered down by their first year follow up. It 
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could also suggest that LOMG patients responded more rapidly 
to treatment. 
The steroid dose in OMG at first year was higher than at second 
year; however, in GMG there was no difference between first 
and second year steroid dosages. On direct comparison 
between OMG and GMG, there was no difference in steroid 
dose at first year or at second year. It appears that OMG 
patients respond more quickly to steroids than GMG, leading to 
clinically significant improvement and reduced steroid doses 
with time.  
Steroid requirements pre-generalisation were no different in any 
of the antibody subgroups; but, post generalisation i.e. in GMG 
patients with AChR and MuSK double positivity, the steroid 
requirement was much higher (80%) compared to AChR single 
positives (25.2%), MuSK single positives, AChR and LRP4 
double positives, and the seronegatives. When compared to the 
MuSK and LRP4 double positive group, it was not significantly 
different. The common factor in both appears to be positivity to 
MuSK Abs. In comparison, the requirement for alternate 
immunosuppressants in AChR single positives compared to 
AChR and MuSK double positives was not significant. It has 
been reported in literature that MuSK MG follows a more severe 
course, and patients were more likely to require alternate 
immunosuppression- more commonly plasma exchange or 
rituximab. We did not see this difference in our cohort, except for 
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higher rates of steroid requirement in AChR and MuSK double 
positives. This would suggest that in our cohort, although the 
clinical presentation between the AChR and MuSK subgroups 
was not significantly different, the double positives were harder 
to treat, implying perhaps a more brittle myasthenia? 
The MG composite scores for the 15 patients who were 
immunosuppressed at recruitment compared to the patients who 
were immunosuppression naïve at recruitment showed a 
significant difference. This was likely to be reflective of the fact 
that patients who required immunosuppression at recruitment 
were at the severe end of the disease spectrum, requiring 
admission to hospital in crises or bulbar/respiratory symptoms. 
MG composite scores in patients who were immunosuppression 
naïve at recruitment but were immunosuppressed at first year 
follow-up did not show any statistical significance and there was 
no difference at second year follow-up either. 
Initial immunosuppression at recruitment does not seem to 
change the Treg percentages as seen when we compared the 
15 immunosuppressed patients at recruitment with the 135 
immunosuppression naive patients. There was no difference in 
the Treg levels at recruitment and at first year follow up in the 24 
patients whose samples were tested at recruitment and a year 
later; and although there was a further drop in Treg levels in 
patients who went on to have immunosuppression, this was not 
statistically significant.  The paired LOMG samples did not show 
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any difference either. We were unable to compare the EOMG 
patient samples as there was no mean difference between the 
two values. This is different to the one study by Wen et al which 
looked at 59 treatment naïve patients, 13 of whom then had 
immunosuppression, where they found that Treg levels in 
treated patients was significantly higher than untreated patients 
and the levels improved after treatment (298). 
IFNg levels were lower in treatment naïve patients compared to 
those who were immunosuppressed at recruitment. There are 
no studies comparing cytokine levels in treatment naïve and 
immunosuppressed patients. It could be postulated that 
treatment naïve patients have milder disease and so their 
inflammatory markers are less than those with more severe 
disease needing immunosuppression. 
 
6.1.5 Neurophysiology 
Previous studies and literature have shown that single fibre 
EMG (SFEMG) has more sensitivity and specificity compared to 
RNS; however, because of the easy availability of RNS this was 
the diagnostic test recommended by AAEM (413). In a study by 
Punga and colleagues (188) they showed that RNS was normal 
in patients with severe GMG and they recommended using 
concentric needle electrode myography instead. In our cohort, 
SFEMG was abnormal in 66.67% compared to 43.24% of RNS 
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abnormalities; this was not statistically significant, although in 
keeping with literature. Only four patients had routine EMG of 
which one showed myopathic changes. Of the 8 seronegative 
patients, 5 had neurophysiology of which two were abnormal 
showing blocks on SFEMG, the other three were normal. 
 
6.1.6 Immunological profile 
It has been reported in previous literature that AChR positivity is 
seen in 85-90% of GMG patients and between 50-75% of OMG 
patients (44, 419). There is wide variability in MuSK antibody 
positivity, with initial reports of 7%, but other papers reporting 
anywhere between 3.8 and 47.4% (151, 200, 420). Most studies 
have shown that AChR titres are lower in LOMG patients with no 
thymic abnormalities (96, 97, 149, 150, 421), patients with 
thymoma had higher titres (no age correlation) and EOMG 
patients with thymic hyperplasia had higher titres (10). A study 
by Iwasa et al differed slightly when they found raised AChR 
titres amongst MG patients in Japan for a brief period of time; 
this was more pronounced in LOMG patients (422). 
Of our 150 patients, the majority were single positive for AChR 
antibodies, with a small proportion positive for MuSK antibodies 
and LRP4 antibodies. We had a large number of patients who 
were double positive for AChR and MuSK, AChR and LRP4, or 
MuSK and LRP4, and 8/150 who were seronegative. Two 
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patients were triple positive but were thought to be single 
positive for AChR with non-specific binding for the other two. 
The reason for this differentiation between double postives and 
triple positives was that in the double positives, the binding was 
to the expressed receptors- either GFP tagged AChR or MuSK 
or untagged LRP4 receptors, whereas in triple positives, the 
binding was to the cell surface/ other proteins as well as the 
expressed receptors. 
Of our 150 patient samples, when tested for all three antibodies 
on RIA and CBA, we had 8 seronegative patients (5.32%) (one 
of these patients was initially positive for AChR on RIA). The 
majority of patients were positive for AChR (71.33%). The rates 
of AChR single positivity in our cohort was lower than previously 
published, however, we had a further 15.33% who were double 
positive, bringing the total AChR positivity to 86.66% which is 
more in keeping with published literature. In routine clinical 
practice, serum is tested for AChR antibodies first and if this is 
negative, they are tested for MuSK antibodies on RIA followed 
by clustered CBA. It is possible that there are a small number of 
patients in the community who have been diagnosed with AChR 
MG, but who may well have a second antigenic target which has 
not been tested for.  
The rates of LRP4 (2%) and MuSK MG (4%) was in keeping 
with published literature.  
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We had quite a few patients who were double positive. AChR 
and MuSK double positivity was seen in 10%, which is slightly 
less than previously published data of 12.5% (423). AChR and 
LRP4 double positivity was seen in 5.33%, again, less than 
previously published rates of 7.45% (207). MuSK and LRP4 
double positivity was seen in 0.67%, this is much less than 
previously published rates of between 14.92% and 19.8% (207, 
423). The previously published data is mainly from a 
multinational retrospective study of 904 stored serum samples. 
Two patients were positive for all three antibodies, although the 
conclusion was that the MuSK and LRP4 antibodies were 
probably non-specifically binding. Triple seropositivity has also 
been described before at a similar rate (423). 
In our cohort of 150 patients, 8 patients were seronegative. 
Among the seronegative patients, ocular symptoms were seen 
slightly less frequently at 87.5% compared to antibody positive 
patients; however, this was not statistically significant.  
In our study, we found that in OMG, AChR positivity was seen in 
75% in EOMG and 80% in LOMG on RIA, and 87.5% and 80% 
respectively on CBA. The difference in positivity on RIA and 
CBA was not statistically significant. The positivity on RIA in 
younger GMG patients was low at 56.5% compared to the 
LOMG patients at 91.4%; however with CBAs the positivity in 
EOMG GMG patients increased to 82.6% and in LOMG patients 
to 93.8%, which was still statistically significant.  
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Zivkovic et al have published similar results in their retrospective 
study where they found AChR positivity to be more common in 
LOMG than in EOMG (p=0.0026). They did not differentiate 
between OMG and GMG, but mention that OMG is much more 
common in LOMG than in EOMG. Jacob et al suggest that 
patients with AChR antibodies positive only on clustered cell 
based assays more commonly have OMG. This is different to 
what our study suggests; however, the study by Jacob et al was 
a small retrospective study, and whilst showing a trend, the 
results were not conclusive (155, 164). 
It appears that the EOMG patients in our cohort, particularly 
those with GMG, may have lower affinity antibodies to AChR 
which were not detected in the solution phase (used in RIA), but 
were detectable on CBAs. As has been shown previously, low 
affinity Abs are still pathogenic in vivo against the AChR clusters 
at the NMJ (163). It appears that EOMG patients have highly 
pathogenic, but low affinity AChR Abs compared to LOMG. 
There was a significant difference in AChR single positivity in 
the females in EOMG and LOMG in our cohort, being much 
more frequent in LOMG patients. This is different to previously 
published data by Burke and colleagues who suggested that 
LOMG patients had lower AChR titres (NB: titres, not positivity) 
and were more likely to have striated muscle antibodies (414). 
There was tendency towards younger female patients in our 
cohort being double positive to AChR and MuSK compared to 
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older female patients, however this was not statistically 
significant. Previous studies by Zisimopoulou et al looked at 
double positivity with LRP4 Abs. They found that it was more 
common in young females, and they had a more severe illness 
than those with single positivity to LRP4. Our study has found 
this with MuSK and AChR; whilst this cannot be directly 
compared, we can infer that as both these antibodies are 
pathogenic to different targets, in combination, they can cause a 
more severe disease (207). MuSK antibody positivity was also 
not statistically significant in our EOMG or LOMG groups or 
between males and females, which is different to published 
literature which suggest that MuSK positivity is more commonly 
seen in young females (151, 154).  
There was no difference between MuSK positivity in EOMG and 
LOMG in ocular patients. MuSK seropositivity in GMG in EOMG 
patients was 33.3% compared to 11.9% in LOMG patients, 
which was not significant. There was no significant difference in 
MuSK seropositivity amongst the EOMG group when OMG and 
GMG were compared, neither was there any difference in the 
LOMG subgroup. Female EOMG patients positive to MuSK Abs 
(30.43%) compared to male EOMG patients (6.25%) did not 
show a statistically significant difference. When female EOMG 
and LOMG patients were compared, although the trend was 
towards the younger females being more likely to be positive 
(30.43% Vs 11.62%), this was not significant (p=0.0610). This is 
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different to previously published data which report that MuSK 
Abs are more common in younger females (151, 154, 407). The 
study by Guptill et al was a large cohort retrospective study; 
however, all the antibody tests were done on RIA, and not on 
CBAs. It is possible that lower affinity MuSK Abs, which may 
well be what is seen in LOMG patients, were missed (NB: the 
majority of our MuSK positives were on CBA alone), skewing the 
data towards the younger females. In the study by Evoli et al, 
who noticed a striking female preponderance, MuSK Abs were 
tested using immunoblot. The study by Huda et al showed that 
although female preponderance was seen with MuSK CBA+ 
RIA- patients, the age of onset was less, and they were more 
likely to have OMG, suggesting a milder phenotype in these 
patients. Our MuSK cohort was predominantly RIA- CBA+. This 
could be one of the reasons why our results differ from 
published literature. For future studies, this subgroup will need 
to be looked into more carefully by recruiting higher numbers of 
patients who are MuSK RIA+, and comparing them with those 
who are MuSK CBA+ RIA-. 
LRP4 seropositivity in our cohort was similar to published data. 
There was no difference between OMG and GMG in EOMG and 
LOMG, and no difference between EOMG and LOMG (both for 
OMG and GMG) either. This is different to previously published 
data which report that LRP4 single positivity is associated with 
milder disease and double positivity with more severe disease 
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(207). Our LRP4 cohort was predominantly double positive with 
less than a quarter of them being single positive. This is perhaps 
why, clinically, as a group, the phenotype was not dissimilar to 
the other subgroups. 
There have been no large prospective studies looking at AChR 
titres with longitudinal data and long term follow up of patients. 
Our study provides novel data on AChR titres. We compared the 
titres of AChR RIA in patients at recruitment and at annual 
follow-up. We found a significant drop in titres over the first year. 
The drop in titres was seen mainly in patients who were 
treatment naïve at recruitment and who were 
immunosuppressed at first year follow-up, and although there 
was a drop in titres in patients who remained 
immunosuppression naïve throughout the first year, it was not 
statistically significant. There was a comparable drop in scoring 
on AChR CBA as well when recruitment samples were 
compared with first year and second year follow-up samples. 
Both AChR RIA titres and MG composite scores fell during the 
first year, with linear correlation; similarly with MG QOL. It 
appears that with a clinical response to treatment, there is a 
corresponding fall in AChR titres. This would make sense 
theoretically. It appears that in an individual patient, falling titres 
may indicate clinical improvement, and vice versa. However, 
functional studies were not done and although this can be 
inferred, it cannot be confirmed. 
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There was a significant difference between AChR RIA titres in 
EOMG and LOMG with the titres being much higher in LOMG. 
Compston et al found in their retrospective study of stored 
serum samples, that patients with thymoma had the highest 
titres of AChR Abs, followed by the EOMG patients, and then 
the LOMG patients. They used 40 years as the age cut off. This 
was similar to data published by Lindsburg et al and 
Mantegazza et al. Somnier et al found lower concentrations of 
AChR in LOMG, but non significantly. In contrast, Lindstrom et 
al did not find any correlation with age. Neither Lindstrom nor 
Somnier divided the groups into thymomatous and non-
thymomatous patients. Our analysis also did not differentiate 
between thymomatous and non-thymomatous patients. As 
explained in previous chapters, the relationship between thymic 
abnormalities and LOMG is not entirely clear. It is postulated 
that abberations in the aged thymus in LOMG mimics thymoma 
behaviour without frank neoplasia, or, a small thymoma could 
have regressed spontaneously before the diagnosis of MG. It is 
therefore possible that our LOMG cohort reflects this 
immunological similarity with TAMG with high AChR titres (97, 
149, 150, 421). 
The Treg proportions we found in our study were much lower 
than those reported in literature where they have been shown to 
be anywhere between 1 and 10% (405), whereas in our cohort 
we found that the readings were much lower than 1%. There 
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were a few outliers amongst these patient samples with higher 
percentages. However, we found that the median for both the 
patient samples and our healthy controls was much less than 
published in literature and concluded that this was due to our 
gating mechanism. We did not think that this would affect results 
as the same staining methods and gating were used for the 
patient samples and healthy controls. However, we accept that 
our data needs to be interpreted with caution because of the low 
percentages, and because of this, may not be directly 
comparable to published literature. 
The percentage of T regs in our patients was significantly lower 
than healthy controls. There was no statistically significant 
difference between EOMG and LOMG at recruitment. The 
EOMG patient samples compared with EOMG healthy controls 
shows a significant difference; LOMG patients compared to 
LOMG healthy controls also showed a difference but to a slightly 
lesser degree. Due to our large sample size, 135 of which were 
treatment naïve samples, we think that these results are 
indicative of the immunopathogenesis in MG, but accept that the 
percentages are too small to make accurate predictions. 
Published data so far have been contradictory, some showing 
reduced Treg numbers, and others no difference in Treg 
numbers in MG (49, 50, 264). What most papers agree on is 
that there is a functional defect in the Tregs, irrespective of 
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numbers/percentages. We did not perform functional studies on 
our patient samples, and so this information is not available. 
When EOMG was compared to LOMG, the only significant 
difference was in IFNg levels which were higher in LOMG 
patients, IL-4 levels were slightly higher in LOMG compared to 
EOMG. There are no large studies comparing cytokines in 
EOMG and LOMG and this is novel data. The LOMG patients in 
our cohort seem to have more severe disease, and higher levels 
of inflammatory cytokines would be in keeping with this. We did 
not compare immune markers between patients with similar 
disease severity in EOMG and LOMG to see if the difference 
was still seen, and if age was a factor here along with disease 
severity. This is perhaps something that could be done in future 
studies. 
When cytokine levels were compared between recruitment 
patient samples and HC, the proinflammatory cytokines TNFa 
and IL-17 were higher, and IFNg and IL-4 did not show any 
difference. The anti-inflammatory cytokine IL-10 was higher in 
patient samples compared to HC. For cytokines IL-17 and IL-10, 
this difference was seen only in EOMG and not in LOMG 
patients. Previous studies have shown an increase in several 
pro-inflammatory cytokines in MG including IFNγ, TNFα and IL-
17 (250, 310). Our study has shown an increase in IL-17 and 
TNFa, and although there is a trend towards higher IFNg in the 
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MG patients, this was not significant. In keeping with literature, 
this increase was seen mainly in EOMG patients (314). 
There was a significant difference in the Tregs in AChR 
antibody-positive patients compared to healthy controls and in 
MuSK positive patients compared to healthy controls, but there 
was no difference between Tregs in LRP4 positive patients 
compared to HCs. NB: We had fewer LRP4+ patients compared 
to the other subgroups. There was a significant difference also 
when T regs were compared between double seropositive 
patients and healthy controls. There was no difference however 
when AChR antibody-positive patients’ T regs were compared to 
MuSK positive patients’ T regs. Although there is some literature 
on cytokines in the antibody subgroups, there is no large scale 
data on Treg levels in the different antibody subgroups. As 
mentioned earlier, our Treg percentages were small and so this 
data needs to be interpreted with caution. 
In AChR MG patients, the pro-inflammatory cytokine IFNg was 
slightly higher, TNFa was higher, IL-17 was higher and the anti-
inflammatory cytokine IL-10 was higher than HC. In contrast, 
MuSK MG patients had no increase in the pro-inflammatory 
cytokines or anti-inflammatory cytokines. This is different to 
previously published data which reports that MuSK MG patients 
have higher IFNg and IL-17 levels, and not AChR MG patients, 
in direct contrast to our study results (315). The majority of the 
patients in this published study were on immunosuppression, 
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some on two or more drugs. We did not perform subgroup 
analysis on patients who were immunosuppressed in each 
antibody category. 
Double sero-positive patients had cytokine levels similar to 
AChR MG with lower IFNa levels, higher TNFa, IL-17 and IL-10 
levels, but no increase in IFNg compared to HC. 
When we compared AChR and MuSK MG patients, there was 
no difference in IL-10. 
Our T reg and cytokine analysis in the antibody subgroups 
shows a mixed anti-inflammatory and pro-inflammatory picture. 
The percentage of CD8 cells producing cytokines (which we 
used as surrogate markers instead of measuring cytokines), was 
not significantly altered other than slightly increased pro-
inflammatory cytokines IFNγ and TNFα in AChR Ab + patients. 
In AChR MG, the main cytokine producing T cell appears to be 
the CD4+ cells, which shows increased production of the pro-
inflammatory cytokines TNFα and IL-17. This, along with 
reduced T regs indicates a ‘pro-inflammatory’ environment. At 
the same time, there is increased production of the anti-
inflammatory cytokine IL-10 indicating an ‘anti-inflammatory’ 




In contrast to AChR MG, in MuSK MG, Tregs are reduced 
indicating a ‘pro-inflammatory’ environment only. 
 
6.1.7 The Thymus 
Previous reports in literature have shown that thymic 
hyperplasia is seen in 50-60% of EOMG patients and is not 
seen in LOMG patients (51, 52, 415). Of our 150 patients, 137 
had imaging to look for thymic abnormalities. The total number 
of abnormalities, including thymoma/thymic mass, thymic 
hyperplasia/enlagment and thymic remnants, are more 
commonly seen in EOMG patients in 50% compared to LOMG 
in 13.86%. Thymic enlagment/hyperplasia (depending on CT 
findings or confirmed on histology) was much more commonly 
seen in EOMG patients in 30.55% compared to 0% in LOMG. 
Thymomas/thymic mass (depending on CT findings or 
confirmed on histology) was seen in 16.67% of EOMG patients 
compared to 10.89% in LOMG patients, which was not 
statistically significant. We did not find any difference in AChR 
titres amongst patients with thymoma in the LOMG and EOMG 
group. Overall, in our cohort, younger patients appear to have 
more frequent thymic hyperplasia/enlargement and 
thymoma/thymic mass compared to LOMG. The data was based 
on scan findings of thymic enlargement with subsequent tissue 
diagnosis in most of these patients. This presumes that a normal 
scan excludes thymic abnormality which may not be the case, 
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particularly in EOMG. This means that our data is not directly 
comparable to published studies, and this would require 
categorising patients into histologically normal and abnormal 
groups; however, our data suggests that thymic hyperplasia is 
much more common in EOMG than LOMG. 
We did not find a difference in AChR RIAs in EOMG and LOMG 
patients with thymic abnormalities. This could be because we 
did not thymectomise all EOMG patients; it is possible that a 
proportion of patients with no radiological abnormalities had 
histological abnormalities which were not picked up, and so a 
proportion of the data may be missing. (10, 97). 
We did not find any difference in thymic abnormalities in the 
different antibody subgroups except for patients with LRP4 
antibodies who were more likely to have thymic hyperplasia 
compared to AChR single positivity. However, it is to be borne in 
mind that we only had 2 LRP4 single positive patients in our 
cohort. Also to be borne in mind, the data was based on scan 
findings of thymic enlargement with subsequent tissue diagnosis 
in most of these patients.  
There was no difference in T regs in patients with normal 
thymus and thymic hyperplasia/enlargement nor was there a 
difference in normal thymus compared to thymoma/thymic 
mass. Previous studies have shown contradictory results on 
Treg numbers in MG with thymic abnormalities, with no 
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consensus. It is not clear why these studies differ but it could be 
due to the different staining and gating used and the different 
patient mix. Once again, with low Treg percentages, 
interpretation of our data is difficult. We analysed our data on 
radiologically abnormal thymuses (most of whom also had a 
histological diagnosis). Perhaps if this is looked into in more 
detail in future studies, we may get data that is comparable to 
published literature. 
There was no difference in cytokines between patients with 
normal thymuses and thymic abnormalities as a whole; CD4 IL-
17 is significantly lower in patients with thymoma/thymic mass 
compared to patients with normal thymuses, CD8 interferon-γ 
and CD8 TNF α are significantly lower in patients with thymic 
hyperplasia/enlargement compared to normal thymuses. This is 
different again to previous literature which has shown increased 
pro-inflammatory cytokines in thymic hyperplasia (249, 309). We 
accept that our study results are not conducive to a direct 
comparison, as not all patients had a histological diagnosis, and 
comparison was made between radiologically abnormal (with 






Our data shows that the incidence of LOMG is increasing, and 
EOMG is more common in females and LOMG more common in 
males, although the difference between younger males and 
females is becoming less significant. OMG is more common in 
EOMG than LOMG; however, there is no difference in the type 
of ocular presentation or generalisation rates in EOMG and 
LOMG. LOMG patients are more likely to have bulbar and 
respiratory symptoms than EOMG patients, and they also 
develop these symptoms significantly earlier than EOMG 
patients. Age seems to be the factor here rather than sex, as 
there is no difference between male and female patients. LOMG 
patients have worse MG composite scores and QOL scores at 
recruitment but seem to respond well to treatment clinically and 
in quality of life, doing much better than EOMG patients. The 
rates of autoimmunity were the same in EOMG and LOMG, but 
family history of autoimmunity was more common in EOMG than 
LOMG. Clinical phenotypes in the different antibody subgroups 
suggests that there is no difference in bulbar, limb, respiratory 
and ocular symptoms in any of the subgroups, except for 
seronegative patients who are less likely to have bulbar 
symptoms.  
LOMG patients have worse MG composite score and QOL 
scores at recruitment but seem to respond well to treatment 
clinically and in quality of life, doing much better than EOMG 
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patients. The rates of autoimmunity were the same in EOMG 
and LOMG, but family history of autoimmunity was more 
common in EOMG than LOMG.  
AChR Ab positivity is seen more commonly in older females 
compared to younger females; all the other antibody subgroups 
are comparable between younger and older patients and 
females and males. AChR and MuSK double positive patients 
require steroids more frequently in GMG compared to other 
antibody subgroups. Seronegative patients in our cohort did not 
require admission to hospital suggesting that they may have a 
less severe illness and a more indolent course compared to the 
antibody positive subgroups. AChR Ab positivity is seen more 
commonly in older females compared to younger females; all 
the other antibody subgroups are comparable between younger 
and older patients and females and males. AChR and MuSK 
double positive patients require steroids more frequently in GMG 
compared to other antibody subgroups. OMG patients respond 
more quickly to steroids than GMG, leading to clinically 
significant improvement and reduced steroid doses with time. 
One could argue that this would suggest that OMG is a milder 
disease than GMG. It has been postulated that ocular muscles 
are more susceptible to being affected by Abs in MG, which is 
why OMG is more common than GMG; hence an alternative 
explanation would be that ocular muscles respond more quickly 
and effectively to steroids compared to muscles elsewhere.  
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Our study has shown a lower rate of AChR single positivity, but 
when double positives were added, the positivity rates were 
similar to published data. EOMG patients were less likely to be 
positive on RIA, possibly due to lower affinity antibodies. AChR 
titres were higher in LOMG compared to EOMG. The titres 
dropped after treatment on annual review. There was no 
difference in AChR titres in patients with (mainly radiological) 
thymic abnormalities. There was no difference in MuSK or LRP4 
positivity in the different subgroups, and we had a lower 
percentage of double seropositivity compared to published 
literature. 
In our patient cohort, IL-10 which is an anti-inflammatory 
cytokine is increased in patient samples. This suggests an anti-
inflammatory environment. At the same time, Treg cell 
population is reduced in patient samples both in EOMG and 
LOMG, and the pro-inflammatory cytokine TNFα is increased in 
patient samples, as is IL-17. This mixed picture would suggest 
that there is a defective balance in immune regulation in MG. 
Our study data shows that there are clinical differences between 
EOMG and LOMG with differences in onset, severity, 
generalisation, MGC scores, and outcomes. There are also 
immunological differences with rates of seropositivity and AChR 
titre levels. Despite the differences, patients in both groups 
respond well to treatment and show an improvement with time, 
both clinically and immunologically. 
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6.2 Future research 
After the completion of the present study in July 2017, we have 
continued the project by recruiting more newly diagnosed 
patients with MG in the East Midlands area. We have continued 
to collect follow up data on the 150 patients initially recruited and 
should have two year follow- up data for all 150 patients by the 
middle of 2019. 
We plan to continue this work with further research: 
 To isolate B cells from PBMCs and identify AChR producing 
plasma cells. 
 Determine levels of membrane-bound B-cell activating factor 
and its receptor (BAFF/BAFF-R) in peripheral blood 
lymphocytes (PBL).  
 Determine the antibody profile to Titin, ryanodine receptor, Agrin 
and ColQ  
 Undertake molecular HLA typing to expand current UK datasets 
contributing to an ongoing genome-wide association study. 
 Perform studies on viral and auto-antibodies on frozen sera and 
PBL to be stored from every case; also on V-beta T-cell receptor 
repertoires, and correlate with clinical data, viral serological 




We sent some of our serum samples to Dr Punga’s lab in 
Sweden, where she and her colleagues have evaluated the 
serum for circulating microRNAs.  
The papers that we have published so far are: 
 
Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-
5p correlate with clinical status in late onset myasthenia 
gravis. 
Sabre L, Maddison P, Sadalage G, Ambrose PA, Punga AR.J 
Neuroimmunol. 2018 Aug 15;321:164-170. doi: 
10.1016/j.jneuroim.2018.05.003. Epub 2018 May 
8.PMID: 29804819  
 
 miR-30e-5p as predictor of generalization in ocular 
myasthenia gravis. 
Sabre L, Maddison P, Wong SH, Sadalage G, Ambrose PA, 
Plant GT, Punga AR.Ann Clin Transl Neurol. 2019 Jan 






  False-positive acetylcholine receptor antibody results in 
patients without myasthenia gravis. 
Maddison P, Sadalage G, Ambrose PA, Jacob S, Vincent A.J 
Neuroimmunol. 2019 Jul 15;332:69-72. doi: 
10.1016/j.jneuroim.2019.04.001. Epub 2019 Apr 
3.PMID: 30959340 
 
 A Prospective Study of the Incidence of Myasthenia Gravis 
in the East Midlands of England. 
Maddison P, Ambrose PA, Sadalage G, Vincent 
A.Neuroepidemiology. 2019;53(1-2):93-99. doi: 
10.1159/000500268. Epub 2019 May 8.PMID: 31067543 
  
Ocular presentation of myasthenia gravis: A natural history 
cohort. 
Kamarajah SK, Sadalage G, Palmer J, Carley H, Maddison P, 
Sivaguru A.Muscle Nerve. 2018 Apr;57(4):622-627. doi: 
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7.2 Appendix 2 Methods for Antibody assays 
Radioimmunoprecipitation assay (RIA/RIPA) 
All the experiments to look for MG antibodies were done at the 
Oxford labs at the Nuffield Department of Clinical 
Neurosciences. All RIA analysis for AChR and MuSK Abs were 
done by the author. For high positive titres, serial dilutions were 
done until the CPM value dropped by half and then the titres 
were calculated. VGCC Ab RIAs were done by Dr Bethan Lang 
and Selina Tomsen. 
All 150 MG patients in the study had serum samples taken at 
recruitment and 120 patients had serum samples at first year 
follow-up. ACHR RIA was tested on all patient samples at 
recruitment and first year follow-up. MuSK RIA was tested on all 
150 of the recruitment patient samples. VGCC antibodies on 
RIA were tested in 139 patients at recruitment.  
General principles for RIA: 
Radioimmunoassay (RIA) or radioimmunoprecipitation assay 
(RIPA) involves precipitating radioactively labelled antigen and 
antibody complex. In the first step patient sera is incubated with 
I125 labelled antigen. Any specific antibody in the sera binds to 
the antigen. In the second incubation step the antigen-antibody 
complexes are precipitated using a precipitation agent. The 
precipitate is washed with buffer. After centrifugation and 
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decanting of the supernatant, radioactivity in the precipitate is 
counted using a gamma counter. The intensity of the 
radioactivity is proportional to the concentration of specific 
antibody in the patient serum. The antibody concentration is 
evaluated quantitatively using a calibration curve (246). 
RIA for AChR antibodies 
Day 1 
1. Serum samples taken out of the -200C/-800C freezer and 
left to thaw at room temperature for a few minutes 
2. When thawed, the eppindorfs were agitated to mix the 
serum and prevent layering (using the small mechanical mixer) 
3. These were aligned in a row on a rack along with one 
healthy control (HC) and one strongly positive (SP) serum for 
AChR antibody 
4. New eppindorfs were labelled for each corresponding 
serum sample and placed on the rack parallel to the test 
samples 
5. PTX solution was poured into a large universal 
tube/sterile port 




7. One pipette was placed into each new eppindorf for ease 
of pipetting and also to make it easier to draw up the test serum 
8. 25 µL of the each test serum, HC and SP samples 
pipetted into the corresponding Eppendorf containing 225 µL of 
PTX making up to 250 µL in total 
9. Another set of eppindorfs placed on a new rack for each 
corresponding sample 
10. 50 µL of serum plus PTX mix was pipetted into the 
labelled eppindorf. The pipette tips used in the earlier step could 
be reused for each individual sample. This would equal 5 µL of 
serum. 
11. The remaining serum and serum plus PTX mix placed on 
the rack in the cold room, ideally covered with foil 
12. The test samples taken to the radioactive zone 
13. Diluted the 125I labelled α bungarotoxin AChR, 
recommended to make up to 1.3 mls, but can be diluted up to 
2.5 mls if a new batch, and the gieger counter reads very high 
counts. Titrated counts to approximately 15,000 CPM per 50 µL 
using the gamma counter 
14. 50 µL of the 125I α BuTX AChR added to the test 
samples. This was mixed very briefly on the vortex mixer. 
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15. The whole rack was placed in the fridge in the radioactive 
zone overnight 
Day two 
16. Taken the test samples (with I125αBuTX-AChR) out of 
the fridge 
17. Antihuman IgG serum-this was diluted up to 5 times i.e. 1 
ml was made up to 5 ml by adding PTX 
18. 50 µL of antihuman IgG was needed for every 5 µL of 
serum of being tested 
19. After dilution, 250 µL of antihuman IgG plus PTX was 
added to each test serum eppindorf. 
20. The solution became cloudy and started precipitating 
21. After approximately 30 minutes at room temperature 
there was a clear layer at the top with a precipitate at the bottom 
22. Added PTX, approximately 600 µL per tube 
23. Centrifuged this (balanced properly) at 11 G, room 
temperature for three minutes 
24. Pellets formed at the bottom 
25. The supernatant was sucked out using the suction device 
taking care to not disturb the pellet 
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26. More PTX was added to each tube till it was full, using a 
squeezy bottle for ease 
27. This needed to be left for a few minutes, then the 
supernatant was suctioned as before 
28. Washed a second time as before, PTX was left for 
approximately 10 minutes to ensure that any excess I125 was 
washed off 
29. After the second wash and suctioning of the supernatant, 
the lids were cut off from the eppindorfs, ensuring a clean cut so 
that they could sit snugly in the gamma counter rack 
30. Placed the tubes in the order of how the results should 
print out i.e. first used the rack marked ‘I counter’, placed the 
first tube in the first lot on the side opposite to ‘I counter’ sign 
going from the left to the right. The ‘stop counter’ rack was the 
last one to go in with the other racks placed parallel in between 
the two if needed 
31. These racks were placed on the right-hand side of the 
counter, perpendicular to the orientation of the space with the ‘I 
counter’ sign to the right and the ‘I counter’ rack furthest away 
from the front.  




33. When the tests were done, the eppindorfs were taken out 
of the ranks using tweezers/scissors, and then thrown in the 
radioactive bin 
34. Before and after working in the radioactive zone, the 
gieger counter was run over all of the areas including the sink to 
check for spillages. Filled in the sheets (X3) making note of I125 
used, batch number and disposal (solid and drain) 
Serial dilutions 
Day two 
1. For results which were highly positive i.e. close to or 
higher than the high positive control, the samples were serially 
diluted and retested. 
2. The sera was diluted from 5 µL to 2.5 µL (100 μL of the 
remaining 200 µL of PTX per serum mix was pipetted into 
another eppindorf and a further 100 µL of PTX was added. 50 
µL of this was pipetted into another eppindorf to get a serum 
concentration of 2.5 µL) 
3. Similarly after each dilution, 100 µL of the remaining PTX 
and serum mix from the earlier step was diluted with 100 µL of 
PTX to get concentrations of 1.25 µL, 0.625 µL, 0.3125 µL and 
0.15625 µL. 
4. The rest of the process was similar to before 
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5. Ideally when using lower test serum concentrations, this 
caused a lower ratio of serum to 125I and to antihuman IgG. To 
avoid this, the remaining concentration of serum made up by 
adding HC serum. For example, for 1.25 μL concentration of the 
test serum, added 2.5 µL of healthy control serum. 
6. For 2.5 µL test serum dilution, no need to add extra HC 
serum; for the other dilutions added 2.5 µL of HC serum each. 
7. For example, if using 16 samples, diluted 40 µL of healthy 
control serum with 360 µL of PTX to make up 400 µL. Then 
used 25 µL of this mix (i.e. 2.5 µL of HC serum) for each test 
sample. This was added at the same time as adding the 
antihuman IgG. 
8. Antihuman IgG was used in the same concentration and 
amount as used in the initial assay. 
Calculation of titres: 
For all our RIA assays, we used the RSR kit. The calculation of 
titres were done using the formula provided by the RSR 
company along with the information sheet provided for each 
sample of 125Iα BuTX AChR. 
nmol/L AChR = (CPM test sample - CPM negative control) X A 
C X K X BX 2.22 
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A – Decay factor between receptor labelling day and day of 
assay  
B - Counter efficiency (which was 80% on the machine in the 
Oxford lab) 
C- Volume of serum used in the assay 
K - Specific activity of 125I at the time it was used. 
A, C and K are on the sheet included with every bottle of 125I 
AChR. 
These titres were multiplied by 10, to give the values in 10-10 
mols/L 
For MuSK RIA assays, the procedure was the same as for 
AChR including dilutions. The assay kit used was RSR125I 
MuSK and the formula to calculate the titres was the same as 
AChR. 
RIAs for VGCC Abs were performed by Dr Bethan Lang and 
Selina Tomsen in the Oxford laboratories. Dr Lang prepared the 
radioactive label for the solubilised cells freshly for each batch of 
VGCC tested. 
Cell based assay 
All CBAs for clustered AChR, MuSK and LRP4 Abs were 
performed and interpreted by the author. All positive assays 
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were repeated at least once. In the case of positive MuSK CBA 
assays, most samples were assayed 3 times (twice by the 
author and once by Dr Mark Woodhall) and interpreted 
independently by the author and 2 others- Dr Mark Woodhall 
and Dr Isabel Leite. 
The list of consumables, media, reagents and antibodies used 
for CBAs are listed in the table below. 
Table 30 Consumables, media, reagents and antibodies used for CBAs 
Media/Reagents/Consumables Supplier 
HEPES Sigma 
Dulbeccos’s Modified Eagle Medium 
(DMEM) 
Sigma 





Trypsin-EDTA solution Gibco 
Poly-L lysine (PLL) solution Sigma 
Trptan blue solution (0.4%) Sigma 
Corning 175 cm (large) Tissue Culture 
(TC) flask 
APPW 
Corning 75 cm (medium) TC flask APPW 
Corning 6-well TC multi-well plate APPW 
Corning 24-well TC multi-well plate APPW 
Glass coverslips VWR 
Glass slides VWR 
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Vectrashield mounting media Vectrashield 
DAPI   
Bovine serum albumin (BSA)   
Formaldehyde 4% (made up from 36%)   
Phosphate buffered saline (PBS)   
Goat anti-Human IgG  Invitrogen 
Donkey anti-Goat IgG Alexa Fluor 568 Invitrogen 
HEK 293 cells TC flasks 
AChR DNA (α, β, δ, ε and rapsyn with 
tagged EGFP subunits) 
  
MuSK DNA (with tagged EGFP)    




All CBAs for clustered AChR, MuSK and LRP4 Abs were 
performed and interpreted by the author. All positive assays 
were repeated at least once. In the case of positive MuSK CBA 
assays, most samples were assayed 3 times (twice by the 
author and once by Dr Mark Woodhall) and interpreted 
independently by the author and 2 others- Dr Mark Woodhall 






Preparation of solutions 
1. DMEM-HEPES: 500 ML of the DMEM +2.3 g of HEPES 
(no BSA) 
2. DMEM-HEPES-1% BSA: To 500 ML of DMEM solution, 
added 2.3 g of HEPES and 5 g of BSA and mixed. 
3. PBS: to 100 mls of distilled water added one tablet of 
PBS and mixed till it dissolved 
4. 4% formaldehyde: 36% solution in the chemical area-
added 10 mls of this to 90 mls of PBS. 
5. DAPI + mounting media: 15 ml of fluorescent mounting 
medium from the fridge and added15 µL (i.e. 1 µL per ml) of 
DAPI (kept covered in foil in the fridge) 
6. Trypsin: 
 Thawed five ml aliquot of trypsin solution stored in -20° 
fridge 
 in 50 ml Falcon tube added 45 ml PBS then 5 ml trypsin 
solution and mix 
 The solution was stored in the fridge until required 
7. PLL: 
 Thawed 1 ml aliquot of PLL stored at -20°C fridge 
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 in 150 ml container added 99 ml PBS or water then 1 ml 
PLL solution and mixed 
 The solution (0.01% in PBS) was stored in the fridge until 
required 
8. Tissue culture media: 
 Took 500 ML of DMEM from the cold room and brought 
to room temperature in the tissue culture hood 
 Thawed 50 ML FCS and 5 ML BSA on the bench in the 
tissue culture 
 Sprayed the lids of each solution with ethanol before 
placing in the TC hood 
 Added 15 ML of FCS to DMEM and mix 
 Added 5 ML PSA to DMEM + FCS and mixed, additional 
reagents as necessary for individuals cell lines were added at 
this point 
 The solution was in the fridge until required 






1. Prepared the tissue culture media, trypsin solution, PLL 
solution as described in the previous steps. 
2. 3 or 4 cover slips placed into each well of a 6 well plate 
using fine forceps 
3. Added 3 ML of PLL solution and checked the cover slips 
were not floating and were covered in the PLL 
4. Left the PLL on for 15 to 20 minutes, up to 2 days if 
necessary 
5. Aspirated the PLL and made sure the cover slips were 
separated from each other. Left to dry in the TC with the lid open 
for more than an hour 
Cell counting: 
6. From the incubator took a T-175 flask which was 
previously seeded with HEK 293 T cells, now 80 to 95% 
confluent. Checked that the HEK 293 T cells were healthy under 
the inverted light microscope. (They are healthy if not moving, 
not all are rounded in shape and if the medium looks clear 
without any growth) 
7. Aspirated the medium from the flask, added 2 mls of 
trypsin and left at 37°C for one minute. Removed the flask and 
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shaken until almost all the cells had detached. If using a small 
flask, used 1 ML of trypsin. 
8. DMEM-FCS-PSA medium added to the flask to make up 
a final volume of 10 ML and transfered the contents to a 20 ML 
University bottle. For example, if using 2 ML is of trypsin then 
8.5 ML of DMEM/FCS/PSA and if using 1 ML of trypsin added 
9.5 ML of medium. 
9. In an eppindorf tube mixed 20 or 50 µL of the cell 
suspension obtained above with either 20 or 50 µL trypan blue 
solution (one in two dilution), mixed well by vortexing and 
carefully loaded 50 µL of the sample into a haemocytometer 
making sure to not overfill. 
10. Cells counted and calculated the number of cells per ML: 
The outer squares i.e. the 4 squares made up of 16 small 
squares each, divided this number by 4,  and multiplied by 2 X 
104. This was the number of cells in million per ML. If counting 
the middle squares (the 25 smaller squares) counted on both 
sides of the haemocytometer, multiplied by 2 X 104. This is the 
number of cells in million per ML.  When counting cells on the 
edges of the squares counted only two edges of the square and 
not all four edges. 
11. Centrifuged the cell suspension in the universal tube at 
1000 rpm for five minutes whilst the cells were being counted 
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12. Carefully aspirated the supernatant from the universal 
and thoroughly resuspended in 10 ML DMEM-FCS-PSA, being 
careful to not aspirate the pellet 
13. Seeded out 600,000 cells per well into 2 ML of DMEM-
FCS-PSA, making sure that all the cover slips were immersed in 
media. (Calculated the volume required according to the cell 
count above, making up enough solution for all wells plus one 
extra for ease of pipetting) (If a T175 flask was 100% confluent, 
you would expect between 40 and 50 million cells in total, from a 
T75 flask between 20 and 30 million). 
14. Incubated at 37°C and 5% CO2 overnight. 
15. Made up a new flask of cells with the remaining cell 
mixture. Taken a 20th of what I started off with for each new 
flask, mixed 0.5 ML with 35 ML of tissue culture media if using a 
large flask, or 0.4 ML and 18 ML of medium if using a small TC 
flask. Checked the flask under the microscope to make sure that 
there were cells in it and put this is back in the incubator. 
16. When making up a new flask of cells, they last for a 
maximum of 4-5 days; to last for the required number of days 
when seeding, added in the following proportions: for 3 days 
added 1: 12, 4 days added 1:24, for 5 days added 1:48. Splitting 
cells i.e. making new cells could be done only after day 3 ideally, 
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1. Checked that the cells had attached and looked healthy 
under the inverted light microscope 
2. Changed the medium in the 6 well plate before 
transfection. 
3. Prepared the DNA/polyethylene amine (PEI) mixture in 
the following order in the TC hood 
 50 µL DMEM without supplements/well 
 3 µg DNA/ well (2.8 µg specific DNA untagged and 0.2 µg 
EGFP) (the EGFP had to be 7% or less than the DNA)  
 15 µg PEI/well 
 For AChR assays the ratio of DNA for each subunit used 
was- 2α:1β:1δ:1ε:1rapsyn, making a total concentration of DNA 
3 µg per well; Rapsyn was already EGFP tagged 
 For MuSK assays, a total of 3 g of MuSK DNA was used 
per well, this was also already tagged with EGFP 
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 For LRP4 assays, the ratios of subunits were- 5 LRP4 
Caspr : 1 LRP4 AP. This needed to be added as 6 µg of DNA in 
total, ie 5μg of LRP4 Caspr and 1μg of LRP4 AP. 
4. It was recommended that we made a master mix of 
DNA/polyethylene amine and preparing an extra well to account 
for pipetting error 
5. Incubated the mixture at room temperature for 10 minutes 
6. While the DNA/PEI mixture was incubating, made sure 
that none of the cover slips were overlapping. 
7. Added the DNA (~50 µL) to each well and left in the 37° 
C incubator (5% CO2) overnight (less than 16 hours). 
Day three  
1. Changed the medium with 2 ML per well of tissue culture 
medium within 16 hours of transfecting. 
Day four 
Cell-based assays 
1. For AChR, MuSK and LRP4, used patient serum in one in 
20 concentration i.e. 12.5 µL of test serum made up to 250 µL of 
medium for each well. 
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2. Diluted the serum samples one in 20 in DMEM-HEPES-
1% BSA and the controls in the same manner. 
3. Transfered the samples to a 24 well plate and added a 
coverslip to each well with the cell side up and left to incubate at 
room temperature for one hour- this was put on the see-saw 
mixer after covering with either foil or foil box. 
4. The wells on the 24-well plate were marked A 1-6 etc, but 
the lids were also labelled. 
5. Aspirated the supernatant and washed the coverslip three 
times in 250 µL of DMEM-HEPES. A serial dispenser used for 
this 
6. Added 250 µL of 4% formaldehyde in PBS and incubated 
for 1 to 10 minutes- put in a dark place i.e. covered with foil and 
put back on the see-saw mixer 
7. Aspirated the solution and washed three times in 250 µL 
of DMEM-HEPES 
8. Added 200 µL of the secondary antibody which was an 
Fc Ab, Goat anti-Human IgG Fc cross adsorbed secondary 
antibody. This was added diluted to 1 in 750 in DMEM-HEPES-
1% BSA. The plates were incubated for 45 minutes at room 




9. Aspirated the secondary antibody and washed it three 
times in 250 µL DMEM-HEPES  
10. Added the tertiary antibody which was the Donkey anti-
Goat IgG Alexa Flour 568. Once again, this was made up into 1 
in 750 dilution using DMEM-HEPES-1% BSA. This was 
incubated for 45 minutes at room temperature, with foil, on the 
see-saw mixer  
11. Aspirated the solution and washed three times in 250 µL 
of DMEM-HEPES and two times in 250µL of PBS.  Left the cells 
in PBS. 
12. To check that the cells had been transfected with a 
fluorescent green dye, one of the coverslips from the culture 
was put facedown on a slide and this was looked at under the 
microscope. If the lighting for EGFP could be seen, then the 
cells were transfected. 
13. Placed a drop, approximately 20 µL of the DAPI + 
mounting solution on the microscope slide and place the 
coverslip on top with the cell side down. Tapped the slide gently 
on its side on a tissue so that it was not too wet. Six coverslips 
per slide were used and the slides were labelled appropriately. 
14. Left it to dry in the dark for at least 30 minutes before 
looking at the cells under the microscope. 
438 
 
15. Examined the slides using a fluorescent microscope with 
filters for DAPI, red and green. Scored the slides according to 
the scoring system detailed below. 
16. All positive samples and any borderline samples were 
repeated. 
17. The slides were stored at 4°C if further examination was 
required at a later date. 
Scoring CBAs 
 0 =  no labelling 
 0.5 = weak labelling of a few transfected cells with no 
obvious EGFP co-localisation 
 1 = weak labelling of some of the transfected cells, with 
precise co-localisation 
 2 = moderate labelling of some (approximately 20 to 
50%) of the transfected cells, with precise co-localisation 
 3 = moderate/strong labelling of approximately 50 to 80% 
of the transfected cells, with precise co-localisation 





The DNA used for the AChR subunits, MuSK and LRP4 
subunits had been prepared by Mark Woodhall. Further DNA 
was also prepared by the author. 
DNA master mix preparation 
Working solutions: 
L broth: 
1 L distilled water in a 2 L glass bottle +10 g triptone +5 g of 
yeast extract +5 g of salt. This was shaken until it was mixed 
properly. This was autoclaved overnight on day one 
Also on day one, made up more L broth and poured 600 ML into 
a big flask. This was autoclaved overnight or first thing on day 
two. 
Agar Plates: 
Agar satchets came with different antibiotics mixed in it, checked 
which one was required for the particular DNA being prepared 
AChR α, β, δ and ε required Ampicillin Agar, Rapsyn tagged 
with EGFP required Kanamycin, MuSK with EGFP required 
Kanamycin, LRP4 Caspr and AP subunits required Ampicillin, if 




This description is for MuSK DNA which required Kanamycin as 
explained below. Poured the contents of the satchet into a glass 
jar which was small enough to fit into the microwave and added 
200 ML of distilled water. Mixed and microwaved for 21/2 
minutes with the lid loose, gave it a shake and microwaved for a 
further 30 seconds; they were mixed uniformly. 
Took this agar mixture into the TC room to a sterile hood. Here 
poured 20 ML each into petri dishes. The mixture was cool 
enough to handle but not so cool that it set in the bottle. Left it in 
the petri dishes for a couple of minutes to form a gel. Closed the 
lids, turned them over and labelled with the antibiotic- example 
kanamycin on the bottom and what the gel is and the date if 
needed. Closed the petri dishes and sealed with paraffin paper. 
Put these in the cold room. These could be used for up to 3 
weeks. 
DNA  
You would need some DNA to start off from previous 
preparations. This was usually in μg/μL concentration for ready 
use. In order to make more DNA in the maxi prep, this was 
diluted by 10 times i.e. 1 µL is made up to 10 µL by adding 9 µL 
of nuclease free water. This gave a concentration of 100ng/µL. 
Day one 
1. This was done in the workspace rather than TC hood 
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2. Cleaned the area with alcohol spray to avoid 
contamination 
3. Kept a Bunsen burner to hand to keep things sterile while 
transferring samples. This needed to be switched on and the 
screw knob turned so that the flame was blue 
4. Turned on the water bath with a thermometer in it; the 
temperature needed to be at 42°C 
5. Brought ice from the washroom in a thermocol box 
6. Got competent cells from the -80° freezer. These were 
small green top tubes. Put this on ice. Needed 50 µL for every 
DNA prepared. If using a small amount from that, placed a red 
dot on the lid to indicate that some had been used. 
7. Nuclease free water. This was part of the DNA kit 
8. Turned on the Bunsen burner and worked underneath the 
blue flame 
9. Added 1.5 µL of master DNA, for example MuSK into a 
labelled eppindorf and 1.5 µL of nuclease free water into another 
eppindorf labelled ‘water control’ (WC) 
10. Then added 50 µL of competent cells into each eppindorf 
and put straight on ice for 20 minutes. Flicked it to mix 
11. Turned off the Bunsen burner 
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12. Heat-shock: after 20 minutes on ice, the eppindorfs were 
put into the water bath on thermocol eppindorf holders for 45 
seconds then put back on ice for two minutes; flicked to mix 
13. Turned off the water bath 
14. Under the Bunsen burner, aliquoted some of the L broth 
prepared into a universal tube, took out the eppindorfs from the 
ice and added 150 µL of L broth into each eppindorf. This was 
left at room temperature 
15. Placed the eppindorfs into the eppindorf rack of the 
shaking incubator for 45 minutes at 37°C 
16. Brought the agar plates out of the cold room and labelled 
them appropriately; for example, if preparing MuSK DNA, 
labelled three agar plates as MuSK 150, MuSK 30 and WC 
(water control). 150 meant using 150 µL of sample and 30 
meant 30 µL. 
17. Turned on the Bunsen burner 
18. After 45 minutes in the shaking incubator, brought out the 
eppindorfs 
19. Turned the gel plates right side up and pipetted 150 µL 
and 30 µL of the DNA/competent cell/L-broth into the 
corresponding agar plates and water control into the third plate. 
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20. Using a spreader, which was a blue plastic hockey-stick 
shaped stick; held the plate with the left-hand and rotated gently 
whilst moving the spreader back and forth  
21. Once evenly spread, closed the lid and placed it in an 
incubator overnight. 
Day two 
1. Prepared 600 ML of L-broth in a flask (one for each DNA) 
and autoclaved first thing in the morning if not done on day one 
2. Brought out the agar plates from the incubator 
3. Got 2 universal tubes for each DNA and labelled them, 
for example MuSK 1 and 2 
4. Added 5ml of L-broth into each tube using a mechanised 
pipette 
5. Got appropriate antibiotics from the -20° freezer; in case 
of MuSK this was kanamycin 
6. Antibiotics added in the ratio of 1:1000 
7. Worked under the blue flame of the Bunsen burner again 




9. Examined the colony formation on the agar plates and 
chose the plate which had discreet colonies visible, either from 
MuSK 150 or MuSK 30 
10. One colony needed per universal tube 
11. Used an inoculator which was a blue plastic stick with a 
hoop like a bubble blower, quickly scraped one of the colonies to 
catch one discreet colony and stirred this into the L broth in the 
universal tube. 
12. Two universal tubes were used per DNA i.e. one was 
used as backup 
13. Put the Universal tubes in the shaking incubator at 37° for 
5 hours 
14. Made sure to book a place on the shaking incubator in 
advance 
15. After five hours, the tubes were cloudy, chose the 
cloudiest of the two and used this one 
16. Got more antibiotics, for example kanamycin from the 
freezer 
17. Worked under the Bunsen burner 
18. Again, used antibiotics in 1:1000 ratio 
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19. For 600 ML L-broth in the flask, needed 600 µL of 
antibiotics 
20. Pipetted the antibodies into the universal tube, gave it a 
mix and poured this into the flask with the L broth. Gave it a swirl 
21. Put the flasks in the shaking incubator balanced 
appropriately at 37° overnight. 
Day three 
1. Took the flask out of the shaking incubator 
2. 2 plastic bottles of 500 ML with lids per flask used 
3. Poured the contents of the flask roughly divided into the 
two bottles 
4. Placed the bottles into centrifuge tubes- these were black 
and looked like Thermos flasks kept in the big centrifuge 
5. Placed the centrifuge tubes with the bottles in them on 
the weighing scales and transferred the L broth around (poured 
extra) so that they were balanced. 
6. The centrifuge needed to be pre-cooled to 4°C and a 
place booked for use 
7. The big rotor was needed, placed the tubes in this, the 
extra tubes were left in place to balance the centrifuge 
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8. The settings were: Rotor D-JLA, speed-5000 rpm, time-
10 minutes, temperature: 4°C 
9. Switched on 
10. In the meantime, prepared the columns 
11. Three blue-and-white columns needed per DNA, these 
were plastic tubes from the DNA kit 
12. Placed these one on top of the other, blue on top of the 
white and there was a filter inside; this was fit on top of the taps 
after opening the cover on the vacuum pump. Opened the 
vacuum pump by turning the knob anticlockwise. 
13. Three washing buffers were needed from the plasmid 
maxi prep kit  
 Cell suspension solution (CRA) 
 neutralisation solution (NSB) 
 cell lysis solution (CLA)-checked if there were precipitates 
and if present incubated them to get rid of it 
14. Three more plastic tubes about the size of Falcon tubes 
and with lids on were required 
15. Once centrifuged, took the bottles out and replaced the 
large rotor with the small rotor 
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16. There was a small pellet at the bottom of the bottles, 
decanted the liquid back into the flask 
17. Resuspended the pellet using 9 ML of CRA per bottle, 18 
ML in total 
18. If there were many bottles they were put in the shaking 
incubator for 5 minutes to resuspend, if not, done with a pipette 
19. Poured 6 ML each into the three smaller plastic tubes and 
divided any excess equally 
20. Added 12 ML of lysis buffer CLA into each bottle and 
mixed them by inverting 10 to 15 times. Occasionally white 
precipitates were seen, this was normal; the solution became 
viscous and could become stringy 
21. Left at room temperature for three minutes 
22. After three minutes added 12 ML of neutralisation buffer 
into each bottle; mixed by inverting 15 to 20 times gently as 
otherwise the genomic DNA would break 
23. Precipitates were seen- this needed to be centrifuged. 
Used balance if odd number of bottles were used 
24. Big centrifuge- same as before, but with a smaller rotor, 
settings were rotor ID-JA 25.50, speed-14,000 RCF, time-25 
minutes, temperature: 4°C 
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25. After centrifuging, took the tubes out 
26. Turned on the pump mentioned earlier 
27. Turned the left gauge to between 300 and 400 bars 
28. Poured the supernatant from the centrifuge tubes one 
into each of the blue with white columns 
29. The plastic tubes used couldbe reused so were washed-
soaked in virkon first 
30. Whilst the liquid was filtering in the columns, prepared 
solutions if not already done 
31. Column wash-added 350 ML of 95% ethanol to the 
column wash 
32. Endotoxin removal wash- added 5 to 7 ML of isopropanol 
33. Once the liquid had filtered in the columns, DNA was left 
bound to the white filter at the bottom 
34. Added 5ml of endotoxin removal wash to the white 
columns after taking out the blue column; allowed this to filter 
through 
35. Once filtered, added 20 ML of column wash to each 
column and wait for this to filter through 
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36. Need three eppindorfs labelled with the date and type of 
DNA 
37. Needed three eluator devices from the DNA kit which was 
‘Promega purefield ‘plasmid maxi prep system’ 
38. Put one eppindorf into each eluator device, kept the lids 
of the eppindorfs open 
39. 1 ml pipette tip with filter and nuclease free water was 
needed 
40. Left the columns for 10 more minutes after all the liquid 
has filtered so that it was dry 
41. Detached the column from the pump, tapped it on some 
tissue and fit in on top of the eluator device; fit on the vacuum 
pump again 
42. Pipetted 1 ML of nuclease free water into the filter, made 
sure the whole surface was wet, this dripped into the eppindorf. 
Left for 10 minutes to make sure everything dripped in; 1 ML 
collection was very good 
43. Put the eppindorfs on ice straight after 






1. Needed: 10 µL pipette, 10 µL pipette tip, nuclease free 
water or TE buffer 
2. Used the nano drop machine which was a small cuboid 
structure with a metallic arm on top connected to a laptop. 
3. Clicked on ‘nucleic acid’ on the computer software 
4. Opened the arm on the machine 
5. Placed 1 μL of nuclease free water i.e. one drop upon the 
black spot without any bubbles 
6. Clicked ‘okay’ on the computer 
7. Made sure sample type said ‘DNA 50’ 
8. Placde another microlitre drop in the black spot with 
nuclease free water, clicked on ‘blank’ 
9. Wiped this clean, then placed the DNA- either 1 or 1.5 µL 
drop 
10. Clicked on ‘measure’ 




12. Wrote this on top of the eppindorf converted into 
micrograms per microlitre concentration 
13. Measured all the eppindorfs 
14. Made a note of the purity- this was the column saying 
260/280. Anything above 1.8 was good 
15. In one of the columns it said 260/230, anything above 2 
was good 
16. 260 was the wavelength of DNA and 280 that of other 
proteins, similarly 230 was a different wavelength of other 
proteins. 
17. Made sure to close the metal arm with a tissue between 
as cushioning 
18. Stored the DNA eppindorfs in the -80° freezer. 
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7.3 Appendix 3 Methods of PBMC isolation and study 
using Flow cytometry 
Whole blood was collected from 135 MG patients and 8 LEMS 
patients at recruitment and 24 MG patients at first year follow 
up, 9 of whom had been immunosuppressed in the first year, 11 
who were immunosuppression naïve at first year follow up and 
the remainder had been immunosuppressed at recruitment. 
Peripheral blood monocytes/lymphocytes (PBMCs) were 
isolated using the method described below by the author within 
4 hours of sample collection. The majority of the PBMC isolation 
was done in the laboratory at the Neurology research unit at the 
Queen’s Medical Centre, Nottingham. Some of the samples 
collected at Birmingham and Oxford were processed at the 
University of Birmingham laboratories. 
The method of PBMC isolation was the same as that used by 
the MS research team at Nottingham (Prof Constantinescu and 
Dr Gran) and was adapted by the author into simple steps as 
below. 





Table 31 Equipment and reagents used for PBMC isolation 
ITEM LOCATION  ORDERING 
Green top vacutainer 
tubes (lithium 
heparin) 
Room temp Via Sandra Lever 
Sterile Universal 
tubes (50ml) (better 
resolution) or Falcon 
tubes (3 or 4) 
Room temp LS-M0144E (MSS) 
Histopaque (same as 
blood volume) 
Fridge H8889 (Sigma) 
Kwill filling tube (1) Room temp UN888 (Universal 
Hospital Supplies) 
10/20ml syringe (1) Room temp DC-M0157E /  
DC-M0160E (MSS) 
Pasteur pipette or 
1ml micropipette 
with its sterile tip 
Room temp LS-M0212E (MSS) 
PBS (~100 ml) Room temp LH-SIG2017E (PBS) 
Trypan blue (90 ul) Room temp T8154 (Sigma-Aldrich) 
Haemocytometer 
with cover glass (1) 






Microscope (1) Room temp Leica 
Aliquot (Eppendorf) 
tube (1) (0.5 ml) 
Room temp LS-M0280E (MSS) 
Marker pen Room temp 163932 (Fisher 
Scientific) 
Centrifuge Room temp Eppendorf centrifuge 
5810 R 
Pipette tips (blue) Room temp LS-M0223E (MSS) 
 
PBMC isolation 
1. Blood- heparinised in green tubes. This was mixed gently by 
inverting the tube 5-10 times 
2. The tubes were kept at room temp until ready for processing 
3. To Work in tissue culture hood- sterile environment. Tubes and 
reagents taken into the hood 
4. 1:3 :: Trigene: water; prepared in a jar 
5. Area and test tube rack sprayed with 70% ethanol 
6. 10mls of histopaque (1.0771) poured into the bottom of sterile 
universal tubes or falcon containers (blue head) × 3 using sterile 
pipettes 
7. Equal amount of histopaque to blood 




9. The histopaque bottle wiped with paper before closing the lid 
10. Kwill filling tube and sterile 20 ml syringe needed 
11. Kwill filling tube attached to the syringe 
12. This was used to draw blood; alternatively, disposable plastic 
pipettes used 
13. Blood put on top of the histopaque; to layer it, not mix it, not to 
push too hard, holding Kwill along the side of the Falcon 
container and dripping in 
14. Histopaque and blood needed to be in 2 layers 
15. New Kwill tube and syringe used for each bottle of blood unless 
samples of the same patient 
16. The remaining blood could be diluted with PBS in order to not 
lose any cells and this was added to the blood with histopaque 
17. Falcon containers- Centrifuged at 5810R, temp: room temp 
250C, speed: 2000rpm, time: 20 mins, acceleration: 9, brake: 0 
18. Braked slowly to keep layers intact and not mixed with each 
other 
19. Samples balanced equally in the centrifuge 
20. After 20 mins + 3 mins to break, the sample was in 4 layers: top 
serum, next cloudy ( WCC + platelets) which was what we 
needed, next histopaque, then RBCs at the bottom 
21. There should not be any blood spatters 
22. Using a disposable pipette or a Pasteur pipette with 1 ml 




23. Samples collected from all 3 Falcon containers that were in the 
centrifuge, then put into another 50 ml labelled falcon container 
24.  Dulbecco’s phosphate buffered saline ( PBS) used at room 
temperature. This was poured into the Falcon container holding 
the PBMC extract to make up to 50ml total. 
25. Shaken slightly 
26. Centrifuged again (first wash); temp: 200 to 250C, speed: 1700 
rpm, time: 10 mins, acceleration: 9, brake: 9 ( this differs with 
different machines) ( 1600-1700 rpm for 5-10 mins, acceleration 
was not important) 
27. After the centrifuge, supernatant poured out into the trigene jar 
28. There was a pellet at the bottom which is WCCs. Tapped gently 
to loosen it 
29. Using a plastic pipette, 10mls of PBS poured to this to dilute it 
30. Tryptan blue ( careful as dangerous) used. This was needed to 
look at cells under the microscope, If the cells were alive, the 
dye would not penetrate and there would be a rim of blue 
around the cells 
31. Tryptan blue:PBMCs::9:1 
32. Using a mechanised pipette set at 90 microlitres, first the tryptan 
blue was drawn and put it into an Eppendorf aliquot tube 
33. The mechanised pipette was set to 10 microlitres and the 
PBMCs drawn up. This was also poured into the same 
Eppendorf tube 
34. The pipette used to mix them up slightly 
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35. Haemocytometer and cover glass used 
36. Using the mechanised pipette, 10 microlitres of the tryptan 
blue/PBMC mixture drawn up 
37. This wsa dropped slowly between the cover glass and the 
haemocytometer 
38. The number of cells counted to see if the harvest was good 
enough! 
39. Haemocytometer placed under the microscope and switched on. 
magnification of x10, occasionally x40 used 
40. Counting cells: the number of cells in the four large corner 
squares (each has 16 smaller squares) (better on x40 lens) 
counted, and total number claculated. The numbers in the 4 
large squares added and divided by 4. This was the cell count in 
million cells per ml 
41. After counting, the remaining PBMCs mixed with more PBS to 
make up to 50mls 





C, speed: 1700 rpm, time: 10 mins, 
acceleration: 9, brake: 9 
43. After the centrifuge, supernatant poured out 
44. There was a pellet at the bottom again, disturbed gently by 
tapping 
45. Nutrient medium needed which is 10%FCS in RPMI 
46. Nutrient medium added in a proportion of  
Nutrient medium (ml)= total PBMC (million)/12 (million) 
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47. 1ml of the PBMC/FCS mix drawn up using a mechanised pipette 
( with a maximum setting of 1000 microlitres) and this was 
poured into another falcon tube 
48. A further 11mls of FCS (nutrient medium) added to make upto 
12 mls 
49. This was divided into 11 FACS tubes labelled before use 
50. Further nutrient medium added to the rest of the cells to make 
up to 30 mls 
51. Centrifuged again (third wash); temp: 200 to 250C, speed: 1200 
rpm, time: 10mins, acceleration: 9, brake: 9 
52. After the third wash, supernatant poured off 
53. Cells at the bottom loosened by gentle tapping 
54. 3mls ( 1 ml for every 10-15 million cells) of freezing medium 
added and gently mixed 
55. Freezing medium (Fetal calf serum FCS 9 parts and dimethyly 
sulfoxide DMSO 1 part) 
56. Cryovials which come in 1ml, 1.5ml and 2ml sizes used. Each 
ml would contain 10-15 million cells 
57. Using a mechanised pipette, 1ml of the PBMC/freezing medium 
mixture transferred into each of the 4 cryovials. If there was any 
leftover, it was divided equally between the vials 
58. The vials needed to be cooled 
59. The vials were put into Mr Frosty/ Cool cell purple box ( or 
between 2 polystyrene blood tube holders if nothing else 
available- idea was to freeze slowly) 
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60.  The purple box was placed in the -800C freezer for 5 days to be 
cooled by 10C per hour 
61. After 5 days, the vials were put into liquid nitrogen for 
cryostorage 
62.  Labelling checked  and a note made of where the cryovials 
were in the canister 
63. The used containers were put into the yellow bins to be burnt 
64.  If the PBMCs were going to be put into the flow cytometer 
straight away, FACS tubes to be used in step no. 49 (we did not 
so this) 
65. This needed further staining and/or stimulation prior to flow 
cytometry 
 
All of our PBMC samples were cryo-stored and analysed in the 
final year of the study. The protocol for the flow cytometry was 
set up with the help of Dr David Onion, Immunologist at the 
QMC, Nottingham. The author performed the staining on all 
samples. The samples were put through the flow cytometer by 
Dr David Onion and team who provided the raw data. The 
results were analysed on ‘Kalusa’ software. The gating was set 
up with the help of the immunologists for the first two samples 
and all subsequent samples were analysed by the author. 
The study was divided into three panels- the first panel for Treg 
cells, the second panel for the cytokines- IFNα, IFNγ and TNFα, 
the third panel for the cytokines- IL-10, IL-17 and IL-4. 
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The panel was set up on a 96 well plate and was as below. 
   Panel (T Reg) 1 
Table 32 Design for 96 well plate for Tregs, panel 1 
US SCC 
L/D 
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Single Colour Compensation (SCC) in FACS Tubes 
CD4  FoxP3  TNF α  IL 17 
CD25  INF γ  CD3  IL 4 
CD127  INF α  CD8  IL 10 
 
The consumables and reagents used are as below: 
Table 34 Consumable needed for PBMC thawing * and stimulation** 
ITEM LOCATION ORDERING 
RPMI (~43.5 ml) Fridge LH-SIG2034E (MSS) 
FCS (5 ml) Fridge / -20 LH-SIG-2022E (MSS) 
p.cod: F9665 
Pen / strep (0.5 ml) Fridge / -20 LH-SIG2031E (MSS) 
Hepes (0.5 ml) Fridge / -20 H0887 (Sigma) 
Glutamine (0.5 ml) Fridge / -20 LH-SIG2024E (MSS) 
Frozen (or fresh) 
PBMCs 
LN2 N/A 
15ml tubes * Room temp LS-M0145E (MSS) 
Pasteur pipette Room temp LS-M0212E (MSS) 
BSA 0.5% (from 30% 
stock) diluted with 
PBS (50ml* dilution) 
Fridge A7284 (Sigma) 
PBS Room temp LH-SIG2017E (MSS) 
FACS tubes (sterile) Room temp LOT 2399001       
2015-04           No. D-
51588 (SARSTEDT) 
96-Well Plates     
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PDB (20 ng/ml tube) 
** (1 mg/ml DMSO) 
stock (take 2 ul)+ 
RPMI (add up to 200 
ul) (total 6 ul dilution 
needed) 





stock (take 5 ul) + 
RPMI (45 ul) (total 
15 ul dilution 
needed) 
Fridge  Product code: 10643- 
1mg (Sigma) 
Brefeldin A (10 
ug/ml tube)** 
(5mg/ml DMSO) 
stock (take 10 ul) + 
RPMI (40 ul) (total 
50 ul dilution 
needed) 
Fridge  Product code: B7651- 
5mg (Sigma) 
CO2 incubator (5% 
CO2, 37 C) 
Room temp Sanyo CE® model 
MCO-17AIC Serial no. 
00303091 
Falcon (universal) 
tubes (3 or 4) (50 ml) 
Room temp LS-M0144E (MSS) 
Water bath or 
incubator* 
    
FACS lids Room temp ETN: 240112 (Elkay) 
Pipette tips (white) Room temp LH-M0226 (MSS) 





Table 35 Consumables and reagents used in PBMC staining 
ITEM (Panel 1-Treg) LOCATION  ORDERING 
CD4 FITC   
  
Fridge (4C)  BD biosciences 
(555346) 
CD 25  PE  Fridge  BD biosciences 
(555432) 
CD127 PE-Cy7    BD biosciences 
(560822) 
FoxP3 Alexa Flour 647  
  
Fridge BD biosciences 
(560045) 
Human FoxP3 Buffer Set 
BD biosciences 
  BD biosciences 560098 
Live/Dead fixable blue 
dead cell stain kit, for UV 
excitation 
  L34962 
OneComp eBeads 
Compensation beads 
  01-1111-42 
FITC Mouse IgG1, κ 
Isotype Control Clone 
MOPC-21  
  BD biosciences 555748 
PE Mouse IgG1, κ Isotype 
Control Clone MOPC-21  
  BD biosciences 555749 
PE-Cy 7 Mouse IgG1, κ 
Isotype Control Clone 
MOPC-21  
  BD biosciences 557872 
Alexa Flour 647 Mouse 
IgG1, κ Isotype Control 
Clone MOPC-21  
  BD biosciences 557714 
ITEM (Panel 2-Th17) LOCATION  ORDERING 
INFγ APC  
  
  Biolegend 506510 




TNFα PerCP-Cy5.5  
  
  Biolegend 502926 
CD3 APC-Fire 750 
  
  Biolegend 344840 
CD4 FITC   Fridge (4C) BD biosciences 555346 
CD8 PE-Cy7  
  
  Biolegend 301012 
Fixation/Permeabilization 
solution Kit 
  BD GolgiStop 554715 
Live/Dead fixable blue 
dead cell stain kit, for UV 
excitation 
  L34962 
OneComp eBeads 
Compensation beads 
  01-1111-42 
APC Mouse IgG1 κ 
Isotype Control  
  Biolegend 400142 
PE Mouse IgG1 κ Isotype 
Control Clone MOPC-21  
  BD biosciences 555749 
PerCP-Cy5.5 Mouse IgG1 
κ Isotype Control Clone 
MOPC-21  
  Biolegend 400150 
APC- APC/Fire 750 Mouse 
IgG1 κ Isotype Control 
Clone MOPC-21  
  
  Biolegend 400196  
FITC Mouse IgG1, κ 
Isotype Control Clone 
MOPC-21  
  BD biosciences 555748 
PE-Cy7 Mouse IgG1 κ 
Isotype Control Clone 
MOPC-21 




ITEM (Panel 3-Th2) LOCATION ORDERING 
IL17 PE    Biolegend 512306 
IL4 PerCP-Cy5.5    BD biosciences 561234 
IL10 APC    Biolegend 506807 
CD3 APC/Fire 750  
  
  Biolegend 344840 
CD4 FITC   Fridge (4C) BD biosciences 555346 
CD8 PE-Cy7    Biolegend 301012 
Fixation/Permeabilization 
solution Kit 
  BD GolgiStop 554715 
Live/Dead fixable blue 
dead cell stain kit, for UV 
excitation 
  L34962 
OneComp eBeads 
Compensation beads 
  01-1111-42 
PE Mouse IgG1 κ Isotype 
Control Clone MOPC-21  
  Biolegend 400140 
PerCP-Cy5.5 Mouse IgG1 
κ Isotype Control Clone 
MOPC-21  
  BD biosciences 550795 
APC Rat IgG2a κ Isotype 
Control Clone R35-95  
  Biolegend 400512 
APC/Fire 750 Mouse IgG1 
κ Isotype Control Clone 
MOPC-21  
  Biolegend 400196 
FITC Mouse IgG1, κ 
Isotype Control Clone 
MOPC-21  
  BD biosciences 555748 
PE-Cy7 Mouse IgG1 κ 
Isotype Control Clone 
MOPC-21  
  Biolegend 400126 
ITEM LOCATION ORDERING 
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EDTA 100 mM (20 
ul/tube)*7 tubes 
Room temp   
Formaldehyde 4% (1 
ml/tube)*7 tubes & 0.5% 
(0.4 ml/tube)*11 tubes 
(40% stock w/ isoton dil.) 
Room temp B8F77119 (Philips-
Harris) 
Isoton diluent Room temp 8448011(Beckman-
Coulter) 
Aluminium foil (kitchen 
quality) 
Room temp Terinex 
PBA (0.5%): BSA (0.5%) in 
PBS: (3 ml/tube)*4 tubes 
(0.25 ml 30% BSA, add 
PBS up to 15 ml) 
Fridge A7284 (Sigma) 
PBS (diluents to BSA) Room temp LH-SIG2017E (MSS) 
 
Protocol for Three Panel T cell studies for Flow Cytometry 
Prep 
1. Medium 
500ml RPMI + 50ml FCS + 5ml Pen/Strep + 5ml Glutamine 
(FCS, Pen/Strep and Glutamine come in bigger bottles and had 
to be aliquoted into the required quantities and re-frozen) 
2. FCS thawed to use in the staining buffer 






1. Switched on the water Bath- checked level of H2O and temp (37 
C) (Press black button to check temp) 
2. Placed bottle of media into the water bath 
3. Once media was warmed, poured 10-15 mls into labelled falcon 
tubes- one for each pt. (ideally if using more than one cryovial 
for one patient, they were pipetted into different falcon tubes, but 
to save time, one used) 
4. Ice obtained in a thermocol box and the cryovials to be tested 
taken from liquid N2 and placed onto the ice (If doing many 
samples, placed in order in a box on ice) 
5. Cryovials thawed individually by holding them in the water bath 
for a minute or so. Shaken to see if the ice had melted 
6. The cryovials taken to the hood. Lids opened slightly to release 
the pressure 
7.  With mechanised 5 ml (or 10 ml) pipette few drops of medium 
taken from the labelled falcon tube and added a few drops into 
the cryovial. Taken care to not overfill. Mixed a couple of times 
and pipetted the whole lot into the falcon tube. The pipette 
emptied gently. 
8. When all the samples were thus thawed, placed the falcon tubes 
in the centrifuge for washing at 1200 rpm, RT for 10 mins 
9. Poured out the supernatant, agitated the pellet and re-
suspended in 10ml of medium. Mixed by pipetting up and down 
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10. Taken 10 ul of this in a labelled eppindorf for cell counting. 90 ul 
of trypan blue needed to be added and cells counted the same 
way as with PBMCs ie outer 4 (4X4) squares divided by 4, or 
inner (5X5) square.  
11. Centrifuged the Falcon tubes again at RT 1200 rpm for 10 mins 
12. Poured out the supernatant and agitated the pellet 
13. Re-suspended the cells in 10ml medium (Less if wanted to use 
less of the cell stimulation cocktail- we diluted to 3ml) 
14. Added 2 ul of cell stimulation cocktail (plus protein transport 
inhibition) for every 1ml dilution, so if diluting to 10 ml, needed 
20 ul (6ul if diluted to 3ml) 
15. Poured the contents of the falcon tubes into labelled 75 cm2 
culture flasks. These could be left in the Falcon tubes if there 
were many samples 
16. Placed these vertically in the incubator (370C) for 4 ½ hours 
 
Afternoon 
1. Took the flasks/falcon tubes out of the incubator after 4 ½ hrs 
2. If in flasks, pipetted into labelled falcon tubes 
3. Filled this up with PBS 
4. Centrifuged at 1200 RPM, 10 mins, RT 
5. Discarded supernatant, agitated the pellet 
6. Re-suspended this with more PBS to fill the falcon tubes 
7. Centrifuged again, same settings 1200 rpm, 10 mins, RT 
8. Discarded supernatant, agitated the pellet 
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9. Whilst the centrifugation was taking place, marked out the layout 
of the stains on the 96 well plate. For the 3 panel assay, used 
one plate for the FoxP3 assay (Panel 1) and another one for 
Panels 2 and 3. 
10. Dilutions now depended on how many wells each sample 
needed to be put into. For the control samples- ideally only one 
control sample, but as this uses a lot of cells, used 2 (or 3) 
control samples, but ensured that the same control used for 
each panel. Control samples diluted more using PBS (calculated 
as 50 ul per well). For the other samples, which only went into 
Isotype Control (IC) and Fully Stained (FS) wells for that 
particular sample, only 300 ul were required (for all 3 panels). 
Usually, when pellets were agitated, there was some liquid left 
after the wash. This usually sufficed. Mixed well and pipetted 
into the wells of a 96 well plate. 
 
11. Next step was Live/Dead staining 
12. This was kept in the freezer- when new, the vial needed to be 
made up by adding 50 ul of DMSO provided in the kit and 
vortexing. Covered this in aluminium foil 
13. Worked with the hood lights off for the next steps 
14. Diluted some of the prepared L/D stain in a 1:10 ratio. Made up 
100 ul in total (which would be sufficient for 100 wells) with 10 ul 
of L/D stain and 90 ul of PBS 
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15. Looked at the planned panel layout to see which wells require 
L/D stain and add 1 ul per well (not to be added to the Unstained 
(US), IC and FMO for L/D, but in our experiment, used L/D in IC 
wells in Panel 3) 
16. Covered this with foil and left to incubate for 30 mins at RT 
                  
17. Prepared the staining buffer 
18. Poured the buffer into a plastic reservoir for ease of use 
19. Needed a multichannel mechanised pipette 
20. Once the plates had incubated for 30 mins, pipetted 100ul of the 
staining buffer into the well plates and centrifuged for 5 mins at 
1200 rpm at RT 
21. Discarded the supernatant by tipping it once into the sink (to not 
tap it into the sink), then gently tapped onto some tissue paper 
22. Pipetted 200 ul of staining buffer into the wells and repeated the 
wash at 1200 rpm, RT, 5 mins 
23. Tapped out as above 
 
24. Next step was Surface/ Extracellular staining 
25. Followed the list below for the extracellular staining for all three 






Stain 1: 20ul of CD4-FITC panel 1, 2 and 3 
Stain 2. 20ul of CD25-PE panel 1 
Stain 3. 5ul of CD127-PE cy7 panel1 
Stain 4. 5ul of CD3-APC fire 750 panel 2 and 3 
Stain 5. 20ul of CD8-PE cy7 panel 2 and 3 
Stain 6. 20ul of IC-FITC mouse (CD4) panel 1, 2 and 3 
Stain 6. 20ul of IC-FITC mouse (CD4) panel 2 and 3 
Stain 7. 5ul of IC-PE mouse (CD25) panel 1 
Stain 8. 5ul of IC-PE cy 7 (CD127 & CD8) panel 1 
Stain 8. 5ul of IC-PE cy 7 (CD127 & CD8) panel 2 and 3 
Stain 9. 5ul of IC-APC fire (CD3) panel 2 and 3 
 
26. Incubated covered in foil at RT for 30 mins 
27. Prepared the Fox P3 buffers A and C for Panel 1 (as below) 
28. Prepared the BD Perm wash buffer for Panel 2 & 3 (as below) 
29. From this point on, Panel 1 and Panels 2 and 3 were washed, 
stained and incubated differently 
30.  Panel 1 (FoxP3): Washed with Staining buffer, 200 ul first and 
centrifuged at 1500 rpm for 5 mins at RT 
31. Emptied the wells and tapped on tissue as before 
32. Now added Buffer A 200 ul/well of Panel 1 
33. Incubated covered in foil at RT for 10 mins 
34. Whilst Panel 1 was incubating, washed panels 2 and 3 with 200 
ul staining buffer per well 
35. Centrifuged at 1500 rpm RT for 5 mins 
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36. Next step was permiabilisation 
37.  Added Fix Perm solution 100 ul per well (This was ready to use 
and came as part of the kit) 
38. Incubated covered in foil for 20 mins in the fridge 
39. Whilst Panel 2 and 3 were incubating, and once Panel 1 had 
incubated for 10 mins after step 33, centrifuged Panel 1 at 1500 
rpm at RT for 5 mins 
40. Emptied the supernatant and tapped dry as before 
41. Added 200 ul per well of the staining buffer 
42. Centrifuged at 1500 rpm, RT for 5 mins 
 
43. Next step was permiabilisation 
44. Added Buffer C (Fox P3 Buffer set, prepared as below) 100 ul 
per well 
45. Incubated at RT covered in foil for 30 mins 
46. Whilst Panel 1 was incubating and once Panel 2 and 3 had 
incubated for 20 mins after step 38, added 100ul per well of 
Perm Wash (prepared as below) to Panels 2 and 3  
47. Centrifuged at 1500 rpm RT for 5 mins 
48. Emptied and tapped  
49. Added 200 ul per well of Perm Wash to Panels 2 and 3 
50. Centrifuged at 1500 rpm RT for 5 mins 
51. Emptied and tapped  
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52. Once Panel 1 had incubated for 30 mins after step 45, added 
100 ul of staining buffer per well and centrifuged at 1500 rpm at 
RT for 5 mins 
53. Emptied and tapped on tissue 
54. Added 200 ul per well of staining buffer and centrifuged again at 
1500 rpm RT for 5 mins 
55. Emptied and tapped on tissue 
56. Next Step was intracellular staining 
Stain 1. 20ul of FoxP3 AlexaFluor 647 panel 1 
Stain 2. 2.5ul of IFNγ panel 2 
Stain 3. 20ul of IFNα PE, panel 2 
Stain 4. 5.5ul of TNFα PerCP cy 5.5, panel 2 
Stain 5. 5ul of IL 17 PE, panel 3 
Stain 6. 5ul of IL 4 PerCP-cy5.5, panel 3 
Stain 7. 5ul of IL 10 APC, panel 3 
Stain 8. 20ul of IC Alexa Fluor 64, panel 1 
Stain 9. 5ul of IC APC mouse IgG1 (IFNγ), panel 2 
Stain 10. 20ul of IC PE mouse IgG1 (IFNα & IL 17), 
panel 2 and 3 
Stain 11. 5ul of IC PerCP-cy5.5 (TNFα & IL 4), panel 2 
and 3 
Stain 12. 5ul of IC APC rat Ig (IL 10), panel 3 
 
57. Once intracellular staining was done, covered both the well 
plates in foil and incubated for 30 mins- Panel 1 at RT and 
Panels 2 and 3 in the fridge 
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58. Whilst the panels were incubating, prepared the Single Colour 
Controls (SCC) using compensation beads 
59. The beads were kept in the fridge. Mixed by vortexing 
60. Each drop ~ 50ul, so added enough drops into an eppindorf tube 
(25 ul needed for each SCC- 12 in total, so at least 6 drops 
needed) 
61. Pipetted well to mix and added 25 ul into each FACS tube or 
another new well plate 
62. Added 2 ul of each colour into the tubes/plate as below except 
for CD8 PE cy 7 (used 0.5 ul) 
 
1. CD4 FITC 
2. CD25 PE 
3. CD127 PE-cy7 
4. FoxP3 Alexa Flour 647 
5. IFN γ APC 
6. IFN α PE 
7. TNF α PerCP cy 5.5 
8. CD3 APCfire750 
9. CD8 PE cy7 (0.5 ul) 
10. IL 17 PE 
11. IL 4 PerCP cy 5.5 
12. IL 10 APC 
 
63. Vortexed to mix 
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64. Incubated covered in foil for 15 mins in the fridge 
65. Once incubated, added 250ul of PBS per tube/well  
66. Ready for Flow cytometry 
67. Covered in foil and left in the fridge overnight 
68. Once the incubation after intracellular staining for Panels 1 and 
2 & 3 was complete, washed 
69. For Panel 1, used staining buffer- 100 ul per well, then 
centrifuged at 1500 rpm RT for 5 mins, emptied and tapped on 
tissue, then 200 ul per well added, centrifuged at 1500 rpm RT 
for 5 mins, empty and tapped on tissue 
70. For Panel 2 &3, used Perm Wash buffer and centrifuged twice 
same as above 
71. Re-suspended both with staining buffer 200 ul per well 
72. Ready for flow cytometry 




50 mls PBS + 1ml FCS (needed three times this if doing more 
samples) 
BD Perm Wash Buffer (for Panel 2 and 3) 




1:10 dilution of buffer from the kit with either distilled water or 
PBS 
Would need ~ 80mls of buffer in total for 4 washes for all the 
wells in a 96 well plate- calculated accordingly. So for 80 ml, 
used 8ml of buffer from the kit and added 72 ml of H2O or PBS. 
Fox P3 Buffer 
Diluted Buffer A: From the kit in 1:10 dilution with H2O or PBS. 
This would be used as a diluent to make Buffer C also, so 
prepared enough quantities.  
For all the wells in a 96 well plate, would need to make up 
~30mls of Buffer A in total, ie 3ml of Buffer A from the kit and 27 
ml of H2O/PBS 
Buffer C: This was made by diluting Buffer B from the kit with 
the diluted Buffer A from above in a 1:50 dilution. 
For all the wells in a 96 well plate, would need 10 mls in total of 
Buffer C, ie 200ul of Buffer B from the kit and 9.8ml of Diluted 
Buffer A 
Flow cytometry: 
Our gating was applied as per the pictures below. For controls, 
we used both single colour controls (SCC) for all the antibodies 
used and Flow minus one (FMO) where all antibodies except 
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one was added. We also did isotype controls (IC) for every 
patient sample tested. 
 



















































































































































































For panel 1, firstly, live cells were identified using the live/dead 
stain and separated into ‘singlets’. These cells were then 
separated into CD4+ cells; the next gating was CD4+ CD127low 
cells, the next gating was for CD25+Fox P3+, so in the end we 
got the Treg cell population which we defined as 
CD4+CD127lowCD25+FoxP3+ cells. The statistical analysis on 
Kalusa was used to calculate the number of live cells, CD4+ 
cells and Treg cells with percentages. 




For Panel 2, once again live singlet cells were isolated. The next 
gating used was for CD3+ cells. These were then separated into 
CD3+CD4-CD8+ and CD3+CD4+CD8- cells. The next few gates 
were for CD8+IFNγ, CD8+TNFα, CD8+IFNα, CD4+IFNγ, 
CD4+TNFα and CD4+IFNα. The statistical analysis on Kalusa 
was used to calculate the number of live cells, and number and 
proportions of CD8+IFNγ, CD8+TNFα, CD8+IFNα, CD4+IFNγ, 
CD4+TNFα and CD4+IFNα. 




For panel 3, the same protocol as panel 2 was used to isolate 
CD4+ and CD8+ cells, the next gates were used to identify 
CD4+IL10, CD4+IL4, CD4+IL17, CD8+IL10, CD8+IL4 and 
CD8+IL17. The statistical analysis on Kalusa was used to 
calculate the number of live cells, and number and proportions 
of CD4+IL10, CD4+IL4, CD4+IL17, CD8+IL10, CD8+IL4 and 
CD8+IL17. 
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